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The aims of this study were to determine the risk of
transmission of HIV from mother to child, to determine factors affecting
this risk, to describe the natural history of HIV infection in children, and
to evaluate available therapy. Sixty eight infants of HIV seropositive
women followed prospectively for a median of 44 months, were
studied together with 30 controls, and 8 other children known to be
HIV infected.
Sixty one children became HIV antibody negative at 6-18
months. Of 11 HIV infected children, all 10 surviving beyond 18 months
remained HIV antibody positive. HIV core antigen was positive in 9/11.
HIV was isolated in culture of samples from 9 children; in all 10 cases
tested, PCR was positive.
56 index children were followed from birth to over 18 months: 3
were HIV infected, giving a rate of 5.4% (95% CI 0.12-14.87%). Early
clinical indications of HIV infection included recurrent respiratory
infections, recurrent diarrhoea, eczematous skin rashes, generalised
lymphadenopathy, and hepatosplenomegaly. Persistent severe
candidal infection heralded the development of AIDS in one infant. HIV
infected children were more likely to have persistent
hypergammaglobulinaemia, CD4 lymphopoenia and
thrombocytopoenia. In the first 2 years, only the difference in IgG
levels, noted by 6 months of life, reached significance.
Of 70 infants and their mothers, 5/9 pregnancies within a year
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of seroconversion resulted in HIV infected children compared with
7/61 in subsequent years (p< 0.001). Increased risk of transmission
was also associated with advanced maternal disease and CD4 count
<300 x 106/l at delivery. Women who bore infected children were
more likely to progress to CDC stage IV during follow-up (p=0.032).
55% (95% CI 23.38-83.25%) of HIV infected children had
symptoms by a year of age, and 82% (95% CI 48.22-97.72%) by 2
years. Median time of progression to stage P2 B-D was 45 months.
Mortality was 9% at 1 year (95% CI 0.23-41.28%), 27% at 5 years (95%
CI 6.02-60.97%). 6/11 children died at median age of 55 months (95%
CI 23.38-83.25%), range 4-82 months. The longest survivor is 76
months. Clinical features associated with progressive disease included
PCP, recurrent bacterial infections, LIP, encephalopathy, oesophageal
Candida, Ewing's sarcoma, cardiomyopathy, and wasting syndrome.
Rapid diagnosis of PCP from nasopharyngeal secretions was shown to
be possible. The new guidelines for PCP prophylaxis would not have
protected one child in our study. Encephalopathy was associated with
a poor prognosis, whereas LIP was compatible with prolonged
survival. High levels of HIV antigen (>50pg/ml) in the absence of
detectable core antibody were associated with progression of HIV
disease and mortality within 2 years, as were rapidly declining CD4
counts and raised IgA levels.
Swabs were cultured for respiratory viruses every 3 months
from 5 HIV infected and 45 uninfected children. HIV infected children
had respiratory symptoms on 14/30 occasions compared with 41 /220
for uninfected children (p<0.01). On 10/30 and 32/220 occasions
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respectively, respiratory viruses were isolated. Respiratory infections
were more likely to lead to hospital admissions in the HIV infected
children.
Blood from 53 infants was typed for HLA-A, B, and DR antigens.
There were no absolute differences in antigenic specificity between
HIV infected and uninfected children. However, the combination A3,
B7, DR2, only found in uninfected babies, was four times commoner in
the study population relative to controls. HLA A1, B8, DR3 haplotype
was found less often than expected, but was disproportionately
represented amongst infected children.
In eight children receiving intravenous immunoglobulin infusions
every 3 weeks. Significant improvement was noted in terms of weight
gain, number of infective episodes, and days spent in hospital. This
resulted in a 49% saving in terms of cost. HIV core antigen was
detected in 5 children prior to treatment but was absent 6 months later.
CD4 counts continued to fall. Six children also received zidovudine.
There was a significant improvement in weight gain, and in
encephalopathy following treatment, together with a reduction in the
rate of decline of CD4 count. This intervention may have affected the
natural history of HIV infection in the study children.
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INTRODUCTION
In the 9 years since the first case of AIDS in the UK was
recognised in 1982 (editorial, br med j 1983), there have been over 5,000
cases reported, 314 of which were in women, and 49 in children. In
Scotland, there have been 277 cases, 33 of whom were women and 5
in Children; 4 of these have already died (Communicable Diseases Scotland Weekly
Report 1991). In England and Wales, most cases come from the
homosexual/bisexual population, whereas in Scotland intravenous
drug users make up around 70%(Bannisteretai 1988). This pattern is more
similar to that seen in Southern Europe.
In Edinburgh, there was an epidemic of intravenous drug
misuse in the early 1980s consequent upon the increased availability of
heroin at this time. In 1982 there was an outbreak of hepatitis B
infection among users, attributed to an increase in sharing needles
owing to an acute shortage caused by the closure of the local legal
supplier. Thus when HIV was introduced into this population in 1983, it
spread rapidly through the drug- using population (Robertson etai 1986 [a]).
The earliest known seroconversion was in January 1983 in a person
recently having returned from Southern Europe, who went on to share
with users in Edinburgh (Bissetetai, 1989), the majority of whom
seroconverted later that year and in early 1984 (Robertson et ai, 1986 [a]).
Seropositive rates of between 38% and 65% in this group have been
reported (Peutherer et al 1985, Robertson et al, 1986 [a], Brettle et al 1986). This Contrasts
sharply with rates of below 5% in Glasgow and London (Foiiettetai 1986,
Webb et ai 1986), and the difference is largely attributable to the difference in
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needle Sharing practices (Robertson etal 1986 [b], Brettle 1986).
The prevalence among the drug using population had
implications for the further spread of the epidemic. Not only were they
a mobile group, sharing in other cities and countries (Brettieetai 1987, Bissetet
ai 1989), opening the possibility of similar epidemics elsewhere, but they
were young and sexually active, and so provided a channel for further
spread into the non-drug using heterosexual population (France etai 1988).
Also a third were women of child bearing age (Brettie et ai 1987), who from
early in the epidemic were becoming pregnant, with the risk of
transmission to their children (Robertson & Bucknall 1986). The impact On
maternal and child health, and the counselling given to infected women
wanting children or already pregnant, would therefore be dependent
on the rate of vertical transmission, and the natural history of the
disease in those infected. At the outset of the study, there was much
debate as to whether termination of pregnancy should be advocated
for all pregnant women who were seropositive for HIV because of the
risks to the mother and child.
Following the recognition of the high rates of HIV infection
among intravenous drug users in Edinburgh (Peutherer et ai 1985, Brettieetai
1986), HIV seropositive women who were either pregnant or who had
recently given birth began to seek medical attention and advice,
regarding the risk of their child being infected with HIV and the likely
outcome for the child should this prove to be the case. At this time, the
risk of transmission to their offspring was felt to be high (Minkoff etai 1987),
but results from prospective studies were not available. Centres which
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reported high rates of vertical transmission of HIV had initially
concentrated on women who had more advanced disease, and a large
proportion of those studied were black or Hispanic. The same risk
might not apply when the mother was Caucasian and had preclinical
disease. As the first cases were described only 3 years previously, and
would therefore represent children more severely affected, many
questions remained unanswered regarding the spectrum and natural
history of HIV disease in children. Guidelines did not exist for managing
children born to HIV seropositive women, and therapeutic options
were at an early experimental stage.
We therefore set out to identify women who were HIV
antibody positive and who had recently had infants or who were in
various stages of pregnancy. On 1 January 1986, a clinic was
established, which not only provided paediatric advice and medical
care for these infants, but also formed the setting for the study of
perinatal transmission of HIV in Edinburgh.
The aim of this study was to answer the following
questions:
a) What is the exact risk of virus transmission from an HIV positive
mother to her infant?
b) Are there identifiable genetic, maternal, or perinatal factors affecting
the transmission of HIV from seropositive mothers?
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c) What are the features which most readily identify those infants and
children who are infected with HIV?
d) What is the natural history of the clinical, immunological and
virological abnormalities in infants and children born to HIV positive
mothers?
e) Which (if any) of the parameters investigated give the earliest
prognostic indicators for disease progression in the infected children?
f) What are the therapeutic options available, and what is their role in
the management of the infected children?




REVIEW OF THE LITERATURE
1 Epidemiology of AIDS
The Acquired Immunodeficiency Syndrome was first described
in mid 1981 when 5 cases of Pneumocystis carinii pneumonia in
previously well homosexual men in Los Angeles, and 26 cases of
Kaposi's sarcoma in New York and Los Angeles were reported to the
CDC. (cdc 1981 [a], cdc 1981 [b]). All these patients had in common an
acquired defect in cell mediated immunity which predisposed them to
rare tumours and opportunistic infections (Gottlieb et ai 1981, Masuretai 1981,
siegaietai 1981, Hymes et ai 1981). However, it is now recognised that sporadic
cases occurred before this time, as early as 1959 (Nahmiasetai 1986, corbittet
ai 1990, Humineretai 1987, Froiandetai 1988). Although the first cases reported
were in homosexual or bisexual men, a similar spectrum of disease
was found to involve haemophiliacs (cdc 1982 m) and transfusion
recipients (cdc 1982 [b], curran et ai 1984). Intravenous drug users (one third of
whom are women) were also implicated (cdc 1983 [a], Ginzburg 1984), and
also heterosexual partners of those with or at risk from AIDS (cdc 1983 m,
Pitchenik et ai 1983, Harris et ai 1983). This raised the possibility of spread among
sexually active women of child-bearing age, and therefore of spread to
their offspring. Affected infants and young children were soon
discovered, some of whom had received blood products (Ammannetai
1983), but in the majority, their mothers were in high risk groups (cdc 1982
[c], Ammann 1983, Joncas et al 1983, Oleske et al 1983, Buck et al 1983, Thomas et al 1984, Rubinstein
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et al 1983, Scott et al 1984, Cowan et al 1984, Vilmer et al 1984).
At this time the aetiology of the syndrome was unknown. The
epidemiology of AIDS suggested that its transmission was akin to
hepatitis B, through blood and blood products, and sexual contact,
and so the search for a transmissible agent, most likely to be a virus,
commenced. In 1983, a type C RNA retrovirus tropic for T lymphocytes
was isolated from a patient with symptoms and signs preceding AIDS
(Barre-sinoussi et ai 1983). This virus was variously called the Human T-cell
Lymphotrophic virus Type III (HTLV III), AIDS Related Virus (ARV) and
Lymphocyte Associated Virus (LAV) (Barre-Sinoussi et al 1983, Broder&Gallo 1984),
and could be cultured from peripheral blood lymphocytes, lymph
nodes, semen, and saliva of patients with either ARC or AIDS (Gaiioetai
1984, Zagury et al 1984, Ho et al 1984, Groopman et al 1984). Over 90% Of these patients
were found to have antibody to the virus, compared with less than 1 %
of healthy individuals or patients with other immunosuppressive
diseases (Gaiioetai 1984,samgadharanetai 1984). In May 1986, the International
Committee on the Taxonomy of Viruses agreed that the virus should
be called HIV - the human immunodeficiency virus.
Throughout the world, three broad patterns of HIV have been
described by the WHO (Chin &Mann 1988). In North America, Western
Europe and Oceania, the primary groups affected are homosexual
men and intravenous drug users; extensive spread of HIV began in the
late 1970s/ early 1980s. There are not many paediatric AIDS cases in
these areas as heterosexual spread, although increasing, accounts for
a relatively small number of new infections. However, in sub-Saharan
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Africa and some parts of the Caribbean, extensive heterosexual spread
began in the mid- to -late 1970s, and so perinatal transmission of HIV
is a major problem. HIV was introduced into Asia, Eastern Europe,
North Africa and the Middle East in the early to mid 1980s, and
although spread is occurring, there is no clearly predominant mode of
transmission, and the prevalence remains low. However, in some
countries this situation is changing rapidly (Chin 1990). In Eastern Europe,
the incidence of perinatal transmission may be low, but spread has
occurred extensively among children in hospitals and other institutions
through repeated use of needles, where disposable equipment is
Unavailable (Anon, Wkly Epidem Rec 1990, Patrascu et al 1990, Rudin et al 1990).
The incidence of AIDS is increasing worldwide, with more than
263,000 cases from over 160 countries reported to the World Health
Organisation. Nearly half of these cases were reported to the Centers
for Disease Control from the USA. Cases from sub-Saharan Africa are
probably under-represented due to difficulties in reporting, and so this
figure grossly underestimates the true total (who Global statistics 1990). The
WHO estimates that during the first decade of the HIV pandemic there
were about 500,000 cases of AIDS in women and children, most of
whom were unrecognised (Chin 199®. As the disease in children carries a
5 year mortality of 80%, the medical, public health and psychosocial
implications are profound.
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2 Pathogenesis of HIV
HIV belongs to a sub-family of human retroviruses known as
lentiviruses, characterised by possession of a large genome,
containing several viral genes, the ability to induce cytopathic effects in
infected cells, causing disease with a long incubation period, and
resulting in immunological disorders and neurological disease (Levy 1986).
The basic structure of the virus is shown in fig 1.2.1. Infection of T
lymphocytes bearing CD4 is well recognised, but HIV can be cultured
from macrophages, microglia and oligodendrocytes in the brain, and
other cells in the skin, gastrointestinal tract, and elsewhere (Levy 1989).
The life cycle (fig 1.2.2) begins with attachment to a specific cell surface
receptor, commonly the CD4 molecule. Fusion of viral and cell
membranes then occurs, releasing core virion into the cytoplasm. Viral
reverse transcriptase synthesises double stranded DNA, which
integrates into the cell chromosome. Then follows a latent phase,
where there is little or no expression of viral gene products. The final
phase of the cycle is initiated when viral replication is stimulated. The
viral RNA and viral proteins are synthesised, and the progeny is
produced at the cell surface by budding.
The subsequent depletion in numbers of CD4 + lymphocytes is
not only caused by death of infected cells, but is also due to cell-to cell
fusion, forming multinucleated giant cells or syncytia, composed of
both infected and non-infected cells (Folks etai 1987). These then develop
ballooning cytoplasm and die. Abnormal cellular immunity results not
only from the CD4+ lymphocyte depletion, but also by qualitative
21
defects in T cell function (Bowenetai 1985), and in children, the reduced
CD4/CD8 ratio is partly due to an increase in CD8+ (suppressor T)
lymphocytes (Oleske et al 1983, Rubinstein et al 1983, Scott et al 1984). In Vitro
abnormalities in lymphocyte proliferation after mitogen and antigen
stimulation can be demonstrated in some HIV infected children, but
normal responses are also seen (Rubinstein et al 1983, Ammann & Levy 1986). In
addition to CD4 + lymphocyte dysfunction, humoral immunity is
abnormal in most HIV infected children (Bernstein et ai 1985). Raised serum
IgG, IgA and IgM due to polyclonal B cell activation occurs commonly
(Ammann 1985, zoiia-Pazner 1986), but panhypogammaglobulinaemia has also
been described (Maloneyetal 1987, Pahwaetal 1987, Espanol et al 1987). Even When
serum immunoglobulin levels are raised, there is impaired antibody
production (Laneetai 1983). It is likely that other direct and indirect effect of
the virus contribute to the immunopathology. The immunological
response of the host may result in cytotoxic T cells attacking both
virus-infected and uninfected cells (siiiciano et ai 1988). Production of
autoantibodies may also contribute to some disorders, such as
immune thrombocytopoenic purpura.
Neurological disease is common in AIDS, both in adults and
children. In the context of immunodeficiency, CNS infection due to
conventional and opportunistic pathogens might be anticipated, which
together with CNS lymphoma and cardiovascular accident are found in
15% of children with neurological deficit (Beiman etai 1988). The majority,
however, develop primary HIV encephalopathy. It is likely that
migration into the brain of HIV infected macrophages occurs early (wiiey
et ai 1986), and infection of brain endothelial and glial cells may occur in
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the majority of patients. After a latent period, reactivation and
expression of HIV antigens may lead to the inflammatory cell invasion
of the CNS which has been observed. Macrophages probably carry
additional virus into the brain and lead to further dissemination (Epstein, et
ai 1988 [a]>. HIV infected macrophages also produce TNF, which has
been demonstrated to be toxic to oligodendrocytes in vitro (Seimaj & Raine
1988). Elevated serum levels of TNF have been shown to be associated
with progressive encephalopathy in children with AIDS (Mintzetai 1989),
and it may that TNF provides the link between HIV-1 infection,
inflammation, and the white matter damage seen in progressive
encephalopathy.
The similarity between the myelopathy associated with HIV
infection and subacute combined degeneration due to vitamin B12
deficiency has led to the search for disorders of methylation within the
CNS. HIV infected children with neurological complications have low
CSF S-adenosylmethionine concentrations which could be the result
of interference with folate metabolism limiting the availability of methyl
groups for myelin synthesis (Surteesetai 1990). The low methylation ratio is
found even in patients who are B12 and folate replete, and may occur
from a very early stage of HIV infection (Keating et ai 1991).
Other strains of HIV directly infect the epithelial cells in the bowel
and HIV infected lymphocytes and macrophages may also be found
within the gut wall (Editorial, Lancet 1989), resulting in chronic diarrhoea and
malabsorption. Mucosal immunodeficiency may also lead to bacterial
overgrowth of the gastrointestinal tract, with alteration in the normal
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flora (McLoughiin et ai 1987). As is the case in CNS disease, toxic cytokines











3 Laboratory diagnosis of HIV infection
In 1985 an enzyme linked immunosorbent assay (ELISA) using
disrupted whole HIV virus as the antigen was developed to detect
antibodies to HIV (Weiss etai 1985), and is the basis of screening. Despite
tho hinh lo\/ol r\f ccknci+iwi+w onrl er^r»ifioi+\/ nf tho ov/oiloHIck dl IQAe /n ;nL-Li IV-/ I ll^l ■ IV/ W Wl V-» I UUI lOIVIVIVjf V-*l I V/4 Vj^v/v/lliv/ivjf Wl VI IV/ U V UIILtUIV/ I \s_» ^nccon 1 r\
etai 1986), problems with false positives will occur when screening a low
risk population (Sivak & warmser 1985). A positive result must therefore be
verified by being repeatedly reactive, and by another test, such as
Western blot, or immunofluorescence assay must also be positive (cdc
1987 [a]). Western blots of sera from the majority of infected individuals
display bands corresponding to most of the major HIV structural
proteins, and for a test to be unequivocally positive, antibodies must
be reactive with multiple bands, ie, p24, p31 and either gp41 or gp160.
If fewer bands are present, the test is considered indeterminate (Busch
1988). Only if no bands are present is the test considered negative. An
indeterminate pattern in ELISA negative individuals is common,
however, and does not correlate with the presence of HIV 1 (Genesca et al
1989). The place of the Western blot as the 'gold standard' for other
assays has therefore been increasingly disputed (Mortimer 1991).
Even if an ELISA with 100% sensitivity were developed, there
would still be a 'seroconversion window' following exposure to the virus
before production of detectable antibody. In most adults, exposure to
the virus is followed within 3-6 weeks by prolific replication of virus.
Antibodies can be detected within 2 or 3 months, and the level of
circulating virus falls subsequently (fig 1.3.1). Antibody levels detected
27
by ELISA and Western blot remain high thereafter. With disease
progression, antibody to core antigens may decline, and the
concentration of virus in the plasma rises (Aiiain etai 1987). However, two
other patterns have been described (Haseitine 1989). Very rarely, a
previously seropositive person may lose antibodies detectable by
ELISA and Western blot (fig 1.3.2), but proviral DNA may be detected
in lymphocytes by PCR (Loche & Mack 1988). Fig 1.3.3 shows a third pattern
where it is possible for the infected person to remain seronegative for a
prolonged period of at least 35 months following initial infection (imagawa
etai 1989). As yet there have been no reports of vertical transmission
occurring during this period and the degree of infectivity remains
unknown. It must be emphasised that patterns 2 and 3 are uncommon,
and in a study, modelling cases of HIV infection with known exposure
in published reports, the median time from exposure to antibody
detection was 2.1 months, 95% of cases seroconverting within 5.8
months (Horsburgh et al 1989).
In children born to HIV seropositive women, the diagnosis of
HIV is complicated by the presence of transplacental^ acquired
maternal HIV antibody which may take up to 18 months to clear (ecs
1988), and also by the more unpredictable response of the immature
immune system to HIV infection. Positive HIV antibody is therefore is
only useful diagnostically after this age. HIV infected children who are
negative for HIV antibody have also been described(Pahwaetai 1986,
Borkowsky et ai 1987). Anti HIV IgM testing is of low sensitivity and specificity
(Parry & Mortimer 1986). Further information has been sought by looking at
the pattern of anti HIV IgM and IgG sub-classes in children at risk of
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HIV infection (Kwang et ai 1987). An alternative to these methods has been
to demonstrate in-vitro production of HIV specific IgG by peripheral
blood lymphocyte cultures from children at risk of infection (Amadori et al
1988).
Assays for the direct detection and quantification of specific HIV
antigen (primarily HIV core protein)have been developed and HIV Ag
can be detected in the plasma of HIV infected individuals (Langeetai 1986).
Studies in adults have shown that in primary infection, detection of HIV
Ag may precede HIV antibody (von sidowetai 1988), although this is not
such a consistent feature of asymptomatic seroconversion (Aiiain etai
1987). Subsequent disappearance of HIV Ag may be due to a low level
of virus replication or to the formation of immune complexes after the
initial antibody response. Reappearance of detectable HIV Ag together
with a decline in HIV anti-core antibody levels is associated with
progression of clinical HIV disease (Attain etai 1987). A larger proportion of
asymptomatic children than adults have persistent antigenaemia
(Borkowsky et ai 1989). While this might reflect a different balance between
active and latent HIV infection in children (Langeetai 1986), persistent
antigenaemia has been reported to be associated with disease
progression and a poor prognosis (Epsteinetai 1988 [b]>. Although cross
sectional studies have now been undertaken (Eiiaurie & Rubinstein 1991), at the
outset of our study no reports were available on the course of HIV Ag
and p24 Ab levels in children over periods longer than 2 years for
correlation with the progression and clinical symptomatology of HIV
infection.
29
Because of the limitations of serological diagnosis, methods
have been developed to detect virus or viral components. HIV can be
isolated from peripheral blood mononuclear cells (Griffith 1987). Since their
initial development, techniques have improved, so that in a recent
study of over 100 seropositive subjects, HIV was isolated from 100% of
symptomatic, and 87% of asymptomatic patients, with all 85
seronegative controls proving culture negative (uirichetai 1988>. In children,
a positive result is useful, but HIV cannot be isolated from the
peripheral blood of all infected children (Cowan etai 1988).
The polymerase chain reaction is an in vitro method of
selectively amplifying specific DNA sequences (saikietai 1985, saiki etai 1988).
It has been used successfully to detect the presence of HIV pro-viral
DNA in the peripheral circulation of HIV infected individuals (Kwoketai 1987,
ou et ai 1988). In adults, PCR may allow detection of HIV infection prior to
seroconversion (Hewlettetai 1988) and has been reported to detect latent
Seronegative infection (Farzadegan et al 1988, Pezzellaetal 1989, Imagawa et al 1989). The
application of PCR has also enabled the earlier diagnosis in children
(Laureetal 1988, Rogers etai 1989, Edwards et al 1989). This technique Still requires
further evaluation, however, as it is at present a research tool with
problems of contamination and standardisation.
Other laboratory abnormalities, such as
hypergammaglobulinaemia or abnormal CD4 count may also suggest
the diagnosis of HIV infection in children at risk (cdc 1987 m). The
European prospective study indicates that raised IgG, A, or M at 6 and
12 months of age is 77% sensitive, and 97% specific for HIV infection.
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Although the CD4/CD8 ratio is specific, at this young age it lacks
sensitivity (ecs 1991). At present, the infection status of children under 15
months who retain maternal antibody but have no other evidence of
infection remains indeterminate (cdc 1987 [b». Prospective follow-up of
children to determine what are the early symptoms, signs and
laboratory criteria most indicative of infection is therefore required.
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4 Vertical transmission of HIV
In the majority of HIV infected children, the virus has been
transmitted from mother to child (Rogers etai 1987). By the end of 1990, 83%
of all AIDS cases less than 13 years of age had mothers at risk of HIV
infection (WH01990). Five percent were haemophiliacs, and a further 10%
had received blood products, but screening of blood has now reduced
almost to zero the incidence of new cases transmitted in this way. The
continuing risk to the paediatric population is therefore largely through
vertical transmission.
Although vertical transmission of HIV is now well documented
(Sprecher et al 1986, Lapointe et al 1985, Jovaisas et al 1985), the exact risk has not yet
been quantified. Rates of transmission appear to vary from 6.9-65%,
depending on the inclusion criteria and duration of the study, as well as
methods used to define paediatric HIV infection (Moketai 1987, Moketai 1989
[a], Blanche et ai 1989, ecs 1991, Minkoff etai 1987). Higher rates were reported in
early studies when identification of cases depended on the observation
of clinical disease in the mother or affected sibling (Scottetai 1983), but
variation still remains in prospective studies (Moketai 1989 [a], ecs 1991, Ryder et
al 1989).
Previous studies have suggested that pre-term labour (Goedertetai
1989), chorioamnionitis (Maynardetai 1990), and advanced maternal disease
(Hiraetai 1989, Ryder et ai 1989) may increase the risk of transmission, but clear
evidence is lacking. High titre antibodies in maternal serum to portions
of the envelope glycoprotein gp120 are reported to be protective by
33
some groups, (Goedert et al 1989, Rossi et al 1989, Devash et al 1990) but Others have
failed to substantiate these findings (Parekh etai 1991). At the time of this
study there were no reports relating time of maternal seroconversion to
risk of transmission.
It has been suggested that HIV infected individuals are more
infective at the time of seroconversion and in the later stages of the
natural history of HIV infection (May 1988, Lagaetal 1989, European Study Group 1989).
This could well be true of vertical as well as for heterosexual
transmission. Furthermore, although it was initially suggested that
pregnancy was a factor possibly leading to a more rapid progression
of HIV disease (Schoenbaum et al 1987, Biggaretal 1989), Subsequent data has
suggested this not to be the case (Seiwyn et ai 1989, Maynard et ai 1990). There is
little long term post-delivery data on the effect of bearing an infected
child on prognosis for its mother.
The variation in transmission rates reported between different
cohorts, and the variable course of HIV disease may in part be a
reflection of individual differences in genetic susceptibility. Several
studies have associated HLA specificities with aspects of HIV infection.
Examples include HLA-B35 and progression from lymphadenopathy
syndrome (CDC stage III) to AIDS in subjects infected predominantly
from intravenous drug use (Smeraldi et al 1986, Smeraldi et al 1988): HLA-DR5 with
HIV-associated Kaposi's sarcoma (Poiiacketai 1983, Prince etai 1984) and
thrombocytopoenia (Rattouxetai 1987) in homosexuals; and HLA-DR3 with
disease progression in haemophiliacs (steei et ai 1988, Kasiow et ai 1990, Fabio et ai
1990) but not in a predominantly homosexual population where the
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opposite trend was apparent (Kuntz Bruster 1989). In addition to individual
specificities, the combination or haplotype HLA- (A1, B8, DR3) has
been associated with susceptibility to infection and relatively rapid loss
of circulating CD4 + lymphocytes (Steel et al 1988, Kaslow et al 1990, Cameron et al
1990).
In principle, HLA phenotype might influence disease
susceptibility in utero, or, amongst those infected, influence disease
progression in infancy. However, children of HIV-infected mothers had
not previously been studied in relation to tissue type.
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5 HIV infection in children
During the first half of the 1980s, much information about AIDS
in children became available, with detailed descriptions of the
syndrome by Oleske et al 0983), Scott et al (1984) and Rubinstein et al
(1983). Because the syndrome was initially described before the cause
was known, the nomenclature can be confusing. The initial
requirement by the CDC for a diagnosis of AIDS in children less than
13 years was for a documented opportunistic infection or AIDS
associated malignancy in the absence of underlying primary or
secondary immunodeficiency (cdc 1984). Lymphocytic interstitial
pneumonitis (LIP) was included as a diagnostic criterion in 1985 (table
I, Appendix I)(cdc 1985). In 1987, after more experience of HIV infection
had been gained, and laboratory techniques for diagnosis improved,
the definition was revised (table 2, Appendix Occdc 1987 [c]). It is
anticipated that this revision will have a substantial impact on future
AIDS surveillance trends (stehr-Green et ai 1988), and some children with a
previous diagnosis of ARC are now classed as AIDS (Faiioon etai 1989). It is
therefore important when reviewing data on AIDS in children to know
which definition was used. Because of the reliance on the availability of
laboratory information for the revised definition, its use is limited in
areas such as rural Africa. The WHO has therefore developed a clinical
case definition for use in such circumstances (table 3, appendix I)(who
1986). In practice, although its specificity is high, the sensitivity and
positive predictive value has been found to be low, and further
amendments have been suggesteddepageetai 1989).
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Not all children with HIV infection meet the criteria for AIDS. For
those who do not, HIV infection cannot be diagnosed on clinical
criteria alone (table 4, appendix I) (cdc 1987 [b]>. In the early stages when
signs and symptoms are non-specific, a diagnosis of HIV infection
based on clinical evidence alone is especially unreliable but laboratory
tests may also be unhelpful. The child's infection status therefore
remains indeterminate. To enable data collection on the incidence of
various ciinical manifestations, CDC has devised a classification
scheme, reproduced in table 5, appendix I. (cdc 1987 [b]). All references
to clinical stage of the study children will be made according to this
classification.
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6 Natural history of paediatric HIV infection
HIV infection may be evident from birth, (Marion et al 1986), and in
1986, 50% of children with AIDS were diagnosed during the first year of
life, and 82% by 3 years of age (cdc 1986 [a]). The European Collaborative
Study reported in 1991 that by 12 months, 26% have AIDS, and 17%
die of HIV-related diseasetEcs 1991). The mean age at diagnosis has
appeared to increase over time, maybe because those with mild or
asymptomatic disease had previously remained undiagnosed. The
onset of AIDS has been delayed over 7 years in some children (Keiiy etai
1987), but in general, it is thought that the incubation period is shorter in
children than adults, and in congenital than transfusion-acquired
infection (Rogers etai 1987, Medley etai 1987). Clinical evidence of infection is
unreliable in the early stages when signs and symptoms are non¬
specific (cdc 1987 tb]). The inclusion of control children in prospective
studies of children at risk of HIV infection is therefore essential, if
clinical and laboratory parameters are to be evaluated. No previous
study of mother to child transmission of HIV had included such a
control group.
Respiratory symptoms are common in the
immunocompromised child, and Pneumocystis carinii is an important
pathogen which must be considered in the differential diagnosis. In
HIV infected children, it is the chief opportunistic infection, occurring in
29% of AIDS cases reported to the CDC up to the end of 1990 (cdc 1991),
and in over 50% if children progressing to AIDS in the first year of life
(Oxtoby 1990, Scott et ai 1989, Krasinski et ai 1989). Characteristic radiological
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appearances are of diffuse reticulogranular infiltrates, particularly in the
perihilar region, progressing to consolidation, but a normal chest X ray
is compatible with the diagnosis (Barter 1987). Cytomegalovirus or
mycobacteria infection, candidal pneumonia and bacterial sepsis may
produce similar findings. Definitive diagnosis has previously relied on
the demonstration of silver staining cysts in material obtained from
open lung biopsy or bronchio-alveolar lavage, requiring an invasive
procedure in an acutely ill child (woiff etai 1977, deBiicetai 1987). Sputum
induction (zamanetai 1988) in infants and small children is not a practicable
technique, and serology is unhelpful (Wiiiiford pster et ai 1988). Non-invasive
methods of identification of Pneumocystis carinii therefore require
development.
Although effective antimicrobial therapy exists, the mortality
from PCP in infancy remains high (Bernstein et al 1989, Vernon etal 1988).
Guidelines for primary prophylaxis for PCP in adults are well
established (cdc 1989). However, CD4 counts are normally higher in
infants than in older children and adults, and PCP commonly occurs in
infants with CD4 counts higher than the 200x106/l recommended in
adults for commencement of primary prophylaxis (Leibovitz et al 1990, Kovacs et
ai 1991). Different guidelines according to age have therefore recently
been produced (cdc 1991). These guidelines are summarised in Table 6,
appendix I, and the recommended regimens for chemoprophylaxis in
table 7, appendix I. The implications of these guidelines for the
management of infants whose HIV infection status is still indeterminate
are yet to be explored.
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Respiratory infections may also be caused by viruses such as
CMV and measles which may cause disseminated infection in these
Children (Pahwa et al 1986, Rubinstein et al 1986, Joshi et al 1985, Markowitz et al 1988). The
natural history of respiratory infections in HIV infected children due to
other viruses common in the paediatric population has received little
attention, and requires further study.
Children commonly present with recurrent bacterial infections
(Scott etai 1984, Bernstein et ai 1985 [a]), and defective humoral immunity has been
demonstrated (Bernsteinetai 1985 [b]>. Even in the presence of
hypergammaglobulinaemia, patients develop symptoms and signs
similar to those suffered by children with primary
hypogammaglobulinaemia. Hence passive immunisation in the form of
intravenous immunoglobulin has been reported to be of benefit (Caivein &
Rubinstein 1986, oieske et ai 1987). At the time of our study, no controlled trial of
treatment with IVIgG had been carried out.
In HIV infected children, serum levels of IgG, IgA and IgM are
typically raised (Amman 1985), and can be 3 or 4 times the upper limit of
the normal range. It has previously been reported that a polyclonal
hypergammaglobulinaemia may be associated with a raised serum
viscosity in very rare cases (reviewed in Martin etai 1989), but no report of
symptomatic hyperviscosity has previously been documented in HIV
infected children.
Present therapeutic options for HIV infected children are
otherwise limited to treatment for specific infective episodescroung 1987),
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and to zidovudine. Since zidovudine was shown to have in vitro activity
against HIV in 1985 (Mitsuyaetai i985) and later to decrease the frequency
and severity of opportunistic infections, and the mortality rate in adults
with advanced HIV disease (Rschietai 1987), much experience on the use
of this drug has been gained. In children, early experience based on
continuous intravenous infusion demonstrated clinical improvement,
particularly in neurodevelopmental abnormalities and in weight gain
(pizzoetai 1988 [a], Blanche etai 1988). Pharmacokinetic studies have shown that
continuous infusions are more effective in maintaining a virostatic
plasma level of 1umol/l than bolus doses and that on an oral regimen
of 720mg/m2/day in 4 divided doses, this plasma level is maintained
for less than half the day (Bans et ai 1989 [a], [t>]). It is unclear whether this is
important clinically, and if zidovudine is to be available to the large
number of affected children, an oral regimen is the only practicable
method of delivery. Data on the efficacy of this drug when given on a




1 Organisation of the study
Subjects
The study aimed to identify all infants born to HIV seropositive
women within Lothian Region: these infants comprised the index
group. Referrals were made by staff in the adult clinics, obstetricians,
midwives, neonatal paediatricians, general practitioners, social
workers, and health visitors upon discovery of a pregnant woman, or
mother and infant, considered to be at risk of HIV infection. As a
control group, infants whose fathers were HIV seropositive, but whose
mothers remained HIV seronegative were enrolled. These mothers
were tested after self-identification of high risk activities, and belonged
to similar socio-economic groups as mothers testing positive. As
additional control material, cord blood from HIV seronegative women
with a history of intravenous drug use was obtained, but these infants
were not subsequently followed. From the time of my appointment as
research fellow, I saw the women in the antenatal clinics where the
purpose and nature of the surveillance was explained, after which
maternal consent was sought. I was also present at delivery to collect
cord blood, and blood from mother, to examine the infant at birth, and
to arrange future visits, either in the clinic, or at home, according to the
mother's preference.
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The study was coordinated from a paediatric HIV counselling
and screening clinic, established in January 1986 and staffed by a
consultant paediatrician with an interest in community child health (J
Mok), and from October 1987 until February 1990, by myself as
research fellow. It was held in conjunction with a similar adult clinic
supervised by a consultant in infectious diseases (RP Brettle). It initially
operated with two sessions per week, during which a health visitor was
present and, at one of the sessions, a dental hygienist also. However,
with the appointment of a full time health visitor and myself, and with an
increasing proportion of the mothers wishing to be visited at home, a
more flexible service developed.
In order to study the natural history of HIV infection a further 6
HIV infected infants born to HIV seropositive women were identified.
Two (cases 6 and 7) were born and identified in Tayside were referred
to the Edinburgh clinic where their subsequent surveillance and
management were undertaken. A family in the west of Scotland (cases
8-10) and one child in Newcastle (case 11) were identified and
supplied with IVIgG from the Scottish National Blood Transfusion
Service. I visited these children every 3 months, carrying out the same
surveillance protocol used for the Edinburgh children. They continued
to be under the care of the local paediatrician. I also undertook the
surveillance and care of one child (case 13) infected with HIV through
a blood transfusion in Edinburgh who was receiving IVIgG, using the
same protocol. This child was cared for by Dr. J. Mok and Dr. O.B.
Eden.
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Surveillance procedure and data collection
All infants were seen at birth, 6 weeks, 3 months, then 3
monthly. Control children were followed for one year, after which the
option of further review was given to their parents. Those index
children who became HIV antibody negative and remained clinically
well were seen 6 monthly between ages 2 and 5, and yearly thereafter.
At each visit, a history was taken of the child's health, with particular
reference to any infective episodes, and visits to the GP. The health
visitor assessed development by means of the Denver Developmental
Screening Test, after which the infant was examined. Measurements
made included weight, head circumference and length (or height).
Nose and throat swabs were taken, and placed together in viral
transport medium. Peripheral blood was taken for virology (HIV
antibody, antigen, virus culture, and PCR), immunology
(immunoglobulins, lymphocyte subsets) and haematology (full blood
count with differential and platelet count). Immunisation procedures
were discussed, and index children were usually immunised by us,
according to the standard time schedule. At that time, DPT or DT was
given with polio vaccine at 3, 6 and 9 months, and measles (or latterly
MMR) at 15 months. Killed polio vaccine (Salk) was given to the
children early in the study, but with further experience of the lack of
documented adverse sequelae after the administration of oral polio
vaccine, and the difficulty in obtaining Salk vaccine, oral polio vaccine
was administered to all infants whose mothers did not show evidence
of severe immune compromise.
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Data on the outcome of the infants who were indeterminate at
the completion of my research fellowship, and on the HIV infected
children who continued to be followed in Edinburgh thereafter was
supplied by Dr. J. Mok and Dr O.B. Eden (case 13). I have continued
to follow case 9 according to the same protocol on a 3-monthly basis.
Whenever possible, the mother was reviewed clinically by an
obstetrician (FD Johnstone) and a physician (L MacCallum) during
each trimester of pregnancy and at delivery, and blood was tested.
Thereafter, she had the option of seeing an adult physician at the same
visit as the child. Families seen at home were given a separate
appointment for mother to be reviewed every three months. In those
infants identified after birth, retrospective review of mother's obstetric
notes was undertaken and, with maternal consent, stored maternal
serum tested for HIV antibody and antigen. Maternal seroconversion
date was calculated as the mid-point between the last HIV
seronegative and first HIV seropositive sample available. For those in
whom no HIV antibody negative sample could be obtained, the mid¬
point between the date of first possible exposure to HIV and first HIV
seropositive sample was taken.
Further management
When infants developed symptoms and signs, either of HIV or
other intercurrent infection, they were referred for review to the
paediatric team, either by the general practitioner, or by their parents
directly. When required, in-patient facilities were available at the
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Regional Infectious Diseases Unit of the City Hospital, Edinburgh,
where their care continued to be under our supervision.
Children were treated with IVIgG on the basis of a history of 2 or
more episodes of bacterial pneumonia, a 3 month history of recurrent
or chronic upper respiratory tract sepsis and/or diarrhoea, or
symptomatic thrombocytopoenia, with laboratory confirmation of HIV
infection, infusions were given 3 weekly with 200mg/kg of IVIgG
supplied by Scottish National Blood Transfusion Service on a hospital
day patient basis according to a protocol originally devised for the
treatment of primary hypogammaglobulinaemia (Leenetai 1986), . The first
infusion was commenced at a rate of 0.6ml/kg/hr, and in the absence
of adverse reactions, this was increased to 2.4ml/kg/hr. This IVIgG
preparation consists almost entirely of IgG with a normal distribution of
IgG subclasses.
As a pilot study, plasma was obtained by plasmapheresis from
donor 11 selected during a previous study by Jackson et al (Jackson et al
1988) for high serum titres of anti p24 and neutralising antibody and
treated as previously described. Titres of anti p24, anti p41 /gp120 and
neutralising antibody, were measured, but not antibody to the
hypervariable loop. Plasma was then infused in patients 6 and 8 at a
dose of 2ml/kg every 6 weeks initially, increasing to 3 weekly after 3
infusions in case 6.
Zidovudine was given orally to 6 children who developed AIDS
defining infections (case 8), neurological disease (cases 11 and 13), or
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whose absolute CD4 count declined (cases 1,2,6,). All were
commenced on 14 mg/kg/day in 3 divided doses, but with further
experience in the literature, changes were made subsequently to a
dose range of 300-600mg/m2/day. At first the intravenous
preparation was given orally, but latterly, a paediatric suspension was
prescribed.
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2 Recording and storage of data
Those infants and mothers identified before birth were entered
into the European Collaborative study, and a standard proforma for
recording data on these children was used as a basis for data
recorded on all the children studied, with some additional information
also being recorded on the form. Samples of the forms used are
included in appendix IV. All data collected since the initiation of the
study in 1986 were entered and stored initially on an Atari computer by
me using a programme based on DBase III. Latterly an IBM PC
compatible system using Dbase IV was used.
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3 Laboratory methods and statistics
Samples were analysed by those colleagues acknowledged
above. Peripheral blood counts were measured using an automated
Coulter technique, with differential leucocyte count performed from a
blood film. From October 1987, lymphocyte subsets were measured
by flow cytometry (Becton-Dickinson). Absolute numbers of
lymphocyte subsets were calculated using as denominator the
absolute lymphocyte count obtained manually from the blood film.
Immunoglobulins were determined by laser nephelometry.
Serological tests
HIV antibody was measured using an antiglobulin enzyme
immunoassay (Abbott Recombinant HIV 1 EIA) followed by a
competitive enzyme immunoassay (Wellcozyme). The first sample
obtained from a subject and found to be a positive result was
confirmed by Western blot. HIV Ag was measured by quantified
enzyme immunoassay (Abbott, UK), and expressed as pg/ml, using
the standard supplied by the manufacturer with an assay cut-off of
3pg/ml. P24 Ab was measured using the Abbott HIV 1 anti-core
enzyme immunoassay. A quantitative value, expressed as p24 Ab
index, was derived by dividing the optical density value of the sample
tested by the cut-off value, and subtracting this from 1.0 (1-{OD
sample/OD standard serum}). Thus the higher the value, the greater
the competition (and amount of p24 Ab) in the sample. Zero values
indicate lack of antibody.
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Lymphocyte culture for HIV isolation
From October 1987, venous blood specimens were collected in
preservative-free heparin, and PBMCs were separated over
Ficoll/Hypaque using a standard technique. They were then cultured
in RPM11640 medium containing 2% penicillin/streptomycin, 10% FCS
and 80 units/ml interleukin-2 (Dupont). Cell culture supernates were
tested at weekly intervals for 4 weeks for the presence of HIV Ag using
an antigen capture assay (Dupont). The levels of p24 Ag attained in
culture and the time of appearance were recorded. A sample was
considered negative if HIV Ag was not detected after 4 weeks'
incubation.
Polymerase Chain Reaction (from P Williams et al 1990)
From September 1988, PBMCs were separated from blood
samples collected in EDTA over Ficoll-Hypaque, washed once on
normal saline and the cell pellet was stored at -20°C for up to 12
weeks. The DNA from the cell pellets was extracted and 1 ug aliquots of
DNA (equivalent to 150,000 cells) were used for each PCR. PBMCs
from 5ml samples of EDTA anticoagulated donor blood were handled
identically to serve as controls. The preparation of cell pellets, DNA
extractions and PCRs were performed on donor and paediatric blood
samples concurrently, in order to be able to detect any cross-
contamination during each experimental stage.
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A double PCR was performed whereby each DNA sample
studied was amplified with four pairs of outer primers, and 1 microlitre
aliquots of the PCR product were then further amplified with each of
the corresponding inner primer pairs in four separate second PCR
arnplifications(Simmondsetai 1990). The products were analysed by agarose
gel electrophoresis and the presence of DNA indicated by staining with
ethidium bromide. Samples were scored as positive or negative by the
presence of a DNA band of the appropriate molecular weight in the
product of the second reaction. With the double PCR, negative
samples do not produce visible bands. Because of the high yield of
DNA from all positive samples, each reaction therefore yields a clear
positive or negative result.
Tissue Typing
Blood samples were immediately added to heparin (25 units/ml
blood), mixed and warmed to 37°C. Carbonyl iron powder (20mg/ml
blood) was added, and the mixture placed in a 37°C water bath for 30
mins with occasional shaking. The sample was then placed on top of a
strong magnet for at least 15 min before the upper 90% was removed.
Lymphocytes were isolated by density gravity centrifugation on
Ficoll/hypaque as described by Boyum (1976).
Lymphocytes were washed and resuspended in RPMI at a
density of 1.5x106/ml. HLA A and B antigen was performed using a
standard microcytotoxicity test (Mittai 1978). Briefly, 1 microlitre of
lymphocyte suspension was incubated for 30 min with 1 microlitre of
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each antiserum in wells of Terasaki trays, then a further 5microlitre of
reconstituted rabbit serum was added as a source of complement, and
incubation continued for a further 60 min. After staining with eosin and
fixing with formalin, the degree of cell death was assessed using an
inverted microscope.
HLA DR typing was performed using an extended (1st stage 1
hour, 2nd stage 2 hours) microcytotoxicity test after enriching for B
lymphocytes by rosetting with neuraminidase treated sheep
erythrocytes (Kiipatrick & Darg 1983). The antisera used were obtained partly
from the United Kingdom Transplant Service and partly from
commercial sources. At least 3 specific antisera were used to detect
each well-defined specificity.
Respiratory virus isolation
Nose and throat swabs taken from each child were combined in
a single vial of standard viral transport containing antibiotics to
suppress bacterial growth and foetal calf serum to stabilise the virus.
The samples were transported to the laboratory within 2 hours. If any
delay was anticipated, swabs in transport medium were stored at 4°C
prior to transport. In the laboratory, cells collected on the swabs were
resuspended in a small volume of transport medium prior to
inoculation into primary baboon kidney, human epithelium cells (HEp2)
and human fibroblasts (MRC5). The inoculated cells were incubated at
36°C and examined twice weekly for evidence of a cytopathic effect.
Further confirmatory tests were carried out on cells affected. Influenza,
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parainfluenza, respiratory syncitial (RS), measles, and herpes simplex
were confirmed using monoclonal or polyclonal antibodies in a
fluorescent antibody test (Gardner & McQuiinn 1985). Adenovirus, Coxsackie
and Echo viruses isolated were identified by neutralisation tests (Hambiing
1963). Rhinovirus was identified by acid stability testing. CMV was
identified on the basis of characteristic cytopathic effect in MRC5 cells.
Statistical methods
The Atari K Graph programme was used for Student's t and Chi-
squared test of significance for parametric data, and for Wilcoxon rank
sum and Wilcoxon signed rank tests of significance for non-parametric
data as appropriate. Odds ratios and confidence intervals in chapter 4
were calculated according to Algorithm AS as described by DG
Thomas (Thomas 1971).
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4 Limitations of the Study
The chief limiting factor on all aspects of the project was the
number of women and children available to study. The study was
conceived at a time when the number of known HIV seropositive
women in Edinburgh was rising, and if the fertility rate among this
group remained constant, it might have been expected that the
number of children born to HIV seropositive women in subsequent
years would increase. Thus, given that in 1985 and 1986 11
children/year were born, it might have been anticipated that in the 30
months of the study, between 40 and 50 children would be born. The
numbers born every year, however, remained constant, so that only 30
were identified from birth over this period, and in 1991, the numbers
have, in fact dropped. With these numbers, the confidence intervals for
transmission rate would inevitably be wide. Our data have been
analysed together with 9 other European centres in the European
Collaborative Study of perinatal transmission of HIV. Although follow-
up of children had begun in 1986, some elements, such as collection
of cord blood, collection of blood from mother at delivery, tissue typing
on cord blood, and routine quantification of lymphocyte subsets only
began when I joined the project, so many details from the earlier
pregnancies are not available.
As more women were becoming aware of their HIV status either
before pregnancy, or in the early stages of pregnancy, termination
would be an option. If those women opting for termination were distinct
in any way from those continuing with their pregnancy, for instance, if
54
those women who were more clinically unwell terminated their
pregnancy, this might well affect the observed rate of transmission.
Although one woman who had already given birth to an infected child
had a termination on developing PCP in the second trimester of a
subsequent pregnancy, it has been shown that knowledge of HIV
status did not affect the decision to continue with pregnancy among
women at this timeuohnstone et ai 1990).
Universal screening of pregnant women was not practised, and
so it is possible that cases would be missed. It was hoped that good
liaison with other professionals, and screening for high risk activities,
with the offer of testing in the antenatal clinic would minimise this risk.
In 1989, voluntary antenatal screening of all women was introduced in
Edinburgh, and two mothers who may not otherwise have been
identified were diagnosed as HIV seropositive during that year. Some
mothers were not identified in the antenatal period, and children were
enrolled when they presented with symptoms or when their mothers
were later identified as being HIV seropositive. These children had to
be excluded from the calculation of the vertical transmission rate.
We aimed to identify early symptoms and signs of HIV infection
and to monitor the neurodevelopmental progress in children at risk of
HIV infection. Because many of these children came from
backgrounds of multiple deprivation, it was important to include a
control group from a similar background. The follow-up included
venepuncture and so it was only justifiable to perform this on babies
whose mothers were at risk of seroconversion (as their sexual partner
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was seropositive). The risk of maternal seroconversion was unknown,
as was the risk to the child should the mother have been in the
process of seroconversion in the latter part of the pregnancy. If the
mother remained seronegative after one year, then the risk to the child
was felt to be negligible, and most mothers refused further follow-up
for research purposes alone. Although the data generated for the first
year of life is useful, we were unable to address the question whether
those children born to HIV seropositive women who subsequently
seroreverted and were presumed uninfected were in any way
distinguishable from children not at risk of HIV. Also the number of
control children was smaller than the index group, partly because they
were less likely to be identified, limiting the power of any significant
difference that might be demonstrated. For the cord blood studies,
therefore, which did not involve venepuncture of the child, samples
were taken from additional seronegative women in high risk groups.
We employed the Denver developmental screen on routine
evaluation of the children in the study. This was chosen because of its
ease of administration, reproducibility, and suitability to be carried out
at home with simple standard equipment. It is, however, a screening
device, rather than intended for diagnosis, and it is possible that more
subtle deficits in the functioning of the children studied may have been
missed. In this, as well as the other aspects of routine assessment,
observer variation was limited by the small number of personnel
involved in the project.
Although the rate of vertical transmission of HIV in the
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Edinburgh population was unknown, available information from
preliminary studies suggested the risk to be at least 20-30% (Friediand &
Kiein 1987, Mok et ai 1987). We anticipated, therefore being able to see a
spectrum of clinical disease among at least 20 children proving to be
infected. This proved not to be the case. Therefore, in order to study
natural history and therapy, additional symptomatic HIV infected
children were enrolled from outwith the original study population.
We were aware that numbers of symptomatic children were
likely to be too small to make randomised controlled therapeutic trials
impossible to perform, and that any preliminary data generated during
the study on the effect of therapeutic intervention would require
confirmation and further exploration with much larger groups of
patients. IVIgG and AZT were used to treat symptomatic children,
which was anticipated to affect natural history of the disease. Our
results regarding morbidity and mortality rates might differ from earlier





THE VIROLOGICAL DIAGNOSIS OF VERTICALLY TRANSMITTED
HIV INFECTION
Aims
The aim of this study was to compare virological methods of
laboratory diagnosis in children at risk of HIV infection.
Patients and Methods
Patients
Seventy four children born to HIV seropositive women were
studied. Eleven (cases 1-11) proved to be HIV infected according to
the CDC paediatric classification (cdc 1987 [b]> (group 1). Sixty one were
HIV antibody negative, clinically free of symptoms that suggest HIV
disease and had normal test of immune function, and so were
presumed uninfected (group 2); 2 were indeterminate (group 3). Thirty
children born to seronegative mothers with seropositive fathers were
studied (group 4), together with samples from 45 healthy HIV 1




Samples taken at routine visits were tested for HIV 1 antibody,
HIV p24 antigen, and cultured for HIV as previously described in
section II.3. In addition, 2 ml blood samples were collected from 10
patients in group 1, 35 in group 2, 2 in group 3, 7 in group 4 and all of
group 5 into EDTA. DNA extraction and PCR was subsequently
performed.
Results
All eleven children in group 1 were consistently HIV antibody
positive, ten being over 18 months of age, whereas no child in group 4
was HIV antibody positive at any time. In group 2, maternal HIV
antibody was lost from 6-18 months, median 12. Fig III.1.1 shows the
percentage of infants positive for HIV antibody by age. The follow up of
the 61 HIV antibody negative children from the time of seroreversion
ranged from 3-60 months, (median 36). One child who seroreverted at
12 months had a positive result for HIV antibody by ELISA and an
indeterminate Western Blot at 30 months, but has remained HIV Ab
negative since. She has suffered from recurrent respiratory tract
infections, and asthma, but is otherwise well. Persistent
seroconversion after seroreversion has not been observed.
Tables III.1.1 and III.1.2 summarise the relevant clinical and
laboratory features of group 1, further details being described in
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chapters 4 and 7. Nine children have been HIV p24 antigen positive on
more than one occasion during follow-up, four before the age of 18
months. In all three children followed from birth, HIV Ag was detected
in serum before the onset of clinical symptoms Case 4 was positive for
serum HIV Ag aged 2 and 4 months, but HIV Ag was not detected in
cord blood.
Samples for HIV culture from nine children were positive on one
or more occasions. HIV was isolated in culture in 3 children who were
HIV Ag negative at the time, one of whom had never been HIV Ag
positive. Umbilical cord blood from case 4 cultured for HIV gave a
negative result, and she died before further specimens were taken. HIV
has not been isolated from repeated blood samples form case 7. No
sample from groups 2 or 3 was HIV Ag or HIV culture positive.
PCR was positive in all 10 cases tested, including case 7, four of
whom were negative for HIV Ag at the time. No sample from groups 2
(n=41), 3 (n = 2), 4 (n = 7) or 5 gave PCR positive results, compared to
all 22 of the samples from group 1.
All PCR positive samples identified in this study were amplified
using primers which span the first and third hypervariable regions of
the env gene (Aiizon et at 1986). Polyacrylamide gel electrophoresis of the
35S-labelled PCR product showed a range of length variants to be
present in each sample. Each pattern of variants was specific for each
patient, and distinct from that of a cloned HIV sequence. This excluded
contamination by sample mixing or by recombinant DNA as a cause of
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PCR positivity.
To investigate the reproducibility of this method for PCR, four
aliquots of a DNA sample from each of the PCR-positive cases were
amplified with the env 1 and env 3 primers in quadruplicate reactions.
Little variability in the pattern of amplified bands were seen. Follow-up
samples from each of the available infected individuals were similarly
tested in order to investigate the stability of the observed patterns over
time. Little variation in the pattern of bands was seen in samples
collected over periods of 3-7 months.
Discussion
Our results confer closely with those of Krivine et al (1990),
indicating that PCR and HIV culture have superior sensitivity to HIV Ag,
although HIV Ag detection is specific. In children under 18 months, HIV
Ag assay remains valuable as an early diagnostic test in assessing
children born to HIV seropositive mothers as it is readily available, and
requires very little serum. Nine of eleven infected children were positive
for HIV Ag, 6 at a time when they were either asymptomatic or had
non-specific symptoms only. Of those followed from birth, HIV
antigenaemia was the first laboratory indicator of HIV infection; cases 1
and 3 also showed a raised IgG on the same sample (as defined in
appendix III). HIV culture was not available at this time. Even children
with severe clinical disease can be HIV Ag negative, howevera.eiie et ai
1988), and so a negative result is unhelpful. Sensitivity may be improved
by pre-treatment to release antigen from immune complexes (Nishanian et
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ai 1990), but this procedure has yet to be standardised.
We observed a positive correlation between detection of HIV Ag
and virus isolation. HIV isolation may be more useful diagnostically in
identifying children negative for HIV Ag at the time of sampling.
However, it is not normally available as a routine test and requires a
much larger sample (5ml whole blood compared to 0.2ml serum for
HIV Ag), which is an important consideration for babies in the first
months of life. Also positive result are not easily quantified. Where both
tests are available, they may provide useful complementary
information.
PCR offers considerable promise for the detection of vertically
transmitted HIV infection, as the method might be capable of yielding
diagnostic results with high specificity and sensitivity at an age when
other methods of detection may not. Although this method requires
more blood than HIV Ag assay, it requires less than HIV culture, and
results are available after a shorter time (48 hours rather than 3
weeks). The possibility of contamination, even with small amounts of
maternal blood, leading to false positive results may limit its usefulness
in diagnosis from cord blood, however. In our series, PCR did not
provide a diagnosis of HIV infection in any child who did not have other
virological indices of infection, as all but one child was older than 18
months at the time of testing, and case 4 was also HIV antigenaemic
by 2 months of age. Further work is therefore required following up
children at risk of HIV infection tested with PCR in the first months of
life.
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There have been three previous reports of the use of PCR in the
diagnosis of vertically transmitted HIV infection, each using a single
PCR amplification followed by identification of the (amplified) product
with a radioactive oligonucleotide probe (Laureetal 1988, Rogers etal 1989, Edwards
etai 1989). Laure et al a988) amplified three consecutive sequences in the
gag (1) and pol (2) regions. Some samples were termed PCR-positive
even when positive results were obtained with only one or two of the
three combinations of primers used, and such results were seen in
children with proven HIV infection. A diagnosis of HIV infection based
on PCR positivity was claimed in 6 of 14 newborn infants tested, but
other laboratory confirmation of HIV infection was present in only one
of these. Also, five out of ten children aged 2-5 years were claimed to
be HIV infected on the basis of PCR positivity alone, although other
laboratory confirmation in these cases was similarly lacking, and all
were HIV antibody negative. Rogers et al 0989) amplified two HIV
sequences in the HIV p24 and HIV gp41 regions, but had a high false
negative rate, with only 6 PCR positive neonates found among 11 who
later went on to develop AIDS. Edwards et al (1989) amplified two
sequences in the gag region, but also had negative PCR results in one
child with symptomatic HIV infection.
Other workers have also failed to find a clear correlation
between indices of HIV infection and PCR reactivity. Imagawa et al (1989)
found a number of individuals who were serum HIV antibody and HIV
p24 antigen negative for several months, yet were PCR positive on
more than one occasion. Conversely, the finding of extremely low
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levels of provirus in certain individuals allows the possibility that false
negative results may occur by testing insufficient DNA. Simmonds et al
(1990) report that PBMC DNA from one seropositive individual contained
only five copies of provirus per 106 cells. Thus considerably more than
1ug DNA would need to be amplified to ensure reproducibly positive
PCR results. It is likely that patients with yet lower amounts of PBMC
provirus may be identified, and these may prove refractory to
screening using PCR during such stages of infection. This emphasises
the importance of continued monitoring of all infants born to HIV
infected mothers. In all samples in this report scoring positive or
negative, there were no discrepancies between the results obtained
with the four independent sets of primers from gag, pol, envl and
env3. The positive PCR results obtained were completely concordant
with the clinical and laboratory evidence of HIV infection in these
children. All control samples (groups 4 and 5) were PCR negative, and
no cases of latent HIV infection were detected in groups 2 and 3.
Mullis and Faloona (1987) described the use of nested primers to
increase the specificity of PCR for target sequencing. Simmonds et al
(1990) have used this technique to improve the sensitivity as well as the
specificity of this method for HIV detection and have reported the
reliable detection of single molecules of target sequence. This is
considerably more sensitive than existing methodologies. Furthermore,
the higher degree of amplification possible allows the direct
visualisation of amplified product, and also permits partial
characterisation of HIV by virtue of its strain-dependent length variation
in several regions of the env gene.
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The demonstration of different length variants of amplified DNA
is interesting. The HIV genome exhibits great diversity in nucleotide
sequence, both between isolates made from different patients, and
between multiple isolates made from the same patient over time (Aiizon et
al 1986, Starcich et al 1986, Hahn et al 1986, Saag et al 1988). In addition, Certain
segments of the region of env- encoding gp120 show extensive length
variation (Aiizon et ai 1986, starcich et ai 1986). In a separate study of HIV infected
haemophiliac patients, Simmonds et al have obtained nucleotide
sequences which confirm the existence of length variants present
within patients' samples. The pattern of variants is similarly patient
specific (Simmonds et ai 1991). Thus it has proved possible to distinguish
variants of HIV both between and within infected individuals, and to
distinguish genuine positive reactions from contamination by
exogenous HIV sequences.
The finding of different length-variant patterns in cases 8, 9 and
10 is of particular interest, as they are siblings. The different patterns
seen imply either vertical transmission of different HIV env variants to
each child, the rapid emergence of different variants within each child
(possibly due to different immune selection pressures), or both.
Unfortunately, library samples of the mother's PBMC DNA spanning
the pregnancies are not available for analysis. PBMC DNA samples
taken from haemophiliac patients over intervals of 2 years can show
considerable change in the patterns of length variants in the env 1 and
env 3 regions in some individuals, while other individuals' patterns
remain relatively unchanged (Simmonds et ai 1991). PCR positivity in case 3 is
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also of interest, as this patient is a dizygotic twin, the other twin being
presumed uninfected (group 2) and PCR negative.
Using a double PCR to amplify hypervariable regions of the HIV
genome, we have been able to diagnose vertically transmitted infection
with apparently 100% specificity and 100% sensitivity, which is not the
case in children under 18 months for any other test available. The
distinctive HIV DNA length-variant patterns observed might be usefully
exploited in further studies as a basis for the investigation of the timing
of vertical transmission, by comparing the patterns amplified from
serial blood samples taken from the mother throughout pregnancy
with those obtained from the infant at birth and during early infancy.
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TABLE 111.1.1 Clinical features of HIV infected children
Case Age* Length of Age at 1st Current stage Age progressed Symptoms
follow up symptoms to P2B-D (age)
69 69 P2A Resp. infections (6)














4(D) 4 Dead Candida (1)
PCP (4)
46 25 P1B Lymphadenopathy
(21)
Eczema (21)




76 40 33 P2A Resp infections (33)
Diarrhoea (33)




Failure to thrive (36)
76 49 12 P2C 24 Pneumonia(12)
LIP (24)
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A PROSPECTIVE STUDY OF VERTICAL TRANSMISSION OF HIV
IN EDINBURGH
Aims
To evaluate the risk of materno-foetal transmission in a group of
mainly asymptomatic women, and to investigate early features of HIV
infection which may identify those children at risk of perinatally
acquired HIV infection who prove infected.
Subjects and Methods
From 1.1.86 to 1.2.90, 68 infants were identified and followed for
a median of 44 months (range 18-70 months). The distribution of the
cohort by year of birth is shown in fig 111.2.1. Mothers of fifty eight
infants were identified in the antenatal period and 10 were referred
either subsequent to the mother's HIV antibody test being positive (9),
or because of symptoms in the child suggesting HIV disease (1).
These infants comprised the index group. Thirty infants were followed
as controls, and cord blood taken from a further 12 controls.
Results
Maternal data
Characteristics of mothers of index and control children are
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shown in table III.2.1. All were Caucasian. Mothers of 24 index infants
already knew of their HIV status, whereas 34 discovered their
diagnosis during the pregnancy. There were three sets of twins in the
index group. Six index women had two study children, and one woman
had three. There were 3 sibling pairs in the control group. Of the 57
mothers of index children, 46 were infected through IV drug use and
11 because of heterosexual contact. More index than control mothers
used drugs during and after the pregnancy, but the difference between
the two groups did not reach statistical significance. During the study
period, one woman had PCP during pregnancy and another two
subsequently died of AIDS. One index mother, and one control mother
died of drug-related causes.
During the follow up period, 14 index infants and one control
child were taken into foster care, with 4 subsequent adoptions in the
index group. 7 index and one control were in the care of grandparents,
three index children with their fathers only, and the rest were living with
their mothers. Although the majority of the women had a partner some
of these had unstable relationships in which the male partner was often
in prison or had left home. Thirty eight of the index infants were known
to have fathers who were themselves HIV seropositive.
Perinatal data
Table III.2.2 summarises perinatal data of index and control
children, with the index cohort separated into children who were
infected, and those presumed uninfected. The mean birth weight was
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significantly lower in index children presumed uninfected (95% CI
2700g-3000g) when compared with controls, (95% CI 3065g- 3484g),
and the difference remained when all children whose mothers used
drugs during pregnancy were excluded from analysis. The effect of
preterm delivery was allowed for by extrapolating preterm birth weight
to term, along the same centile of the standard Tanner chart, and index
children presumed uninfected were still significantly lighter than
controls.
All but one index infant were delivered vaginally. Neonatal
special care was required mainly for drug withdrawal symptoms and
intrauterine growth retardation. Intensive care was necessary for 2
index infants: in one because of problems arising from preterm
delivery. These consisted of meningitis with septicaemia resulting in
ventriculoperitoneal shunts for hydrocephalus. The other child
developed the respiratory sequelae of meconium aspiration. Multiple
intracardiac tumours were discovered in one index infant, which have
not caused symptoms since the neonatal period. No infant received a
blood transfusion and there were no neonatal deaths. The features of
HIV embryopathy (Marion etai 1986) were not observed in any infant.
Although hepatosplenomegaly was documented during the neonatal
period in 5 index infants, this did not persist beyond 3 months. Two




On 1.8.91, the median age when last seen was 54 months for
index infants (range 18-88 months), 18 (3-54) months for controls. No
child in the index group has been lost to follow up. During the period of
the study, case 4 died of PCP. Outcome of the infected children is
described in detail in chapter 4, and summarised in table III. 1.1. One of
the children presumed uninfected has cystic fibrosis while another died
aged 31 months at home from Group A Streptococcal septicaemia
after a 24 hour history of diarrhoea and vomiting. Two infants died
suddenly in the first three months of life, one from aspiration and the
other was found dead in its cot, having been previously healthy, and
so is thought to have been SIDS. Neither had any clinical or laboratory
evidence of HIV infection, but their infection status remains
indeterminate.
Signs and symptoms observed in index and control children
are shown in table III.2.3, with index children separated into those
infected and presumed uninfected. Significant lymphadenopathy was
defined as the presence of nodes >0.5 cm in diameter in more than
two non- contiguous sites (excluding inguinal) and persisting beyond
three months. Chronic or recurrent respiratory infections were those
which occurred on 3 or more occasions within a 3 month period.
Recurrent diarrhoea was defined as loose stools that persisted beyond
48 hours, required treatment, and occurred on more than one
occasion per month. Failure to thrive was diagnosed when the child's
sequential weights declined across the centile lines.
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As seen in table III.2.3, signs and symptoms were non-specific
and were seen in control as well as index children. Lymphadenopathy
and recurrent respiratory infections were seen in appreciably more
index children, even those presumed uninfected, when compared with
controls. All index children presumed uninfected had symptoms and
signs which resolved with time, in contrast to those of the infected
children. Neurological signs were detected only in the child with
neonatal meningitis (ataxic diplegia). Five index and one control have
had evidence of developmental delay on Denver screening, but the
progress of the cohort as a whole has been within normal limits.
Of the 68 index children, all have received diphtheria/tetanus
(DT) or diphtheria/tetanus/pertussis (DPT) immunisation, 37
inactivated polio vaccine, 31 oral polio vaccine, while measles vaccine
was given to 25 children and measles/mumps rubella (MMR) vaccine
to 51 children, including the symptomatic children. No adverse
reactions were reported in any child or family member.
Laboratory results
Laboratory abnormalities are shown in table III.2.4. No
significant differences were seen when the index children were
compared with the controls. Within the index children, however, those
presumed uninfected were less likely to have persistent
hypergammaglobulinaemia, lymphopoenia, CD4 lymphopoenia, and
thrombocytopoenia, as defined in the table. However, in the first 2
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years of life, a significant difference was found only in
hypergammaglobulinaemia. Abnormal laboratory results in index
children presumed uninfected tended to be transient findings which
returned to the normal range on repeat testing.
On sequential analysis of laboratory data by age, non- infected
children and control children were indistinguishable on all parameters
apart from cord blood IgG, which was significantly higher (p<0.05) in
index children (mean 15.7g/l) than in controls (mean 11.0g/l),
reflecting maternal hypergammaglobulinaemia among the HIV
seropositive women. Sequential data within the index group are
displayed in table III.2.5. Hypergammaglobulinaemia was noted as
early as 6 months, and often predated clinical signs. The small number
of samples available from infected children meant that significance was
not demonstrated until 9-12 months of age. With progression of clinical
disease, other useful laboratory markers were CD4 lymphopoenia and
thrombocytopoenia.
Rate of maternofoetal transmission
Final analysis of the cohort was delayed until 18 months had
elapsed. Five index children showed evidence of HIV disease, one of
whom was referred because of symptoms, and one was first seen at
21 months after mother was found to be seropositive. Of 65 index
children over the age of 18 months, 61 were HIV antibody negative,
and presumed uninfected. The two who died at 3 months of age were
classed as indeterminate status ccdc 1987 [b]). To calculate a transmission
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rate of HIV from mother to child, the indeterminate children have been
excluded. Of 66 children, 5 were HIV infected. However, it is only
appropriate to include those children followed from birth in the
calculation of vertical transmission rate. Three such children out of 56
were infected, giving a rate of 5.4% (95% C11.12 -14.87%).
Discussion
Initial reports of paediatric AIDS concentrated on children who
presented With end Stage disease, (Oleske et al 1983, Rubenstein et al 1983, Scott et al
1984) and they are not typical of the entire clinical range of HIV infected
children. Increasing awareness and experience of children at risk of
AIDS have allowed an improved classification of signs and symptoms
observed in paediatric HIV infection (cdc 1987 [b». The children in our
study with proven HIV infection had common, non-specific clinical
findings which might have been managed differently had they
presented in another setting. The haematological and immunological
abnormalities that we observed were not exclusive to the infected
children, and this again underlines the importance of regular follow up
with sequential data and the inclusion of control children.
Most index mothers were infected through needle sharing
during intravenous drug use. As most of these women come from
areas of multiple deprivation this is likely to affect their infant's health
and development adversely. A previous study from Edinburgh of
women who identified themselves as being at risk of HIV infection
showed no significant differences in social characteristics of those who
76
subsequently tested positive, compared with HIV negative women
(Johnstone et ai 1988). Rather, similarities were seen in infant morbidity (low
birth weight, intra-uterine growth retardation, preterm delivery) in both
groups of women, which were increased three fold when compared
with the general population. Our choice of control infants was such that
both groups were comparable in social and epidemiological factors, as
well as maternal intravenous drug use during pregnancy. Despite that,
the mean birth weight of the index infants presumed uninfected was
significantly lower than that of the controls, even allowing for maternal
drug use and prematurity. This could be a direct effect of HIV during
pregnancy.
More of the index children than controls were in alternative care.
The chaotic lifestyles led by some parents who continue to abuse
drugs were common to both groups, but in the index group, ill-health
in the mothers has also meant that their children have to be taken into
care. This has required close liaison with the Lothian Region Social
Work Department whose staff have established guidelines for placing
these Children (Black& Skinner 1987).
In estimating the vertical transmission rate, we waited until
children were over 18 months of age, although the recommendation
was that children aged over 15 months who test antibody positive are
defined as infected (cdc 1987 [b]). Our experience is that maternal
antibody can persist until 18 months of age, and had we defined four
such children as infected, we would have overestimated the rate of
transmission. Children referred because of HIV related symptoms
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would also add to an over-estimate of infection. Therefore in the
calculation of infection risk, the more accurate estimate of risk will be
derived from the inclusion only of those children monitored from birth.
The risk of vertical transmission from our data was 5.4%, lower than
that previously reported (Moketal 1987, ECS 1991, Minkoffetal 1987, Blanche et al 1989),
although still within the confidence intervals of the European
Collaborative Study <ecs 1991). Our results must be interpreted with
caution, however, as numbers are small, and as yet, the prognosis for
children aged over 18 months who lose maternal antibody is unknown.
Although not observed in our cohort, children have been reported to
lose antibody only to seroconvert later on in childhood (Aiutu etai 1987>
while others have been documented to remain antibody negative with
positive antigen teStS and VirUS Culture (Moketal 1987, ECS 1988, Borkowsky et al
1987).
The virological diagnosis of HIV infection has been discussed in
the previous chapter. We were unable to detect any other laboratory
parameter which consistently predicts HIV disease when sequential
index and control data were compared. In HIV infected children,
immunoglobulin concentrations (especially IgG) started to rise before
clinical signs were obvious. Early clinical manifestations were usually
non-specific, although one child presented with oral and cutaneous
candidiasis rapidly followed by PCP, which is a well recognised pattern
(ecs 1991). When recurrent respiratory infections, lymphadenopathy and
hepatosplenomegaly are seen in conjunction with laboratory
abnormalities (hypergammaglobulinaemia, CD4 lymphopoenia,
thrombocytopoenia), a diagnosis of HIV infection can be strongly
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suspected in a child especially when a mother has engaged in high risk
activities. Our study therefore stresses the importance of continued
careful follow up of all children at risk of HIV infection, to detect early




Characteristics of mothers of 68 index and 30 control children
Index Control
n = 68 n = 30
n (%) n (%) P
Mean age at delivery 24 23.4 NS
Single mother 23 (34) 8(27) NS
First born 30 (43) 17 (59) NS
Drug use during pregnancy 27 (39) 5 (17) NS
Drug use since pregnancy 29 (42) 6(21) NS
Infant in alternative care 22 (32) 2(7) <0.05"
TABLE III.2.2
Perinatal data of 66 index and 30 control children
Index Control
Infected Uninfected
n = 5 n = 61 n = 30
Boys 0 27 17
Born <37 weeks'gestation 0 11 3
Birth weight < 10th centiie 1 19 3
Neonatal special care 1 16 4
Mean birth weight (g) 2925 2860* 3285*
Mean birth weight (g) 2925(n = 4) 3028~(n = 37) 3394 (n = 25) "
of babies born to drug free mothers
* p<0.01}










n = 50 3 II COo
Recurrent resp. infections 4 (80%)* 12 (24%)* 2 (7%)
Recurrent diarrhoea 3 (60%) 10 (20%) 4(13%)
Eczematous rash 4(80%)" 9(18%)" 1 (3%)
Sig. lymphadenopathy 4 (80%)" 9 (18%)" 2 (7%)
Hepatosplenomegaly 4 (80%)" 11 (22%)" 2 (7%)
Failure to thrive 1 (20%) 3 (6%) 0
Oral Candida 1 (29%) 2 (4%) 3 (10%)
Cutaneous Candida 3 (60%) 19 (38%) 4 (13%)
TABLE III.2.4





n = 56 OCOIIc
Hypogammaglobulinaemia " 0 18 (32%) 6 (20%)
Hypergammaglobulinaemia " 4 (80%)# 4 (75)# 1 (3%)
Neutropoenia (< 1.0x109/l) 1 20%) 3 (5%) 3 (10%)
Lymphopoenia (<2.8x10^/1) 1 (20%) 2 (4%) 2 (7%)
CD4 lymphopoenia (< 1.0x10^/1) 1 (20%) 1 (2%) 2 (7%)
CD4/CD8 <1 2 (40%) 5 (9%) 1 (3%)
Thrombocytopoenia (< 100x10^/1) 2 (40%) 3 (5%) 0
* p<0.05 }
*
p<0.01 } Chi-squared test
* p<0.001}
"










































1Nl 242 10.24. 1.40 5 1.30 9 ND3.4 281400
9-12months
1Nl 254 12.46.0* 1.30 6 1.0 ND2.75 249352
15-18months
INl 357 14.97.5* 1.50 7 1.2 1.322 9 180372
21-24months
INl 435 16.67.7" 1.30 7 1.51 1.282 03 115380*
Infected Notinfected
FIGURE III.2.1
Distribution of index children
by year of birth
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CHAPTER 3
DO MATERNAL FACTORS INFLUENCE THE RISK OF VERTICAL
TRANSMISSION OF HIV?
Aims
Having estimated the current rate of vertical transmission in
Edinburgh at 5.4% which is lower than all published series, for reasons
which are unclear, we analysed some factors which might influence
HIV transmission from women to their offspring over 7 years in order to
identify those which may have contributed to the low vertical
transmission rate.
Subjects. Materials and Methods
Mothers and infants including cases 6-11, were followed as
previously described. Data from fifty six children and their mothers
(including case 12, who was identified after the conclusion of my
research fellowship) followed prospectively, and fourteen children
diagnosed after the neonatal period were analysed.
Results
Seventy children of 58 HIV seropositive mothers (3 pairs of
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twins, 7 sibling pairs, and 1 sibship of 3) were followed for a median of
4 years (range 0.5-7 years) post-delivery. Twelve children (cases 1-12)
born to 10 women were infected. Their case histories are outlined in
Appendix II. One woman had 3 infected children (cases 8, 9, 10). The
mothers of cases 4 and 12, who both developed AIDS during
pregnancy, had each had a previous uninfected child 4 and 7 years
before the birth of the index case, when they were seropositive but
asymptomatic. The mothers of cases 5 and 7 went on to have an
uninfected child 2 years later.
Maternal characteristics
These are summarised in table III.3.1. Forty four (75%) of
women were infected through needle sharing, 13 were infected
heterosexually, and one is thought to have received an infected blood
transfusion. As illustrated in figure III.3.1, there was no difference in the
mean duration of mother's infection between those who transmitted
and those who did not. However, five of the nine pregnancies within a
year of seroconversion resulted in infected children compared with 7 of
the 61 in subsequent years (p<0.001). It would appear that a smaller
proportion of women whose risk factor was intravenous drug use
transmitted to their children. However, more of the mothers infected
heterosexually had pregnancies within the first year of seroconversion.
Excluding these 9 pregnancies, 4/7 mothers who transmitted,
compared with 47/54 who did not had used intravenous drugs; this
difference is not significant (OR 3.91, 95% CI 0.48-27.1).
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Table III.3.2 contains details of pregnancy outcome. There was
no difference between the 2 groups on any parameter measured. The
Caesarean section rate was very low in our series. The diagnosis of
chorioamnionitis based on maternal pyrexia during labour and
macroscopic placental appearance was not made in either group,
although the mother of one infected child (case 7) had an unexplained
pyrexia 48 hours after delivery. The only placental abnormalities seen
were infarction in 2 mothers of uninfected children. The mother of an
uninfected child who later died of AIDS suffered a severe wound
infection following her Caesarean section. The mother of cases 8-10
breast fed, but all the other infected children were artificially fed.
At the start of their pregnancies, 56 women were asymptomatic.
Two women were classified as stage 4.C2, one on the basis of oral
hairy leukoplakia, and one suffered oral candidiasis. Neither produced
infected children. Both women who developed PCP as their first AIDS
defining illness during pregnancy bore HIV infected children. Three
mothers of HIV infected children and 2 mothers of 3 uninfected
children have died of AIDS. Outcome for the mothers of HIV infected
children is summarised in table III.3.3.
During the period of follow-up, nine mothers of infected children
have progressed to stage IV at a median of 3 years (range 0-6.5), and
19 mothers of uninfected children at a median of 5 years (range 1-7).
As shown in figure III.3.2, women who bore infected children were
likely to progress more rapidly to stage IV during the period of follow
up (log rank statistic 4.603, giving a p value of 0.032).
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Laboratory data are shown in table III.3.4. Mothers of all three
infected children tested during pregnancy had CD4 counts less than
300x10®/l. Counts are available for the majority of women within 1 year
of delivery, when a greater proportion of women bearing infected
children had low numbers. Maternal HIV antigen and p24Ab were not
discriminatory. In nineteen women, PBMCs were cultured for HIV
during pregnancy. HIV was isolated in 4. None of the 19 transmitted to
their children, and so no conclusion can be drawn.
Discussion
The number of pregnancies resulting in HIV infected children
among this group was small, and there may be associations with
increased risk of transmission which failed to reach significance in our
study. However, important associations have been identified. In
Edinburgh we have detailed seroconversion data, enabling us to
demonstrate the greater risk of transmission of HIV to a child born
shortly after mother's seroconversion. During primary HIV infection,
high titres of cytopathic virus have been demonstrated in plasma (ciark et
ai 1991), and so the foetus may be more susceptible to infection on
exposure to this high virus load, especially before any maternal
immune response has been mounted. In addition, although few
mothers were symptomatic at delivery, but the only two with AIDS both
transmitted to their children, supporting previous studies suggesting
that advanced immunodeficiency increases the risk of vertical
transmission (Ryder etai 1989). Similar variations in a woman's infectivity
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have been suggested from heterosexual transmission studies (May 1988).
Counselling of HIV seropositive women wishing to have children
should take these factors into account.
Because of the small number of children born by Caesarean
section, we were unable to explore any relationship between the mode
of delivery and risk of transmission. In a retrospective twin study,
Goedert et al (1991) have suggested that contact with the cervix and
birth canal may be important, but others have failed to demonstrate
any association (Semprini et ai 1987, Lindgren et ai 1991). It has been suggested
that breast feeding carries a greater risk of transmission than bottle
feeding (Blanche etai 1989), and the recent European study indicates and
odds ratio of 2.25 (95% CI 0.97-5.23) in favour of transmission for
breast fed infants compared with those exclusively bottle fed <ecs 1992).
Studies of post-natal transmission of HIV indicate that breast milk may
be an efficient route from recently infected mothers (ziegieretai 1985, van de
perreetai 1991). Only 6 infants in our study were breast fed, and although it
is interesting that the mother of cases 8-10, who transmitted twice at
times of 'low risk', breast fed on all three occasions no conclusions can
be drawn. Current guidelines are to discourage HIV seropositive
WOmen in the UK from breast feeding (Royal College of Obstetrics and Gynaecology
1987). For the majority, however, the decision to bottle feed had been
made before any discussion of the possible risks of breast feeding had
occurred. Only one woman in our study who breast fed was aware of
her HIV status (and the guidelines) at the time.
Our data also suggest that asymptomatic women who bear HIV
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infected children may progress more rapidly to stage IV than those
who do not. A previous study has suggested that the progression of
disease in this group of women is related to the duration of maternal
HIV infection (undgren et ai 1991). Our knowledge of seroconversion times
has meant that in a larger study population we have demonstrated no
difference in the duration of maternal HIV infection between the two
groups which would account for this; rather the data suggest a
difference in rate of progression. If bearing an infected child is
confirmed as being a bad prognostic indicator, this may affect
decisions regarding the introduction of anti-retroviral therapy for the
mother.
Although the majority of infected children were born before CD4
counts were measured routinely, the data we have supports an
association between low CD4 counts and transmission, as was found
in Zaire (Ryder etai 1989). Other laboratory markers of HIV disease
progression include HIV antigenaemia and loss of p24Ab (Forsteretai 1989).
In common with other groups (Goedertetai 1989), we found no correlation
with p24Ab levels. The presence of HIV Ag in maternal serum has been
associated with transmission by some groups (Scarlatti et ai 1991) but not by
others (Devash et ai 1990). In our study, a greater proportion of women who
transmitted HIV to their children were HIV antigenaemic, but the
difference did not reach statistical significance. Further studies on
larger groups of women and children are therefore required.
In our prospective study, the rate of perinatal transmission of
HIV in Edinburgh is 5.4% (95% CI 1.12 14.87%), lower than the
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published series, although still within the confidence interval of the
European Collaborative Study (ECS 1991) and indeed, the rate among
asymptomatic mothers followed prospectively from birth for at least 18
months is 2/51 (3.9%, 95% CI 0.48-13.46%). At present, few of our
mothers fall into the higher risk categories identified in this study. In the
coming years, a greater proportion of HIV infected women in
Edinburgh will have more advanced disease. Future studies may test
the hypothesis that the perinatal transmission rate will increase with






Maternal age (mean) 20.9 24.4 NS
Previous pregnancies 1.5 1.43 NS
Previous live births 1.16 1.01 NS
History of drug use 4 (33%) 49 (84%) <0.001
Drug use during pregnancy 2 (17%) 21/54 (39%) NS





n = 12 n = 58
P
Preterm <37 weeks 1 (8%) 9 (16%) NS
Birth weight (mean) 2735g 2850g NS
Birth weight < 10th Centile 2 (17%) 13 (22%) NS
Caesarean section 0 3 (5%) NS
Placental abnormalities 0 2 (3%) NS
Breastfeeding 3 (25%) 3 (5%) NS
TABLE III.3.4
Laboratory characteristics of the mothers
Infant
Infected Uninfected d OR CI
CD4 count at delivery < 300x106/l 3/3(100%) 8/49(16%) <0.01 0 0. 0.58
1st available CD4 count <300x106/l 7/12(58%) 7/49(14%) <0.01 8.4 1.7, 43
Maternal HIV Ag +ve during pregnancy 2/9 (22%) 2/38(5%) NS 5.14 0.3, 78
Maternal HIV Ag +ve at any time 5/12(42%) 8/56(14%) NS 4.3 0.8, 20
Maternal p24Ab -ve at any time 4/10 (40%) 14/41 (34%) NS 1.3 0.2, 6.5
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FIGURE III.3.2
























THE SPECTRUM OF CLINICAL DISEASE IN HIV INFECTED
CHILDREN
Aims
To describe the natural history and clinical manifestations of HIV
infection in the children studied, with reference to the current literature.
Methods
All 11 children born to HIV seropositive women identified during
the study are described, together with the clinical features of case 13,
infected through transfusion.
Results
The 11 perinatally infected children were identified at a median
age of 21 (range 0-46) months and followed for a median of 33 months
(range 4-66). Full details of their case histories are found in appendix II.
Table 111.4.1 outlines the progress of the group. Ail were
asymptomatic at birth, with a mean birth weight of 2.77kg. Earliest
symptoms and signs were seen in case 4, with persistent candidal
infection after 1 month, but 6 (55%) had developed symptoms before
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the age of 1 year (95%CI 23.38-83.25%), and a further 3 had persistent
lymphadenopathy. By the age of 2 years, 9/11 (82%) were
symptomatic (95% CI 48.22-97.72%). Early non-specific symptoms
and signs are detailed in table III.4.2.
During the period of follow up, 7 perinatally infected children
have progressed to AIDS as defined in table 3, appendix I, the median
age of progression being 45 months. One child remains asymptomatic
at 42 months. Six children have died at a median age of 43 months,
range 4-82 months. In both the two surviving children with AIDS, the
indicator disease was LIP.
Features of advanced HIV disease in cases 1-11 are listed in
table III.4.3. One child died in the first year of life (mortality 9%, 95% CI
), 3 in the first 5 years of life (mortality 27%, 95% CI ). Six (55%)
died at a median of 55 months, range 4 - 82 months. Case 13 has also
progressed to AIDS, but being infected through a blood transfusion is
excluded from consideration of natural history of vertically acquired
HIV infection: he is included in the subsequent account of clinical
features of HIV infection in children. PCP was the terminal illness in 2
children, and in no other child was the diagnosis of PCP proven. No
other opportunistic infections were documented. Three children with
signs of encephalopathy died within 18 months of its development.
Other terminal illnesses were bacterial pneumonia (case 8), HIV
wasting syndrome (case 10), and cardiac failure secondary to
cardiomyopathy (case 2).
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In contrast, a more favourable outcome has been noted in
those children who have developed radiological evidence of LIP. In all
four, the diagnosis was made during an acute respiratory infection,
when chest X rays showed typical changes which did not resolve on
follow up films. Three remained free of chronic respiratory symptoms
but case 13 had reduced exercise tolerance and finger clubbing and
has required steroid therapy.
Of those infected children who have not progressed to AIDS,
case 5 remains asymptomatic at the age of 46 months. Cases 1 and 7
have had symptoms in the past, but are currently well at 69 and 76
months.
Discussion
Our cases illustrate well the spectrum of HIV disease in children
with perinatal infection described in larger studies <scott etai 1989, ecs 1991).
The children we studied were normal at birth, but congenital HIV
infection may give rise to low birth weight, microcephaly and
hepatosplenomegaly, and some have described a dysmorphic
syndrome (Marionetai 1986). Most infants however, present later as did our
children, with non-specific signs, such as recurrent respiratory
infection, eczema, diarrhoea and failure to thrive (ecs 1991). In only one
child was AIDS diagnosed in the first year of life. This contrasts with
the early data from the USA, where in 50% children with AIDS, the
diagnosis was made during the first year of life, and in 82% by 3 years
of age (cdc 1986 [a]). Larger prospective studies have documented the
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mortality from HIV in the first year of life of 17%, 26% having developed
AIDS by one year(Ecs 1991). Those surviving the first year, however,
show a tendency to improve rather than deteriorate during the second
year.
Bacterial Infection
Abnormal humoral immunity is a prominent feature of HIV
infection in children, and recurrent or serious bacterial infections occur
more commonly in paediatric HIV infection than in adults (Rubinstein 1986).
Serious bacterial infection in the children in our study were limited to
the respiratory system. We were unable to isolate the causative
organisms in all episodes of pneumonia, but the commonest
organisms reported are Haemophilus influenzae, Pneumococcus, and
Salmonella (Bernstein, Kriegeretai 1985), so our therapy reflected this
knowledge. Our patients developed their infections while at home, but
in hospitalised patients, nosocomial pathogens may present problems,
and a knowledge of the locally prevalent organisms influence the
choice of antibiotics used. In addition to pneumonia, we have also
seen chronic bacterial infections such as otitis media and sinusitis, and
also skin and soft tissue infections, and urinary tract infections as
reported by Other grOUpS(Bernstein etal 1985 [a], Shannon &Ammann 1985).
Viral Infection
Children who acquire HIV perinatally, may have an immune
system incapable of developing effective antibodies to the common
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viral infections of childhood. They are especially at risk of severe
complications of viral infections. The role of virus infections in the
respiratory tract is discussed in chapter 5. Two infants born to HIV
seropositive mothers who proved uninfected, and one of the HIV
infected children (case 1) developed measles, which in all cases was
uncomplicated. In the immunocompromised child measles may take
an atypical course and fatal measles pneumonia has been described in
the absence of any identifiable rash (Markowitz et ai 1988). Measles may
OCCUr despite previOUS immunisation (CDC 1988 [a], Krasinski & Borkowsky 1989).
Although 4 children reported contact with chicken-pox, none
developed clinical infection, which may become disseminated with
pneumonia and encephalitis, and chronic cutaneous varicella zoster
can occur. Antiviral treatment has become available with the advent of
acyclovir. However, treatment may fail if pneumonitis has already
developed, making early recognition and prompt administration
essential (Nyergesetai 1988). There is concern that as the number of people
receiving treatment for varicella zoster increases, resistant strains will
appear. This has already been demonstrated in a child with AIDS who
developed chronic cutaneous lesions despite multiple courses of
acyclovir (Pahwaetai 1988). In children receiving regular intravenous
immunoglobulin therapy, some passive protection may be afforded,
assuming the donors are immune. In the cases of reported exposure,
hyper-immune measles and zoster immunoglobulin were given but
prophylaxis must be given early to be of use (Krasinski & Borkowsky 1989).
CMV is commonly isolated from HIV infected children, but its
role in symptomatology can be difficult to ascertaingacobson & miiis 1988).
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This virus was isolated from the respiratory or urinary tracts in four
children in our study (cases 1,2,3,7), and all remained well with no
evidence of disseminated infection. Primary herpes family infections
may present only with a spiking pyrexia which resolves after a few days
(Pahwaetai 1988). Dissemination of live virus can lead to severe
complications involving many organ systems. Once established, these
infections are very difficult to treat. Early diagnosis of these infections is
therefore very important. For symptomatic disease, gancyclovir
(DHPG) and foscarnet have had reported efficacy in adults (Morris 1988 [a]),
but to date, little experience has been reported in children.
HIV infected children may have atypical antibody responses to
Epstein Barr virus (Birx & Redfieid 1986). EBV genome has been found in
lymph nodes, lung and salivary glands of these children (Andimanetai 1985),
and has been implicated in the pathogenesis of LIP, polyclonal
polymorphic B cell proliferative disorder, and lymphomas (Andimanetai
1985, Fackieretai 1985). No such work was carried out on our children.
Funaal Infection
Candidal infection of the mouth and napkin area is common in
all children in the first year of life, and usually responds to nystatin or
miconazole. The European Collaborative study indicates that
persistent oral candidiasis is highly predictive of progression to
AIDS(ecs 1991). In case 4, who developed PCP at 4 months, persistent
mucocutaneous candidiasis was the first clinical sign of
immunodeficiency. Six other children (including case 13) have had oral
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Candida, extending into the oesophagus in case 8. Case 8 was treated
with ketoconazole but clotrimazole has also been shown to be effective
(Young 1987). Fluconazole is reported to be more effective than
ketoconazole in adults but was not yet licensed for use in children (dewit
etai 1989). In extensive oesophageal Candida, amphoteracin B and
flucytosine intravenously may be required, and the condition is likely to
recur unless maintenance treatment is initiated(Giatt et ai 1988). We did not
see other fungal infections, such as cryptococcosis which are much
less common in children than adults (Faiioonetai 1989).
Opportunistic Infection
Pneumocystis carinii pneumonia was the only opportunistic
infection diagnosed in our group, and is discussed in detail in chapter
6. Infection with latent organisms such as toxoplasma are less
common than in adultS(Pizzoetai i988[a». Other important opportunistic
infections which have been described include disseminated
mycobacterium avium-intracellulare infection and cryptosporidiosis
(Rogersetai 1987, seiiketai 1987). In both these infections, treatment has proven
to be difficult. In the former, clofazimine plus rifampicin and ethambutol
may be tried (Young 1987), but in cryptosporidiosis, the role of spiramycin
haS yet to be established (Current et al 1983, Soave & Johnson 1988).
Respiratory Disease
Four children (cases 3, 6, 9, 13) developed LIP. This is an AIDS-
defining illness found almost exclusively in children, and occurs in
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about half of the cnildren with AIDS (Rogers etai 1987). It is characterised by
the progressive development of diffuse bilateral reticulonodular
infiltrates, sometimes with hilar and mediastinal lymphadenopathy
(Rubinstein et ai 1986). Case 13 was symptomatic, having decreased exercise
tolerance, with tachypnoea, and digital clubbing. Case 9 had a chronic
cough, and was prone to intercurrent chest infections but was
otherwise asymptomatic. All four children had generalised
lymphadenopathy, but glands were particularly enlarged in cases 9
and 13, who also had hepatosplenomegaly, and very high levels of IgG
(>50g/l). Case 6 had intermittent salivary gland enlargement. These
features are all known to be associated with LIP. The definitive
diagnosis is made by open lung biopsy, but in our series a
presumptive diagnosis was based on the typical clinical and
radiological features. Although leading to chronic hypoxaemia, and
susceptibility to superimposed acute respiratory infections, LIP is
associated with a relatively good prognosis, with a median survival of
72 months (Rubinstein et al 1986, Scott et al 1989, Blanche et al 1990). Three Of the fOUr
children are still alive, at a median age of 76 months, and case 6 died
at 81 months of causes unrelated to the respiratory system. Elevated
titres to EBV have been described in children with LIP (Birx & Redtieid 1986),
but this was not a feature observed in our series. HIV has been
cultured from bronchial lavage fluid (Zzaetai 1985); this procedure was not
carried out in the children we studied. Case 13 was given
corticosteroids with symptomatic improvement, although this is
potentially hazardous in an already immunocompromised host (Rubinstein
1986). Management may also include supportive measures, such as
continuous oxygen therapy. Zidovudine has not been shown to affect
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its cours6(Heibert et ai 1987), but in some children, spontaneous resolution
may occur.
Neurological Disease
The central nervous system is susceptible to the consequences
of immune compromise in terms of meningitides and encephalitides,
and also to cerebrovascular disease, and malignancies, in particular,
primary CNS lymphoma (Epstein et ai 1988 [a]). Of the four children in the
study who had CNS abnormalities, three were investigated by CT scan
and 2 by MRI, but no focal lesions were demonstrated. Like the
majority of children with neurological symptoms (Beiman etai 1988), they
were felt to be suffering from a primary HIV encephalopathy. We have
observed many of the common manifestations of HIV encephalopathy,
which include acquired microcephaly, cognitive changes, delay in, or
loss of motor milestones, and bilateral pyramidal tract signs. In case
11, encephalopathy presented early in the clinical course and case 13
had gross motor symptoms intermittently. In cases 6 and 10, CNS
manifestations occurred late in the terminal phase of the disease.
More subtle neurodevelopmental abnormalities have been
reported to occur in most infected children (Pizzoetai 1988 [a]). Even in
those who have no symptoms, sequential assessment can
demonstrate a decline in IG scores over time in children who may be
assessed as being in the normal range on an isolated occasion.
However, data may be difficult to interpret in series where there has
been no control group of children of the same socio-economic
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background, with equivalent patterns of maternal drug use.
Developmental delay in these children is likely to be multi-factorial
when compared to a 'normal' population, and we have found no
difference between cases 1-5, 7-9 and uninfected index children.
Zidovudine has been shown to result in a significant improvement in
neurological function(Pizzo et ai 1988 [t>], Blanche et ai 1988). This was certainly so
in case 11, and probably so in case 13. However, despite these
encouraging findings, zidovudine may only arrest or delay further
deterioration, and case 11 eventually deteriorated neurologically
despite being on zidovudine.
Nutrition
Seven children failed to thrive during the period of study. Failure
to thrive is a common feature of chronic illness in childhood, and of
children in the socio-economic group to which many HIV seropositive
families belong, even in the absence of identifiable disease. Thus good
dietary advice is important even for those children who are
asymptomatic, or who have only early signs of HIV infection. Attention
to nutrition is particularly essential for children whose energy
requirement is increased by chronic infection. Persuading an ill child to
eat is sometimes impossible. Nasogastric or nasoduodenal feeding,
continuously or overnight, becomes a possible method of treatment,
and was instituted in case 8 for some time. In no child was parenteral
feeding contemplated, not only because of the hazards of indwelling
catheters in an immunocompromised child, but also because in those
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children unable to tolerate enteral feeding their general condition was
such that it was felt not justified to prolong life in this manner.
In HIV infection, nutritional problems may be compounded by
diarrhoea with or without vomiting, and recurrent or chronic diarrhoea
was an early feature of symptomatic disease in eight children.
Commonly no organism is isolated, but in case 10, whose severe
diarrhoea and wasting was the cause of her death, an
enteropathogenic E Coli was grown. Other organisms implicated
include rotavirus, CMV, Cryptosporidium, Isospora belli, and atypical
mycobacteria(Young 1987). For those in whom no pathogen can be
isolated, the cause may be multifactorial, as discussed in section 1.2. A
regimen of oral gentamicin and cholestyramine has been suggested to
treat those children whose diarrhoea persists despite discontinuing
oral feeding and giving intravenous fluid replacement(Shapiro & Kain 1988).
Zidovudine has been demonstrated to be effective in some
cases(Bianche et ai 1988), and was commenced for this reason in case 10. It
may be that in this case, however, treatment was started too late to be
of any benefit.
HIV associated Thrombocvtopoenia
Three children developed thrombocytopoenia (platelet count
<20x109/I), including case 13. UP was the presenting symptom of
HIV infection in cases 6 and 13. HIV related thrombocytopoenia is
indistinguishable clinically from idiopathic immune thrombocytopoenia
and commonly presents long before any symptoms or signs of
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immune deficiency develop (Sauisbury et ai 1986). The exact mechanism
remains unclear, but patients with HIV-related ITP have markedly
elevated platelet IgG, IgM and C3C4, as well as serum immune
complexes containing anti-HIV 1 antibody (Karpatkin et ai 1988). Most
children remain asymptomatic, requiring no intervention. However,
spontaneous bleeding and bruising occurred in all three in our series
on occasions when platelet counts dropped to below 20x10^/1. Case
13 was treated with high dose immunoglobulin and his platelet count
reverted to normal within 6 months. Case 6 continued to have
spontaneous nosebleeds and petechiae while receiving regular IVIgG
at 200mg/kg 3 weekly, but never developed more serious bleeding
problems. His platelet count returned to normal at the time when he
lost p24Ab, and only dropped again when his marrow was depressed
during chemotherapy for his sarcoma.
Case 3 developed ITP while receiving IVIgG, and her platelet
count dropped persistently to below 5x10^/1. High dose intravenous
immunoglobulin (1g/kg), shown to be effective in some cases even
when refractory to steroid therapy (Poiiacketai 1988), led to a transient rise
in platelet count, but this was not sustained. Following favourable
reports of its use (Oskenhendier et ai 1988) anti-D has been used, which is
maintaining her platelet count above 20x10^/1. No child has been given
corticosteroids, and splenectomy has been avoided, as both therapies
expose the child to further immune compromise. Following the
observation that platelet counts tend to rise after commencement of
zidovudine therapy, particularly in those patients who had previously
low levels (Hymesetai 1988), zidovudine has been used as a method of
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treatment for thrombocytopoenia (Swiss Group for ciinicai studies 1988). Its
mechanism of action is as yet unclear, but it may be related directly to
anti-viral effect (Pottage etai 1988). In cases 6 and 13 resolution of
thrombocytopoenia antedated commencement of zidovudine.
Cardiomyopathy
Case 2 developed a dilated cardiomyopathy at the age of 69
months, presenting acutely with symptoms and signs of left ventricular
failure. Case 13, who became HIV infected as a result of surgery for
congenital heart disease, has also developed a degree of cardiac
failure, not felt to be related to his previous defect. Cardiac
abnormalities in children with HIV infection were first reported in 1985
dssenberg et ai 1985, sherron et ai 1985), and may be found in 93% of HIV infected
children; diminished contractility, suggestive of intrinsic myocardial
dysfunction is found in 27% (Upshuitz et ai 1989). The diagnosis of cardiac
dysfunction may be made during severe systemic illness, with fever,
hepatosplenomegaly, and pulmonary disease, in which case the
prognosis is poor (Stewart etal 1989).
Focal myocarditis has been described, and myocardial
inflammation is relatively common, but it is unusual to demonstrate a
causative organism (Upshuitz et ai 1989). In our case, endomyocardial
biopsy was unhelpful. At present it is unclear whether HIV has a direct
effect on the heart. It is also possible that zidovudine, which has been
demonstrated to cause a mitochondrial myopathy (Daiakasetai 1990) has a
role in the aetiology in some cases.
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HIV related cardiomyopathy has been shown to respond to
standard treatment for cardiac failure(stewart et ai 1989). Case 13 was
controlled on diuretics, but case 2 required digoxin and captopril in
addition, and despite treatment, succumbed. Death attributed to
cardiac causes occurred in 4/30 children in one series (Upschuitz et ai 1989).
Neoplasia
It is well recognised that tumours develop more frequently in
immunosuppressed individuals. AIDS in adults is particularly
associated with Kaposi's sarcoma, but although KS has been reported
in children (Bucketai 1983), it is relatively uncommon. Non-Hodgkin
lymphoma is 360 times more common in AIDS patients than in the
general population of under 20, and primary lymphoma of the brain
and Burkitt's lymphoma 1000 times more frequent (Berai etai 1991).
Tumours of smooth muscle origin, and fibrosarcoma of the liver have
also been reported in children with AIDS (Chadwick et ai 1990, Ninaneetai 1985).
There have been no previous reports of Ewing's sarcoma in HIV
infected children. Impaired T cell surveillance, multiple co-infecting
organisms, chronic antigenic stimulation with polyclonal B cell
expansion, and abnormal regulation of cytokines and growth factors
may all play a role in tumour development (Levine 1989). In our case, the
tumour was responsive even to a modified regimen of chemotherapy,
but at the price of further immune compromise. Multicentre studies are
required to determine the optimal therapeutic regimens in this difficult
clinical situation. With increased survival of children with HIV infection,
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it is possible that more will present with tumours in the future. A cancer
registry which will include all children born to HIV seropositive women,
even those who are presumed uninfected is therefore required to
detect any increased susceptibility to tumour development.
Skin Disease
Cutaneous manifestations of HIV infection occurred in the
majority of the children. Five had eczematous skin rashes, which have
been described to occur frequently in such children (Rubinstein & Bernstein
1986) and 3 had petechiae secondary to ITP. Infectious manifestations
included four with mucocutaneous candidal infection, case 2 with
widespread impetigo, and case 9, with primary herpes, which in her
case was uncomplicated. Two children developed widespread
molluscum contagiosum, both at a time when their CD4 counts were
falling. In both cases, facial papules were prominent, which is unusual
in children who are not immunocompromised (Warner & Fisher 1986, Penneys &
Hicks 1985). Both resolved spontaneously once T cell numbers had
increased on zidovudine therapy.
Although, like the European Collaborative study as a whole, the
description of early symptoms and signs of HIV infection is
substantially unbiased by treatment (ecs 1991), the natural history of HIV
infection in this group of children has undoubtedly been modified by
therapeutic manoeuvres. This may partially account for the more
prolonged survival than we had expected from early studies (Scott etai
1984, Rubinstein et ai 1983). However, treatment would have to begin very early
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in order to affect the prognosis of those infants developing AIDS within
the first months of life. Survival of children with perinatally acquired HIV
has now been described until early teenage (Gibt>, personal communication), but
in the absence of major advances in therapy, HIV related disease will
continue to be a major cause of morbidity, and the ultimate prognosis
remains bleak.
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Early symptoms and signs in children infected perinatally with HIV
Sian/svmDtom No (n = 11)








Failure to thrive 6
TABLE III.4.3
Symptoms of advanced HIV disease in perinatally infecti
SvmDtom No (n = 111
POP 2









VIRUS INFECTIONS OF THE RESPIRATORY TRACT IN HIV
INFECTED CHILDREN
Aims
To investigate whether the rates of respiratory viral isolation,
and severity of respiratory symptoms in HIV infected children were
higher than in non-HIV infected children from the same socio¬
economic group.
Methods
Fifty of the children born to HIV seropositive mothers in
Edinburgh were enrolled, and studied up to the age of 2 years. The five
infected children (cases 1-5) formed group A. Forty five index children
considered not to be infected with HIV (group B) were studied from
September 1987-September 1989. Nineteen children whose fathers
were HIV seropositive but whose mothers were HIV seronegative were
also investigated for one year (group C).
At the three monthly visit, history and examination were
performed as previously described. One set of nose and throat swabs
was taken at each visit; repeat specimens taken during hospital
admissions were not analysed in this study. Results were analysed
using Chi-squared test for statistical significance.
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Results
Three hundred and one samples were collected for investigation
from sixty nine children over a 24 month period, and are summarised
in detail in table III.5.1. Although a small number of opportunities for
obtaining nose and throat swabs were missed, this was not
significantly different between the groups. Group A had significantly
more respiratory infections, and more samples positive for viral
isolation than group B. Over the first year, however, groups B and C
did not differ (table III.5.2).
The viruses isolated are listed in table III.5.3. There was no
difference between all 3 groups in the proportion of positive virus
isolations associated with symptoms. Symptoms usually accompanied
infections with influenza A, parainfluenza, RS and adenovirus infection,
whereas isolation of CMV or Coxsackie was more often asymptomatic,
rhinovirus occurring about equally in symptomatic and asymptomatic
children. CMV was isolated on more than one occasion from nose and
throat swabs in HIV infected and noninfected children alike. Although
upper respiratory tract symptoms accompanied this finding on some
occasions, in no child was there any suggestion of CMV pneumonitis.
Statistical analysis of the difference between groups was not
undertaken due to the small number of viral isolations in each group.
Six of the 10 proven viral infections in group A necessitated admission
to hospital, compared with 9/32 in group B, a difference which was
significant (p<0.05). All 3 children with influenza A infection were
admitted. Others were RSV (3 group B), parainfluenza (2 group A, 1
B), adenovirus (2 A, 1 B) and measles (1 B). No child required assisted
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ventilation, and specific antiviral therapy was not required.
The three children from group A who suffered from recurrent
infections were commenced on IVIgG infusions, as prophylaxis against
recurrent bacterial infections as described in chapter 9. In these 3
children, the proportion of virus isolation positive specimens before
treatment was initiated was 7/11, compared with 3/13 in the
subsequent period while they were receiving regular IVIgG infusions, a
decrease which also was significant (p<0.05). No child was
commenced on zidovudine during this time.
In one child in group B, influenza A infection was associated
with a profound drop in CD4 count, from 2.04 x 109/l to 0.27 x 109/l,
and in CD4/CD8 ratio form 1.9 to 0.5, returning to previous levels on
recovery from the illness. We therefore analysed the effects of
respiratory symptoms and viral isolation on mean CD4 counts for
groups A and B. No significant difference in mean values were
observed between samples taken when asymptomatic and at the time
of symptoms or viral positivity for either group, although the mean was
lower in all cases in infected children (0.99 x 109/l in group A and 2.69
x 109/l in group B). Similarly, no change was seen in CD8 +
lymphocyte levels.
Discussion
The susceptibility of HIV infected children to recurrent and
chronic bacterial respiratory infection is coincident with a functional
antibody deficiency (Pahwaetai 1986). As HIV infected children also have a
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cellular immunodeficiency, it might therefore be anticipated that these
children may suffer more acute viral infections (as in Severe Combined
Immunodeficiency) than HIV uninfected children.
Despite the small number of children proving HIV infected
available for study, we have demonstrated an increased rate of
respiratory viral isolation in HIV infected children in the first two years of
life compared with appropriate controls which reaches statistical
significance. Although it may at first appear that the infected group
were sampled more often (6.0 times per child in the infected children
compared with 4.9 times per child in the uninfected children), this is
due to the differing ages of the children at the start of the study, and
some children not having reached 2 years at the close of the study.
Neither the number of missed sampling opportunities nor the
frequency of sampling differed between the 2 groups (table III.5.1). The
increased rate of viral isolation observed may be due to HIV infection
causing greater susceptibility after exposure to viruses other than HIV,
or to a greater virus load and more prolonged excretion during any
given episode, making viral isolation on sampling at intervals more
likely. We have not, however seen the chronic excretion of agents such
as parainfluenza virus, which has been reported by others (Josephs etai
1988).
A recent study has suggested that HIV infected children who
develop RSV bronchiolitis have prolonged viral carriage, and a high
mortality rate of 20% (Chadwani et ai 1990). However, both the deaths in the
study by Chadwani et al occurred in children who were severely
immunocompromised (CD4 counts less than 0.2 x 109/l) and had
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superimposed opportunistic infection. It is perhaps fortuitous that our
HIV infected children escaped RSV infection when RS infections were
widely occurring in the community, but the uncomplicated course of
other viral infections, such as parainfluenza suggests that their immune
function was relatively well preserved at the time, as these children had
a mean CD4 count of 0.99 x 109/l.
In our study we used two different control groups of children
who had the same social background as the HIV infected children, and
have demonstrated that children born to HIV seropositive mothers who
are not HIV infected do not differ in rates of respiratory infection from
those not exposed to the risk of HIV infection. In all three groups poor
housing, overcrowding, and parental smoking habits may contribute to
a higher than average morbidity in this respect.
The finding of fewer positive viral isolates in HIV infected
children following IVIgG therapy is interesting, although given the small
number of children involved, these results should be interpreted with
caution. One possible explanation could be that children outgrow
susceptibility to viral infection after the first year of life, but this is not
borne out by the rates in group B children, which were constant
between the two years. Nonetheless, immunoglobulin therapy has
been shown to prevent Echovirus infection (Nagington etai 1983), reduce the
shedding of RSV (Hemmingetai 1987), and may have beneficial effects in
CMV infection (Moms 1988 [b]), suggesting that the reduction of viral
isolates may be a beneficial side effect of IVIgG therapy.
We conclude that respiratory viral infections occur more
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frequently in HIV infected children. Given the ubiquitous nature of these
agents and the lack of available specific therapy for treatment or
prophylaxis, further studies are required in larger groups of HIV
infected children to assess the incidence of recurrent viral infections
and their influence on the progression of HIV disease together with the
role of immunotherapy, such as the early use of IVIgG.
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TABLE III.5.1
Virus isolation in HIV infected (group A), and HIV uninfected (group B) children born to
HIV seropositive women
Group A Group B p*
no. of patients 5 45
no. of samples 30 220
age range (mean, median) 3-24(14.5,15) 3-24(14.0,15) NS
no. of missed sampling opportunities (%) 4/34 (12%) 22/242 (9%) NS
no. of symptomatic resp. infections 14 41 <0.01
no. of positive virus isolations 10 32 <0.05
* using the Chi-squared test
TABLE III.5.2
Virus isolation in uninfected children born to HIV seropositive (group B) and HIV
seronegative (group C) women
Group B Group C p_
no of patients
no. of samples
age range (mean, median)
no. of missed sampling opportunities










Viruses isolated from symptomatic and asymptomatic children born to HIV seropositive
women
Virus Symptomatic Asymptomatic Total
A B A B
Adenovirus 2 2 0 1 5
Influenza 0 3 0 0 3
Parainfluenza 2 2 0 1 5
RSV 0 3 0 1 4
Rhinovirus 1 4 0 3 8
CMV 3 1 2 5 11
HSVI 0 1 0 1 2
Coxsackie B 0 0 0 2 2
Measles 0 1 0 0 1
Echo 0 0 0 1 1
Total 8 17 2 15 42
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CHAPTER 6
DIAGNOSIS. TREATMENT AND PROPHYLAXIS OF PNEUMOCYSTIS
CARINII PNEUMONIA
Alms
To describe the diagnosis of PCP from non-invasive sampling of
respiratory secretion, and to assess the impact of the new CDC
guidelines for PCP prophylaxis on our cohort.
Methods
Laboratory diagnosis of PCP
Following addition of an equal volume of sputolysin (Behring
Diagnostics) and glass beads the sample obtained from
nasopharyngeal aspiration was vortexed for one minute and then
incubated at 37°C for three minutes. Ten ml of phosphate buffered
saline pH 7.2 was added and the mixture centrifuged at 2500g for 20
minutes. The pellet was resuspended in 1ml PBS and cytospin
preparations made on two poly-lysine coated slides. A cytospin
preparation of positive rat lavage material was used as a positive
control. After fixation for 30 minutes in equal volumes (50%) methanol
and acetone, trypsin (0.25%) digestion for ten minutes at 37°C
followed. A standard wash procedure of three five minutes with PBS
was carried out.
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Mouse monoclonal antibody to P. Carinii (Northumbria
Biologicals Limited) was added to the test and positive control slides
and PBS only, and incubated for 40 minutes. After repeat washing
antimouse IgG (Fab) conjugated to fluorescein isothiocyanate was
added and a further incubation of 40 minutes followed. After a last
wash procedure substituting PBS pH 8.4 for the final change, the slides
were mounted and viewed under UV light.
The sample was considered positive when three typical cysts
showing all-over fluorescence were seen, further confirmed by
methenane silver treatment of the control slide.
2) Analysis of CD4 counts
Routine measurement of CD4 counts became available in 1987.
All samples obtained from the study population after this time were
used.
Results
Two children in our series had proven PCP. In case 11 PCP was
the terminal illness, and diagnosis was made at autopsy by silver
staining. In case 4, described in appendix II, the diagnosis was
successfully made from nasopharyngeal secretions using the
fluorescent antibody technique described above.
The ranges for CD4 counts within the uninfected children are
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shown in table 111.6.1. CD4 counts in cord blood showed a wide
variation, and 9/42 samples from non-infected and control children
were CD4 lymphopoenic (< 1,000x10®/!). Case 4 is the only infected
child on whom cord blood data are available, but she had a normal
count of 2,340x10®/! at birth. At 3 months, when she already had
candidiasis, her CD4 count, at 1,940x10®/!, was still outwith the
recommended level for prophylaxis (cdc 1991), and was only found to
have dropped further to 1,080x10®/! when she presented with PCP.
Two index children who later proved uninfected had CD4 counts less
than 1,500x10®/! in the first year of life, and so would have been
treated had these guidelines been available, and one control child had
a similarly low CD4 count.
Of the other HIV infected children, 5 had CD4 counts sufficiently
low to merit prophylaxis (cdc 1991). Of the three who received none, case
11 developed PCP, but at a stage when he was otherwise grossly
debilitated, with an extremely poor quality of life. Two children, cases 6
and 13 received prophylaxis, and neither developed PCP. Case 6 failed
to tolerate cotrimoxazole and was commenced on monthly aerosolised
pentamidine when his CD4 count dropped below 200x10®/l, in
accordance with adult guidelines. Case 13 was commenced on oral
cotrimoxazole 3 times weekly at the time of diagnosis of HIV infection.
No side effects were experienced by either child.
Discussion
In HIV infection, the diagnosis of PCP has important
implications, not only for the treatment of the acute illness, but also for
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longer term prognosis. In general, children present with moderate to
severe disease and significant hypoxia, as did case 4 (Bernstein etai 1989).
Overall mortality due to PCP is quoted at 31%-70% in different series
(Kovacs et al 1991, Bernstein et al 1989, Connor et al 1991), but in infants leSS than 6
months old, mortality has been reported as high as 87% during the
acute episode, and 100% by 1 year (Chowetai 1989). Because of the risks
involved in, and the technical expertise required for paediatric
bronchoscopy, treatment is usually empirical. If the child succumbs,
autopsy may give the answers, as in case 11, but if the child responds
to high dose cotrimoxazole, the differential diagnosis between a
bacterial pneumonia and PCP remains unresolved. This then creates
difficulties in classification and staging of the child's disease, and in
making therapeutic decisions, such as whether to commence
zidovudine or PCP prophylaxis.
Identification of PCP from upper respiratory tract secretions may
only be possible in cases of overwhelming infection, and failure to
detect PCP by this method does not exclude the diagnosis. However, it
is in the most severe cases that the patient is least able to tolerate
more invasive procedures. Because our technique is rapid, other
methods can still be used thereafter without undue delay. We believe
therefore that it should be used as the first line investigation of
suspected PCP.
Case 4 was treated promptly with high dose cotrimoxazole. In
adults, this has been reported to be at least 80% effective in treatment
of first time episodes, being equally effective in this respect as
intravenous pentamidine (Corkeyetai 1988), and it remains first-line
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treatment. There is a high incidence of hypersensitivity reactions to the
sulphonamide, and myelosuppression may occunwofsy 1987), but case 4
escaped these sequelae. Intravenous pentamidine may also cause
neutropoenia, and tissue accumulation in the liver, kidney, adrenal and
spleen than in the lung, producing toxic effects in these organs(Donneiiyet
ai 1988). Aerosolised pentamidine has been shown to produce higher
levels in the lungs with little systemic absorption, and may become the
treatment of choice in the futu re(Montgomery etai 1988). Case 4 died before
alternative treatment was considered. It has since been suggested that
early use of corticosteroids may prevent deterioration (Montaner et ai 1990),
but there was no experience of their use in infants at this time. Survival
following ventilation for PCP in children has been described (Connor etai
199D, but the prognosis for children requiring mechanical ventilation is
extremely gloomy, such that the justification for this course of action
must be severely questionedtvemonetai 1988).
Our ranges for CD4 counts by age agree with other series (Denny
etai 1990). If the CDC guidelines for PCP prophylaxis had been followed
case 4 would not have received prophylaxis before presenting with
PCP, but 2 children who subsequently proved HIV uninfected would
have been treated unnecessarily. More studies are therefore required
to identify those children at particular risk of developing this severe
early consequence of HIV infection. In infants under a year in whom a
definitive diagnosis of HIV has been made, particularly in the presence
of candidiasis (ecs 1991) there is a case for universal prophylaxis
irrespective of CD4 count.
Current CDC recommendations for the choice of prophylactic
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agents are listed in Appendix I, table 7. It remains to be seen whether
these measures will have an impact on the mortality from HIV infection,
or whether other manifestations of immune compromise will merely
assume a more prominent role in causing morbidity and mortality.
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TABLE III.6.1
CD4 counts from HIV uninfected children.
























































CDC recommended level for starting PCP prophylaxis
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CHAPTER 7
THE PROGNOSTIC VALUE OF HIV ANTIGEN. CORE ANTIBODY. CD4
LYMPHOCYTE AND IMMUNOGLOBULIN MEASUREMENT - A
LONGITUDINAL STUDY
Aims
This study set out to quantify HIV Ag, p24 Ab levels, and
measure CD4 lymphocyte counts and immunoglobulin levels, to relate
these to the onset of symptoms, clinical progression and therapeutic
intervention.
Patients and Methods
Cases 1-11 were identified at age 0-47 months (median 21
months). Three had been followed since birth, two were identified while
still asymptomatic, and 6 presented with symptomatic disease. The
median duration of follow-up was 36 months (range 4 - 69). In those
surviving, the median follow-up was 51 months (range 24-69).
Results
Of the 11 children, 10 had symptoms and signs of HIV infection,
one child (case 5) had lymphadenopathy, hypergammaglobulinaemia
(IgG of 20g/l) and reversed CD4/CD8 ratio (0.8), but remained
clinically well. Nine children had detectable HIV Ag during follow-up,
and in 5, HIV Ag was detected before the onset of symptoms. Clinical
128
details can be found in appendix II and are summarised in table 111.4.1,
pill). Laboratory data is contained in table III.7.1. In order to illustrate
the different patterns in laboratory indices with time, sequential HIV Ag,
P24 Ab, CD4 counts and weights on all 11 children are illustrated in figs
III.7.1-11. The 50th centile for weight is that defined on standard
Tanner charts, and that for CD4 count is derived from table 111.6.1.
Six children (cases 2,4,6,8,10,11) had HIV Ag levels above
50pg/ml and were negative for p24Ab (group 1). All died at ages 4-82
months, median 45 months. Four (cases 1,3,7,10) had low or negative
HIV Ag values, and none has died nor progressed to AIDS during the
period of follow up of 40-69 months (group 2). Of these, 2 have been
negative for p24 Ab, but all now have detectable p24Ab. Two children
(cases 5 and 6) have been positive for p24 Ab, but also HIV
antigenaemic (group 3). Both remained clinically stable while positive
for both HIV Ag and p24 Ab. Case 6 subsequently became negative for
p24 Ab, meeting the criteria for inclusion in group 1 and so he changed
group at this point. Clinical deterioration ensued. Case 2 was HIV Ag
negative for 30 months, during which time her clinical condition was
stable, and only developed HIV Ag >50pg/ml at 72 months of age,
after which she is included in group 1. Group 1 children also showed a
significantly greater rate of fall in CD4 count than group 2 (p<0.01,
Wilcoxon rank sum test). CD4 count remained stable in cases 5 and 6
while they met group 3 criteria.
Data are available on 6 children in the first 2 years of life, and 3
were followed from birth. Case 4 was negative for p24 Ab from birth,
with rapidly increasing HIV Ag to 145pg/ml at her death at the age of 4
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months. Cases 1,2, and 3 had positive values for p24 Ab initially, but
levels declined, coincident with emergence of low levels of HIV Ag. In
these children, who were clinically stable, HIV Ag became negative and
p24 Ab was subsequently detected.
CD4 counts are available for 6 children at the onset of
symptoms. The mean count was 3.02x109/l, which is well within the
normal range (see table 111.6.1, page 125). Although in most cases CD4
counts only began to fall once clinical symptoms and signs were
apparent, case 10 remained clinically well for 6 months after her CD4
counts had dropped precipitously.
Table III.7.1 also shows the rate of decline of CD4 counts for
each child. Those who died had a greater rate of decline per year
(median 90%, range 25%-99%) than those who remained stable
(median 15%, range 0%- 25%). This is true even for case 4 who died
with a CD4 count of 1.08x109/l, as discussed previously. Four of the
other children who died had unrecordable counts in the terminal
phase. A CD4 count persistently less than 0.1x109/l was associated
with death after a median of 6 months (range 3-8 months).
Raised IgG levels above the normal range for age were seen in
all children reaching 6 months of age; by 6 months in cases 1 and 3
followed from birth, and at presentation in all others. Levels rose to a
median peak of 28g/l (range 4-72g/l), at the age of 47 months (range
4-63). Nine children also had raised IgM, reaching a median peak of
3.4g/l (range 2.25-5g/l) at 51 months (range 15-82). There was no
relationship between either IgG or IgM levels and progression of
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disease. Four children (cases 6, 8,10, 11) had raised IgA levels. In all
cases levels rose before progression of clinical disease, and was
associated with a poor prognosis. All children had died within 2 years
of IgA being above the normal range.
The effect of IVIgG and AZT on laboratory parameters is
discussed in subsequent chapters. Cases 6 and 8 received plasma
rich in anti p24 antibody on 2 and 6 occasions respectively. Both had
at this time received IVIgG infusions for 18 months. One child (case 8)
had received zidovudine in the past, but this had been discontinued
because of toxicity and poor compliance. She was extremely ill with
unresolving pneumonia, and died 8 weeks later. Case 6 remained
clinically stable during treatment. Figure 111.7.12 shows the serological
response in case 6. The plasma infusions were effective in clearing HIV
Ag completely, and raising p24 Ab levels 2 hours after completion of
the infusion. However, as p24 Ab levels declined, HIV Ag reappeared
between 7 and 14 days later, returning to the previous level by 6
weeks. On the 3 weekly infusion regimen HIV Ag reemerged despite
positive p24 Ab. Children in group 1 treated with IVIgG and AZT, they
still had a poorer prognosis than children in group 2.
Discussion
Our results indicate that HIV Ag assay is valuable as an early
diagnostic test in children born to HIV seropositive mothers. Nine of
eleven infected children were positive for HIV Ag, 6 of whom were at
the time either asymptomatic or had symptoms not specific for HIV
infection. Our study also underlines the importance of regular
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prospective follow up of all children born to HIV infected mothers, as
peak HIV Ag levels may occur in the asymptomatic phase, and would
be missed if the child were only identified on becoming ill.
Other studies have correlated persistent HIV antigenaemia and
lOSS Of p24 Ab With a poor prOgnOSiS(Epstein et al 1988 [b], Ellaurie & Rubinstein
1991). Our results also suggest that high levels of HIV Ag in the absence
of p24 Ab rather than the duration of antigenaemia is significant in HIV
infected children whose disease progressed. Our observation of the
difference in the rate of decline of CD4+ lymphocytes between groups
1 and 2 has been described in adults (Andrieu etai 1988), but there has been
no previous report in children.
A decline in p24 Ab has been reported to precede HIV
antigenaemia, and to correlate with a poor prognosis in adults (Forsteretai
1987). In children born to HIV seropositive women, such a finding is
difficult to interpret because of the inevitable decline of passive
maternal antibody in the first year of life. There have been no previous
reports relating p24 Ab levels at birth with progression of disease in
children, although our data, and others' suggest that maternal p24 Ab
during pregnancy does not correlate strongly with the risks of
transmission (Goedertetai 1989). Our preliminary longitudinal study of three
children suggests that absence of maternal p24 Ab at birth may be
associated with rapid progression in children who are infected, but
further studies on larger groups of children are required.
Two of the children studied (group 3) were simultaneously p24
Ab positive and HIV antigenaemic. In 2 previous reports (Borkowsky et ai
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1989, Eiiaurie & Rubinstein 1991) this feature was found in half of the children
studied, but no attempt was made to correlate this finding with
prognosis. In adults it occurs infrequently (Andrieuetai 1988). This may be
because high levels of antibody are produced as a response to HIV Ag
by the immune system of the child. Children may also be more likely to
have active viral replication, and the rate of spontaneous mutation of
HIV is such that the p24 Ab produced by the host lacks specificity,
and so avidity. It is interesting, however, that in the children we studied
this state was not associated with rapid clinical deterioration. In case 6,
clinical status and CD4 counts remained stable until p24 Ab became
undetectable.
The association between declining CD4 count and progression
to opportunistic infections and AIDS is well documented in adults (Masur
et ai 1989, Philips et ai 1989, schecter et ai 1987). In children, interpretation of falling
CD4 counts is complicated by the fall that normally occurs within the
first years of life (Faicao et ai 1987), but our findings that low CD4 counts of
<0.1x109/l and a rate of decline of >60%/year are associated with a
poor prognosis supports the findings of other groups (Blanche etai 1990,
Montorte et ai 1990). The rate of decline of CD4 numbers, rather than the
absolute number, may provide a useful guide as to when to
commence therapy, rather than waiting for symptoms to develop.
The usefulness of immunoglobulin measurement in the first
months of life has been discussed in chapter 2. We have found no
correlation between the levels of IgG and progression of HIV disease,
although very high levels may lead to symptoms of hyperviscosity (see
chapter 9). The association between IgA levels >4g/l and shortened
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survival is well documented in adults (Pederson etai 1990), but is not thought
to be as good a predictor of development of AIDS as CD4 counts or
B2 microglobulin and neopterin (Faheyetai 1990). Its predictive value in
children has yet to be explored.
The use of plasma rich in p24 Ab has not been reported in
children, although clinical benefit has been described in adults (Jackson et
ai 1988). We therefore chose a dose of plasma equivalent to that which
had already been used in Jackson's study, and continued as long as
case 8 survived, and as long as supplies lasted in case 6. Little is
known about the role of host immunity in HIV infection, but if HIV
antibody has a protective role then passive HIV specific immunisation
may have a place once humoral immunity becomes defective. If HIV
Ag itself is a direct cause of symptoms or progression in HIV infection,
a reduction of HIV Ag levels may be beneficial (Jackson etai 1988). We
demonstrated that infusion of this plasma rich in p24 Ab was effective
temporarily in removing circulating HIV Ag. However, the effect was
short-lived, HIV Ag reappearing in 2 weeks. Further studies are
required to determine the dosage, volume and frequency of
administration necessary for sustained antigen suppression before
clinical effects can be evaluated.
We conclude that HIV antigenaemia may precede symptoms in
HIV infected children, when CD4 counts are well maintained, and thus
HIV Ag may be a more useful aid to early diagnosis. High levels of HIV
Ag, loss of p24 Ab, and low or rapidly declining CD4 counts are poor
prognostic signs irrespective of current clinical status, or therapeutic
intervention.
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FIGURE III.7.2
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FIGURE III.7.5
Laboratory parameters for case 5
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FIGURE III.7.6
Laboratory parameters for case 6
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FIGURE III.7.7
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FIGURE III.7.9
Laboratory parameters for case 9
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CHAPTER 8
HLA ANTIGEN FREQUENCIES IN CHILDREN BORN TO HIV
INFECTED MOTHERS
Aims
This work represents a preliminary study to look for HLA
associations in the study children.
Patients and methods
The subjects were 48 infants from the Edinburgh cohort and
also cases 6-10. Whenever possible, tissue typing was performed
immediately after birth from cord blood; otherwise samples were
obtained during follow-up visits. Tissue typing for HLA-A, B, and DR
antigens was carried out as previously described (section II.3) and
control data from unselected babies born to healthy mothers were
taken from a previous study gazwinska & wipatrick 1987).
Results
The HLA antigen frequencies obtained from 47 unrelated babies
are listed on tables III.8.1 and III.8.2. The frequencies for the total
group under study differed little from those of the control group born to
healthy mothers (unselected for HIV status). However, there were
marked increases in frequencies of HLA-B18 (RR = 7.9; x^=7.9;
p = 0.005), B7 (RR = 1.9; p>0.05) and DR2 (RR = 2.0; x2 = 3.74;
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p=0.05). The associations with HLA-B18 and DR2 were not prior
hypotheses, however, and so are not statistically significant after
correction for the number of antigens tested.
Comparing HLA antigen frequencies between HIV infected and
uninfected babies, the most striking difference was in HLA-DR3, which
was 3-fold higher in the infected infants. Frequencies of HLA A1 and A2
were also elevated in the infected group, while HLA-A3 was
proportionately more abundant in the HIV uninfected group.
The rather high frequencies of both B7 and DR2 prompted us to
examine the second commonest HLA antigen combination in the
general population, A3, B7, DR2, as well as the much commoner A1,
B8, DR3 combination which has formerly been implicated in disease
susceptibility by others (table III.8.3). The combination A3, B7, DR2
(which often occurs as a haplotype) was four times commoner in our
study population relative to the controls (RR = 3.9; x2=9.1; p< 0.003),
but was found only in babies who were not HIV infected. The
combination A1, B8, DR3, in contrast, was found less often than
expected in our study group (RR=0.39; p=0.06) and was
disproportionately represented amongst the infected babies.
Five families were also studied (one member of each was
included in the unrelated series). There were three sets of twins, a pair
of brothers and a set of three sisters. Of all the twins, only one child
(case 3) was HIV infected and she shared one haplotype with her
uninfected sister; the two uninfected twin pairs shared one and two
haplotypes, respectively. The brothers, neither of whom were infected,
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shared one haplotype. Two of the three sisters, cases 9 and 10, all of
whom were HIV infected, were HLA identical. Case 8 shared one
haplotye with the other two.
Discussion
The low rate of transmission seen in the Edinburgh cohort may
be related to the genetic characteristics of our study population. The
HLA antigen frequencies in the babies reported here, representing a
relatively deprived social group, differed somewhat from our controls,
which were babies of healthy parents unselected for HIV status, but
who were by comparison affluent and with no history of intravenous
drug use. Most notably, the relative incidence of the two commonest
HLA antigen combinations (which usually occur as haplotypes) were
reversed. Our data are consistent with an earlier report that A1, B8,
DR3 is associated with susceptibility to infection (steei et ai 1988> and
support the speculation the A3, B7, DR2 might confer some measure
of protection.
On the basis of this small survey, it is clear that tissue typing
would be of little value as a predictive test in babies born to mothers
known to be HIV positive. There were no absolute differences in any
antigenic specificity when comparing HIV infected and uninfected
children, and our family studies revealed no obvious relationship
between haplotype inheritance and disease susceptibility of
progression. However, HLA antigens may be associated directly or
indirectly with susceptibility to transplacental infection, and this might
manifest itself as varying transmission rates in different populations. In
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particular, a high A3, B7, DR2/A1, B8, DR3 ratio may contribute to a
low transmission rate, and this possibility may merit further
investigation as a specific hypothesis.
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TABLE III.8.1
HLA Class 1 antigen frequencies in unrelated neonates born to HIV seropositive women
Specification Infected %
n = 8
Uninfected % Total %
n=38 n=46
A1 50 23.7 28 (39)
A2 75 36.8 41 (52)
A3 12.5 42 37 (32)
A11 0 18 15 (11)
A23 0 0 0 (4.5)
A24 12.5 15.8 13 (17)
A25 0 15.8 13 (4.5)
A26 25 0 4.3 (3)
A28 12.5 2.6 4.3 (4.5)
A29 0 5.3 4.3 (5.3)
A30/31 12.5 5.3 6.5 (5.3)
A32 12.5 7.9 8.7 (3.8)
B5 0 5.3 4.3 (4.2)
B7 37.5 47 46 (31)
B8 25 18 20 (31)
B13 12.5 2.6 4.3 (5)
B14 0 10.5 8.7 (9)
B15 0 7.9 6.5 (10.6)
B16 0 5 4.3 (6.8)
B17 25 10.5 13 (8)
B18 12.5 10.5 11 (1.5)
B21 25 0 4.3 (4-5)
Bw22 0 7.9 6.5 (5.3)
B27 0 5.3 4.3 (6.8)
B35 12.5 15.8 15 (14)
B37 0 0 0 (3)
B40 0 10.5 8.7 (11.4)
B44 25 15.8 17 (27)
Figures in parentheses are the corresponding proportions for control neonates born to healthy
mothers unselected for HIV status.
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TABLE III.8.2
HLA class 2 antigen frequencies in unrelated neonates born to women infected with HIV
Specificity Infected % Uninfected % total %
n = 7 O)COIIc n = 46
DR1 0 10 8.7 (12)
DR2 43 44 43 (28)
DR3 43 15 19.6 (39)
DR4 29 28 28 (25)
DR5 14 18 17 (13)
DRw6 29 18 19.6 (34)
DR7 29 33 32.6 (26.5)
DRw8 0 2.6 2 (3.8)
DRw9 0 5.1 4.3 (0)
TABLE lil.8.3
HLA antigen combinations in unrelated infants born to HIV seropositive women
Combination Infected % Uninfected % total %
n = 7 n = 38 n = 45 in =132)
A1,B8, DR3 28.6 7.9 11.1 (24.2)
A3, B7, DR2 0 28.9 24.4 (7.6)
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CHAPTER 9
INTRAVENOUS IMMUNOGLOBULIN IN HIV INFECTED CHILDREN
1) EVIDENCE FOR THE EFFICACY OF THERAPY
Aims
The aims were to evaluate the clinical effect of at least 12
months' IVIgG therapy, to document any changes in laboratory indices
of viral activity, and to assess the financial implications of committing
children to maintenance treatment with IVIgG.
Patients, Materials and Methods
The first eight patients identified with clinical and laboratory
evidence of HIV infection were studied (cases 1,2,3,6,8,9,11,13).
Clinical manifestations have been discussed in chapter 4, and detailed
descriptions of the cases are found in appendix II (summarised in table
III.4.1, page 111). Symptoms and signs at the commencement of
IVIgG therapy summarised in table 111.9.1. Monitoring and treatment
regimens were as previously described.
The financial implications were calculated on the basis that the
cost of immunoglobulin for a 15kg child is £45 and of materials,
medical, nursing and administrative staff time, £40, estimated at 1987
prices, based on 10 minutes of medical time, 1 nurse between four
154
children for the duration of the infusion (2 hours), and minimal
administration at each visit. This gave a total of £85 per visit, or £1600
per year. The cost of in-patient paediatric care in SE Scotland was
£960 per week <csa 1988) at the time of this study. Statistical analysis of
episodes of infection and changes in weight velocity utilised the
Wilcoxon rank sum test, and the days spent in hospital the Chi-
squared test.
Results
After 12 months on treatment, subjective improvement in
general well-being was reported in all 8 patients (see appendix II). The
number of infections sufficiently severe to require hospital review was
significantly reduced on therapy (fig III.9.1). Improvement in weight
gain was seen in the cohort as a whole, as shown in fig III.9.2, the most
dramatic change being seen in those children in whom failure to thrive
had been a presenting feature. Changes in other signs and symptoms
are summarised in table III.9.2.
The average number of days spent in hospital in the 12 months
immediately prior to treatment (9 months from birth in case 1) was 220
(range 0-60), compared with 56 (range 0-20) in the first 12 months on
IVIgG (p< 0.001). Assuming an unchanged rate of infection, the
difference between actual and expected number days of
hospitalisation would be 181.6, resulting in a saving on inpatient costs
of £24905, standing against treatment costs of £12800. Thus the net
saving in costs is £1513/patient/year, or 49%, even without taking the
travelling costs and time lost to the family in attending hospital into
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consideration.
Symptomatic thrombocytopoenia, seen in 2 patients prior to
therapy showed no immediate improvement on this dose of IVIgG, and
a further child developed purpura while on therapy.
Hypergammaglobulinaemia, seen in all patients prior to treatment, was
not significantly changed by therapy, and CD4 counts continued to
decline, as shown in fig III.9.3.
All patients were HIV seropositive by ELISA and virus was
isolated in culture from all 8. Five children (1,2,3,8,and 11) were
antigenaemic and p24Ab negative prior to the start of therapy.
Changes in HIV Ag level after commencing therapy are shown in figure
III.9.4, p24 Ab levels changing in a reciprocal manner. Loss of HIV Ag
was sustained in three children, but case 8, who had much more
advanced disease on commencing therapy, became antigenaemic
again 9 months into therapy, and case 2, 30 months later (see figs
III.7.1-11, page 136-146). Two children (9,13) have been consistently
HIV Ag negative, and in one child (6) insufficient data are available
before the start of therapy, but 12 months into treatment he was HIV
Ag positive (>150pg/ml).
Treatment was well tolerated in all children. One child developed
symptoms attributed to hyperviscosity, as described below, but he has
had further infusions at a slower rate without incident. No other side
effects have been observed.
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Discussion
Anecdotal evidence of the benefits of IVIgG therapy after short
periods of follow-up had been reported previously by a number of
groups using regimens varying from 200mg/kg monthly coieskeetai 1987)
to 300mg/kg every 2 weeks (Caivein & Rubinstein 1986). All demonstrated
reduction in febrile episodes and number of bacterial infections. A
more detailed analysis of clinical effect was provided by Schaad et al
(1988), but the length of follow up was limited to only 6 months in 4 of the
7 children described. Oleske et al in a larger but non-randomised
study(oieske et ai 1987) suggested that mortality is decreased. Calvelli and
Rubinstein (1986) and Gupta et al (Gupta etai 1986) also noted changes in T
cell and cell mediated immune function in vivo. However, in all studies,
interpretation of results was hampered by the small numbers involved
and the lack of control data. During the course of our study, a large
multicentre trial was commenced in the United States (nich ivigG study Group
1991). Because of the limited treatment options, and the small number of
children involved, at the time when this study was carried out, we felt
an untreated control group was not appropriate. However, because we
followed these children prospectively from the time of their diagnosis
as being HIV positive, we obtained reliable sequential data for a
comparable 12 month period immediately before treatment was
commenced. This enabled us to use each patient prior to treatment as
his own control. Long term studies now suggest that in children
surviving past the first year of life, the symptoms of HIV children tend to
improve in the second year(Ecs 1991). The age range of the children we
studied was very wide (9 months to 47 months) so although it is
possible for spontaneous improvement to have occurred in cases 1
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and 3, it would have been less likely for the others. In addition , no
previous group had documented changes in HIV Ag and p24 Ab levels
following treatment, nor had the financial implications been assessed.
Our group showed a great deal of heterogeneity in terms of
age, duration and severity of symptoms prior to therapy, posing
difficulties when analysing the cohort as a whole. These were partly
overcome by using the patient as his own control, and also, for
example, by standardising growth data in terms of velocities. The
choice of our dosage regimen aiming to provide the optimum benefit
with minimum distress for the child was based upon data from
treatment of primary hypogammaglobulinaemia (Leen etai 1986). It is
possible, however, that higher doses may be required more frequently
in hypergammaglobulinaemic patients, since the half life of IgG is
reduced at higher serum concentrations. This issue of optimal dosage
will only be resolved by further studies of efficacy.
Disappearance of HIV Ag has been described in adults following
the infusion of plasma high in p24 Ab and neutralising capacity has
been described previously (Jackson etai 1988). No studies of normal
immunoglobulin therapy have documented changes in HIV Ag, and in
view of the small numbers involved, further studies will be required to
verify these findings. The mechanism of action is likely to be different,
as plasma donors are screened for HIV infection and the IVIgG
preparation has no anti-HIV antibody. The production of HIV Ag is an
indicator of enhanced expression of viral genes (Nabei 1988), and may
reflect the expression of latent virus following activation of helper T
cells. Bacterial and viral infection increase T cell activation, and the
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disappearance of HIV Ag following therapy may be due to the
reduction of viral activation following the decrease in infective
episodes. The continued decline in the CD4 count was disappointing,
but the disappearance of HIV Ag with IVIgG therapy suggests that the
progression to AIDS may be delayed, since the loss of p24 Ab and the
appearance of HIV Ag are recognised bad prognostic signso-angeetai
1986).
The clinical benefit of therapy we have demonstrated, together
with the quality of life enjoyed by our patients leads us to conclude,
with Schaad's group (Shaadetai 1988), that there is no case for withholding
therapy in symptomatic children, pending the results of the double
blind placebo controlled trial(NicH ivigG study Group 1991). What remains
unclear is at what point in the course of disease treatment should be
commenced, given that 5 of our children were in the early stages of
symptomatic disease (CDC stage P2 A/F). Further studies are also
needed to optimise the dosage regimen. A controlled trial will be
necessary if we are to consider treatment in asymptomatic children.
This is likely to be problematical because of the lack of a reliable
diagnostic test of HIV infection in young children. As the number of HIV
infected children grows over the next few years, routine therapy has
major implications in budgeting of hospital in patient and day care
facilities, which we have addressed by demonstrating the cost benefit
of therapy, at least in the short and medium term. It is unlikely,
however, that IVIgG will delay progression indefinitely, and further
advances in immunotherapy, such as the introduction of specific anti-
HIV neutralising antibody in combination with IVIgG and anti-retroviral
therapy will be required if we are to improve the ultimate prognosis for
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these children.
2) HYPERVISCOSITY AS A POTENTIAL HAZARD DURING
THERAPY
Aims
To report an HIV infected child in whom infusion of IVIgG led to
serious symptoms suggestive of hyperviscosity.
CASE REPORT
The patient (Case 13) became infected with HIV after blood
transfusion at the age of 4 months, before screening of blood for HIV
antibody was available. His history is summarised in appendix II. At 40
months he was commenced on regular infusions of IVIgG according to
the standard regimen.
Treatment with IVIgG was not associated with any adverse
reactions until the age of 4 years 10 months, when, due to an infusion
pump malfunction, the patient received the infusion 30% faster than
usual. He suddenly became confused, distressed, and was unable to
see. He was dysarthric before becoming totally aphasic, and a
transient right facial palsy was noted. Pupils remained equal and
reactive to light, eye movements remained full and no abnormality
could be detected on ophthalmoscopy. Tone, power and reflexes
remained equal and symmetrical. The IVIgG was immediately
discontinued, and a normal saline infusion set up. After 30 minutes, he
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fell asleep. Two and a half hours later there were no residual
neurological symptoms or signs. In retrospect, his parents commented
that he had had very brief episodes of confusion and drowsiness
during previous IVIgG infusions, on one occasion waking up after a
sleep appearing unable to speak. The effect had lasted a few minutes.
On the day of his severe adverse reaction his serum IgG, IgA
and IgM levels were 53.2g/l, 1.3g/l and 4.8g/l respectively. No
paraprotein bands were found on protein electrophoresis. His serum
relative viscosity measured by capillary viscometer was 5.0 before and
after the infusion (normal range 0.42-2.78). A computerised
tomography scan subsequently showed no abnormality, and the
patient has had no recurrence of symptoms suggestive of
hyperviscosity, continuing his 3 weekly infusions at a slower rate of
1.3ml/kg/hr. Subsequent viscosity measurements have varied
between 3.0 and 5.0 (data not shown) and there was no difference in
viscosity levels before and after IVIgG therapy. Immune complexes
were also measured before and after IVIgG therapy and no change
was observed.
Following this incident, we studied a further 7 children (Cases 1-
3,6-9) treated with IVIgG, none of whom had suffered side-effects
associated with IVIgG infusions. We also investigated 20 of the children
born to HIV seropositive mothers who were presumed uninfected. The
mean (+_ SD) viscosity in the HIV infected group was significantly
raised with a value of 3.2 _+ 0.96) compared with the non-HIV infected
group (2.3 _+ 0.39; p<0.01, Student's t- test).
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The relationship between serum IgG, IgA and IgM levels and
the serum relative viscosity was investigated in the above samples and
additional samples collected from the HIV infected children and the
serum relative viscosity was found to correlate both with IgG levels
(r=0.74, p<0.001) and with IgM levels (r=0.66, p<0.001). There was
no significant correlation between serum viscosity and IgA levels
(Table III.9.3). In other HIV infected children, serum viscosity was
measured on stored samples taken before and immediately following
IV IgG infusions. No rise in viscosity could be demonstrated in any
sample. Protein electrophoresis revealed no oligoclonal or monoclonal
bands in any of the specimens tested.
Discussion
Intravenous immunoglobulin has been used widely for the
treatment of primary hypogammaglobulinaemia and ITP. Adverse
reactions are rare, and in most clinical situations, serum
immunoglobulin levels are low or normal in the recipients. In HIV
infection, serum IgG levels prior to IVIgG infusion are usually high, and
problems with hyperviscosity had only once been previously described
in an HIV infected adult (Martin etai 1989).
The hyperviscosity syndrome has been described in adults with
paraproteinaemias (Faheyetai 1965), and in patients with autoimmune and
rheumatic diseases, when it is attributed to aggregates of intermediate
size, or to polyclonal IgG polymers (Someretai 198O). Although we have
shown that the serum viscosity is raised along with serum
immunoglobulin levels in these children, there have been no previous
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reports of hyperviscosity symptoms occurring after IVIgG infusion.
Clinical manifestations are rare in patients with viscosities less than 4
(Somer 1987). However, the 'symptomatic threshold' may be very variable,
although remaining constant for any given patient. In case 13, the
threshold was exceeded during one of the IVIgG infusions; no other
patient developed symptoms during a rapid infusion of IVIgG.
CNS involvement in HIV infection is discussed in chapter 4. We
could not definitely exclude CNS infection in our patient as we did not
have the opportunity to examine his cerebrospinal fluid at this time.
Nonetheless, it is possible that in a HIV infected patient with very high
IgG levels, hyperviscosity might contribute to symptoms previously
attributed to CNS infections and that methods of treatment which lower
viscosity may be beneficial.
On the basis of our findings, we therefore recommend that in
HIV infected children with very high serum immunoglobulin levels, the
clinician is alerted to the problem of hyperviscosity. Caution should be




Clinical features of the children on commencement of IVIgG
Case Age 1st symptoms IVIgG started CDC Stage Clinical features
(mths) (mths)




2 9 24 2A Recurrent URT sepsis
Recurrent pneumonia
Diarrhoea
3 9 14 2A Recurrent URT sepsis
Recurrent fever
Eczema























Symptoms and signs of the children before and in the 12 months after commencing IVIgG
Feature Before After p
Total (median) no. episodes pneumonia 13(2) 4(0) NS
Total (median) months diarrhoea 49(9) 21(3) <0.05
No. patients with: URT sepsis 8 8 NS
Eczema 5 5 NS
Lymphadenopathy 8 6 NS
Hepatosplenomegaly 7 8 NS
Thrombocytopoenia 2 2 NS
Table III.9.3.
Serum Viscosity and Immunoglobulin Levels of HIV Infected Children.
Case CDC Staae laG IqA laM Viscosity
13 P2C 53.2 1.3 4.8 5.0
9 P2C 46.8 0.3 2.3 3.5
6 P2F 29.6 3.3 2.4 3.5
3 P2A 24.0 0.7 2.2 2.0
7 P2A 18.8 0.7 1.2 3.6
2 P2A 17.2 1.2 0.9 3.2
1 P2A 14.8 1.6 1.1 3.0




Number of episodes of infection Weight gain
3 6 8 9
Case number
I Pre IVIgG 0Post IVIgG I Pre IVIgG □ Post IVIgG
Change in CD4 counts after IVIgG Change in HIV Ag after IVIgG
0 3 6 9 12
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THE USE OF ZIDOVUDINE IN SYMPTOMATIC HIV INFECTED
CHILDREN
Aims
To study the clinical effects and toxicity of zidovudine in children
with symptomatic HIV infection.
Patients and methods
Cases 1,2,6,8,11, and 13 received zidovudine for a median of 25
months (range 12-42). All had already received IVIgG for a median of
18 (range 1-31) months previously. Cases 8 and 11 had received IVIgG
for 2 and 1 months only before commencing zidovudine. Clinical
features are detailed in chapter 4 and appendix II and the laboratory
parameters in chapter 7. The principles of dosage and administration
are outlined in section II. Details for each case are summarised in table
111.10.1.
Results
Clinical benefit was seen in terms of improvement in
neurological signs and symptoms in both patients with evidence of
encephalopathy at the time when zidovudine was introduced, most
dramatically seen in case 11. Case 8 who had been on IVIgG for 2
167
months had no recurrence of oesophageal candidiasis once
zidovudine was commenced, and also suffered fewer infections. The
other 3 children had mild non-specific symptoms and signs only on
commencement of therapy, and although they remained stable,
showed no dramatic improvement. Of the four children who
commenced zidovudine more than a year after IVIgG only one had
been admitted to hospital because of infection on one occasion in the
previous 12 months, and so no change in rate of infectious episodes
could be demonstrated. Weight gain in the 12 months before and after
AZT was commenced is summarised in fig III. 10.1; gain in weight for
each case is illustrated in figs 111.7.1-11, page 136-146, and similar data
for case 13 in fig III. 10.4. There was a significant improvement in weight
gain (p<0.01, Wilcoxon rank sum) for the group as a whole, the 4
children who were least well at the start of therapy showing the
greatest change.
Five children had a history of HIV antigenaemia. No clear
relationship was observed between commencement of therapy and
change in HIV Ag or p24 Ab (fig III.10.2). HIV Ag reemerged during
therapy in cases 2, 6, and 8 after 1-14 months, perhaps representing
zidovudine resistance. CD4 counts were low in all children prior to
commencement of therapy, median 0.44x10^/1, range 0.05-0.64 x
10^/1. Following AZT, levels stabilised or rose in the next 6 months
before declining again at a slower rate than previously (p <0.05,
Wilcoxon signed rank test, fig III. 10.3).
Compliance with therapy was good on a TID regimen in all but
one patient (case 8), despite all being started on the intravenous
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preparation. This had a foul metallic taste, and had to be disguised in
juice. Zidovudine in case 8 was administered via a nasogastric tube
because of her refusal to swallow it, and her compliance was erratic.
This was reflected in MCVs, which in the other 5 rose from a mean of
78 (range 68-85) to 103 (range 96-114) over the first year, whereas in
case 8 they remained unchanged (85 to 87).
Early side effects were seen in case 2, who developed
headaches and aching limbs between 2 and 4 weeks into therapy. No
action was taken and symptoms subsided spontaneously. Two
children (cases 8 and 11) developed marrow toxicity 6 and 9 months
into therapy, both requiring blood transfusions for low haemoglobin.
Unlike the other children, both these cases had had low haemoglobin
levels before treatment was commenced. In case 8, AZT was stopped
when a neutropoenia developed (0.8x10^/1). A pancytopoenia
developed in case 11, haemoglobin falling to 7g/dl, total white count to
0.8x109/l, and platelets to 42x1012/l. AZT was stopped for 2 weeks
and then recommenced at half dosage. Zidovudine was discontinued
in case 6 because of marrow depression during chemotherapy, but no
toxic effect had been seen prior to this. In the others, haematological
parameters (excluding MCV) remained stable. Mean platelet count was
199x1012/l on commencing AZT, and 212x1012/l after one year, a
difference which is not significant, and no transient rise was seen
during the first months.
Discussion
By the time the children in our series were commenced on
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zidovudine, information from studies in large groups of adults, and
results of preliminary studies in children demonstrating its clinical
benefit in delaying disease progression were already available. As the
number of symptomatic children available for study in our series was
small, no controlled trial was considered either possible or appropriate.
Cases 1, 2, 6, and 13 had been receiving IVIgG for at least 17 months
before AZT was commenced. However, cases 8 and 11 commenced
AZT only shortly after IVIgG, so the individual contribution of each
therapy to any change in condition is impossible to distinguish. Our
findings are compatible with those of the recent large multicentre trial
of oral zidovudine, (McKinney et ai 1991), which has demonstrated a marked
improvement in cognitive function in those under 3 years, and in
weight gain on a dose of 720mg/m2/day in 4 divided doses. Results of
long term follow up in this study are not yet available, but our
experience suggests that these benefits demonstrated initially are not
maintained, and further progression of HIV disease is not delayed
indefinitely.
Our patients all commenced oral zidovudine when HIV Ag levels
were low or negative. We were therefore unable to confirm previous
observations of the reduction in HIV Ag following therapy (Epstein etai 1988
[b], Blanche etal 1988, Jackson et al 1987). However, despite a raised MCV,
suggesting adequate compliance and absorption, HIV Ag became
positive in two children and persisted while on therapy, and
reappeared transiently in a further two. Such gradual reemergence of
HIV Ag has also been described in adults (ig wiiiiams et ai 1990). This
suggests that viral suppression may be incomplete or the development
of resistance to zidovudine. We were unable to demonstrate any
170
consistent increase in p24 Ab following therapy (Blanche etai 1988).
A rise in CD4 count following zidovudine therapy is well
recognised (Dournon et al 1988, Fischl et al 1989, Blanche et al 1988, McKinney et al 1991), but
after reaching a peak at around 2 months, counts decline to pre-
treatment levels by 4 to 5 months, and continue to decline thereafter.
The variation in response to zidovudine in our group of patients may
reflect variation in the time taken to develop resistance, but it is
encouraging that CD4 counts remained stable in cases 1 and 2 during
3 years on therapy.
Three children remained free from side effects, despite
prolonged use of the drug. McKinney et al (1991) also found AZT to be
well tolerated, but side effects included vomiting (5%), insomnia (3%)
nervousness (2%) and abdominal pain (2%). Haematological toxicity
occurred in 61%, with 26% suffering from anaemia and 48%
neutropoenia. 23/88 children required transfusion. Clinical findings
suggestive of encephalopathy on dose reduction, such as occurred in
case 6 has been reported previouslyoneibert et ai 1987). There are, however,
no other reports in children. Overdosage has been described, with no
adverse effect (Moore et ai 1990). This is an important consideration, given
that the drug has to be given in households many of which are at
greater than average risk of accidental poisoning within the home (sibert
1975).
In adults on long term therapy, adverse reactions have
decreased over time (Fischi et ai 1989), but concerns over long term toxicity
remain. Myopathies have long been described(Bessenetai 1988, Gorardetai
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1988), and the mitochondrial myopathy reported more recently may
occur after an average of 12.8 months of therapy (Daiakasetai 1990). ECG
changes were seen in 3% of children in McKinney's series, and
echocardiographic abnormalities in 2% (Mcwnneyetai 1991). It is concerning
that two children in our series developed cardiomyopathy on therapy.
Case 13 had a history of major cardiac surgery, but he had normal
contractility until he had been on zidovudine for 18 months, and case 2
died of cardiac failure associated with a dilated cardiomyopathy.
Therefore the possibility of this being an AZT-related phenomenon
must be taken seriously. It is disappointing that no autopsy material
was available from case 2 for study.
Our findings are therefore in keeping with others' (Pizzoetai 1988 [b],
Blanche et ai 1988, McKinney et ai 1991) that in children with symptomatic HIV
infection, the benefits of treatment outweigh the risk of toxicity. Further
work needs to be done to determine the optimal dosage regimen to
achieve maximum antiviral activity with minimal toxicity, and to
determine the optimal time to commence therapy.
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TABLE 111.10.1
Clinical features of children on commencement of zidovudine
Case AZT started Dose
(months) (months)
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MANAGEMENT OF CHILDREN BORN TO HIV SEROPOSITIVE
WOMEN - A COMPARATIVE STUDY
Aims
Although numbers of children at risk of HIV infection are
growing, experience in any one centre at this time is limited, and so
collaboration between centres is essential if the maximum information
is to be obtained in the shortest space of time. This has been achieved
in the European Collaborative Study, which involves 10 centres in 6
countries <ecs 1988). Standardisation of procedure and data collection is
therefore required, but the practicalities of obtaining this data may be
extremely variable. Factors influencing management will include
cultural (or sub-cultural) differences, socio- economic background of
families involved and their compliance. Other factors include levels of
medical and technical staffing and the expertise of individual members
of the team, as well as the physical lay-out of the clinic and the
accepted methods of medical practice within an institution.
My aims in this study (sponsored by the Council of Europe)
were therefore to compare the practical management of children born
to HIV seropositive mothers in a Southern European centre (Padova,
Italy), and in a Northern European Centre (Berlin), with that of our own
centre in Edinburgh. I also aimed to increase my experience of the
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spectrum of manifestations of HIV disease in children, and of therapy.
Methods
In September 1989,1 visited Universita degli Studi di Padova,
Italy, and Universitatklinikum Rudolf Virchow, Freie Universitat, Berlin
(before the reunification of Germany) for two weeks each. I attended
the HIV clinics, interviewed staff, reviewed the patient's case files, and
in Padova, spent some time in the virology laboratories.
The Setting
The social geography of the three centres is compared in table
111.11.1. Padova is the regional centre of referral for paediatrics from the
province of Veneto. The city itself is small, population 230,000, and
many of the patients live in the surrounding small villages and towns.
This meant they had to travel considerable distances to attend the
clinic. Although in 95% of the children seen, there was a history of drug
misuse in at least one parent (in 10% the father only). Unlike
Edinburgh, very few of the mothers appeared to knew each other from
any drug sub-culture. Practically all had adequate housing and a
telephone, and the majority drove cars. By contrast, Berlin is a huge
city, population 2 million. Because of the difficulties of travelling to the
rest of West Germany, it was a static population. There were chronic
housing shortages, and many young people wanting to leave the
family home resorted to 'squats' or living in caravans. It is in such areas
that drug use occurred and from which many of the children studied
came.
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In Italy, the cohesion of the families affected by HIV remained
strong. Many mothers were married or in stable relationships and
much of the support for the mothers came from the extended family.
This was also reflected in the small number of children requiring
fostering or adoption. Children were usually cared for within the family
until school age, and so it was when children at risk of HIV infection
were reaching five or six years, that the problem of integration into a
peer group had to be addressed. In Berlin and Edinburgh, many
women were not living in stable relationships, and their lifestyle were
less compatible with good child rearing. In Berlin, children have
required foster care, but none as yet has been adopted. Although day
care, and kindergartens were well established in Berlin, priority for
places went to mothers who had employment outside the home. If
women received benefit from the state to live, it was considered that
there is no reason why they should not care for their children, and so
they tended to come lowest in the list of priorities. Some children had
been found places, however. Both in Berlin and Edinburgh many of the
issues relating to the care of children at risk of HIV infection within such
institutions had been addressed.
The clinics and surveillance procedure
All children were seen according to the protocol of the
European Collaborative Study, although only those children identified
from birth qualified for inclusion into the study itself. The system and
personnel used for the surveillance varied greatly, as summarised in
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table III. 11.2. In both centres I visited, some HIV infected children from
risk groups other than vertical transmission were followed, whose data
I have not included.
In Padova, all routine reviews took place in the once weekly,
clinic, where up to 10 children were seen in a morning. Infants were
delivered in and referred from maternity hospitals covering a wide area,
so few were known to the clinic antenatally. Cord blood might be
collected by the staff in the maternity hospital at delivery, but this did
not occur in majority of cases. The first contact with the clinic was
therefore at a month or 6 weeks of age.
The general impression was one of a very formal setting.
Different rooms were occupied by the nurses, the paediatrician, the
neurologist, the neuropsychologist, and the adult physician. On arrival,
the child's blood was taken. Then followed the general medical
interview and examination, which could involve the participation of up
to three medical personnel. The child then received a detailed
neurological examination, again in accordance with a strict protocol,
and then a neurodevelopmental assessment. All infected children had
a yearly CT scan and CSF was obtained while they were under
sedation. At some stage, if she wished, the mother could also be seen
herself. The whole process took most of the morning, making it a long
day for those having to travel some distance. Despite this, the children
were on the whole cooperative, reflecting the attitude of their parents
who seemed to recognise the importance of the child's medical review.
However, as attendance at the clinic depended solely on the
motivation of the parents, it may be that those who were less motivated
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were the ones who failed to attend and were lost to follow-up. There
was no system of home visiting.
In Berlin a small set of rooms were designated for use by the
HIV clinic. Up to four children were seen every day for routine follow-up
or treatment, but rarely would more than one or two be on the
premises at the same time. One doctor would conduct the interview
with the help of the nurse, and carried out the general and neurological
examination, and venepunctures. The whole visit lasted on average,
about an hour. The older children were assessed by the psychologist
on a separate occasion. The social worker was available so that
relevant problems could be discussed and help sought during the
same visit. Compliance was high when the children were in alternative
care, and in all cases was greatly enhanced by the taxi service
arranged for and paid by the hospital to bring the families for their
appointments. Three home visitors deal with practical help for the
families, such as housework and child care for mothers who were
unwell, as well as nursing procedures at home.
Laboratory Evaluation
All centres performed a core of laboratory tests as agreed by
the European Collaborative Group, and listed in section II. In addition,
biochemical parameters, including urea and electrolytes, liver function
tests and proteins were measured in Padova and Berlin. In Berlin
protein electrophoresis was performed and IgG subclasses measured.
The virological tests available at each centre are listed in table III. 11.3.
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Results
Tables III.11.4 and III.11.5 give details of the children being
followed in the 3 centres, and their clinical features. The experience of
the natural history of the disease is similar in all 3 centres, the onset of
symptoms occurring in the first year for the majority of children. In
Berlin and Edinburgh there were deaths not necessarily associated
with HIV, Berlin having a sudden infant death in a five month old.
In all three centres, all symptomatic children remained HIV
seropositive at each test. Table 111.11.6 shows the results of other
laboratory tests. In Padova, in vitro antibody production in the first
months of life was a useful indicator of infection in 8 of the 9 infected
children followed from birth.
The diagnosis of HIV infection in children who were
asymptomatic, or with symptoms not specific for HIV posed problems.
In Padova 5 children classed as stage P1 had other immunological
abnormalities supporting the diagnosis, as had 2 in Berlin. All eight
children were hypergammaglobulinaemic, 7 had CD4/CD8 <1.0, but
only 2 had an absolute CD4 count <1.0x10^/1. Seven had persistent
HIV antibody beyond 18 months, the other child seroreverted and
remained negative. Seven were virus culture positive on more than one
occasion, and 7 had been HIV antigenaemic on more than one
occasion. Of the 5 Padova children, all four who were tested were
positive for IVAP. Although none had symptoms definitely related to
HIV, 7 of the 8 had persistent lymphadenopathy, 4 had
181
hepatosplenomegaly, one failed to thrive, one had recurrent diarrhoea,
and one recurrent fever.
There was another group of children for whom the basis of HIV
infection is made on virological parameters alone. In Padova, 6
children were defined as stage P1A. Four were over 18 months and
had seroreverted to become HIV antibody negative. Five were virus
isolation positive on one occasion, and 1 on 2 occasions. Three were
positive by PCR on more than 2 occasions, 2 on one occasion, and for
one the result was equivocal. Two had been HIV antigenaemic, and 2
produced a response on IVAP. For two children, the diagnosis of HIV
infection was based on viral culture alone, but the other four had had a
combination of positive tests.
In Berlin, although many children had at one time one positive
culture or viral antigen result, in only 5 children was this found on more
than one occasion, or by more than one test. A further child had no
virological indices of infection, but persistently low CD4 counts, and
decreased reaction to mitogen stimulation, suggestive of impaired cell
mediated immunity.
Treatment
Options available for the treatment of symptomatic HIV infection
include specific treatment for infective episodes, IVIgG infusions and
zidovudine. The criteria for the use of IVIgG in Edinburgh is described
in chapter 9, and children were treated in the same paediatric ward to
which they were admitted during any acute illness. Similar criteria were
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used in the other centres. Twelve children in Padova, including the 4
who died, were treated monthly with a dose of 400mg/kg. One room in
the clinic is set aside for this purpose, so that the children were
assessed during the weekly clinic. In Berlin 8 children were treated
monthly, also with 400mg/kg. Most children received their treatment in
the clinic, but they sometimes went to a paediatric ward if they were
well known there.
No definite criteria for commencing zidovudine had been
established. Five children meeting the criteria for paediatric AIDS were
being treated in Padova, and 2 in Berlin. Until recently all were using
the regimen of 400mg/m2/day. Padova used a twice daily dosage
regimen, Berlin four times daily. On this small sample, no conclusion
could be drawn on clinical benefit, and no pattern could be seen in
laboratory parameters before and after commencing therapy. One
child in Berlin had suffered myelosuppressive side effects, with
anaemia and neutropoenia. In Padova and Edinburgh, children on
zidovudine were reviewed at the time of their IVIgG infusions, which
they all received, every 4 and 3 weeks respectively. In Berlin, blood
counts were checked every 2 weeks because of the danger of
myelosuppression, and the neutropoenic child was seen weekly.
CMV retinitis is a complication I had not seen before my visit to
Berlin. In this child, its progression was extremely rapid, affecting both
eyes to render the child almost completely blind in the space of two
weeks. The child was being treated with CMV hyperimmune globulin,
which because of its short half life in vivo, has to be given every 2
weeks. Another child in the Berlin group without CMV related
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symptoms was also being treated on this regimen after being found to
excrete CMV chronically from the nasopharynx and in urine. She
received regular ophthalmology checks.
Discussion
My visit to two other European centres gave me the opportunity
to compare and contrast different methods of management of children
with the same spectrum of clinical problems, and where the same
research questions were being asked. Provision of the optimum level
of care means that a balance has to be struck between what is ideal for
the child, what is acceptable to the child and its family, and the
requirements of the research, which is also in the patient's interest.
Constraints include available resources, both financial and in terms of
the background and training of the personnel involved.
The differences between centres in assumption of roles is
illustrated well by that of the nurse. In Padova, the nurse was primarily
the technician, who carried out the practical procedures such as
venepuncture and setting up the infusions, and was neither involved in
management decisions, nor in counselling. In Berlin, she was the first
point of contact when the child came into the clinic, and her role was
that of assisting the doctor with practical procedures, and she carried
the major part of the administration. In Edinburgh, a specialist nurse,
the health visitor, with additional skills in screening of child
development, and in health surveillance within the community, assisted
the doctor during visits, but was not involved in the administration of
the project, and did not perform technical procedures.
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In Italy, the importance given to the family in society, and so to
the children within it, meant that most parents appreciated the value in
having their children checked even if they appeared well to reassure
them this was the case. They were sufficiently motivated to travel long
distances at their own expense, and to spend a long morning at the
hospital for this to be achieved. The advice given by the physicians at
the visit was generally accepted and complied with. The chief role of
the clinic was seen to be the provision of medical care and the
generation of research data.
Both in Berlin and in Edinburgh, the social circumstances of the
families were much more prominent in dictating the management of the
children. HIV infection was only one factor influencing the morbidity in
these families, and addressing other issues may be equally important
for the overall well-being of the child. Thus part of the role of the clinic
was to facilitate the provision of care in other areas than purely
medical. This involved liaison with the psychologist (for mother's
needs), and with other agencies such as fostering agencies, and those
involved in day care and education. These other services provided by
the clinic were important motivation factors for the family, particularly if
the child is clinically well.
The long term nature of follow up necessitated continuity and
consistency in care. When only a small number of children are
involved, a single doctor can provide this. However as numbers grow
this ideal becomes increasingly impractical. In Edinburgh, during the
period of study, this continuity was provided by only 2 doctors working
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in close cooperation, one of whom met the mother and child at birth,
which is a good time to develop a good rapport. In Berlin, the number
of medical staff involved was still small enough to allow rapport to be
developed, even though staff may eventually change, and regular
communication with the coordinating physician ensured continuity.
The large number of personnel involved in Padova meant that
consistency has to be achieved by adherence to a rigid protocol. A
meeting of all the personnel following the clinic to discuss any
problems assisted continuity.
HIV is a family disease, and paediatric AIDS cannot be viewed in
isolation. The ability of a mother to cope will be diminished if her health
or that of her partner deteriorates. In both centres I visited, I was told
that good liaison existed with the adult physicians, but in Berlin, this did
not extend to the detailed exchange of clinical data. The health of the
mother was well known in as much as it affected her ability to care for
the child, and the home visitors were involved in the care of the family
as a whole on this basis. In Padova, some data from mothers was
collected in the paediatric clinic, but data on the mothers prior to
delivery was less readily obtainable.
In this area particularly, the advantage of the paediatric follow
up being based alongside the adult clinic, as in Edinburgh, was clearly
visible. Not only could data be exchanged freely, but information about
other family members could also be gleaned informally, and
knowledge of women in the clinic who were found to be pregnant
enabled forward planning and preparation. Joint clinical meetings with
the staff in the adult clinic also gave a broader base of knowledge of
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the local progression of the HIV epidemic and put the developments in
the children into perspective. The main disadvantage was that
although the premises were used for infectious diseases clinics other
than HIV, few other children were seen, and some mothers were very
conscious that if their children were seen in the clinic, others would
presume they were HIV infected. This problem was partly combated by
having the option of home visiting.
Cooperation and communication are essential to the
advancement of knowledge of HIV, and multicentre studies will achieve
results in a shorter time than would be possible in one centre alone.
However, it is important when devising trial protocols or guidelines for
management to take into account cultural factors which will influence
their effectiveness. Even between different European cities it is
inadvisable to take a regimen of management which may work
excellently in one place, and copy it absolutely in another. Similarly, the
same protocol may be executed in very different ways in different
centres, and this may influence the results obtained. It is even more
important to recognise this when devising protocols for use in
situations as diverse as the USA and central Africa, urban ghettos and




Demographical features of the 3 centres
Padua Berlin Edinburah
Population 230,000 2,000,000 550,000
Area of referral Large district Within city Majority within city
Major risk factor for HIV Drug use Drug use Drug use
Deprivation No Yes Yes
Family support Good Poor Variable-often poor
Fostered/adopted <5% 33% 10%
Pre-school day care Unusual Difficult to get Common
TABLE III. 11.2
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HIV Ab Yes Yes Yes
HIV Ag Pos/neg Pos/neg Quantitative
p24 Ab No No Quantitative
Western blot Routine Not routine Not routine
PCR Experimental Experimental Experimental
HIV isolation Yes ? reliable Yes
IVAP Yes No No
TABLE III.11.4
























Clinical features of the HIV infected children
Padua Berlin Edinburgh
Median onset of 6(1-60) 5(3-42) 12(1-36)
symptoms/mths (range)
No. died 4 0 5
Age range survivors/mths 34-60 21-60 48-72
Median survival/mths 51 34 44
No. PCP 2 0 2
No. CMV 1 1 0
No. LIP 1 3 3
No. recurrent bacterial 3 2 2
infections
Candida 1 0 6
Neoplasia 1 0 1
Encephalopathy 4 2 3
TABLE III.11.6
Laboratory features of infected children
Padua Berlin Edinburgh
HIV Ab+ All All All
HIV isolation 25/25 10/10 10/11
HIV Ag + 23/31 3/10 9/11
IVAP 8/9 - -
Raised IgG 17/20 symptomatic 8/8 symptomatic 11/11
Low IgG 0 0 0




In this study, we aimed to identify all those children born to HIV
seropositive women in the Edinburgh area, and by prospective follow-
up, estimate the rate of perinatal transmission, and observe the natural
history of HIV infection in this population. Information from antenatal
and neonatal anonymous screening programmes (Tappinetai 1991)
suggest that at the time of the study we were successful in identifying
the population at risk. As we only included children followed
prospectively from birth in the calculation of vertical transmission rate,
we have prevented any bias towards subsequent identifcation of
symptomatic (and therefore infected) children.
Diagnosis of HIV infection in infants who have maternally
derived HIV antibody remains a major problem. We had hoped to
study early indices of HIV infection from cord blood, and to this end, I
was present at every delivery of an HIV seropositive woman between
October 1987 and February 1990. During this time, only one child from
the 30 deliveries of HIV seropositive women I attended proved to be
infected, so that unfortunately, no conclusion could be reached.
There have been developments in diagnostic techniques by
other workers. Although anti HIV IgM had proven disappointing (Parry &
Mortimer 1986), IgA anti-HIV has been shown to have superior sensitivity to
IgM, being present in 66% of infants subsequently proven to be
infected, and in none who seroreverted (weibienetai 1990). Other
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techniques, such 33 in vitro pruuuuuGn ui Hiv specific sniiDody (Amadori
etai 1988), and PCR (Ou etai 1988) look promising but these are still under
evaluation and not routinely available. Because of the technical
difficulty and the risks involved in obtaining and processing blood
specimens from small babies, the possibility of diagnosis from
alternative sources, such as saliva and urine have been explored, and
saliva has been shown to be an adequate alternative using a sensitive
test such as the gag ELISA (Bums et ai 1991).
HIV isolation in culture and PCR are useful techniques, but
remain research tools only available in a few centres. We did not
identify any cases in addition to those already confirmed by
conventional laboratory techniques, but we did not have the
opportunity to evaluate a large series from samples taken in the early
months of life, when other methods are less useful. There also remains
an urgent need for improved methods to evaluate the seronegative
index children who remain clinically well with normal immune function,
as seven women have embarked on subsequent pregnancies, having
observed that the index child was symptom free and antibody negative
(presumed uninfected). Although PCR may prove a useful tool, it must
be stressed that the demonstration on viral DNA sequences may not
imply overt infection, and little is known about the immune response to
HIV in children infected antenatally. As yet there have been no long
term follow-up studies of children who have had blood analysed for
PCR at birth or in the first few days of life to determine its reliability in
predicting HIV infection status in the long term.
Candidates for other useful early markers include B2
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microglobulin and neopterin. B2 microglobulin is a sub-unit of the
human leucocyte class I antigen, and upon immune-system activation,
is released by both T and B lymphocytes into the circulation (chan etai
1990). Neopterin is produced and released by macrophages following
stimulation by gamma interferon, and is closely correlated with
activation of cell mediated immunity (Fuchsetai 1988). Elevated levels of
both substances have been shown to be associated with advanced
HIV disease (laceyetai 1987, abita et ai 1985), and more recently have been
shown in adults to occur early in the course of HIV infection (sonnerborg et
ai 1989). In children, the normal range of these 2 markers is wide (miiman &
gutteberg 1987, shintaku et ai 1982), and may be raised by intercurrent viral
infections (Cooperetai 1984). However, persistently high concentrations in
CDC stage PO patients has been suggested to be indicative of HIV
infection (chan etai 1990). Whether these markers have any additional
value over other indices in the first year of life, however, remains to be
seen.
This study was commenced at a time when the estimated rate
of perinatal transmission of HIV was in the region of 50% (scott etai 1984,
Minkoftetai 1987). Later, prospective studies have quoted lower rates, but
the rate of 5.4% that we have found was unexpected, and remains
lower than any of the published series, although still within the
confidence intervals of the European Collaborative Study (ecs 1991).
From the point of view of the study, it is disappointing that although we
have followed the largest group of infants born to HIV seropositive
women in the UK, the resulting numbers of HIV infected children has
been small. This has limited our ability to study prospectively the
natural history of paediatric HIV infection and to undertake controlled
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therapeutic trials. In all the subsequent studies of the cohort comparing
HIV infected with uninfected children, the numbers in each group have
been unbalanced. The inclusion of other HIV infected children
identified outwith the prospective study has enabled us to draw some
conclusions regarding natural history and therapy, but studies in larger
groups of children are required to verify and to explore these findings
further.
In following infants born to HIV seropositive mothers, the
physician's view of what is best for the child and the importance of
research may be different from that of the parents. When the child is ill,
the need for medical attention is usually recognised by all parties, but
when the child is asymptomatic, it is not so obvious. As the study
continues, there will be increasing numbers of older children, who are
thought to be uninfected, but because of the lack of a perfect
diagnostic test for HIV, absolute assurances cannot be made. At
present it is felt that such children should continue to be seen. As they
reach school age, they will ask questions themselves about the reason
for attending hospital, which their parents will find difficult to answer.
It is likely that most children infected with HIV from their mothers
acquire the infection in utero. HIV has been isolated from amniotic fluid
(Mundy etai 1987), placenta, (Hiii et ai 1987), and foetal tissue at 8-20 weeks
gestation (Jovaisas et al 1985, Sprecher et al 1986, Lyman et al 1990, Lewis et al 1990), and
CD4+ cells susceptible to infection have been identified in placental
tissue (Maury et ai 1989). The possibility of perinatal transmission from
contact with infected cervical secretions (Pomerantz et ai 1988), or postnatally
from breast milk (Ziegleretal 1985, Lepage et al 1987, ECS 1992) alSO exists. The lOW
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rate of Caesarean section, and the very small numbers of women
breast feeding meant that we were unable to explore the additional risk
to the child of exposure to either of these possible sources of HIV
infection.
The low number of infected children in our series has led us to
look at factors which might influence the risk of transmission, both
within a population of HIV seropositive women, but also between
cohorts. We were able to show that women who produced children
shortly after seroconversion, and also those with more advanced
disease, defined by symptomatic disease at the time of pregnancy, or
by low CD4 counts, were more likely to transmit HIV to their offspring.
These observations in addition to studies showing that high titres of
antibodies to portions of gp120 may be protective (Goedertetai 1989, Rossi etai
1989) suggest that the development of, and later deterioration in the
maternal immune response to HIV as disease progresses is likely to
result in transmission. Much is yet to be discovered regarding the host
immune response to HIV which may be relevant in the understanding
of maternal factors influencing vertical transmission.
Foetal factors may also determine the susceptibility of the foetus
to infection, as illustrated by case 3, whose dizygotic twin proved
uninfected. Discordance for HIV infection between twins is well
recognised (Menez Bautista et ai 1986, Thomas et ai 1990), and is not unipue to HIV,
being also described in congenital rubella (Forrester et ai 1966). It has been
suggested (Thomasetai 1990) that the smaller twin is more likely to be more
seriously affected, but in our case the infected twin was the larger. A
recent multicentre study (Goedertetai 1991) has suggested that the first twin
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is more likely to be affected, especially if delivered vaginally, as was
case 3. This finding has raised the question whether the discordance is
not due to foetal differences in susceptibility, but the different perinatal
events such as length of time in contact with the birth canal and
maternal blood and secretions.
The median survival in our cohort was 67 months, which is
longer than that reported by Scott et al a989). However, our cohort is
largely followed from birth, whereas many of Scott's patients were
referred because of symptoms. A lower proportion of children
presenting with early onset opportunistic infections or severe
encephalopathy, who have a worse prognosis than those without
these features (Blanche etai 1990). Although the number of opportunistic
infections was low, many of the manifestations of HIV infection have
been illustrated by our group, and much practical experience gained.
Also, collaboration with other centres in Europe has led to useful
epidemiological data being accumulated (ecs 1991).
We have described the prognostic value of serial measurement
of CD4 counts, HIV Ag and p24 Ab levels. The absence of antibody
with neutralising activity against HIV has been shown to be associated
with disease progression (Weberetai i987,seietai 1988), and children with
measurable neutralising antibody were those who were clinically
stable, most having LIP (Robert-Gurotf et ai 1987). The frequency of antibodies
mediating cellular cytotoxicity is also lower in those children with AIDS
than infected children without AIDS (Ljunggren et ai 1990). More recently,
clinical outcome has been shown to be related to titres of antibodies
which inhibit syncytium formation, children with LIP having significantly
196
higher titres than those with opportunistic infection (Brenner etai 1991). Such
studies use experimental techniques, however, and their application in
routine clinical practice remains to be evaluated.
We have also explored the hypothesis that genetic factors may
influence HIV disease by studying HLA types among the children, and
concluded that differences in the prevalence of HLA types between
populations may be related to the observed differences in transmission
rates. However, the HLA type of an individual child born to an HIV
seropositive woman is not likely to be helpful in predicting its risk of
being infected.
Although much knowledge has been accumulated over the
period of this study in the treatment of HIV children, therapeutic
options remain limited, and those so far available appear to delay,
rather than arrest the progress of disease. The benefit we have
reported of IVIgG infusions in HIV infected children with recurrent
bacterial infection has very recently been confirmed in a large multi¬
centre placebo controlled trial (nich ivigG study Group 1991). Although no
difference could be demonstrated in survival, for children with CD4
lymphocyte counts > 200x106/l, there was a significant reduction in
serious bacterial infection, and in the number of acute hospital
admissions. Further studies are needed, however, to define more
accurately whether there is a sub-group of children most likely to
benefit from therapy.
Zidovudine administration is now well established in clinical
practice for children with symptoms of HIV infection. Remaining
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questions include when to start treatment and the optimum dose to
give. In adults, it has been shown that a lower dose of 500mg daily is
equally effective and less toxic than that of 1500mg daily originally
recommended, but the minimum effective dose is still to be established
(Volberding et al 1990).
Trials are under way to determine at what time zidovudine
should be commenced. One American study was terminated by the ES
National Institute of Allergy and Infectious Disease after preliminary
data suggested that initiation of therapy in those with CD4 counts less
than 500/mm3 delayed progression to symptomatic disease (volberding et
ai 1990). However, the Anglo-French 'Concorde' trial, which is a multi¬
centre trial comparing AZT and placebo administration in
asymptomatic HIV seropositive adults, continues (Editorial, Lancet 1989). One
concern over early commencement of treatment is the development of
zidovudine resistance, which is related to the duration of therapy (Larder
et ai 1989). Such mutant strains can be detected after 6 months of
therapy, and mutations may occur more rapidly in those who progress
to AIDS (Boucher et ai 1990). Early use may encourage the selection of
zidovudine resistant strain in the future, with potential loss of benefit of
the drug once clinical illness occurs (Friediand 1990), and the use of
combinations of antiretroviral drugs may be required to control
selective zidovudine resistant variants (Rooke etai 1989).
Another possible use of anti-retroviral therapy is to reduce the
risk of vertical transmission of HIV. Administration of zidovudine to
transgenic mice has been shown to prevent viraemia in their offspring
(Sharpe et ai 1988). Transfer across the placenta in human has been
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demonstrated (uebesetai 1990) with good levels produced in foetal tissue,
and there are reports of zidovudine being tolerated well during
pregnancy, with no adverse effects on the foetus (Chavanet et ai 1989).
However, the amount of protection from transmission afforded by such
intervention is unknown, and further experience may yet indicate an
unacceptable level of foetal toxicity.
It is clear there is a requirement for other modes of therapy to
be developed. Preliminary trials using 2",3'- dideoxycytidine(ddC) have
shown some in vivo effect, with a different toxicity profile to zidovudine
(Yarchoan et ai 1988, Merigan et ai 1988), but the purine 2',3'-dideoxyinosine (ddl)
has proved the most promising of the other 2",3' dideoxynucleosides.
Unlike zidovudine, haematological toxicity is not a problem, but
peripheral neuropathy, pancreatitis, and hepatitis may result from dose
above 9.6mg/kg/day (Yarchoan etai 1990). One further advantage is that it
can be given once a day (Cooieyetai 1990), and ddl has been shown to
have in vitro activity against zidovudine resistant strains of HIV (Larderetai
1989). On a twice daily regime, decreases in serum p24 Ag, and rises in
CD4 counts at up to 20 weeks have been demonstrated (Lambertetai 199®.
DDI has also been shown to cross the placental barrier but the effect
on the foetus is unknown (Ponsetai 1991).
Interruption of other steps in the cycle of HIV replication may
also be possible. Soluble CD4, which blocks the initial binding of gp120
env protein of HIV to CD4 has been studied intensively (Fisher etai i988,
Hussey et al 1988, Deen et al 1988, Capon et al 1989, Perno et al 1990). Clinical thalS have
shown no significant clinical or immunological toxicities, despite the
concern that excess quantities of CD4 could disrupt immune function
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(Kahn etal 1990, Schooleyetal 1990, Editorial, Lancet 1990). H0W6V6T, its hslf lit© is Short
at 1 hour (Kahn etai 1990), and macrophages may still become infected
through CD4 independent mechanisms (Broder 1990); brain and muscle
cells may be unprotected (ciaphametai 1989).
Other agents shown to have some anti HIV activity have
included fusidic acid (Uoyd et al 1988, Faber et al 1987) and dithiocarb (Lang et al
1988, Reisinger et ai 1990). It is likely that treatment of HIV in the future will
depend on the development of more effective combinations of drugs,
as has been the case with haematological malignancies, rather than
the discovery of a 'miracle cure'. New compounds to use alone or in
combination are therefore required if survival is to be further
prolonged.
Efforts have already been made to control the further spread of
HIV by screening blood products, provision of clean needles, and
education programmes promoting safe sexual practices (Chin 1990).
However, a programme of prevention involving major changes in life¬
style is not likely to enjoy universal application. In the future, one hope
for the control and eradication of this disease lies in the prospects for
the development of a safe and effective vaccine, not only for
prophylaxis against primary HIV infection, but also for
immunotherapeutic use to delay the progression of clinical disease
(Schiid & Minor 1990). Vaccine development, however, has proven
problematical, not only because the virus infects the very cells required
to mount an immune response (Laurence & schiid 1989), but also because of
the requirement to find suitable animal models (Newmark 1989). Because of
the long latency between HIV infection and clinical disease, the use of
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live attenuated viruses similar to those used in other viral infections is
precluded by virtue of the fact that it will be impossible to assess their
safety before use (Schiid & Minor 1990). Attention is therefore being focused
on development of subunit preparations based on recombinant DNA
technology, which also provided an effective hepatitis B vaccine.
Suitable viral subunits are likely to be the env and gag proteins.
Antibodies against env protein are able to neutralise viral infectivity
(Boiognesi 1989), and high levels of antibody to gag is associated with a
prolonged symptom free period (ungeetai 1989), but results of preliminary
tests on volunteers are awaited, and suitable adjuvants still need to be
found (Koff & Fauci 1989).
Meanwhile, AIDS remains a devastating terminal disease,
affecting children who may already be socially disadvantaged.
Advances in the management of these children, therefore, not only
involves research into diagnosis and treatment, but also into methods
of support for them and their families, many of whom have other
affected members. This will not only involve material, psychological,
and spiritual support for the families themselves but also addressing
the issues of confidentiality, ostracism, peer group education, and
education of the general public. While we strive to improve the quantity





We have described the methods used and results obtained from
this study designed to answer questions a-g posed in the introduction.
Our conclusions, relating to those questions can be summarised as
follows:
a) The risk of virus transmission from an HIV positive mother to her
offspring among a population of Caucasian women, the majority of
whom have a history of intravenous drug use and are asymptomatic at
the time of pregnancy is 5.4% (95%C11.12-14.87%).
b) There are no clearly identifiable genetic factors influencing
vertical transmission of HIV. HLA antigens may be associated with
susceptibility to transmission, and in particular, a high A3, B8, DR2/A1,
B8, DR3 ratio may contribute to a low transmission rate, but this
hypothesis needs to be explored further.
Important maternal factors influencing transmission are the
timing of pregnancy in relation to seroconversion, and the stage of
maternal disease. Pregnancies in the first year of seroconversion are
more likely to result in HIV infected offspring. Progression of clinical
disease in the mother and a low CD4 count during pregnancy may
also increase the risk to the foetus. There may be other factors also
influencing the risk of perinatal transmission, such as maternal HIV
antigenaemia, which failed to reach significance in our study, and
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require follow-up of larger groups of women and children to identify.
Similarly, perinatal factors, such as mode of delivery or method of
feeding could not be explored because so few women underwent
Caesarean section or breast fed.
c) In our experience, early clinical indications of HIV infection
include recurrent respiratory infections, recurrent diarrhoea,
eczematous skin rashes, generalised lymphadenopathy, and
hepatosplenomegaly. Although candidiasis in infancy was not
significantly more frequent in HIV infected children, persistent severe
candidal infection has been demonstrated to herald the development
of AIDS. Useful laboratory indices in the first 18 months of life include
IgG, which may be raised by 6 months of life, and HIV Ag, which was
positive in the first 18 months in all five children on whom data is
available. HIV isolation in culture and PCR may provide the diagnosis,
but negative results, however, are unhelpful. HIV antibody is the most
useful test in older children.
d) In children proving to be HIV infected, median time for
development of HIV related symptoms was 12 months; 55% had
symptoms by a year of age (95% CI 23.38-83.25%), and 82% by 2
years (95% CI 48.22-97.72%). Median time of progression to stage P2
B-D was 45 months. One child remained asymptomatic at 42 months.
Clinical features associated with progressive disease included PCP,
recurrent bacterial infections, LIP, encephalopathy, oesophageal
Candida, Ewing's sarcoma, cardiomyopathy, and wasting syndrome.
The development of encephalopathy was associated with a poor
prognosis (100% mortality within 18 months), whereas LIP was
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compatible with prolonged survival (maximum 5 years from inital
diagnosis).
PCP was fatal in both cases. Rapid diagnosis from
nasopharyngeal secretions without requiring invasive sampling was
shown to be possible. Adherence to the CDC guidelines for PCP
prophylaxis which have since become available would not have
protected the child in our study from this infection, and it may be
justifiable to treat all infants born to HIV seropositive women with
cotrimoxazole until their HIV infection status is known.
HIV infected children suffer more symptomatic respiratory
infections than those proving not to be HIV infected, and respiratory
viruses can be isolated more frequently from their upper respiratory
tracts. Respiratory infections are more likely to lead to hospital
admissions in these children. Further studies are needed to explore the
influence of intercurrent viral infection on the progression of HIV
disease.
Both HIV infected children followed from birth who survived to 6
months were hypergammaglobulinaemic, as were all the other children
at presentation. IgG peaked at a median of 28 (range 4-72) g/l at an
age of 47 (range 4-63) months. Levels of IgM reflected IgG. Reverse
CD4/CD8 ratio was not seen until a median age of 27 months (range
13-46 months), and CD4 lymphopoenia until a median of 27 months
(range 4-46 months). Rate of decline of CD4 counts ranged from 0%
to 99% per annum. In those followed from birth, decline in p24Ab level
was associated with detection of HIV Ag in the serum, but as p24 Ab
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levels rose, HIV Ag was not detected in the majority of children. Loss of
p24 Ab and later detection of HIV Ag was seen later in the course of
the disease, levels of >50pg/ml being predictive of poor outcome.
e) In young babies, severe candidiasis may herald the onset of
AIDS, but the other early clinical features we observed were unhelpful
prognostically. High levels of HIV Ag (>50pg/ml) in the absence of
detectable p24 Ab were associated with progression of HIV disease,
and mortality within 2 years. A rapidly declining CD4 count (>60% p.a.)
similarly is a poor prognostic sign. Levels of IgG and IgM did not
correlate with prognosis. The four children with raised IgA levels,
however, showed rapid progression of disease with death within 2
years.
f) Intravenous immunoglobulin infusions given to children
suffering from recurrent respiratory infection or recurrent diarrhoea
leads to an improvement in weight gain, number of infections, and
number of acute hospital admissions, and for this reason is a cost
effective way of managing these children. Intravenous immunoglobulin
therapy may also reduce the frequency of viral as well as bacterial
infections. Zidovudine has been shown to be associated with
improvement in CNS symptoms, and in those children given the drug
on the basis of declining CD4 counts, stabilisiation of CD4 counts was
achieved for 6 months, and a slower rate of decline observed
thereafter. Numbers were too small for placebo controlled trials.
g) i) HIV infection in childhood is likely to carry a high mortality,
although our follow-up is insufficiently long to determine whether the
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infection is universally fatal. Mortality was 1/11, or 9% at 1 year (95%
CI 0.23-41.28%), 3/11, or 27% at 5 years (95% CI 6.07-60.97%). 6/11
children died at median age of 55 months (95% CI 23.38-83.25%),
range 4-82 months. The longest survivor is 76 months.
ii) Of those children presumed uninfected, none has shown
symptoms or signs of HIV disease, and (with the exception of one
fatality) all remain well. Maximum follow up is still only 74 months,





Provisional case definition for AIDS surveillance of children (in use 1985 to
1987).
For the limited purposes of epidemiological surveillance, CDC defined a case of
paediatric AIDS as the condition of a child with both of the following:
1) A reliably diagnosed disease at least moderately indicative of underlying
cellular immunodeficiency
2) No known cause of underlying cellular immunodeficiency or any other
reduced resistance reported to be associated with that disease
The diseases accepted as sufficiently indicative of underlying cellular
immunodeficiency were the same as those used in defining AIDS in adults. In the
absence of these opportunistic diseases, a histologically confirmed diagnosis of
chronic LIP was considered indicative of AIDS unless test(s) for HIV showed negative
results. Congenital infections (eg toxoplasmosis or herpes simplex virus infection in
the first 6 months after birth) must have been excluded.
Specific conditions that must have been excluded in a child were as follows:
1) Primary immunodeficiency diseases: severe combined immunodeficiency,
DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia telangiectasia, graft-versus-
host disease, neutropoenia, neutrophil function abnormality, agammaglobulinaemia,
or hypogammaglobulinaemia with raised IgM values
2) Secondary immunodeficiency associated with immunosuppressive therapy,
lymphoreticular malignancy, or starvation
Modified from CDC:MMWR 1985; 34: 517-21 by Falloon et al (1989)
207
Table 2
Summary of September 1987 revision of surveillance case definition for AIDS
Without laboratory evidence of HIV infection (test not done or inconclusive) a patient
with AIDS:
A Does not have another cause of immunodeficiency, such as the following:
1) High dose or long term systemic corticosteroid therapy or other
immunosuppressive-cytotoxic therapy <3 months before the onset of the indicator
disease
2) Hodgkin disease, non-Hodgkin lymphoma (other than primary brain
lymphoma), lymphocytic leukaemia, multiple myeloma, other cancer of
lymphoreticular- histiocytic tissue, angioimmunoblastic lymphadenopathy < 3
months after diagnosis of the indicator disease
3) A genetic (congenital) immunodeficiency syndrome or an acquired
immunodeficiency syndrome atypical of HIV infection (such as one with
hypogammaglobulinaemia)
and
B Has had one of the following AIDS indicator diseases definitely diagnosed:
1) Candidiasis of the oesophagus, trachea, bronchi, or lungs
2) Extrapulmonary cryptococcosis
3) Cryptosporidiosis with diarrhoea persisting > 1 month
4) Cytomegalovirus disease of an organ other than liver, spleen, lymph nodes in
a patient > 1 month of age
5) Herpes simplex virus infection causing a mucocutaneous ulcer persisting > 1
months
or bronchitis, pneumonitis, or oesophagitis in a patient > 1 months of age
6) Primary lymphoma of the brain in a patient <60 years of age
7) Kaposi sarcoma in a patient <60 years of age
8) LIP and/or pulmonary lymphoid hyperplasia in a child <13 years of age
9) Mycobacterium avium complex or M. kansasii disease disseminated to site
other than lungs, skin, or cervical or hilar lymph nodes
10) PCP
11) Progressive multifocal leukoencephalopathy
12) Toxoplasmosis of the brain in a patient >1 month of age
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II With laboratory evidence of HIV infection, a patient with AIDS:
A Has had one of the already listed AIDS indicator diseases definitely
diagnosed or one of the following AIDS indicator diseases definitely diagnosed:
1) Multiple or recurrent bacterial infections (at least 2 within 2 years) in a child
< 13 years of age, including septicaemia, pneumonia, meningitis, bone or joint
infection, abscess of internal organ or body cavity (except otitis media or superficial
skin or mucosal abscesses)
2) Coccidioidomycosis disseminated to a site other than lungs or cervical or
hilar lymph nodes
3) HIV encephalopathy
4) Histoplasmosis disseminated to a site other than lungs or cervical or hilar
lymph nodes
5) Isosporiasis with diarrhoea persisting >1 month
6) Kaposi sarcoma
7) Primary lymphoma of the brain
8) Other non-Hodgkin lymphoma of B cell or unknown immunologic phenotype
(small, noncleaved Burkitt or non-Burkitt lymphoma or immunoblastic sarcoma)
9) Disseminated nontubercular mycobacterial disease involving a site other than
lungs, skin, or cervical or hilar lymph nodes
10) Tuberculosis involving at least one site other than lungs
11) Recurrent nontyphoid Salmonella bacteraemia
12) HIV wasting syndrome
or
B One of the following AIDS indicator diseases diagnosed presumptively:
1) Oesophageal candidiasis
2) Cytomegalovirus retinitis with loss of vision
3) Kaposi sarcoma
4) LIP or pulmonary lymphoid hyperplasia in a child <13
5) Acid-fast infection (species not identified) disseminated to a site other than
lungs, skin, or cervical or hilar lymph nodes
6) PCP
7) Toxoplasmosis of the brain in a patient > 1 month
III With laboratory evidence against HIV infection (negative test), a patient with
AIDS:
A Does not have another cause of underlying immunodeficiency
and
B Has had PCP definitely diagnosed
or
Has had definitive diagnosis of one of the AIDS indicator diseases listed in section I
plus a T-helper lymphocyte count <400/mm3
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Table 3
World Health Organisation clinical case definition of AIDS in children
Major signs
Weight loss or failure to thrive
Chronic diarrhoea (>1 month)




Repeated common infections (otitis, pharyngitis, etc)
Persistent cough (>1 month)
Generalised dermatitis
Confirmed maternal HIV infection
Paediatric AIDS is suspected in an infant or child presenting with at least 2
major signs associated with at least 2 minor signs in the absence of known causes of
immunosuppression.
* Generalised lymphadenopathy = lymph nodes measuring at least 0.5cm and
present in 2 or more non- contiguous sites
Table 4
CDC case definition of HIV infection in children less than 13 years of age
1) Children <15 months of age with perinatal infection have one of the
following:
a) HIV in blood or tissues confirmed by culture or other laboratory detection
method
b) Symptoms meeting CDC case definition for AIDS
c) Antibody to HIV (repeatedly reactive screening test plus positive
confirmatory test result) and evidence of both cellular and humoral
immunodeficiency (increased immunoglobulin levels, decreased absolute helper T
cell count, absolute lymphopoenia, reduced helper-suppressor T cell ratio and
symptoms (class P2)
2) Older perinatally infected children or children who acquired infection through
another mode of transmission have one of the following:
a) HIV in blood or tissues confirmed by culture or other laboratory detection
method
b) Antibody to HIV (repeatedly reactive screening test plus positive confirmatory
test result)
c) Symptoms meeting CDC case definition for AIDS
Modified from CDC MMWR 1987; 36: 225-36
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Table 5
Classification system for HIV infected children less than 13 years of age
PO Indeterminate infection in perinatally exposed children younger than 15
months of age who have antibody to HIV.
P1 Asymptomatic infection
A Normal immune function. Normal immunoglobulins, FBC, lymphocyte
subsets
B Abnormal immune function.
One or more (unexplained): hypergammaglobulinaemia, T helper cell lymphopoenia,
decreased T helper/T suppressor ratio, absolute lymphopoenia C Immune function
not tested
P2 Symptomatic infection (causes other than HIV excluded)
A Nonspecific findings.
More than 2 months persistence of 2 or more (unexplained): fever, failure to
thrive, or >10% weight loss, hepatomegaly, splenomegaly, generalised
lymphadenopathy (as above), parotitis, diarrhoea with 3 or more loose stools daily
persistently or recurrently (2 or more episodes with dehydration within 2 months)
B Progressive neurological disease.
One or more loss of developmental milestones or intellectual ability; impaired
brain growth (acquired microcephaly and/or brain atrophy on scan); progressive
symmetrical motor deficits with 2 or more of paresis, abnormal tone, pathologic
reflexes, ataxia, or gait disturbance.
C Lymphoid interstitial pneumonitis Histologically confirmed with diffuse
interstitial and peribronchiolar infiltration of lymphocytes and plasma cells without
identifiable pathogen or chronic pneumonitis with bilateral reticulonodular infiltrates
with or without hilar adenopathy on chest radiograph for at least 2 months,
unresponsive to antimicrobial therapy and without other identifiable pathogen
D Secondary infectious disease
D1 Those listed in CDC definition of AIDS PCP; chronic cryptosporidiosis;
disseminated toxoplasmosis (onset after 1 month of age); extraintestinal
strongyloidosis; chronic isosporiosis; candidiasis (oesophageal, bronchial, or
pulmonary); extrapulmonary cryptococcosis; disseminated histoplasmosis;
noncutaneous, extrapulmonary or disseminated mycobacterial infection (species
other than leprae); CMV infection (onset after 1 month of age); extrapulmonary or
disseminated coccidioidomycosis; nocardiosis; progressive multifocal
leukoencephalopathy; chronic mucocutaneous or disseminated HSV infection (onset
after 1 month of age)
D2 Recurrent serious bacterial infections Two or more within 2 years: sepsis,
meningitis, pneumonia, abscess of internal organ, bone or joint infection
D3 Other infections Oral candidiasis (persisting 2 months), 2 or more episodes
of herpes stomatitis within 1 year, multidermatomal or disseminated herpes zoster
E Secondary cancers
E1 Those listed in CDC definition of AIDS Kaposi sarcoma, B cell nonHodgkin
lymphoma, primary lymphoma of brain
E2 Others
F Other diseases possibly caused by HIV infection Hepatitis, cardiomyopathy,
nephropathy, haematological disorder (anaemia, thrombocytopoenia),
dermatological disease
Modified from CDC (1987). MMWR 36: 225-36
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Table 6
Recommended indicator levels of CD4+ lymphocytes for the initiation of
prophylaxis for PCP are:
<1.500 x 106/l for children 1-11 months
<750 x 10 /1 for children 12-23 months
<500 x 1 Qp/I for children 24 months to 5 years
<200 x10 /I for chidlren 6 years and older
Table 7
Drug regimens for PCP prophylaxis
1. Recommended regimen (children > 1 month of age
Trimethoprim/sulfamethoxazole (TMP-SMX) I50mg TMP/m /day with 750mg
SMX/m /day given orally in divided doses twice a day 3 times per week on
consecutive days.
Acceptable alternative TMP-SMX dosage schedules:
A 150mg TMP/m2/day with 750mg SMX/m /day given orally as a single daily
dose 3 times per week on consecutive days.
B I50mg TMP/m2/day with 750mg SMX/m2/day orally divided bd and given
7 days /week
C 150mg TMP/m2/day with 750mg SMX/m2/day given orally divided bd and
given 3 times per week on alternate days.
II Alternative regimens if TMP-SMX not tolerated
Aerosolised pentamidine (>5 years of age) 300mg given via Respirgard II
inhaler monthly.
Dapsone (>1 month of age) img/kg (not to exceed 100mg) given orally
once daily.
If neither is tolerated, some clinicians use intravenous pentamidine (4mg/kg)





Born at 42 weeks gestation by spontaneous vaginal delivery after an
uneventful pregnancy, she weighed 3.25kg at birth. Her mother had used intravenous
drugs and was known to be HIV seropositive. At six months she was admitted for a
week with an upper respiratory tract infection, improving after treatment with
amoxycillin. Parainfluenza virus type 3 was isolated from nasal secretions. At that time
she had bilateral axillary lymphadenopathy and a 3cm palpable liver. A month later
she was admitted for 2 weeks with measles and an inflamed right eardrum. She was
treated with hyperimmune measles immunoglobulin and erythromycin and improved.
At 9 months she was failing to thrive and was admitted with a week's history
of vomiting and watery diarrhoea. She was miserable, irritable and had a purulent
nasal discharge. Her weight was 6.5kg (below 3rd centile) and she had an inflamed
right eardrum. There was generalised lymphadenopathy and hepatomegaly with no
splenomegaly. She failed to improve and after a week developed a Haemophilus
influenzae pneumonia. No pathogenic organisms were isolated from the stools. She
was treated with erythromycin and 3 weekly IVIgG infusions and improved. There was
a particular improvement in her mood on the morning following her first infusion; she
became alert with spontaneous laughter for the first time. She was discharged after 5
weeks, and thereafter she began to gain weight and remained free of infections
sufficiently severe to merit hospital admission.
She continued on her IVIgG infusions but although clinically she remained
stable, her CD4 count began to decline. By 28 months of age the count was
600x10®/l. She was commenced on oral zidovudine for this reason, and tolerated the
drug well. No side effects were noted. At 39 months, she developed widespread
molluscum contagiosum over her arms, face and trunk. No specific treatment was
given, and the lesions gradually resolved over the next 6 months. Since than she has
remained well, and continues to thrive. Her neurological development remains within
normal limits, and she attends normal school.
Case 2
This infant was born at 38 weeks gestation by forceps delivery after an
uneventful pregnancy, weighing 3.33kg. Her father, but not her mother had a history
of IV drug use. Neonatal jaundice responded to phototherapy and she was
discharged at 6 days, only to be readmitted for social reasons, her mother having
developed hepatitis B.
At two months, she was admitted to hospital with rotavirus gastroenteritis,
and at 10 months she was admitted for 12 days with cough, bilateral otitis media and
a glandular fever-like illness, with lymphadenopathy, hepatosplenomegaly, and 12%
atypical mononuclear cells in the peripheral blood. EBV serology was negative. She
improved, but was again admitted for 3 days a month later because of a troublesome
cough. At the age of 12 months she was admitted with right lower lobe pneumonia,
which resolved after antibiotic treatment, although no organisms were isolated. There
were two further admissions over the next 5 months because of a troublesome cough
attributed to previous pertussis infection, vaccination having been declined.
HIV infection was confirmed at 17 months, when both parents were also
diagnosed. At 23 months she continued to have recurrent upper respiratory infections
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and impetigo, not requiring hospital admission. Her height and weight were on the
50th centile. A purulent nasal discharge and peri-oral impetigo were present, with
generalised lymphadenopathy, and hepatosplenomegaly.
She was commenced on IVIgG at 24 months, and in the following year had
two episodes of diarrhoea and occasionally a runny nose. She was admitted to
hospital once with vomiting, diarrhoea, and pyrexia, all of which settled
spontaneously with no pathogens isolated. There was an improvement in mood
similar to that in case 1. Over the next year she had three brief admissions for
diarrhoea, and for social reasons. Her mother developed POP when she was 3 years
of age.
At 42 months, she developed widespread molluscum contagiosum infection,
associated with a sudden fall in her CD4 count to 50x10 /1. She was commenced on
oral zidovudine and although for the first 2 weeks she complained of headaches and
sore legs, thereafter she tolerated it well. At 48 months she was admitted with
impetigo over the scalp treated effectively with topical preparations and oral
antibiotics. Her mother died of cerebral toxoplasmosis when she was 54 months, and
she was looked after by paternal grandparents.
At 69 months she was admitted complaining of breathlessness, dizziness,
and reduced exercise tolerance. She was tachypnoeic, tachycardic, and was found to
have cardiomegaly. Cardiomyopathy was diagnosed on the basis of
echocardiography: endomyocardial biopsy was unhelpful in defining the aetiological
agent. She was treated initially with digoxin and diuretics, but 3 months later,
captopril was introduced. Thereafter she had increasingly poor exercise tolerance,
and having previously been well nourished, she began to fail to thrive. She was finally
admitted at the age of 82 months in terminal cardiac failure, and died 5 days later.
Permission for post mortem was not given.
Case 3
The first of dizygotic twins born at 37 weeks, weighing 2.18kg; her mother
was known to have shared needles, and worked in the sex industry. Her neonatal
course was complicated by jaundice requiring phototherapy, and by a chlamydial eye
infection. At three months of age she was admitted with a persistent cough, and
purulent nasal discharge. She also had otitis media, which was treated with
antibiotics.
At 14 months she presented pyrexial and lethargic, with a history of chronic
otitis media. She had a generalised maculopapular rash, compatible with measles,
although no organism was isolated, and had generalised lymphadenopathy and
hepatosplenomegaly. She was commenced on IVIgG. She had one further admission
at 18 months of age with a viral illness, but remained otherwise well. Her weight gain
parallelled that of her twin sister.
At 27 months, she developed widespread bruising and her platelet count was
low, at 20x109/l. At this time she also had persistent cough and fever, and a chest
Xray showed appearances typical of LIP. Because of recurrent bruising and platelet
counts persistently below 20x10 /1, she was commenced at 50 months of age on
high dose IVIgG (1 g/kg), and later on anti D. She remains otherwise well, and has
now started at her local primary school.
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Case 4
The mother of this female infant developed PCP at 35 weeks gestation and
the baby was delivered at term weighing 3.05kg. There were no neonatal problems.
Cord blood was positive for HIV Ab on ELISA, negative for HIV antigen, HIV p24 Ab,
and viral isolation. CD4 count was 2.34x10 /1 and her initial progress was
uncomplicated. By one month she developed persistent candidal infection of the oral
cavity and napkin area, and by 2 months she had become HIV Ag positive. Her CD4
count at this time was 1.94x109/l.
At four and a half months she presented with a two week history of mild
upper respiratory symptoms, with two days of pyrexia, an unproductive cough, and
increasing tachypnoea, sufficiently severe to impair feeding. Examination revealed a
pale, mildly cyanosed and lethargic, but responsive infant. She had a tachycardia of
160/min and respiratory rate of 80/min, with bilateral intercostal and subcostal
indrawing and scattered crepitations on auscultation. Lymphadenopathy and
hepatosplenomegaly were noted, along with candidal dermatitis of the napkin area.
The chest X-Ray showed extensive bilateral pneumonitis. She was hypoxic
(oxygen saturation 60%), with a pC02 of 5.37kPa and hydrogen ion of 39.7mmol/l.
On admission the neutrophil count was 6200/cu mm, CD4 1.79 x109/l and CD4/CD8
ratio, 1.4. Serum IgG was normal (4g/l), and IgA and IgM elevated (0.9g/l and 2.1 g/l).
HIV Ag was positive (140pg/ml). Secretions obtained by nasopharyngeal aspiration
were sent for microbiological investigation.
Pending results the infant received oxygen supplementation and high dose
cotrimoxazole and acyclovir intravenously. The identification of Pneumocystis carinii
was confirmed the following day (see chapter 6). The infant's condition initially
stabilised, but deteriorated 24 hours later. Despite giving hydrocortisone and
intravenous immunoglobulin, she failed to maintain oxygen saturation of >80% even
in 100% Fi02, and developed C02 retention (pC02 9.75kPa) and respiratory acidosis
([H + ] 73.7mmol/l). Definite knowledge of the diagnosis, and its implications for the
child's long term prognosis meant that the parents could be counselled appropriately.
Their wish for her not to receive mechanical ventilation was respected, and she died
on the fourth day of her admission. Post mortem confirmed the widespread alveolar
exudate within the lungs in which round organisms were detected by silver staining.
No other organisms were detected. Her mother died 18 months later from cerebral
toxoplasma having suffered multiple cerebrovascular accidents and a further episode
of PCP.
Case 5
This female infant was born at 37 weeks gestation weighing 2.8kg. Mother's
partner had a history of intravenous drug use, but the mother herself had never
shared needles. Neonatal course was uneventful and she was discharged at 2 days.
In the first year of life she had recurrent wheeze and eczema, but was otherwise well.
The diagnosis of HIV infection was made when she was 21 months, mother
having been identified on antenatal screening during a subsequent pregnancy. At this
time, she had generalised lymphadenopathy and hepatosplenomegaly, and had had
some diarrhoea. These all resolved, however, and although persistently HIV
antigenaemic, she remains p24 Ab positive and asymptomatic. She attends her local
nursery school.
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Case 6 reported by Forsyth et al (1987)
This 29 weeks' gestation baby weighed 930g at birth. Both parents had a
history of intravenous drug use. He required ventilation for a few days, and was given
phenobarbitone prophylactically but no withdrawal symptoms developed. He
developed intestinal obstruction at 10 weeks of age due to a right inguinal hernia,
which was repaired. He was discharged to the care of foster parents thereafter.
He remained well until at 8 months he was admitted with a right upper lobe
pneumonia, successfully treated with ampicillin and flucloxacillin. Three months later
he began to develop petechiae and was noted to bruise easily. At 13 months he was
admitted for investigation , and was found to have a platelet count of 16 x 10 /1, with
otherwise normal coagulation. It was at this time that the diagnosis of HIV was made.
He received steroids, and high dose intravenousjmmunoglobulin, after which his
piateiet count fluctuated between 20 and 50 x10a/l. He continued to bruise easily, but
never developed major haemorrhage.
He subsequently developed generalised lymphadenopathy. He had recurrent
upper respiratory tract infections, and intermittent episodes of diarrhoea. He required
emulsifying cream for eczema, and intermittent Slophylline for wheeze. At 2 years of
age he developed oral thrush which responded to Nystatin. At 33 months, he began
to complain of pain in his right leg, with stiffness and a limp. His left eye was also
drooping. There was little to find on formal neurological examination, however, and
CT scan of the brain was normal. These symptoms resolved spontaneously.
At 37 months he commenced regular IVIgG infusions, and subsequently
remained very well, with few problems, other than mild upper respiratory tact
symptoms and no requirements for admission to hospital. Chest X ray appearances
were however, consistent with lymphocytic interstitial pneumonitis. He had persistent
HIV antigenaemia, and because of this, infusions of plasma rich in HIV core antibody
were commenced, which he received from 51-57 months. He was started on
zidovudine at 58 months, when he was still free of symptoms, but growing poorly. He
developed recurrent coughs and pyrexiae, had intermittent parotid swelling, and had
a parainfluenza B respiratory infection at 49 months.
By 67 months, he was anorexic, with nausea and vomiting. His weight was
static, and his mother noted that he was falling a lot, although again there was little to
find on neurological examination. Because of a falling CD4 count he was commenced
on oral cotrimoxazole, which he failed to tolerate, so he was given regular nebulised
pentamidine.
At 74 months, a painless mass was noted over the head of the left fibula.
Radiography showed destruction of the metaphyseal region of the bone, with
expansion and erosion of the cortex, and associated soft tissue swelling. This was
diagnosed as a Ewing's sarcoma. No other bony abnormalities were found on
technetium bone scan or limited skeletal survey, and no chest metastases were
evident.
He was commenced on a modified regime of chemotherapy, consisting of
vincristine, actinomycin, and etoposide, but only received two doses of etoposide,
due to a severe rash and constitutional upset. The second Dulse of chemotherapy
was commenced when he was still neutropoenic (0.72x10 /1), so that only 2 of 3
doses of tenoposide and one dose of vincristine were given. Because of marrow
suppression, zidovudine was discontinued. Two months later an excision was
performed, but there was residual tumour in the capsule. He received a further course
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of vincristine and actinomycin thereafter, but tolerated this so badly that further
courses were not contemplated. During this time HIV Ag fell from 116pg/ml to
27pg/ml.
A month later he complained of lumbar pain, together with weakness down
the right side. There was painful limitation of movement, but spinal radiographs and
isotope bone scans were normal. A week later he developed headache, drowsiness,
attacks of flushing, and a left lower motor neurone facial palsy. There was an
increased cell count in the CSF (233 lymphocytes/ml), a protein of 2500mg/l, and
glucose <0.5mmol/l (blood glucose 5.2 mmol/l) but no organisms, and no HIV Ag or
Ab was detected. CT scan showed cerebral atrophy only, and MRI scan showed no
focal lesions. Thereafter, he became increasingly encephalopathic, with fluctuating
tetraparesis, cranial nerve palsies, thalamic pain, and short term memory loss. His
condition deteriorated, and he became cachectic and comatose. He died at home at
the age of 81 months. Post mortem permission was not given.
Case 7
This child was born at 38 weeks gestation to a known IV drug user, and
weighed 2.82kg. Neonatal period was uneventful, but she developed a chlamydial eye
infection at 2 weeks of age. She was discharged home initially, but was fostered from
6 weeks, and was later adopted. She was discovered to be hepatitis B Ag positive
after her foster mother contracted hepatitis, and at this time HIV infection was also
diagnosed. At a year of age she was noted to have generalised lymphadenopathy,
but she remained otherwise well until three years, when she presented with a 4 month
history of recurrent diarrhoea, from which Campylobacter had been isolated on one
occasion. She also had candidal infection of the perineum, and complained of
lethargy, sleeping up to 5 hours during the day and 12-14 hours at night.
At 39 months she was commenced on IVIgG, had no further episodes of
diarrhoea, and her sleep requirement diminished dramatically. Thereafter she
remained well, with only one episode of respiratory infection, with cough and left
lower lobe changes on X ray, but this responded to oral antibiotics. IVIgG was
discontinued when she was 5 years of age and she remained well thereafter.
Case 8
The second of four children, she was born by spontaneous vaginal delivery at
43 weeks gestation weighing 3.15kg. Her mother received blood after the birth of her
first child 2 years previously but the donors were traced and are HIV seronegative.
There is no history of IV drug use. She was admitted at the age of 9 months, having
been found near-drowned in a bath at home, from which she made a good recovery.
At 28 months she was admitted for exploration of both groins as she was thought to
have herniae. Inguinal lymphadenopathy only was found, which later resolved, the
lymph node showing reactive hyperplasia. She had pertussis at 30 months and was
admitted for 4 days with a UTI. At 37 months, she was admitted again with scalds to
both her hands. During her admission she had an upper respiratory tract infection
and Haemophilus was isolated. No chest X-ray was done at that time.
From 44 months she developed recurrent episodes of fever and cough, with
both clinical and radiological evidence of bronchopneumonia. Mycoplasma
pneumoniae and Haemophilus influenzae were isolated on different occasions from
her sputum. She had also had persistent diarrhoea for the past five months. She was
failing to thrive, her weight having fallen from the 50th centile at 18 months to less
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than the third.
Initial investigations included a sweat test, which initially yielded an equivocal
result with a sodium of 59mmol/l. Two repeat tests revealed sodium of I08mmol/I
and chloride of 93mmol/l. Cystic fibrosis was assumed, and on this basis she was
commenced on pancreatic supplements, and intensive physiotherapy and antibiotic
treatment. There was no clinical improvement, and so the sweat test was repeated
after 2 days of oral fludrocortisone, 2mg/m2/day. Sweat sodium thereafter was
31 mmol/l and chloride was 24mmol/l.
During her admission, at 47 months, she deteriorated, with pneumonia,
weight loss and watery diarrhoea. Haemophilus was grown from her sputum along
with Candida albicans, which was also in her mouth and pharynx. Oesophageal pain
and barium studies were strongly suggestive of oesophageal candidiasis. Serological
tests for PCP were negative. She responded to antibiotic and antifungal therapy. No
organisms were isoiatea" from stool specimens.
The diagnosis of HIV infection was made at this point, and she was
commenced on IVIgG, and shortly after on AZT orally, 400mg/m /day. Over the next
three months she improved, requiring 1 further admission for 3 days for a
Haemophilus influenzae chest infection. AZT was stopped a week after this admission
because of leucopoenia. Although AZT was recommenced, her compliance was
poor, and she did not tolerate it well. She refused to take it by mouth because of the
foul taste, and required an nasogastric tube for its administration. It is therefore
unlikely that she received a therapeutic dose.
Over the next year her main problems were recurrent bacterial pneumonia,
but she began to gain weight, and was well enough to start school with her peers.
However, from 64 months she had unresolving widespread consolidation on chest X-
ray. Despite physiotherapy and recurrent courses of oral and intravenous antibiotics,
she became cachectic and died at 67 months. Post mortem was not performed.
Case 9
The younger sister of case 8 was born at 40 weeks gestation by spontaneous
vaginal delivery. She was a face presentation. Birth weight was 2.75kg. Before the
family was diagnosed as being HIV seropositive, at 12 months of age, she was
admitted with a left lower lobe pneumonia, which was slow to resolve clinically and
radiologically. Sputum was not obtained, but Strep.pneumoniae was isolated from
blood cultures. She was initially treated with Ampicillin/flucloxacillin, but this was
subsequently changed to benzylpenicillin.
She was 24 months when case 8 was diagnosed HIV seropositive. At this
time she was thriving, with a few shotty lymph nodes, but otherwise well. A month
later, however, she was admitted with pneumonia, initially responding in the absence
of positive cultures to benzylpenicillin. However, later that months she was readmitted
with similar symptoms. Gastric aspirates were cultured and grew Staph.aureus and
Haemophilus influenzae. She again had patchy changes on the right, and
consolidation at the left base on chest X-ray. She was treated this time with
cotrimoxazole, and made a good clinical recovery. Residual radiological changes
were suggestive of LIP.
At 26 months she was commenced on IVIgG. At this time she had extensive
generalised lymphadenopathy and hepatosplenomegaly. She continued to thrive
thereafter, and in the following year had only one episode of respiratory symptoms
218
requiring hospital admission. She had chicken pox, for which she was given acyclovir
and hyperimmune Zoster immunoglobulin. She also had oral thrush. At 41 months
she had herpes stomatitis, treated with acyclovir, requiring a 3 day admission, but its
course was uncomplicated. She has had 2 further short admissions for exacerbation
of respiratory symptoms, but radiologically, her LIP has not progressed further, and
she has no chronic symptoms. When last seen at 76 months she was asymptomatic
and thriving. She had small cervical lymph nodes only, her hepatosplenomegaly
having regressed, and her chest was clear.
Case 10
The younger sister of cases 8 and 9 she was born by spontaneous vaginal
delivery at 38 weeks gestation, weighing 3.04kg. She had chicken pox aged 11
months, at the same time as case 9, for which she received ZIG. The course of the
illness was uncomplicated. At 12 months she was asymptomatic, but had generalised
lymphadenopathy and hepatosplenomegaly. Over the next 9 months, although she
showed a marked deterioration in CD4 count and was HIV Ag positive, she remained
very well, continued to thrive, and her only additional findings were of oral thrush and
some mild eczema. Her parents were unwilling for her to start any treatment on the
basis of laboratory findings alone.
At 21 months she developed chronic purulent rhinitis, and shortly after, she
began to have watery diarrhoea. IVIgG was commenced at 23 months, but she
deteriorated rapidly. Enteropathogenic E Coli type 0128 was isolated from her stools.
She developed candidal dermatitis in addition to oral Candida, but no lower
respiratory tract signs. She lost weight precipitously, becoming anorexic and
cachectic. She was commenced on an IV infusion of zidovudine, with no
demonstrable improvement. She showed marked developmental regression, losing
speech completely. Gross motor function was impossible to assess because of her
profound weakness. She died at 25 months, 2 weeks after case 8. Again, no post
mortem was performed.
Case 11 (reported by Matthes et al (1988)
This child from Newcastle was born by spontaneous vaginal delivery at term
weighing 3.15kg. He received the usual childhood immunisations, including measles,
without problem and developed normally. He walked at 13 months, and by 21 months
was starting to join words. At 21 months his mother was admitted with PCP, was
found to be HIV seropositive, and died. HIV infection was then confirmed in this child
and his father, but not his brother, aged 6. This mother received a blood transfusion
after the birth of her first child, but the source of infection has not been confirmed.
He was well until aged 22 months, when he had a pertussis infection proven
on culture requiring hospitalisation for 4 days. At that time he had generalised
lymphadenopathy, and his weight had dropped below the 10th centile. Despite early
treatment from day 7 of the illness with erythromycin, Bordetella pertussis could still
be isolated at 28 days. A month later he had a unilateral submandibular lymphadenitis
with Streptococcus pyogenes cultured from the fauces. This responded rapidly to
drainage (culture negative) and intravenous benzylpenicillin.
At 26 months he had a severe pneumonia. The chest X-ray demonstrated
consolidation in the right lower and middle lobes, with patchy shadowing in the upper
lobe. Haemophilus influenzae was isolated from the sputum but he failed to respond
to antibiotic treatment until given high dose cotrimoxazole, which produced clinical
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and radiological resolution. Ten days after being admitted his speech rapidly
regressed to expressive aphasia with only vowel sounds, but with no cognitive
impairment. He also developed a considerable spastic diplegia with inability to walk.
A CT scan showed cerebral atrophy. Sensory and motor nerve conduction studies
gave normal results. His CSF showed no white cells and normal concentrations of
glucose and protein. No bacteria, fungi, or viruses were cultured. IgG antibodies to
HIV were selectively increased in the CSF. HIV Ag was not measured.
He was treated with IVIgG, initially weekly, then 3 weekly. A month later he
was commenced on oral zidovudine 100mg/m2 four times daily, equivalent to
16mg/kg/day. The intravenous preparation was given orally, and there were no early
haematological or neurological toxic effects. Subsequently, his general well-being
improved, he began to gain weight, and his neurological symptoms regressed. In
particular, his spasticity reduced, so that he was able to run, and his reflexes returned
to normal. He began to articulate several single words. A repeat CT after nine weeks
treatment showed considerable improvement.
This improvement was sustained for about a year. He had a chronic cough,
and his speech remained poor, but he was otherwise well. At 38 months he had a
further admission with pneumonia, and at this time he was again unable to walk, or
even pull himself to stand, and continued to have generalised lymphadenopathy and
hepatomegaly. He also had a discharging ear. He was found to be pancytopoenic,
and required platelet transfusion. No organism was isolated, but he received high
dose cotrimoxazole and after 2 weeks, this was changed to dapsone. He was
discharged 3 weeks later, having lost 3kg. A month later he developed persistent
diarrhoea, and his general condition had deteriorated further. At 44 months he
developed yet another pneumonia clinically consistent with PCP, to which he
succumbed. Post mortem findings confirmed PCP.
Case 12
This baby's mother who had given birth 7 years earlier to an uninfected child,
developed PCP during this pregnancy. There was also a history of heavy alcohol
consumption throughout pregnancy. The baby was born at 38 weeks gestation
weighing 2.17kg. From birth he had feeding problems, with irritability and vomiting
and failed to thrive. At 3 months of age HIV was isolated from lymphocytes in culture,
when HIV antibody was still positive. He is developmentally delayed and failing to
thrive (weight at 9 months being 5.34kg), probably the result of the foetal alcohol
syndrome. Although he has recurrent upper respiratory infections, he remains
clinically well. HIV infection is manifested by persistent generalised lymphadenopathy
only.
Case 13
This patient became infected with HIV during cardiac bypass surgery for
transposition of the great arteries at the age of 4 months, before screening of blood
for HIV antibody was available. He remained well until 14 months when he began to
develop recurrent upper respiratory tract infections, and at 21 months of age
developed ITP refractory to treatment with high dose IVIgG, and to prednisolone. At
the age of 3 years 6 months, his platelet count had returned to normal, but he
continued to have recurrent respiratory infections, failed to thrive, and had
generalised lymphadenopathy and hepatosplenomegaly. Chest X ray showed
appearances typical of LIP. The serum IgG, IgA and IgM levels were respectively 34.8,
2 and 2.8 g/l (normal ranges were 5-13, 0.47-2.63 and 0.36-1.92 g/l respectively). HIV
infection was then diagnosed, based on retrospective screening of donor plasma and
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subsequent HIV testing of the child. He was commenced on regular infusions of
IVIgG when his serum IgG level was 50g/l.
Treatment with IVIgG was uneventful until his neurological reaction at the age
of 4 years 10 months, described in detail in chapter 9, and apart from upper
respiratory tract symptoms, and intermittent oral thrush, he remained well, and
started at his local primary school.
At 5 years and 3 months he became more lethargic, falling asleep at school,
and very reluctant to walk, with a mild ataxia but nothing more specific to find on
general examination. He was found to be delayed on Griffiths developmental testing
for gross motor function, but intellectually, he showed no deterioration. MRI scan
showed evidence of cerebral atrophy and some minor changes in the white matter,
but nothing focal. His CD4 count at this time was 0.3x109/l. He was commenced on
zidovudine, and showed improvement in gross motor function thereafter. At 5 and a
naif years he was diagnosed as having bilateral sensorineural deafness on routine
screening at school, and was fitted with hearing aids. Intellectually, however, he kept
well up with his peers at school, but fell further from the third centile for height and
weight.
At six and a half years he developed persistent oral candidiasis. A month later
he was found to have oral hairy leukoplakia. His height had been static for the past
year at this point. At the age of 7, he became drowsy and lethargic. Neurological
examination revealed blurred optic discs, pathologically brisk reflexes, and bilateral
extensor plantar responses. CT scan revealed progressive cerebral atrophy, but there
was no change on MRI. His zidovudine was increased to 720mg/m / day.
At 7 and a half years, he had a markedked decrease in exercise tolerance, with
demonstrable hypoxia on exercise, although he remained 91 % saturated in air at rest.
This was attributed to LIP, and he was commenced on a course of oral prednisolone
(2mg/kg/day initially), with some improvement. However, a month later he was
admitted with a pyrexia. No focus could be found, but he still had oral thrush, and so
fluconazole was commenced.
A month later, he was found to be in cardiac failure, with decreased right
ventricular function on echocardiography. He was treated with frusemide, and his
steroid dose was cut further. He remains on a maintenance dose of prednisolone.
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APPENDIX III - Definitions of normal levels of laboratory indices
Immunoglobulin levels expressed in q/l
igG igA igM
Birth 5.0-13.0
3 months 2.45-6.6 0.11-0.57 0.22-0.9
6 months 2.85-7.6 0.14-0.76 0.28-1.10
9 months 3.3-8.8 0.15-0.88 0.33-1.35
12 months 4.2-11.2 0.21-1.26 0.37-1.50
24 months 5.0-13.0 0.26-1.47 0.36-1.92
Normal ranges as defined by the Scottish National Blood Transfusion Service, based









below lower limit of normal for age
above upper limit of normal for age
< 1.0 x10 /I neutrophils
<2.8 x10*VI lymphocytes
<1.0 x 10^/1 CD4 lymphocytes in infants <18 months
<100 x 10 /1 platelets
APPENDIX IV
Proformata for recording of information are contained in the following five pages. The
format of the ECS forms altered to a minor degree during the study, but the
information recorded was the same throughout.
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INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MULTI-CENTRE EEC STUDY




Mother's date of birth (day, month, year)
Country of birth
Marital Status
Single (1), Married (2), Divorced, Separated, Widowed (3), Cohabiting (4)
Ethnic Group
Asian (1), White (2), Biack (3), Oriental (4), Other (5)
Age when leaving full-time education, years
Obstetric History
Number of previous livebirths
Number of previous stillbirths
Number of previous miscarriages
Number of terminations
Mothers Risk Group
History of Intravenous Drug Abuse (Y/N)
Trimester of last use: pre-conception (0), 1st (1), 2nd (2), 3rd (3), unknown (9)
Needle sharing? never (1) past (2) present (3) unknown (9)
Sexual partner of Bisexual (Y/N)
Sexual partner of Haemophiliac (Y/N)
Sexual partner of Intravenous Drug Abuser (Y/N)




Date of first HIV+ test (day, month, year)
.£» tT-A C C.w »\j \j (Sufi S I O OftTH.
Current clinical status
Current HIV staging (CDC)
Specify symptoms
Date of onset
Specific HIV treatment in pregnancy? If so specify
mfiT6a«o fy <_ COH cco,\JT






















Hospital where delivery took place
Obstetrician (initals)
Delivery
Caesarean Section: Elective (1), Emergency (2)
Vaginal: Spontaneous (3), Instrumental (4)
Scalp Electrodes (Y/N)











with parents (1) fostered (2) adopted (3)
remained in hospital (4) other (5)
if remained in hospital, say why: *
Feeding: breast (1) bottle (2) breast and bottle (3)
was breast feeding tried and abandoned? Y/N
Died? Y/N
Date of death: (day/month/year)






















Take sample required; Please record laboratory results on yellow form
Please store serum and cells at -70°C
tC53
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MULTI-CENTRE EEC STUDY
MEDICAL EXAMINATION












Recurrent fever of unknown origin requiring medical attention Y/N




Septicaemia, Meningitis, Urinary tract infection, Pneumonia. Other
Communicable Disease Y/N
meales(1) mumps (2) rubella (3) varicella (4) zoster (5) Other (6)
Complications
Skin Infection requiring medical attention Y/N
Staph (1) Strep (2) Herpes (3) Candida (4) Other (5)
Non-infectious skin eruption Y/N
Petechiae/Purpura (1) Eczema (2) Kaposi Sarcoma (3) Other (4)
Palpable Lymph Nodes Y/N
Axillary (1) Postoccipital (2) Cervical (3) Inguinal (4) Epitrochlear (5) Other (6)
Chronic parotid swelling Y/N
Oral Candida persistent or recurrent despite therapy Y/N
Upper repiratory tract infection Y/N
chronic otitis media (1) sinusitis (2) chronic purulent rhinitis (3) Other (4)
Lower repiratory tract disease confirmed by X-ray Y/N
Lymphocytic interstitial pneumonitis or pulmonary lymphoid hyperplasia (1)
pneumonia (2) bronchiolitis (3) Other (4)
specify organism, if known
Opportunistic infection Y/N

































<^Ring)lindings and specify as appropriate: R/F/U/N refers
to titres Rising/Falling/Unchanged/No previous test
Date blood drawn: / /
day month year
HIV/ELISA +/- Specify system used
Specific antibodies p24 + / - R/F/U/N
gp41 + / - R / F U N
Other (specify) + / - R/F/U/N
Western blot +/- R/F/U/N
Specific antibodies p24 + / - R / F / U N
gp41 + / - R/F/U/N
Other (specify) + / - R F U N
Virus culture
+ / - Specify identification system(s)
+ / - Specify identification system(s)
Antigen assay +/- R/F/U/N
Specify identification system
Other tests (eg IVAP, PCR, IgM) Specify method











Toxo IgG Latex (at 9 months to exclude congenital infection) (+/-)
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Summary: Five human immunodeficiency virus (HIV) antibody positive
children developed recurrent infections requiring multiple hospital ad¬
missions. These comprised mainly upper respiratory tract infections, otitis
media, pneumonia and diarrhoea, and there was failure to thrive despite
adequate antibiotic therapy. They were commenced on iv immunoglobulin
(IVIG) therapy and are now relatively free of serious infections and are
gaining weight. This therapy was associated with a major reduction in the
hospitalization required. In HIV antibody positive children the onset of
serious infections, particularly with encapsulated gram-positive organisms,
should be taken as an indication for the commencement of regular iv
infusions of immunoglobulin.
Keywords: Human immunodeficiency virus; sepsis; paediatric aids; immuno¬
therapy.
Introduction
Infection with human immunodeficiency virus (HIV) in infants may result
in antibody as well as cellular immune deficiency (Rubinstein et al., 1983;
Bernstein et al., 1985). The main clinical features of this are shown in Table
I. Preliminary data in infants with^cquired immunodeficiency syndrome
(AIDS) or the AIDS-related complex (ARC) suggest that such infants
benefit from iv immunoglobulin (IVIG) therapy (Cavelli & Rubinstein,
1986). Of 38 children born to HIV-seropositive mothers in Edinburgh, two
suffer from recurrent bacterial infections without typical opportunistic
infections. We report the preliminary results of treatment with IVIG in
these two children, and in an additional three children treated similarly with
Scottish National Blood Transfusion Service IVIG.
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Diminished in-vivo primary antibody response to T-cell-dependent (tetanus toxoid,
KLH, bacteriophage ax 174) and T-cell-independent (pneumococcal) antigens
Depressed or absent amplification of the primary antibody response on secondary
challenge with antigen
Depressed or absent IgM to IgG class switch in the secondary response
Poor in-vitro responses to the lymphocyte mitogens PHA and Con A (both primarily
T-cell-dependent) with especially poor responses to PWM (B- and T-cell-dependent) and
staphylococcal Cowan A protein (T-cell-independent)
Case reports
Patient 1
This patient was born at 42 weeks gestation by spontaneous vaginal delivery
after an uneventful pregnancy and weighed 3-25 kg at birth. Her mother had
previously abused drugs intravenously and was known to be HIV antibody
positive. The infant was monitored regularly as part of a prospective study
of perinatal HIV infection.
At the age of 6 months, the patient was admitted to hospital for a week
with an upper respiratory tract infection, improving after treatment with
amoxycillin. At that time, bilateral axillary,lymphadenopathy and a 3-cm
palpable liver were noted, and HIV antibody seropositivity confirmed. A
month later she was admitted for a fortnight with measles and an inflamed
right eardrum. She was treated with hyperimmune measles
immunoglobulin (0-1 ml kg-1) and erythromycin and improved. Bilateral
cervical lymphadenopathy was also present.
At 9 months she was failing to thrive and was admitted with a week's
history of vomiting (x 4/day) and watery diarrhoea (x 5/day). Her
grandmother had had similar symptoms a week earlier. She was miserable,
irritable and had a purulent nasal discharge. The weight was 6-5 kg (below
third centile) and she had an inflamed right eardrum. There was bilateral
cervical, axillary and inguinal lymphadenopathy and the liver was still 3 cm
palpable with no splenomegaly. She failed to improve and after a week
developed crackles in both lung bases. Relevant investigations at that time
revealed Hb 11-2 g 1_1, WCC 13-1 x 109r\ 59% lymphocytes (21-2% T.
cells, 20-7% T8 cells, T4/T8 ratio of TO), normal LFTs, IgG 6-6 gT
(3-6-9-6), IgA 1-25 g 1_1 (0-16-0-97), IgM 1-35 (0-35-1-40). The chest X-ray
showed bilateral perihilar shadowing and the nasal discharge gave a profuse
Immunoglobulin therapy for HIV-positive children 69
growth of Haemophilus influenzae. No pathogenic organisms were isolated
from the stools.
She was treated with erythromycin and weekly IVIG infusions and
improved. There was a marked improvement in her mood commencing on
the morning following her first infusion, having become alert with
spontaneous laughter, and she was discharged after 5 weeks.
The infusion protocol used was lOOmgkg-1 for the first two infusions
(days 1 and 4) and 200mgkg_I subsequently (days 7, 14 and 3-4 weekly
thereafter). The immunoglobulin preparation was manufactured at the
Protein Fractionation Centre, Edinburgh, and was reconstituted as a 4-5%
aqueous solution.
In the 13 months since the institution of this treatment she has had three
mild upper respiratory tract infections not requiring hospital admission, a
PUO and a parainfluenza virus infection both requiring admission, but
diarrhoea has not recurred. She has a dry erythematous rash affecting the
face and napkin area, which appears 3—4 days before, and clears 1—2 days
after each infusion. The lymphadenopathy is unchanged, the liver no longer
enlarged, and she currently weighs 9-3 kg (third centile). She is
developmentally normal with no abnormal neurological signs.
Patient 2
This patient was born at 38 weeks gestation by forceps delivery after an
uneventful pregnancy and weighed 3-33 kg. Her mother denied iv drug
abuse. Neonatal jaundice responded successfully to phototherapy and she
was discharged after 6 days.
At the age of two months she was admitted to hospital with rotavirus
gastroenteritis, and at the age of 10 months was admitted for 12 days with
cough, bilateral otitis media and an uncharact^rized glandular fever-like
illness. Cervical lymphadenopathy, 2-cm hepatomegaly and 6-cm
splenomegaly were noted with WCC 50><1091-1 (12% atypical
mononuclear cells) and negative EBV serology. She improved but was again
admitted for 3 days a month later because of a troublesome cough.
At the age of 12 months she was admitted with right lower lobe
pneumonia, which improved after antibiotic treatment although no
organisms were isolated. There were two further admissions over the next 5
months because of a troublesome cough attributed to previous pertussis
infection, vaccination having been declined.
HIV seropositivity was first confirmed at the age of 17 months, and was
also confirmed in both parents. At that time she was anti-HBc positive but
anti-HBs negative; there was lymphadenopathy in the right axilla and both
groins. The liver was just palpable but the spleen was not.
At the age of 23 months she continued to have recurrent upper
respiratory tract infections and impetigo, not requiring hospital admission.
The weight was 12 kg, height 85 cm (both 50th centile). A purulent nasal
discharge and peri-oral impetigo were present, with enlargement of the
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occipital, left axillary and both inguinal lymph nodes. The liver was
palpable at 1 cm and the spleen at 0-5 cm. Investigations showed Hb 11-9
gl-1, WCC 8-9xl09l_1, with normal differential count, platelets
53 x 109 1_1 (rising spontaneously to 108 x 1091— 1 a month later), total IgG
slighty raised at 14-6 gl-1 (5-0—13-0), IgA 1-35 g I-1 and IgM 0-85 gl-1
(both normal).
She was commenced on IVIG at 24 months and in the 10 months since
the initiation of this treatment she has had two episodes of diarrhoea and
occasionally a runny nose. She was admitted to hospital once with vomiting,
diarrhoea and pyrexia, all ofwhich settled spontaneously with no pathogens
isolated. There was an improvement in mood similar to that in Patient 1,
but less marked, and she is currently bright and cheerful. She also has a dry
macular rash on the face and thighs which appears shortly before and
disappears following infusions. She currently weighs 13-7 kg (50th centile).
Patient 3
This patient was born by spontaneous vaginal delivery at term weighing
3-15 kg. He received the usual childhood immunizations and developed
normally. At 21 months his mother was admitted with Pneumocystis carinii
pneumonia, was found to be HIV seropositive, and died. HIV seropositivity
was then confirmed in this child and his father, but not in his brother aged 6.
The transmission of infection is assumed to have been vertical although the
source of infection in the family is uncertain.
He was well until aged 22 months, when he had a pertussis infection
requiring hospitalization for 4 days. At that time he had bilateral cervical,
axillary and inguinal lymphadenopathy and weighed 10-3 kg (below tenth
centile). A month later he had a submandibular swelling of uncertain cause.
When this was incised no pus was found anjl its histology was normal.
At 26 months he had a severe pneumonia. The chest X-ray demonstrated
consolidation in the right lower and middle lobes with patchy shadowing in
the upper lobe. Haemophilus influenzae was isolated from the sputum but he
failed to respond to antibiotic treatment until given high dose
cotrimoxazole, which produced clinical and radiological resolution. Ten
days after being admitted he developed a spastic paraparesis and expressive
dysphasia. The serum IgG level was 16 gl-1, circulating T4 count
0-98 x 1091-1, and Tg 1-3 x 109 l^1. The CSF contained a higher anti-HIV
antibody titre than did blood, and a CT scan demonstrated cerebral
atrophy. Primary HIV encephalopathy was diagnosed and he commenced
treatment with IVIG. Two weeks later he was started on AZT (100 mg m-2
qds by mouth). He was discharged 10 days later.
There has been considerable improvement during the 3 months of
follow-up. He is now able to run and there is improvement in the dysphasia.
The inguinal nodes are palpable, the liver 2 cm enlarged, and he weighs
12-35 kg (above tenth centile). The CT scan is normal and the T4 and Tg
numbers are 2-48 x 109 P1 and 0 68 x 109 P1 respectively. The serum IgG
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concentration is 18-9gl 1 (6-16), IgA 1-9 (0-65-3-0) and IgM 1-78
(0-25-2-0).
Patient 4
This patient was born by spontaneous vaginal delivery at 43 weeks gestation
weighing 3-15 kg. She was well until aged 28 months, when she was
admitted for exploration of both groins as she was thought to have herniae.
Inguinal lymphadenopathy only was found, which later resolved, and the
lymph node biopsy showed reactive hyperplasia. She had whooping cough
at 30 months and was admitted for 4 days at 33 months with a urinary tract
infection.
At the age of 44 months there was a marked deterioration in her health,
with recurrent right-sided pneumonia necessitating four hospital
admissions lasting 8, 7, 7 and 38 days respectively, the sputum yielding
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admissions respectively.
During the last admissions she weighed 10-1 kg (below third centile, age
46 months) and HIV seropositivity was confirmed. Both parents had
previously abused drugs and were also found to be HIV seropositive. She
was started on azothymidine (AZT) lOOmgm-2 qds by mouth, regular
antibiotics and IVIG.
During the 3 months of follow-up her weight has increased to 12 kg (still
below third centile) and she has been admitted once for 3 days on account of
a Haemophilus influenzae chest infection. AZT was stopped a week after this
admission because of leucopenia (WCC 2-9 x 1091-1).
Patient 5
This patient underwent corrective surgery for 3 congenital cardiac lesion
aged 4 months, when he was transfused blood from a donor later found to be
HIV seropositive (prior to HIV antibody screening of all blood donations).
His cardiovascular progress was satisfactory and he was otherwise well apart
from low weight (below third centile).
From the age of 14 months he had frequent respiratory tract infections
and tonsillitis, one of which required hospital admission.
At 21 months he presented with a petechial rash. The liver was palpable
at 3 cm as was the tip of the spleen, apd the platelet count was < 10 x 109l-1
with normal/increased megakaryocytes in the bone marrow. The serum
IgG concentration was 29 gl-1. He was commenced on prenisolone
2mgkg-1 day-1 for a week, later reducing to 5 mg day-1, but platelet
counts did not rise. Over the following 3 months he received three courses
of high-dose IVIG (2 gkg-1), which produced transient increments only in
platelet counts. These were to 62 x 109 l-1 on day 3 of the first course, falling
to < 10 byrday 7; to 190 x 109 1— 1 on day 5 of the second course, falling to
< 15 by day 14; to 120 x 109 1 ~1 on day 3 of the third course, falling to < 11
by day 14. Whilst on prednisolone 5 mg on alternate days, aged 25 months,
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the platelet count rose to 59xl09l 1 and has been between 20 and
139 x 109 1~1 since.
When aged 26 months he had otitis media and gastroenteritis. Over the
next 15 months he had two mild upper respiratory tract infections and a
further three episodes of otitis media, causing perforation of the right
eardrum.
At 42 months he was admitted with pyrexia, diarrhoea and vomiting
which settled after treatment with iv cotrimoxazole. Bilateral cervical
lymphadenopathy was present and the liver was palpable at 2 cm, the spleen
at 1 cm. HIV seropositivity was confirmed. The oldest library serum sample
available, taken aged 21 months, also showed HIV seropositivity.
He was started on regular low-dose cotrimoxazole (40 mg bd) and IVIG
and in the 2 months of follow-up has been free of infections. Pre-infusion
serum IgG levels remain very high (currently >46 gl-1).
Discussion
The usual clinical presentation in infants, with recurrent bacterial
infections, is very similar to that of patients suffering from primary
hypogammaglobulinaemia. Despite the polyclonal increase in
immunoglobulin concentrations, the very poor primary and secondary
specific responses to antigen challenge (Table I) (Rubinstein et al., 1983)
render such infants susceptible to bacterial infection. Clinical benefit may
result from the administration of normal immunoglobulin by virtue of its
content of antibodies whose specificities may be more appropriate to any
prevailing infection.
In view of the clinical and immunological similarities to
hypogammaglobulinaemia, IVIG has been' used in the treatment of infants
with AIDS. Some of the immunological abnormalities associated with
AIDS are reversed by treatment with IgG. Peripheral blood T cells from
infants with AIDS are unable to suppress Pokeweed Mitogen
(PWM)-driven IgG secretion from normal peripheral blood lymphocytes.
Following treatment with IVIG for 4—13 months this function returns to
normal (Gupta, Novick & Rubinstein, 1986). In one series of 31 children
with AIDS there was a reduction in the incidence of septicaemia from 18/27
in non-IgG-treated controls to"4/14 in IgG-treated infants associated with
such therapy (Calvelli & Rubinstein, 1986).
Pre-infusion IgG levels are rather difficult to interpret at this stage in the
treatment of these children, as there is a background of polyclonal increase
in IgG concentrations. Consequently, they have not yet been used to
modify the regime of treatment given, which is similar to that used initially
in the antibody replacement therapy of patients who suffer from primary
hypogammaglobulinaemia (Leen, Yap & McClelland, 1986).
The point at which one should initiate treatment with IVIG in such
children is a matter for debate. We would suggest that after two or
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Table II. Clinical features of five children with HIV infection treated with IVIG
1 2 3 4 5
Sex F F M F M
Present age (months) 22 34 29 49 44
Lymphadenopathy Y Y Y — Y
Enlarged liver/spleen Liver Both Liver — Both
Encephalopathy — — Y — — •
Thrombocytopenia — — — — Y
Otitis media x 2 x 1 — — x 4
Pulmonary infections 1 2 2 5 1
Days in hospital in 12 53 26 34 60 7
months before IVIG therapy
Months of IVIG therapy 13 10 3 3 2
On AZT — — Y Y* —
On regular antibiotics — — — Y Y
Days in hospital since 20 6 0 3 0
IVIG therapy started
* Stopped after 1 month because of leucopenia.
more serious infections occur, involving infection with encapsulated
gram-positive organisms, then long-term treatment with IVIG is probably
indicated.
Regular IVIG therapy did not prevent the occurrence of infections
during the period of follow-up (2—13 months, Table II), but infections
while receiving this treatment were less severe, as borne out by the major
reduction in the duration of hospitalization. Consideration should therefore
be given to starting therapy in asymptomatic HIV antibody positive
children since it is possible that intercurrent infection with organisms other
than HIV may be a co-factor in the progression of the HIV infection. This
could perhaps occur by infection causing T4 lymphocyte activation,
including that of latently HIV infected cells, with consequent viral
replication and acceleration of disease progression.
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MOTHER-TO-CHILD TRANSMISSION OF HIV
INFECTION
The European Collaborative Study*
Summary 271 children born to HIV-infected mothers
in 8 European centres are being followed
up from birth in amulticentre, collaborative study. By June,
1988, 45% had been followed for over 1 year: 10 had
developed AIDS orAIDS-related complex, all by the age of
9 months, of whom 5 had died. 22 other children had
symptoms or signs suggestive ofHIV infection; of these, 12
had immunological abnormalities, 9 ofwhom were infected.
5 children had problems not related to HIV, including 3
neonatal deaths. The other 234 children are
immunologically normal and clinically well. The median
age ofantibody loss was 10-3months, although 1 did not lose
antibody until over 18 months. None lost antibody and then
became and remained seropositive. Of 100 children
followed for more than 15 months, 19 had persistent
antibody, and 5 were antibody-negative but presumed to be
infected because of virus isolation or antigen detection; these
5 children were clinically and immunologically normal. The
estimated vertical transmission rate was 24%.
Introduction
By June 30,1988,1528 women and 356 children under 13
years ofage had been reported to theWHO EuropeanAIDS
surveillance centre. Half the women were intravenous drug
abusers of child-bearing age; three-quarters of the children
had acquired their infection from a mother who either had
AIDS or who was at risk of AIDS.1 Since the number of
women with human immunodeficiency virus (HIV)
infection greatly exceeds those with AIDS, these figures
considerably underestimate the number of children who
may be at risk.
'Coordinating centre: C. S. Peckham, Y. D. Scnturia, A. E. Ades, M. L.
Newell, Institute of Child Health, London WC1N 1EH, UK.
Collaborating centres: C. Giaquinto, A. Dc Rossi, L. Chicco-Bianchi,
F. Zacchello (Univcrsita dcgli Studi di Padova, Italy); J. Y. Q. Mok, R.
Hague (City Hospital, Edinburgh, UK); I. Grosch-Wdmer, S. Koch (Frcic
Univcrsitat, Universitatsklinikum Rudolf Virchow, West Berlin); C. A.
Canosa (Dcpartamento de Pediatria "La Fc", Valencia, Spain); F. Omcnaca
Teres, M. C. Garcia Rodriguez (Hospital Infantil La Paz, Madrid, Spain);
H. J. Scherpbier (Acadcmisch Medisch Centrum, Amsterdam, The
Netherlands); A. B. Bohlin (Department of Paediatrics, Huddingc, Sweden);
A. De Maria, C. Gotta, A. Tcrragna (Istituto G. Gaslini, Genova, Italy).
The natural history of HIV infection in haemophiliac
children has been well investigated;2 much less is known
about the risk or long-term outcome of perinatal infection.
Reported rates of infection for children bom to HIV-
seropositivc mothers range from 0 to 65%.3 However, some
studies are based cither on prospective follow-up ofchildren
who already have symptoms or whose mothers have had a
child with AIDS; others are based on small numbers or
short follow-up.**
The prognosis for children with AIDS is poor,10 but little
is known about outcome for the much larger proportion of
HIV-infected children with less severe or no symptoms. We
report results from the first 271 children enrolled in a
multicentre European study," which was set up to
determine rates of transmission of HIV infection from a
seropositive mother to her infant; to assess factors thatmight
influence transmission such as mode of delivery,
breastfeeding, and mother's clinical status during
pregnancy; and to determine die natural history of perinatal
HIV infection.
Subjects and Methods
HlV-seroposilive women are systematically identified in the
antenatal period at all the participating centres. Children are
included only if the paediatrician is aware of the mother's
seropositive status before or at the time of birth; all such children are
included. One paediatrician in each centre coordinates the follow-
up. Children are examined shortly after birth and at 3-monthly
intervals. Information gathered at birth includes details ofmaternal
history (eg, symptoms in pregnancy, dateofHIV test, likely route of
transmission, marital status, age, and parity). Perinatal details
include mode ofdelivery, birthweight, gestational age, the presence
ofcongenital abnormalities or drug withdrawal symptoms, and any
abnormal clinical findings. At subsequent examinations, the last
date ofbreastfeeding is recorded, with an interval history and details
of immunisations; a physical and developmental examination is
done and height, weight, and head circumference are measured.
Particular attention is paid to the presence of lymphadenopathy,
hepatosplenomegalv, persistent oral Candida, skin infections, non¬
infectious skin eruptions, confirmed bacterial sepsis, persistent or
recurrent diarrhoea, persistent fever, radiologically confirmed
pneumonia or pneumonitis, developmental delay, and abnormal
neurological findings. A social history is obtained with particular
reference to the child's carer and the health of the mother.
A blood sample is taken at each visit and HIV antibody is
measured by enzyme-linked immunosorbent assay (ELISA) and
western blot. Virus culture and antigen tests are requested every 6
months. An in vitro test of IgG antibody production12-'3 is done in
Padua and Genoa. Other investigations include absolute
lymphocyte count, platelet count, immunoglobulin subsets, and a
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TABLE I—CLINICAL HISTORY OE CHILDREN W.O HAD AIDS OR ARC
Birth¬ Gestational Major clinical manifestations AIDS-ARC Age last Virus T4 T8 IgGt
Sex weight (kg) age (wk) in order of appearance onset (wk) seen (wk) ever Antigen (at las visit)
M 3-22 40 POC; L; HS; IP; LDM; Enc; DCMV 18 28* - - 02 2-3 188
M 350 40 L; HS; POC (resolved) 9 108 + - 12 2-4 25 1
F 2 50 39 HS; L; POC; DCMV 9 12* + + 4-5 4 1 9-7
F 1 84 37 L; HS; POC; LDM; FIT; acquired
microcephaly; spastic quadriplegia; PCP
34 86* + + 0-2 0-3 15
M 304 40 L; HS; motor delay; hypertonus; POC (resolved); PS 37 86 + - 1-3 34 8 6
M 334 40 POC; L; HS; lymphoid interstitial pneumonitis 17 19* + + 16 12 3-6
M 3 16 37 POC; L; D; SID 24 28* ND ND 4 1 1-3 2-8
M 2 90 39 POC; L; HS; IP; PS 12 25 + + 10 06 21 3
F 327 40 D (resolved); L; HS; pneumonia; FTT 36 117 + - 0-6 16 66
F 265 41 POC; L;HS; PCP; FTT 24 53 ND + 10 05 10 2
•Died; tlgG at last visit before treatment.
1*00 = persistent oral Candida; L = iymphadcnopaihy; HS «=hcpatosplenomegaly; IP-interstitial pneumonitis; LDM = !oss of developmental milestones;
Enc = encephalopathy; DCMV = disseminated CMV; FIT = failure to thrive; PCP = Pneumocystis carinii pneumonia; PS = parotid swelling; D = chronic
diarrhoea; SID = sudden infant death; ND = not done.
measure of B-cell function in response to diphtheria and tetanus
immunisation. Urine is cultured for cytomegalovirus (CMV)
shortly after birth and blood is tested serially for toxoplasmosis IgG.
Virus cultures and antigen tests are done as previously described."
Positive virus cultures are confirmed by anugen capture. Centres
differ in the frequency of virus and anugen tests and not all centres
performed both tests.
Definitions of Infection
Infecuon was defined by persistence ofantibody (as measured by
ELISA, confirmed by western blot) beyond the age of 15 months,
clinical AIDS or AIDS-related complex (ARC), or the presence of
virus or p24 andgen. Children who lost anubody and did not have a
positive virus culture or antigen test were presumed not to be
infected. Maternal antibody may persist well into the second year of
life therefore, in the absence of virus isolation or anugen detection,
the infection status of anubody-posiuve children under 15 months
old was considered indeterminate.
AIDS was defined according to Centers for Disease Control
(CDC) surveillance criteria.14 A child was considered to have
AIDS-related complex (ARC) if interstitial pneumonitis, persistent
oral Candida, or progressive encephalopathy had been present for at
least 2 months, with two or more of: persistent general
lymphadenopathy, hepatomegaly or splenomegaly, chronic or
recurrent episodes of diarrhoea, failure to thrive, or parotid
swelling. All such children would be included in class P2 of the
CDC classification system for HIV infecuon in childhood." The
date of onset of AIDS or ARC was taken as the date of the first
clinical examination when this definition was met.
Results
Maternal Characteristics
By the end of June, 1988, 271 children born to 264
mothers were enrolled including 3 pairs of twins and 4
second births. Compliance with follow-up has been good:
only 8 of 147 children under 18 months have not been seen
For over 6 months, and 11 of 116 children over 18 months
"lave not been seen for over 12 months. The age ofmothers
ranged from 14 to 38 years (median 24-7); 67% of mothers
veremarried or cohabiting; and for 65% this was their first
child. All but 12 were Caucasians. 85% of mothers, and a
'urther 7% of partners, had a history of intravenous drug
ibuse, and only 3% had no risk factor identified. 14 mothers
5%) had AIDS or ARC before delivery.
°eriiiatal Outcome
Mean birthweight was 2-82 kg (range 0-79-4 48) and
ncan gestation 38 weeks (range 25-43); 142 were boys, 129
;irls. Drug-withdrawal symptoms were present in 68 (25%)
but, apart from problems related to prematurity, perinatal
findings were unremarkable. Congenital abnormalities were
noted in 7: Poland's syndrome, Polydactyly, syndactyly,
cleft palate, polycystic kidneys, hydronephrosis from
pyeloureterostenosis, and cystic fibrosis. Another child had
cerebral palsy and a ventriculoperitoneal shunt sited because
of neonatal meningitis. 2 infants died in the first 48 hours,
both of birth asphyxia: one was a girl of 790 g born at 25
weeks' gestation, the other a 2440 g boy delivered by
emergency cacsarean section at 37 weeks' gestation; a third
child who weighed 1225 g at birth after 33 weeks' gestation
died of respiratory distress syndrome and intracranial
bleeding after 20 days. These 3 deaths are presumed not to
be HIV-related.
Birthweight standard deviation (SD) scores (birthweight
standardised for gestational age and sex) were derived from
the most appropriate British and North American
standards.1617 HIV infection was not related to gestational
age, to birthweight, or to birthweight SD scores.
Birthweight SD scores were below zero in all centres,
(overall mean -0-84 SD units), and were related to
mothers' use of drugs and to centre, with differences
between Spanish (mean — 110 SD units), Italian (-0-61),
and north European (— 0-90) centres. When these
differences between centres were allowed for by multiple
regression, differences were found between the birthweight
SD scores of infants bom to mothers who did not use drugs
in pregnancy (SD score -0-70) and infants with drug
withdrawal symptoms (— 1 08). Infants whose mothers had
used drugs in pregnancy but had no withdrawal symptoms
had an intermediate mean birthweight SD (-0-87). This
was a statistically significant linear trend (t248 = 2-15,
p = 0-032).
Clinical Folloiv-up
178 of268 children who survived the neonatal period have
been followed up for at least 6 months and 123 for over 1
year. Table I shows the 10 children who had developed
AIDS or ARC, of whom 5 have died: 4 with opportunistic
infections, and 1 recorded as a sudden infant death. All the
children with AIDS or ARC were antibody-positive, 8 out
of 9 tested were virus-positive, but not all had
immunological abnormalities (table I). The age of onset of
AIDS or ARC is shown in fig 1 which includes only the 34
children known to be infected. It shows the age when last
seen, or the age at onset of AIDS or ARC. 29% of infected
children have developed AIDS or ARC, all by the age of 9
months.
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TABl-li II—CLINICAL AND INFECTION STATUS OF CHILDREN OVER
15 MON THS
1 3 . S 7.9 11 13 IS 17 T9 21 23 ?S 77 29
Age (months)
Fig 1—Age at onset of AIDS or ARC or age at last follow up of 34
Infected children.
22 other children have non-specific signs or symptoms of
HIV infection, assessed solely on the basis of clinical
examination. (Findings included: persistent generalised
lymphadenopathy, persistent hepatomegaly or spleno¬
megaly, chronic diarrhoea, acquired microcephaly, growth
retardation, or regression ofdevelopmental milestones.) 9 of
these children are presumed infected and all have lowT4:T8
ratios( < 1-O)orhypergammaglobulinaemia,comparedwith
1 of 5 presumed not infected and 2 of8 indeterminate. Some
children previously in this category have had total resolution
of their symptoms. The only child with neurological
abnormalities—epilepsy and acquired microcephaly—was
antibody-negative at 63 weeks and presumed not to be
infected. Apart from 1 child with cystic fibrosis and 1 with
cerebral palsy, the remaining 234 children were clinically
well and had no signs of neurological damage or
developmental delay at the time of their last visit. There
were no cases of AIDS dysmorphic syndrome" and no
immunological abnormalities in this group.
HIV Antibody Status
Fig 2 shows the estimated cumulative percentage to lose
antibody at each age. (Age at antibody loss was taken to be
midway between the last positive and the first negative test.)
Children who died of AIDS or ARC, all of whom were
antibody-positive when last seen, are assumed to have had




of HIV Well Total
Presumed infected
Persistent antibody 8* 8 3 19
Antibody negative,
virus'antigen positive 0 0 5 5
Presumed not infected
Antibody negative 0 4 72 7b
Total 8 12 80 100
•Includes 4 children who died with AIDS/ARC but who would have been
over 15 months at the time of analysis.
among those who lost antibody, was 10-3 months. 53% lose
antibody by I year (95% confidence interval 45%-62%).
By 15months, 69% would be expected to have lost antibody
(95% CI 61%-77%). However, of the 107 seronegative
children, 6 have lost antibody after 15 months; one had been
antibody-positive at 181 months. No child has lost antibody
and then become, and remained, antibody-positive; 20
children have been observed for at least one year after they
became seronegative.
Transmission of Infection
Only the 96 children who were older than 15 months
when last tested were included to establish the transmission
rate for perinatal infection. 15 (16%) of this group remained
antibody-positive and are therefore presumed infected, and
an additional 4 children died of AIDS or ARC but would
have been over 15 months had they survived. Of the 81 who
were antibody-negative, 5 (6-2%) are considered infected
because of at least 1 virus isolation or positive antigen test.
This is probably an underestimate of the prevalence of
infection in the antibody-negative group, as these tests are
insensitive and not done at every follow-up. A minimum
estimate of the transmission rate was therefore 24% (95%
CI 16-32%).
Clinical findings were related to presumed infection
status (table 11). Of the 76 antibody-negative children
surviving to 15 months, 4 (5%) have HIV-related
symptoms, compared with 8 of 11 (73%) with persistent
antibody who have not shown AIDS or ARC. None of the 5
antibody-negative but presumed infected children had
HIV-related symptoms. (The difference between the two
presumed infected groups in the frequency of HIV-related
symptoms is significant; p = 0-026, Fisher's exact test,
2-tailed.)
Age (months)
Fig 2—Loss of antibody.
Risk Factors
We found no evidence that mother's clinical status at
delivery, mode of delivery, or breastfeeding1''-*0 influenced
transmission rates, but the small sample size and other
confounding variables made accurate risk estimates
impossible.
Discussion
The management of HIV infection in infants is
complicated by the difficulty of early diagnosis. At first it
was believed that maternal antibody would disappear by 6 to
12 months, but with antibody loss reported at ages of 15
months or even later," the definition of infection was revised
to include only those children in whom antibody was
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present after 15 months. In our study, 6 children who lost
antibody did so after 15 months. Several children have been
reported to lose antibody only for it to reappear at 20 to 24
months,21 but in our study no children have yet lost antibody
and then become, and remained, antibody-positive. All
childen with AIDS orARC have been antibody-positive. In
children, loss of antibody may not prove absence of
infection: children have been reportedwith negative ELISA
and western blot, but have been posidve on virus or antigen
testing and presumed, therefore, to be infected.2223 These
were all children with symptoms and evidence of
immunosuppression. By contrast, in this study, the 5
antibody-negative children found to be positive on virus or
antigen tests were immunologically normal and without
clinical symptoms at their last assessment; 4 have been
followed up for periods of between 5 and 12 months since
hey first became seronegative. This observation is not
consistent with the view that antibody is lost as the children
oecome ill, and requires confirmation from prospective
itudies. New laboratory tests such as the in vitro test of IgG
intibody production,1213 the in situ hybridisation technique
described by Harnish,24 and western blot analysis of the
intibody profiles of mother and child25 may facilitate the
rarly diagnosis of HIV infection in children. The
wlymerase chain reaction technique26 shows promise, but
vill need careful evaluation of its sensitivity and specificity.
We found an overall transmission rate of 24% for
>erinatally acquired HIV infection, but this is probably an
inderestimate because of the insensitivity of virus and
ntigen tests. Higher rates based on antibody status at less
han 15 months have been reported,59 but these will tend to
>e overestimates: for example, had antibody presence after 1
ear been used to define infection in our study, the
ransmission rate would have been 53% not 24%. Case
election may also account for differences in reported
ransmission rates: in the early stages of the study data were
arwarded to us on children who had not been identified in
tie first 3 weeks of life and did not fulfil the study criteria,
dost of this group had HIV-related symptoms and were
lfected.
Our preliminary report" suggested an association
etween clinical symptoms in the mother in the antenatal
eriod and the early onset of AIDS or ARC in infants,
lowever, no association was apparent with more data and
te use ofHIV infection rather than AIDS or ARC as the
leasure of outcome. Most children in the European study
'ere bom to mothers who abused intravenous drugs; as well
i exposure to intrauterineHIV infection, these infants were
[ increased risk of other congenital infections, low
irthweight, neurological disorders resulting from drug
ithdrawal, and other perinatal problems. The observed
tcess perinatal mortality is probably due to the background
F drug abuse—as demonstrated by the association of low
irthweight and drug abuse during pregnancy—rather than
i effect ofHIV infection alone. Inmany, social deprivation
as encountered after birth, which could have adversely
Tected the child's development and health.
Most of the 271 children bom to HIV-positive mothers in
le European study remain clinically well. However, for the
1 children over 15 months of age who arc presumed to be
fected the outcome is poor (table 11): 8 had acquired AIDS
' ARC, 5 of whom had died and only 8 (33%) remain
ithout symptoms. Neurological problems occurred in 3 of
e AIDS or ARC children; they were present in only 1
lild who was presumed not infected. Neurological
manifestations ofHIV infection may become evident as the
children are followed for longer periods.27 Like other
investigators,"2" we are unable to confirm an AIDS
dysmorphic syndrome. The importance of not labelling
children as infected on the basis of signs less severe than
AIDS or ARC was confirmed by the resolution in some
children of nonspecific HIV-related findings, with loss of
antibody. However, nonspecific symptoms or signs with
low T4:T8 ratios and hypergammaglobulinaemia strongly
suggested infection. Continued follow-up of children who
become antibody-negative is essential since it still cannot be
assumed that they have escaped infection, even if they are
clinically well.
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Summary
Increasing numbers of children born to human immunodeficiency virus (HIV)
antibody-positive women are being identified, but guidelines as to their management
are lacking. We have therefore established a paediatric counselling and screening clinic
for managing such children in Edinburgh. During a period of 3 years, 49 infants and
children of 43 HIV seropositive women have been seen. After a median follow-up
period of 23 months, four children were found to have clinical evidence ofHIV disease
which was non-specific and could have been missed had they not been regularly
monitored. Thus, close surveillance of infants born to seropositive women is
important. Identifying a single clinic where this is done has allowed experience to
accumulate on issues beyond the medical management of these infants as well as
contributing to the clinical care of infants with symptoms. Based on this experience,
we have developed guidelines for managing children bom to HIV antibody-positive
women.
Introduction
The human immunodeficiency virus (HIV) is now known to be infecting
increasing numbers of women, many of whom are young and sexually active.
Therefore obstetric and perinatal issues need to be considered.1 Debate
continues as to whether termination of pregnancy should be advocated for all
pregnant women who are seropositive for HIV because of risks to the mother
and child. Little is known about the natural history of perinatally acquired
HIV infection, nor do guidelines exist for managing children born to women
who are infected with HIV.
In Scotland, studies of intravenous (IV) drug abusers have been shown that
between 38 and 54% are infected with HIV.2"5 We therefore set out to identify
women who were HIV antibody-positive and who had recently had infants or
who were in various stages of pregnancy. On 1 January 1986, a clinic was
established to provide paediatric advice and to monitor the progress of these
infants. This report describes the experience during the first 33 months and
the guidelines for management that we have developed.
0163-4453/89/020119+06 S02.00/0 © 1989 The British Society for the Study of Infection
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Methods
Paediatric counselling and screening clinic
The clinic is staffed by a consultant paediatrician with an interest in
community child health (JM). It is held in conjunction with an adult
counselling and screening clinic supervised by a consultant in infectious
diseases (RPB). It operates with two sessions a week, during which a health
visitor is present and, at one of the sessions, a dental hygienist also. Referrals
are made by staff in the adult clinic once a pregnant woman is identified. Other
sources include staff in antenatal clinics, neonatal paediatricians, general
practitioners, social workers, and health visitors upon discovery of a woman
and infant considered to be at risk of HIV infection. Latterly, with the
introduction of a research registrar, the women have been seen in antenatal
clinics where the purpose and nature of the surveillance is explained, after
which maternal consent is sought. The research registrar has also been present
at delivery so as to collect cord blood, to examine the infant at birth and to
arrange future visits for the mother, either in the clinic or at home according
to her preference.
Surveillance procedure
The procedure adopted is summarised in Table I. Infant and mother are seen
at 6 weeks, 3 months, and 3-monthly thereafter. At each visit, a clinical history
is taken to elicit symptoms of HIV disease. The health visitor assesses
development by means of the Denver Developmental Screening Test, after
which the paediatrician examines the infant. Measurements made include
weight, head circumference and length (or height) of the infant. Peripheral
blood is taken for virology (HIV antibody, antigen and virus culture),
immunology (immunoglobulins, T-lymphocyte subsets) as well as hae-
matology (full blood count with differential and platelet count).
Immunisation procedures are discussed and, due to difficulties at other
clinics in obtaining inactivated polio vaccines, the children are usually
immunised by us. Other child care issues are raised, and the child's mother has
the option of seeing an adult physician at the same appointment, if she so
wishes. Families seen at home are given a separate appointment when a
physician visits the mother.
Further management
When an infant manifests signs or symptoms of HIV or other infection, in¬
patient facilities are available at the infectious diseases unit of the City
Hospital, Edinburgh where admission is under the care of the consultant
paediatrician. Recurrent bacterial infections are seen in children infected with
HIV, despite hypergammaglobulinemia.6 We have instituted regular IV
infusions of 200 mg/kg body weight of immunoglobulin (IV IgG obtained
from the Scottish National Blood Transfusion Service) every 3 weeks to
symptomatic children who present with recurrent bacterial sepsis.7 When,
despite iv IgG, the absolute T4 cell count has declined or when HIV
antigenaemia and loss of core antibody have persisted, zidovudine (14 mg/kg
per day) has been given orally.
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Table I Guidelines for managing children born to HIV antibody-positive
mothers
At 3 monthly intervals.
Clinical review, particularly for infections
Developmental screening
Laboratory investigations:
Virology (HIV antibody and antigen status)
Immunology (T4 and T8 lymphocyte counts and immunoglobulin values)
Haematology (full blood counts including platelets)
Immunisation
When necessary, liaison with
Adult physician regarding the mother's health
Social work staff on housing and financial matters or alternative arrangements for care of
the child
Educational staff (at parent's request)
Physiotherapist, dietitian
Self help groups for emotional support
Table II Clinical and laboratory evidence ofHIV infection in four children
Persistent lymphadenopathy 4
Hepatosplenomegaly 4
Recurrent respiratory infections 4
Eczematous rashes 3
Purpura 2
Positive HIV culture 4
Persistent HIV antibody 4
Positive HIV antigen test 4
Hypergammaglobulinaemia 4
Thrombocytopenia (< 150 x io9/l) 4
Absolute T4 lymphocytopenia (< iooo/l) 4
The chaotic lifestyles led by some parents who continue to abuse drugs have
neant that their children have to be taken into care. This has required close
iaison with the Lothian Region Social Work Department whose staff have
:stablished guidelines for placing these children in alternative care.8
Results
?rom 1 January 1986 to 30 September 1988, 49 infants (age range 1-53
nonths) born to 43 HIV seropositive women have been seen. Of the 43
nothers, 37 were infected through IV drug abuse, and six because of
leterosexual contact. The mothers' age at delivery of the index infant ranged
rom 17 to 33 years (mean 24-1 years). For 22 mothers, this was the first child,
wo having had a further child following the birth of the index case. Only 14
:ontinued to use IV drugs during pregnancy but at least 20 have misused
irugs since.
During the follow-up period, nine infants were taken into foster care (with
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Fig. I. HIV antibody positive children as a percentage of total tested.
four subsequent adoptions), three were in the care of grandparents and the rest
were living with their mothers. Fifteen mothers were single. Some of those
with a partner had unstable relationships in which the male partner was often
in prison or had left home. Nineteen of the infants were known to have fathers
who were themselves HIV seropositive. After a median follow-up of 23
months, four children showed clinical evidence of HIV infection. Signs and
symptoms appeared at 6-9 months and are detailed in Table II. In these four
children, the clinical evidence forHIV disease was non-specific and could have
been missed had they not been regularly monitored. In addition, these four
children had recurrent infections which benefited from IV IgG therapy in
terms of reduction in episodes of respiratory sepsis and diarrhoea. They also
gained weight and spent fewer days in hospital.7 Two of these children have
been given zidovudine orally for nine months without any adverse effects.
Of 37 infants over 15 months of age, four remain HIV antibody-positive.
Figure 1 shows the percentage of infants HIV antibody-positive at various
ages. The median age at loss ofmaternal HIV antibody was 12 months (range
6-18). The remaining 45 children (age range 1-53 months) were clinically well
when last seen and the developmental progress of the cohort as a whole has
been within normal limits.
Of the 49 children, 47 received diphtheria/tetanus (DT) or diph¬
theria/tetanus/pertussis (DPT) immunisation, 37 inactivated polio vaccine,
ten oral polio vaccine, while measles vaccine was given to 20 children over 15
months of age who were HIV antibody-negative, clinically well and had
normal tests of immune function. An adverse reaction was not reported in any
child or family member.
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Discussion
delines for managing children born to HIV antibody-positive women need
e based upon adequate data. Prospective studies are therefore needed to
blish the prevalence of perinatal transmission as well as the natural history
[IV disease in infants.9 The guidelines that we propose reflect our clinical
laboratory data. In establishing that which we have described, a
iiatrician was appointed to co-ordinate the surveillance of all the children,
iburgh has the largest cohort in the U.K. of such infants. This reflects, in
, the needle-sharing habits of drug abusers but is also due to there being
ngle centre for referrals and where expertise is accumulated. Close
litoring of these infants leads to detection of early signs of HIV disease (as
ur four HIV-infected children), and therapy such as regular infusions of
mmunoglobulin and oral zidovudine. Good rapport with the mothers has
meant that no child has been lost to surveillance.
t the time of writing, routine antenatal screening for HIV antibody is not
:tised in Edinburgh. However, most women at the time of booking are
d about high risk activities and are offered the option of testing. Women
are HIV-seropositive and who wish to continue the pregnancy are
rred to the paediatricians. The number of infants attending the clinic is
)ably less than the actual number of infants at risk ofHIV infection in the
rburgh area. Even so, due to close liaison with obstetricians, paediatricians,
sicians and social workers in Edinburgh, the degree of under representation
robably small.
uidelines, as well as the rationale, for immunising children infected with
7 have been published.10 Lack of adverse reactions to live virus vaccines in
;r the children or other family members supports previous experience,
lso stresses the importance of separating HIV-infected children with
ptoms from those without symptoms when considering immunisation,
risks of natural measles for unvaccinated HIV-infected children who are
cally and immunologically healthy far outweigh the theoretical risks of
sles vaccination.
ccording to current recommendations,11 HIV-seropositive women should
r pregnancy and termination should be offered to those who are pregnant,
ur experience, such sweeping statements deter women from seeking early
natal care so that most present too advanced in pregnancy for termination
e considered. At our clinic, individual advice is given to each woman
emplating pregnancy and she is strongly urged to have a thorough medical
laboratory evaluation. Pregnancy is contra-indicated if signs of HIV
ase are detected or if immunological function is abnormal.
Lost seropositive women in Edinburgh have been infected by abusing
5s. They come from areas of the city with problems of multiple
•ivation.5 Therefore, the problems of drug abuse, unemployment,
risonment, and single parent families compound the diagnosis of HIV
:tion. Parental skills are lacking so that close liaison between doctors and
al workers is essential. The paediatric clinic has also served as a resource
re for social workers as well as for other health care professionals, self-help
ips and members of the public. Information on the risks of perinatal
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transmission and on the care of infants considered to be at risk is scanty so that
we have had to prepare guidelines for carers. Also, we have identified the social
isolation and anxiety of mothers when facing the uncertain future for their
children and for themselves. Attempts have been made therefore to start a self-
help group for HIV-seropositive mothers. We also envisage that due to clinical
deterioration in a mother's health, it may be difficult for her to care for her
infant, so we intend to start a supported accommodation unit for mothers and
infants.
The mobility of IV drug abusers has recently been appreciated.6 With
reports that suggest a rise in seroprevalence rates in England and Wales,12
other cities in the U.K. will experience problems with infants born to sero¬
positive women as Edinburgh has done. Costs of the paediatric clinic relate
only to the salaries of medical and nursing staff (£23,000 per annum). Other
expenses are borne by the adult counselling and screening clinic.6 At a time of
limited resources, the establishment of a single centre in a region for the
referral, review and management of infants at risk of transmission ofHIV from
the mother appears to be the most efficient approach to this difficult problem.
(Dr Hague is a research registrar funded by the Medical Research Council. We also
acknowledge funding from the AIDS Virus Education and Research Trust and the
Scottish National Blood Transfusion Service. We thank Dr D. Jeffries and Dr J.
Peutherer for performing HIV cultures on samples from the infants; Dr O. B. Eden
for haematological tests; Dr C. M. Steele for determining lymphocyte subsets; and
the staff at the City Hospital Screening Clinic for continued interest and support.)
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Vertical transmission of HIV: a prospective study
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summary Forty nine infants of HIV seropositive women were followed up for a median of 24
months, together with 24 controls. The infection status of 11 index children under 18 months of
age was indeterminate; 34 were presumed uninfected while four showed clinical and laboratory
evidence of HIV disease. Based on current definitions of HIV infection and excluding children
under 18 months old as well as those who had not been studied from birth, two out of 28 children
were infected. The estimated rate of maternofetal transmission was therefore 7-1%. In children
with proved infection, sequential laboratory data showed that hypergammaglobulinaemia was
noted as early as 6 months and often predated clinical signs. This observation, in the presence of
non-specific clinical findings, was helpful in alerting the paediatrician to a diagnosis of HIV
infection.
Vertical transmission of the human immuno¬
deficiency virus (HIV) is now well documented,1-3
although the exact risk has not yet been quantified.
Rates of transmission appear to vary from 22-65%,
depending on inclusion criteria and duration of the
study as well as methods used to define paediatric
HIV infection.4-6 The diagnostic value of an HIV
antibody test is limited by the presence of passively
acquired maternal antibody in infants. Clinical
evidence of infection is also unreliable, especially in
the early stages when signs and symptoms are non¬
specific.7 The inclusion of control children is there¬
fore essential, in order that clinical and laboratory
parameters can be evaluated. So far, no study of
mother to child transmission of HIV has included a
control group.
In the United Kingdom, Edinburgh has been
reported to have the largest population of intra¬
venous drug users infected with HIV, one third of
whom are young women.8 Most were infected
during an epidemic of needle sharing in 1983-4, and
most are asymptomatic at present. Centres which
reported high rates of vertical transmission of HIV
had initially concentrated on women who had more
advanced disease. We postulated that the same risk
might not apply when the mother had preclinical
disease. Infants born to HIV seropositive women
were therefore enrolled into a prospective study to
evaluate the risk of maternofetal transmission and
to define the natural history of perinatally acquired
HIV disease in those who were infected.
Subjects and methods
SUBJECT SELECTION
The paediatric counselling and screening clinic at
the City Hospital in Edinburgh was established in
January 1986 to monitor all infants born to HIV
seropositive women. Edinburgh is one of the centres
collaborating in the European Multicentre Study on
perinatal transmission of HIV.
Most HIV infected pregnant women were identi¬
fied in the antenatal period. If the woman chose to
continue with her pregnancy, permission was sought
for inclusion of her infant in the study. Thirty nine
infants were thus enrolled, together with 10 who
were referred either subsequent to the mother's
HIV antibody test being positive, or because of
symptoms suggesting HIV disease. These 49 infants
comprised the index group.
Twenty four infants born to HIV seropositive
fathers but whose mothers remained seronegative
were included as controls. Mothers were tested after
self identification of high risk activities, and belonged
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to similar socioeconomic groups as mothers who
tested positive.
PROCEDURE AT FOLLOW UP
The procedure at follow up was identical for
children in both index and control groups. Those
infants identified antenatally were seen and ex¬
amined at birth, at age 6 weeks, and 3 months, and
at intervals of three months until the age of 2.
Thereafter review occurred every six months if the
child remained well. Others were seen according to
the protocol from the time of referral.
At each visit, a history was taken according to a
standard questionnaire and the child examined for
symptoms and signs of HIV disease. Developmental
screening was performed using the Denver develop¬
mental screening test. Length, weight, and head
circumference were documented. Blood was then
taken for laboratory tests.
LABORATORY METHODS
At intervals of three months HIV antibody was
measured in both index and control children using
an antiglobulin enzyme immunoassay (Abbott
Recombinant HIV 1 ETA) followed by a com¬
petitive enzyme immunoassay (Wellcozyme). For
index children, HIV 1 antigen was measured by
quantified enzyme immunoassay (Abbott HTLV 3
antigen EIA). Lymphocytes were cultured for HIV
every six months in all index children; positive
results were confirmed by antigen capture.
Other investigations on peripheral blood included
measurement of haemoglobin, total white cell and
differential count, T lymphocyte subsets, platelet
count, and immunoglobulin concentrations as pre¬
viously described.4
The significance of various comparisons were




Characteristics of mothers of index and control
children are shown in table 1. All were white. Thirty
seven index mothers were infected through intra¬
venous drug use and six were heterosexual contacts.
No differences were seen between the two groups of
women in the use of drugs during pregnancy,
although more index mothers resorted to drug use
after the birth of the child. No woman had AIDS or
AIDS related illnesses before the delivery of the
child, although one developed Pneumocystis carinii
pneumonia during a third pregnancy that was
terminated at 18 weeks' gestation. The remaining 42
index mothers were clinically free of HIV related
Table 1 Characteristics of43 index and 24 control mothers
Index Control
No (%) No (%)
Mean age at delivery (years) 24-1 23-6
Single mother 15 (31) 5 (21)
First born child 21 (43) 11 (45)
Drug use during pregnancy 14 (29) 2 (8)
Drug use since pregnancy 20 (41) 2 (8)*
Infant in alternative care 12 (24) 1 (4)
*p<0-05 (x: test).
symptoms. There were two sets of twins and four
sibling pairs among the index children.
INFECTION STATUS OF INDEX CHILDREN
Four index children showed clinicai evidence of HIV
disease (table 2), two of whom were referred
because of symptoms. All had positive cultures for
HIV, with HIV antigenaemia and persistence of
HIV antibody beyond 18 months of age. These
children were definitely infected.
Of the remaining cohort, 11 were under 18
months of age and because of presence of maternal
antibody, were classified as indeterminate status.7
None had positive results for HIV antigen or
culture. Of 38 index children over the age of 18
months, 34 were HIV antibody negative, HIV
antigen as well as culture negative. They were
clinically free of symptoms that suggest HIV disease
and have normal tests of immune function. These 34
children were presumed uninfected.
PERINATAL DATA
Table 3 summarises perinatal data of index and
control children, with the index cohort separated
into children who were infected and those presumed
uninfected. The mean birth weight was significantly
lower in index children presumed uninfected (95%
confidence interval (CI) 2714 to 3078 g) when
compared with controls, (95% CI 3069 to 3527 g)
and the difference remained when all children
whose mothers used drugs during pregnancy were
excluded from analysis. The effect of preterm
delivery was allowed for by extrapolating preterm
birth weight to term, along the same centile, and
index children presumed uninfected were signi¬
ficantly lighter than controls.
All but one index infant were delivered by
spontaneous vaginal delivery. Neonatal special care
was required mainly for drug withdrawal symptoms
and intrauterine growth retardation. Intensive care
was only necessary for two index infants because of
problems arising from preterm delivery. These
consisted of meningitis with septicaemia resulting
in ventriculoperitoneal shunts for hydrocephalus
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CLINICAL OUTCOME
The median age when last seen was 24 months for
index infants (range 3 to 52 months), 12 months for
controls (range 3 to 30 months). No child has been
lost to follow up. Within the index group, children
whose infection status was indeterminate have been
excluded from analysis. Signs and symptoms
observed in index and control children are shown in
table 4, with index children separated into those
infected and presumed uninfected.
Appreciable lymphadenopathy was defined as the
presence of nodes >0-5 cm in diameter in more than
two non-contiguous sites (excluding inguinal) and
persisting beyond three months. Chronic or
recurrent respiratory infections were those which
occurred on three or more occasions within a three
month period. Recurrent diarrhoea was defined as
loose stools that persisted beyond 48 hours, required
treatment, and occurred on more than one occasion
per month.
Failure to thrive was diagnosed when the child's
sequential weights declined across centile lines.
As seen in table 4, signs and symptoms were non¬
specific and were seen in control as well as index
children. Lymphadenopathy and recurrent respira¬
tory infections weie seen in appreciably more index
children, even those presumed uninfected, when
compared with controls. All index children pre¬
sumed uninfected had symptoms and signs which
resolved with time; they never had positive HIV
antigen or culture results.
Neurological signs were detected only in the child
with neonatal meningitis (ataxic diplegia). The
developmental progress of the remaining cohort was
within normal limits.
LABORATORY RESULTS
Laboratory abnormalities are shown in table 5. No
significant differences were seen when the index
children were compared with controls. Within
the index children, however, those presumed un¬
infected were significantly less likely to have per¬
sistent hypergammaglobulinaemia, lymphopenia,
T4 lymphopenia, and thrombocytopenia. Abnormal
laboratory results in index children presumed
uninfected tended to be transient findings which
returned to the normal range on repeat testing.
Sequential laboratory data within the index group
are displayed in table 6. Hypergammaglobulinaemia
was noted as early as 6 months, and often predated






Significant lymphadenopathy 4* 9* 0*
Recurrent respiratory infections 4 13* 2*
Recurrent diarrhoea 4* il* 5
Eczcmatous rash 3 7 1
Hcpatosplenomcgaly 4* 4* 0
Failure to thrive 1 3 0
*p<()()5 (x: test). Other comparisons between index and control children, as well as within index children, did not reach significance.








Neutropenia (< l()x l()g/l)
Lymphopenia (<2-8x l()g/l)
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transmission, as estimated from our data, was 7-1%,
lower than that previously reported.4"6 This could
be explained, in part, by the fact that all the infected
women were free of HIV related symptoms during
pregnancy. Testing for HIV antigen was performed
in eight mothers during pregnancy, and in 22 after
delivery of the infant—all were found to be nega¬
tive. Our results must be interpreted with caution,
as the numbers are small and as yet, the prognosis
for children aged over 18 months who lose maternal
antibody is unknown. Although not observed in our
cohort, children have been reported to lose antibody
only to seroconvert later on in childhood,14 while
others have been documented to remain antibody
negative with positive antigen tests and virus
culture.4 5 15
Recent developments in diagnostic techniques,
such as in vitro production of HIV specific anti¬
body,16 or polymerase chain reactions for amplifi¬
cation of viral DNA,17 are still under evaluation and
not routinely available. A recent study found that
six of 14 asymptomatic newborns, and five of 10
seronegative children of infected mothers were
positive for HIV-DNA, using the polymerase chain
reaction technique.18 Using more sophisticated
tests, the numbers of infected children in our cohort
could be higher. There is, however, an urgent need
for improved methods to evaluate the seronegative
index children who remain clinically well with
normal immune function, as four mothers have
embarked on subsequent pregnancies based purely
on the observation that the index child was symptom
free and antibody negative (presumed uninfected).
We were unable to detect any laboratory predictor
of HIV disease when sequential index and control
data were compared. In the children with proved
infection, immunoglobulin concentrations (es¬
pecially IgG) did, however, start to rise before
clinical signs were obvious. Clinical manifestations
are non-specific, but when seen in conjunction
with laboratory abnormalities (hypergammaglobu-
linaemia, T4 lymphopenia, thrombocytopenia), a
diagnosis of HIV infection can be strongly suspected
in a child especially when mother has engaged in
high risk activities.
In future, we hope to use the polymerase chain
reaction to detect HIV-DNA in the index children
presumed uninfected. It must be stressed that the
demonstration of viral DNA sequences does not
imply overt infection, as little is known about the
immune response to HIV in children infected
antenatally. Our study stresses the importance of
continued careful follow up of all children at risk of
HIV infection, to detect early markers of infection
as well as to determine the outcome of those who
appear symptom free.
The study is supported by the Medical Research Council, the
Scottish National Blood Transfusion Service, and the AIDS Virus
Education and Research Trust. Wc are grateful to Lesley Boyd for
typing the manuscript. Welhank Dr D J Jeffries and the staff at the
virology department. St Mary's Hospital. London for initiating
HIV cultures on the cohort; the laboratory staff at the hacmatology
department. Royal Hospital for Sick Children. Edinburgh for their
cooperation; and staff in Wards 7a and 15 at the City Hospital for
their help.
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Intravenous immunoglobulin in HIV infection:
evidence for the efficacy of treatment
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summary Eight children with symptoms of HIV infection were treated for 12-26 months
(median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three
weeks. Significant improvement was noted in all children in terms of weight gain, number of
infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment
compared with costs accrued previously during inpatient admissions. Immunoglobulin concen¬
trations, which were raised at the start of treatment were not altered, and T4 counts continued to
decline slowly. HIV core antigen was detected in four children before treatment, but all became
core antigen negative after treatment was commenced, this effect being sustained in three.
Intravenous immunoglobulin therefore has major clinical benefit, and by reducing viral activity
may delay disease progression.
HIV infection in infants and children is associated
with high morbidity and mortality,' and present
therapeutic options are limited to treatment for
specific infections,2 and to zidovudine, which has
many documented side effects and unknown long
term sequelae.3 As in adults, these infants may
present with opportunistic infections and features
suggestive of deficiencies of cellular immunity,
with reversed T4/T8 ratios.4 5 In addition, how¬
ever, children commonly present with recurrent
bacterial infections,1 h and defective humoral im¬
munity has been shown.7 Although serum concen¬
trations of IgG, IgA, and IgM are typically
raised,'3 panhypogammaglobulinaemia has been
described.Even in the presence of hvper-
gammaglobulinaemia, which is attributed to
polyclonal B cell activation.12 patients behave as
though they were hvpogammaglobulinaemic. Hence
passive immunisation in the form of intravenous
immunoglobulin has been reported to be of
benefit.13 14 The aim of this study, therefore, was to
make a fuller evaluation of the clinical effect of at
least 12 months' treatment, to document any
changes in laboratory indices of viral activity, and to
assess the financial implications of committing
children to maintenance treatment with intravenous
immunoglobulin.
Patients and methods
Eight patients with clinical and laboratory evidence
of HIV infection were identified, five of whom
have been described in a preliminary report.1"'
Clinical features at the start of intravenous immuno¬
globulin treatment are summarised in table 1.
Children were treated with intravenous immuno¬
globulin on the basis of a history of two or more
episodes of bacterial pneumonia, a three month
history of recurrent or chronic upper respira¬
tory tract sepsis or diarrhoea, or both, or symp¬
tomatic thrombocytopenia, with laboratory
confirmation of HIV infection. All were treated
every three weeks with 200 mg/kg of intravenous
immunoglobulin supplied by Scottish National
Blood Transfusion Service on a hospital day patient
basis.lh
The procedure and laboratory methods adopted
at each visit were as previously described.17
The financial implications were calculated on the
basis that the cost of intravenous immunoglobulin
for a 15 kg child is £45 and materials, medical,
nursing, and administrative staff time is £40: this
gives a total of £85 per visit, or £1600 per year. The
cost of inpatient paediatric care in south east
Scotland is £960 per week.18
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P2A Recurrent upper respiratory sepsis, diarrhoea,
eczema, failure to thrive
P2A Recurrent upper respiratory sepsis, recurrent
pneumonia, diarrhoea
P2B Prolonged pertussis, encephalopathy, recurrent
pneumonia, diarrhoea
P2D3 Recurrent pneumonia, diarrhoea, oesophageal
Candida, failure to thrive
P2C Purpura, pneumonia, oral Candida, lympho¬
cytic interstitial pneumonitis
P2C Upper respiratory sepsis, recurrent pneu¬
monia, lymphocytic interstitial pneumonitis,
eczema
P2F Purpura, night sweats, upper respiratory sepsis,
pneumonia, eczema
P2F Purpura, recurrent fever, upper respiratory
tract sepsis, eczema
*Stage according to the Centers for Disease Control criteria.2
Results
After 12 months on treatment subjective improve¬
ment in general well being was reported in all eight
patients. Case 3 showed an initial dramatic improve¬
ment in his encephalopathy, as previously des¬
cribed,19 but later deteriorated to become severely
handicapped before finally succumbing to a
pneumonic illness 17 months into treatment. The
other seven children remain well enough to attend
normal school (n=2) or nursery (n=5) regularly.
Table 2 summaries clinical findings before and after
treatment. The number of infections sufficiently
severe to require hospital review was significantly
reduced on treatment, as was recurrent diarrhoea.
Improvement in weight gain was seen in the cohort
as a whole (p<0-01); the most dramatic change was
seen in those children in whom failure to thrive had
been a presenting feature.
The total number of days spent in hospital for all
eight children in the 12 months before treatment
(except for case 1 in whom only nine months from
birth had elapsed) was 220 (range 0-60), compared
with 56 (range 0-20) in the first 12 months on
intravenous immunoglobulin (p<0-001). Assuming
an unchanged rate of infection, the difference
between actual and expected number of days of
hospitalisation would be 181-6; this would result in a
saving on inpatient costs of £24 905 compared with
treatment costs of £12 800. Thus the net saving in
costs of £1513/patient/year, or 49%, even without
taking into consideration the travelling costs and
time lost to the family in attending hospital.
Symptomatic thrombocytopenia, seen in three
patients before treatment showed no immediate
improvement on this dose of intravenous immuno¬
globulin, and a further child developed purpura
while on treatment. Hypergammaglobulinaemia,
Table 2 Clinical outcome after treatment
Before (median) After (median) p Value
Range of weight velocity (g/month) -212 to +312 (117) 150 to 582 (300) <0 01*
Total No of serious infectious episodes 34 (3) 6 (1) <0 05*
Total No of episodes of pneumonia 13 (2) 4 (0) NS
Total months of recurrent or chronic diarrhoea 49 (9) 21 (3) <0-05*
No of patients with:
Upper respiratory tract sepsis 8 8 NS
Eczema 5 5 NS
Significant lymphadenopathy 8 6 NS
Hepatosplenomegaly 7 8 NS
Thrombocytopenic purpura 3 2 NS
*Comparison of symptoms and signs experienced by the cohort in the 12 months before and in the subsequent 12 months after treatment.
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involved, further studies will be required to verify
these findings. The mechanism is likely to be very
different, as plasma donors are screened for HIV
infection and the intravenous immunoglobulin
preparation has no anti-HIV antibody. It has been
suggested that the production of HIV antigen is an
indicator of enhanced expression of viral genes,23
and may reflect the expression of latent virus after
activation of helper T cells. Bacterial and viral
infection increase T cell activation, and the dis¬
appearance of p24 antigen after commencing
treatment may be due to the reduction of viral
activation after the decrease in infective episodes.
The continued decline in the T4 count was dis¬
appointing, but the disappearance of core antigen
with intravenous immunoglobulin treatment
suggests that the progression to AIDS may be
delayed, as the loss of anti-p24 antibody and the
appearance of core antigen are recognised bad
prognostic signs.24
The clinical benefit of treatment we have shown,
together with the quality of life enjoyed by our
patients, leads us to conclude (in agreement with
Schaad's group19) that there is no case for with¬
holding intravenous immunoglobulin treatment in
symptomatic children. This precludes a double blind
placebo controlled trial at this stage, although
further studies may be necessary to optimise the
dose regimen. What remains unclear, however, is at
what point in the course of disease treatment should
be commenced, given that five of our children were
in the early stages of symptomatic disease (CDC P2
A/F).25 A controlled trial will be necessary if we are
to consider treatment in asymptomatic children.
This is liable to be problematic, however, because at
present there is still no reliable diagnostic test of
HIV infection in young children. As the problem of
HIV infection in children grows over the next few
years, routine intravenous immunoglobulin treat¬
ment has major implications in budgeting of hospital
inpatient and day care facilities. We have shown the
cost benefit of treatment—at least in the short and
medium term. In is unlikely, however, that intra¬
venous immunoglobulin will delay progression
indefinitely, and further advances in immuno¬
therapy, such as the introduction of specific anti-
HIV neutralising antibody in combination with
intravenous immunoglobulin and anti-retroviral
treatment, will be required if we are to improve the
ultimate prognosis for HIV infected children.
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Research Council. We would also like to thank the AIDS Virus
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The polymerase chain reaction in the diagnosis of
vertically transmitted HIV infection
Paul Williams, Peter Simmonds*, Peng Lee Yap, Peter Balfe*, John Bishop*,
Ray Brettlet, Rosie Haguet, David HargreavesJ, James Inglist,
Andrew Leigh Brown*, John Peutherer§, Selma Rebus§
and Jacqueline Mokt
The presence of HIV-1 DNA sequences in DNA from peripheral blood mononuclear
cells (PBMCs) was investigated in a two-stage polymerase chain reaction ('double' PCR)
using four sets of nested primers. The PBMCs tested were obtained from 46 children
born to HIV-seropositive mothers, seven 'control' children born to HIV-seronegative
mothers and seropositive fathers, and 45 healthy adult blood donors who were HIV
seronegative. Nine of the children had symptomatic HIV infection and other laboratory
features characteristic of HIV infection: all nine were PCR-positive with each set of
primers in each of their 22 blood samples tested. The remaining 44 children had no
clinical or laboratory evidence of HIV infection, and each of their 50 samples was
PCR-negative with each set of primers, as were all blood donor samples. PCR-positive
samples were tested in more detail using two of the sets of primers, which spanned
hypervariable regions in the env gene. Polyacrylamide gel electrophoresis of DNA
amplified from these regions yielded patterns of amplified DNA length variation which
were characteristic for each child, and which changed little with time (in serial samples
obtained over periods of 3-7 months). This excluded contamination as a cause of PCR
positivity. This is the first report of the use of a double PCR for the diagnosis of HIV
infection. The results demonstrate the specificity of this PCR method in diagnosis, with
failure to reveal in this cohort any cases of vertically transmitted HIV-1 infection in
addition to those already confirmed by conventional laboratory techniques.
AIDS 1990, 4:393-398
Keywords: HIV, polymerase chain reaction, nested primers, hypervariable regions,
diagnosis, vertical transmission.
ntroduction
"he laboratory diagnosis of HIV infection in children is
isually made by demonstration of the persistence of em¬
ulating HIV antibody beyond 18 months of age, by cul-
ure of HIV, or by the detection of HIV core (p24) anti-
;en. Other abnormalities present, such as hyper- or hypo-
^mmaglobulinaemia or an abnormal CD4 (helper) lym-
ihocyte count, may also facilitate diagnosis [1 ]. In the
symptomatic child, however, it may be difficult to con-
irm HTV infection as circulating transplacental^ acquired
maternal antibody may take up to 18 months to clear [2],
and other laboratory tests may be negative for antibody
[3,4], HIV p24 antigen or virus culture [5].
The polymerase chain reaction (PCR) is an in vitro
method of selectively amplifying specific DNA sequences
[6,7]. It has been used successfully to detect the pres¬
ence of HIV proviral DNA in the peripheral circulation of
HIV-infected individuals [8,9]. PCR may allow detection
of HIV infection prior to seroconversion [10] and has
been reported to detect latent seronegative infection in
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dults [11-13] and to enable diagnosis of HIV infection
i children [14-16].
. prospective study of HIV infection in children born to
HV-seropositive mothers is currently in progress in Edin-
'urgh [17]. In the course of this study, several diagnostic
idicators ofHIV infection in infants are being compared.
7e report here the results of a comparison of PCR anal-
sis of DNA extracted from peripheral blood with other




ifty-three children were studied. Nine had symptomatic
HV infection, according to the Centers for Disease Con-
ol (CDC) paediatric classification of HIV infection [l]
group 1); 29 were asymptomatic children born to HIV-
tfected mothers but fromwhose circulation maternal an-
body had cleared and who tested negative for serum
[IV p24 antigen and HIV culture (group 2); eight were
hildren bom to seropositive mothers but from whose
irculation maternal antibody had not cleared (group 3),
nd seven were children bom to seronegative mothers
ith seropositive fathers (group 4). The negative control
imples studied were from 45 healthy HIV-1-seronega-
ve blood donors with no risk factors for HIV infection
group 5).
erology, HIV p24 antigen assay and virus culture
2rum samples were tested for HIV-1 antibody by en-
/me immunoassay (Wellcome Diagnostics, Dartford,
K, and/or Abbott Diagnostics, Maidenhead, UK) and
[IV p24 antigen by antigen-capture assay (Abbott). Pe-
pheral blood mononuclear cells (PBMCs) were sepa-
ited over Ficoll-Hypaque and cultured in RPMI-1640 cul-
tre medium (Gibco Europe Ltd, Uxbridge, UK) supple-
lentedwith 10% fetal calf serum, 2% penicillin and strep-
)mycin, 80U/ml recombinant human interleukin-2 (Du
ont, Stevenage, UK), and 3 gg/ml phytohaemagglutinin.
ulture supernatants were harvested at weekly intervals
ad tested for the presence of p24 antigen (Du Pont),
eactive samples were confirmed by neutralization [18].
lood samples
wo-millilitre blood samples were collected into
hylenediamine tetraacetic acid (EDTA) and PBMCs
ere separated over Ficoll-Hypaque. PBMCs were
ashed once in normal saline and the cell pellet was
ored at — 20°C for up to 12 weeks. The DNA from the
;11 pellets was extracted in 0.4ml lysis buffer (50 mmol/1
DTA, 0.1 mol/l NaCl, 50mmol/1 Tris HC1) containing 1%
ircosyl and 100 gg/ml proteinase K, followed by extrac-
3nwith phenol (twice) and chloroform prior to precipi-
tion in 70% ethanol overnight at — 20°C. After resuspen-
sion in distilled water and quantification by 260 nm light
absorption, 1 pg aliquots of DNA (equivalent to 150000
cells) were used for each PCR. PBMCs from 5ml sam¬
ples of EDTA-anticoagulated donor blood were handled
identically. The preparation of cell pellets, DNA extrac¬
tions, and PCRs were performed on donor and paediatric
blood samples concurrently, in order to be able to detect
any cross-contamination during each experimental stage.
Polymerase chain reaction
A two-stage PCR (double PCR) was performed, us¬
ing four pairs of HIV-specific primers [19]. In the
first PCR, 1 pg target template DNA was present in
50 pi 67 mmol/1 Tris-HCl (pH8.8), 16.7 mmol/1 ammo¬
nium sulphate, 6.7 mmol/1 MgCl2, 10mmol/1 2-mer-
captoethanol, 6.7 pmol/1 EDTA, 33 pmol each of de-
oxyadenosine triphosphate (uATP), deoxyguano-
sine triphosphate (dGTP), deoxycytidine triphosphate
(dCTP) and deoxythymidine triphosphate (dTTP),
170 pg/ml bovine serum albumin, 10% dimethyl-
sulphoxide, 0.5 pmol/1 each outer nested primer and
0.015 U/pl Taq polymerase (Cetus). The target DNA was
amplified using a 'Cetus' (Perkin-Elmer Cetus, Beacons-
field, UK) thermal cycler; 25 heat cycles were used, each
of 0.6min at 94°C, 0.7min at 50°C and 3min at 68°C.
One microlitre of the reaction mixture from the first
PCR was then transferred to a second tube containing
20 pi of the same medium as before, but with a second
pair of primers lying within the region amplified initially,
and a farther 25 heat cycles were carried out with the
same programme. Recombinant HIV-1 plasmid positive
(pBH10.R3) and herring sperm DNA negative controls
were included in each PCR assay.
Four outer primer pairs complementary to different parts
of the HIV genome were used simultaneously in the
first PCR reaction, and the four inner primer pairs were
subsequently used singly in four separate second PCR
reactions. The four amplified sequences were in the
gag, pol, and env regions of the genome. Two of the
primer pairs spanned hypervariable sequences in the
env region. Details of the method are reported else¬
where (P. Simmonds et al, submitted for publication).
The sequences used were: gag primers 881: 5'-GGTA-
CATCAGGCCATATCACC sense 1214 base pair (bp); 882:
5'-ACCGGTCTACATAGTCTC antisense 1669 bp; 883: 5'-
GAGGAAGCTGCAGAATGGG sense 1407 bp; 990: 5'-
GGTCCTTGTCTTATGTCCAGAATGCTG antisense 1646
bp: pol primers 001: 5'CATGGGTACCAGCACACAAAGG
sense 4149 bp; 004: 5' TCTACTTGTCCATGCATGGCTTC
antisense 4380 bp; 002: 5'GGAGGAAATGAACAAGTA
GATAAATTAGTCAG sense 4175 bp; 003: 5'-TCACTAGC-
CATTGCTCTCCAATT antisense 4290 bp; envl primers
401: 5'GAGGATATAATCAGTTTATGG sense 6539 bp;
404: 5'-AATTCCATGTGTACATTGTACTG antisense 6976
bp; 402: 5'GATCAAAGCCTAAAGCCATG antisense 6560
bp; 403: 5'CAATAATGTATGGGAATTGG antisense 6876
bp; env3 primers 406: 5'-TCAGGAGGGGACCCAGAAATT
sense 7316 bp; 247: 5'-GATCCCATAGTGCTTCCTGCT-
GCT antisense 7816; 407: 5' -GGGGAATTTTTCTACT-
GTAAT sense 7361; 405: 5' TATGAGGGACAATTGGA-
GAAG antisense 7665 bp.
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rhe 20 pi product of the second PCR was elec-
trophoresed on a 3% low-melting-point agarose gel con¬
taining ethidium bromide to detect amplified product
DNA With this detection method, the presence of HIV-1
DNA in the initial sample is indicated by the presence of
i single band of the correct size following electrophore¬
sis. This PCR method has a sensitivity sufficient to detect
i single molecule of target HIV DNA in up to 5 pg hu¬
man DNA [19]. In earlier experiments, PCR amplification
[using human primers) of human DNA sequences pre¬
pared by this method gave consistently positive results
[19], validating the method of DNA preparation.
ro assess length polymorphisms in the env region in
samples found HIV PCR positive by the above method,
lie second PCR amplifications with the envl and env3
3rimers were repeated in the presence of 5 pCi 35S-dATP
[Amersham International pic, Aylesbury, UK) per 20 pi
reaction volume. To increase the incorporation of la¬
belled nucleotide in the amplified DNA, the concentration
af unlabelled triphosphates was reduced to 8.25 pmol/1.
rhe product was electrophoresed on denaturing poly-
ictylamide gels. The molecular weight of the amplified
DNA was estimated using appropriate markers.
of the primer sets, while none of the group 2 (n = 32),
group 3 (n = 11), group 4 (n = 7) or group 5 samples
gave positive results with any of the primers. Figure 1 il¬
lustrates the results of samples tested.
1 2 3. 4 5 6 7 8 9 10 11 12 13 14
Results
lach DNA sample studied was amplified with four pairs
if outer primers, and 1 pi aliquots of the first PCR prod-
act were then further amplified with each of the corre-
iponding inner primer pairs in four separate second PCR
implifications. The products were analysed by agarose
»el electrophoresis and the presence of DNA indicated
ay staining with ethidium bromide. Samples were scored
is positive or negative by the presence of a DNA band of
he appropriate molecular weight in the product of the
iecond reaction. With the double PCR, negative samples
lo not produce visible bands. Because of the high yield
)fDNA from all positive samples, each reaction therefore
ields a clear positive or negative result. Table 1 records
he results for the five groups of cases studied in each of
he regions amplified. All 22 of the samples taken from
he children in group 1 gave positive results with each
Fig. 1. Results of testing peripheral blood mononuclear cell (PBMC)
DNA from children at risk for HIV infection with four sets of
nested primers as follows: (a) gag primers; (b) pol primers; (c) envl
primers; (d) env3 primers. Columns 1-7: seven seropositive chil¬
dren (cases 9, 7, 8, 6, 5, 1, 4). Columns 8, 9: two seronegative chil¬
dren. Columns 10, 11: two serologically indeterminate children.
Column 12: positive control (65 ag of plasmid pBH10.R3). Column
13: negative control (negative T- lymphocyte cell line 08166). Col¬
umn 14: molecular weight markers (pTZ18R, Haelll digest; bands
of 767, 458/434, 281/267, 174 and 142 base pairs are visible.
All PCR-positive samples identified in this studywere am¬
plified using primers which span the first and third hyper-
variable regions of the env gene [20]. Polyacrylamide gel
electrophoresis of the 35S-labelled PCR product showed
a range of length variants to be present in each sample
(Fig. 2). Each pattern of variants is specific for each pa¬
tient, and distinct from that of the cloned HIV sequence
shown. This excluded contamination by sample mixing
or by recombinant DNA as a cause of PCR positivity.
To investigate the reproducibility of this method, four
aliquots of a DNA sample from each of the PCR-positive
"able 1. Categorization of negative and positive polymerase chain reaction (PCR) results*.
Region of HIV-1 genome amplified (no. positive/no. tested)
Number of Number of
Iroup Age in months (mean) patients samples gag pol envl env3
I) Infected 2-66 (41.2) 9
D Presumed uninfected 18-54 (34.1) 29
5) Indeterminate 1-13 (5.9) 8
t) Paediatric controls 10-36 (23.4) 7
>) Adult controls 45
22 22/22 22/22 22/22 22/22
32 0/32 0/32 0/32 0/32
11 0/11 0/11 0/11 0/11
7 0/7 0/7 0/7 0/7
45 0/45 0/45 0/28 0/28
PCR amplification of the HIV-1 regions shown was performed on the number of samples shown. The env7 and env3 regions were amplified in only 28
if the 45 blood donors.






Fig. 2. Analysis of amplified DNA by high-resolution polyacry-
lamide gel electrophoresis. Radioactive polymerase chain reac¬
tion products in the envl and env3 regions were electrophoresed
to investigate length variation of the infecting virus strain within
and between seropositives. From left, lanes 1-9: cases 1, 2, 3, 4,
5, 6, 7, 8, 9. Lane 10: seronegative child. Lane 11: 65 ag pBH10.R3
single band). Size of markers in base pairs as indicated.
:ases were amplified with the envl and env3 primers in
quadruplicate reactions. Representative results are shown
n Fig. 3, where little variability in the pattern of ampli-
ied bands can be seen. Follow-up samples from each of
he available infected individuals were similarly tested in
3rder to investigate the stability of the observed patterns
aver time. Little variation in the pattern of bands was seen
n samples collected over periods of 3-7 months, as il-
ustrated by the samples from case 8 in Fig. 3.
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ig. 3. Reproducibility of pattern of length variation in envl and
■nv3 regions. Lanes 1—4: four replicate reactions with DNA from
:ase 6. Lanes 5-8: case 1. Lanes 9-12: case 7 (only three repli-
:ates of env3 shown). Lanes 13-16: case 8. Lanes 17-20: case 8
enesected 3 months later.
~able 2 compares the PCR results with the results of
erum antibody and HIV p24 antigen assays and virus cul-
ure, and also gives other relevant clinical and laboratory
letails of the cases studied. All nine children who were
'CR-positive were HIV-1-antibody-positive by enzyme-
nked immunosorbent assay (ELISA) testing (confirmed
>yWestern blotting in each case). Four of the nine were
nv p24 antigen-negative at the time of PCR positivity
cases 1, 4, 5, 8), two of whom have never tested HIV
>24 antigen-positive. The disappearance of HIV p24 anti-
;enaemia in cases 1,3 and 4 occurred in associationwith
itravenous immunoglobulin G treatment [21], Seven of
fie nine were HIV virus culture-positive on one or more
ccasion. Case 5 has remained persistently negative for
oth culture and serum HIV p24 antigen, despite being
positive for antibody and PCR The child has had hyper-
gammaglobulinaemia and symptoms for 17 months, with
a progressive decline in CD4 lymphocyte count. Case 6
was positive for serum p24 antigen aged 2 and 4 months,
but umbilical cord blood cultured for HIV virus gave a
negative result. The 29 group 2 and eight group 3 chil¬
dren, all of whom were PCR negative, have been asymp¬
tomatic with normal serum immunoglobulin levels and
negative HIV p24 antigen assay at each 6-monthly follow-
up clinic visit, and show no evidence of CD4 lymphocyte
depletion where tested. These data constitute strong ev¬
idence for the absence of HIV infection in these cases.
Discussion
PCR offers considerable promise for the detection of ver¬
tically transmitted HIV infection, as the method might be
capable of yielding diagnostic results with high specificity
and sensitivity at an age when other methods of detection
may not.
There have been three recent reports of the use of PCR
in the diagnosis of vertically transmitted HIV infection,
each using a single PCR amplification followed by iden¬
tification of the (amplified) product with a radioactive
oligonucleotide probe [14-16], Laure et al. [14] ampli¬
fied three conserved sequences in the gag(l) andpol(2)
regions. Some samples were termed PCR-positive even
when positive results were obtained with only one or
two of the three combinations of primers used, and such
results were seen even in children with proven HIV in¬
fection. HIV infection by PCR positivity was claimed in
six of 14 newborn infants tested, but other laboratory
confirmation of HIV infection was present in only one of
these. Also, five out of 10 children aged 2-5 years were
claimed to be HIV-infected on the basis of PCR positivity,
although other laboratory confirmation in these cases was
similarly lacking; moreover, all were HlV-antibody-nega-
tive. Rogers et al [15] amplified two HIV sequences in
the HIV p24 and HIV gp4l regions, but had a high false-
negative rate with only six PCR-positive neonates found
among 11 who later went on to develop AIDS. Edwards
et al. [16] amplified two sequences in the gag region,
but similarly had negative PCR results in one child with
symptomatic HIV infection.
Other workers have also failed to find a clear correla¬
tion between indices of HIV infection and PCR reactivity.
Imagawa et al [13] found a number of individuals who
were serum HIV-antibody and HIV p24 antigen-negative
for several months, yet were PCR-positive on more than
one occasion. Conversely, the finding of extremely low
levels of provirus in certain individuals allows the possi¬
bility that false-negative results may occur by testing in¬
sufficient DNA Simmonds et al [19] report that PBMC
DNA from one seropositive individual contained only five
copies of provirus per 106 cells. Thus, considerably more
than 1 gg DNA would need to be amplified to ensure re-
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Table 2. Details of HIV-infected children.
Cases













44 60 56 35 50 4 (D) 24 (D) 49 66 (D)
P2A P2C P2A P2F P2A P2D1 P2B P2C P2D3
3 18 6 9 33 1 21 12 9
29 46 42 _ _ _ 24 _ 50-60'
0-+ 0, 18-+ 14—+ 0, 33-+ 0— 0-+D 9—+D 12-+ 9-+D
3 + 6 + , 9 — -» 42+ -► 18+-+ 6+-+ 36+-+ None 9+-+D 26+-. 44+ -+D
3 + -+28 — —>44 + 52+ -+ 30+ -+41 6+ 15H—+22 — —► None 4 + 15+-+D None 44+ -+54 -
6,9 42-+ 23, 51 3—+12 None 2, 4 15—+D None 48—+D
12-+ None 27-+52 15-+ 36-+ None 9, 12 26-+ None
24, 26, 39 40, 47, 56 35, 36, 37, 42, 51 14, 17, 18 None None 15 33 57
40 None None None 39, 40, 45 Cord None None None
39, 40, 41, 42 53, 56, 58 49, 53, 54 24, 27, 31 41, 43, 47 2 24 42, 45, 47 66
■ 63 +
Age, age in months at end of study (July 1989) or at death (D); Centers for Disease Control (CDC) stage of HIV infection at the end of study or at death;
first symptoms, age in months when symptoms started; zidovudine commenced, age in months zidovudine (AZT) started (in cases 1, 2, 3, 7, 9); HIV
seropositive, age in months when serum HIV antibody-positive; raised serum IgG, age in months when polyclonal elevation in serum immunoglobulin G
!lgG) concentration present ( + ) or not ( —); raised serum IgA, age in months when polyclonal elevation in serum IgA concentration present ( + ) or not
); p24 antigen +, age in months when p24 antigen detected in serum; p24 antigen —, age in months when p24 antigen not detected in serum; HIV
culture +, age in months when virus grown from peripheral blood; HIV culture —, age in months when failure to culture virus from peripheral blood;
'BMC PCR tested, age in months at which blood sample peripheral blood mononuclear cells (PBMC) taken for analysis by polymerase chain reaction
PCR) for HIV-1; —», same result as the last one shown obtained in each subsequent 3-monthly sample; -»D, same result as the last one shown obtained
n each subsequent 3-monthly sample, until death; None, these outcomes not shown in any sample tested; Cord, this outcome found in umbilical cord
alood. 'Zidovudine given from 50-60 months, then stopped because of leucopenia. All other children studied had normal total serum immunoglobulin
concentrations, tested negative for p24 antigen and virus culture, and those aged over 18 months had become HIV seronegative.
producibly positive PCR results. It is likely that patients
ivith yet lower amounts of PBMC provirus may be iden-
ified, and these may prove refractory to screening using
PCR during such stages of infection. This emphasizes the
mportance of continued monitoring of all infants bom to
TlV-infected mothers. In all samples in this report scor-
ng positive or negative, there were no discrepancies be-
ween the results obtained with the four independent sets
Df primers from gag, pol, envl and env3- The positive
PCR results obtained were completely concordant with
he clinical and laboratory evidence of HIV infection in
hese children. All control samples (groups 4 and 5) were
PCR-negative, and no cases of latent HIV infection were
detected in groups 2 and 3.
dullis and Faloona [22] described the use of nested
3rimers to increase the specificity of PCR for target se¬
quencing. Simmonds et al [19] have used this technique
o improve the sensitivity as well as specificity of this
nethod for HIV detection and have reported the reliable
detection of single molecules of target sequence. This is
:onsiderablymore sensitive than existing methodologies,
'urthermore, the higher degree of amplification possible
illows the direct visualization of amplified product, and
ilso permits partial characterization of HIV by virtue of
ts strain-dependent length variation in several regions of
he env gene.
rhe demonstration of different length variants of am-
ilified HIV DNA is of considerable interest. The HIV
;enome exhibits great diversity in nucleotide sequence,
X3th between isolates made from different patients and
between multiple isolates made from the same patient
[20,23-25]. In addition, certain segments of the region
of env-encoding gpl20 show extensive length variation
[20,23]. In a separate study of HIV-infected haemophilic
patients, Simmonds et al have obtained nucleotide se¬
quences which confirm the existence of the length vari¬
ants present within patients' samples. The pattern of
variants is similarly patient-specific (Simmonds et al., in
preparation). Thus it has proved possible to distinguish
variants ofHIV both between and within infected individ¬
uals, and to distinguish genuine positive reactions from
contamination by exogenous HIV sequences.
The finding of different length-variant patterns in cases
7, 8 and 9 is of particular interest, as they are siblings.
The different patterns seen imply either vertical trans¬
mission of different HIV env variants to each child, the
rapid emergence of different variants within each child
(possibly due to different immune selection pressures),
or both. Unfortunately, library samples of the mother's
PBMC DNA spanning the pregnancies are not available
for analysis. PBMC DNA samples taken from haemophilic
patients over intervals of 2 years can show considerable
change in the patterns of length variants in the envl and
env3 regions in some individuals, while other individu¬
als' patterns remain relatively unchanged (Simmonds et
al, in preparation). PCR positivity in case 4 is also of in¬
terest, as this patient is a dizygotic twin, the other twin
being presumed uninfected (group 2) and PCR-negative.
Using a double PCR to amplify hypervariable regions of
the HIV genome, we have been able to diagnose vertically
transmitted infection with apparently 100% specificity and
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100% sensitivity. The distinctive HIV DNA length-variant
patterns observed might be usefully exploited in further
studies as a basis for the investigation of the timing of
vertical transmission, by comparing the patterns ampli-
5ed from serial blood samples taken from the mother
throughout pregnancy with those obtained from the in¬
fant at birth and during early infancy.
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Neurologic signs in young children with human
mmunodeficiency virus infection
IE EUROPEAN COLLABORATIVE STUDY*
Neurologic and neurodevelopmental problems
ere investigated in a cohort of 39 human im-
unodeficiency virus (HIV)-infected children
id 164 antibody-negative children born to
IV-positive women. All children were fol-
wed from birth for between 1 month and 4
;ars. Serious neurologic manifestations were
■esent in 5 of 16 children (31%) who developed
quired immunodeficiency syndrome/acquired
lmunodeficiency syndrome-related complex,
though in 2 the neurologic signs were prob-
ily not related to HIV. This can be compared
ith a prevalence of 0 of 23 in children who
mained asymptomatic or who had less severe
[V-related symptoms or signs and 2 of 164
%) in uninfected children. Neurologic signs in
e uninfected group were associated with the
esence of drug withdrawal at birth and pre-
aturity. These findings contrast with reports
a high prevalence of neurologic findings in
ast studies of HIV-infected children.
TRODUCTION
A wide range of neurologic manifestations related
human immunodeficiency virus (HIV) infection
ve been reported in children born to seropositive
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mothers. These include developmental delay, cogni¬
tive deficits, loss of developmental milestones, im¬
paired brain growth, pyramidal signs, seizures, pseu¬
dobulbar palsy and more rarely ataxia, myoclonus and
extrapyramidal rigidity. A high incidence (34 to 90%)
of neurologic involvement has been described in chil¬
dren with acquired immunodeficiency syndrome-re¬
lated complex (ARC)/acquired immunodeficiency
syndrome (AIDS), and most have presented before 2
years.1"3 HIV antigen and virus have been detected in
cerebrospinal fluid and brain in children with perina-
tally acquired infection.2'4 However, these studies are
retrospective and biased towards symptomatic chil¬
dren; little is known about the prevalence of neurologic
disease in HIV-infected children with less severe
symptoms.
The aim of this study is to describe the prevalence
and natural history of neurologic involvement and the
temporal relation between neurologic manifestations
and the progression of HIV disease in a cohort of
children born to mothers with HIV infection.5,6
METHODS
The study was based on 350 children currently
enrolled in the European Collaborative (EC) study
and followed up to April 1989.7,8 The children, all born
to HIV-seropositive mothers in 8 European centers,
were followed prospectively from birth. Infants were
examined clinically in the first week of life and then
every 3 months following a standard protocol includ¬
ing neurologic developmental as well as clinical and
laboratory findings. All treatment was recorded,
though the EC protocol contains no particular instruc¬
tions on therapy. In each center a single pediatrician
was responsible for clinical examinations. Most cen¬
ters arranged detailed neurologic and developmental
examinations, and in some these were conducted by
specialists in these fields. What was recorded under
the EC protocol were assessments of each child's
language, personal/social, fine motor and gross motor
development as "pass," "suspicious," "fail" or "loss of
milestones." The neurologic assessments required
were encephalopathy, paresis, abnormal gait, seizures
and pathologic reflexes.
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Infection status was defined as the persistence of
tibody after 18 months, the identification of virus
antigen in antibody-positive children ages less than
months or the presence of AIDS/ARC. Of the 350
ildren 39 were infected, 164 were antibody-negative
d presumed not infected and in 147 the infection
itus was indeterminate. This latter group has been
:luded from the analysis.
rhe analysis relates the progression of HIV disease
the onset of neurodevelopmental signs and symp-
ns. The following definitions were used. AIDS was
Fined by the Centers for Disease Control, Atlanta,
teria,9 and ARC as in previous publications of the
J study.5,6 In addition a definition was constructed
significant HIV-related symptoms or signs, falling
irt of AIDS/ARC, as two or more of the following:
-sistent generalized lymphadenopathy, persistent
oatomegaly, persistent splenomegaly, chronic or re-
•rent diarrhea, unexplained fever, failure to thrive,
s of milestones or parotid swelling; or persistent
il Candida infection. Unlike the definition ofAIDS/
1C, this definition of significant symptoms is not
)% specific. As a result symptoms in children who
et this definition at any one time may resolve
sr.10
^ child was defined as having serious neurologic
ns if at least one of the following was reported on
) successive examinations and had not resolved:
:ephalopathy (static/progressive); seizures; paresis;
;hologic reflexes; abnormal gait; loss of develop-
ntal milestones. If any of these signs occurred on
) examinations and then resolved, or if failure on
least one component of the developmental assess-
nt occurred (gross motor, fine motor, language,
sonal/social) on two successive examinations at
st 2 months apart, this was regarded as evidence of
linor neurologic or developmental problem.
Children were categorized according to the maternal
tory of intravenous drug use: those with drug with-
wal symptoms in the perinatal period; others whose
thers had used drugs intravenously in pregnancy;
1 children of former intravenous drug users or
thers with no history of intravenous drug use.
time at risk of development of neurologic problems
s the age when the criterial episode began, or age
ast examination. Differences between groups in the
idence rates of neurologic involvement are assessed
exact one-tailed probabilities assuming a null hy-
hesis of equal rates.11
SULTS
'here were 203 children with known infection sta¬
in the study cohort. Thirty-nine were infected and
who had lost antibody were presumed uninfected
;hey remained immunologically normal with no
^-related signs or symptoms.
Their mothers were predominantly white (95%) and
primiparous (65%), with a median age of 24 years
(range, 16 to 38). Thirty percent lived alone and 84%
were or had been injecting drug users. The median
follow-up time was 18 months; 89% had been followed
for more than 6 months, 67% more than 12 months
and 28% more than 2 years. Over 90% of the children
had been seen within 9 months of February 1, 1989,
and this level of compliance was observed irrespective
of infection status and mother's drug history.
Serious neurologic signs were present in 5 (13%) of
the HIV-infected and in 2 (1.2%) of the 164 antibody-
negative children. Minor signs were noted in a further
2 infected and 5 uninfected children.
Infected children. Sixteen of the 39 infected chil¬
dren developed AIDS or ARC, 14 had HIV-related
symptoms or signs and 9 were asymptomatic. Five of
the asymptomatic children had been followed for less
than 1 year. Table 1 shows the relation between seri¬
ous neurologic signs and clinical status when last seen.,
Neurologic signs were present in 5 of 16 children with
AIDS or ARC, in 0 of 14 who had significant HIV-
related symptoms or signs, and in 0 of 9 who were
asymptomatic when last seen. The incidence of neu¬
rologic signs among children with AIDS/ARC was
significantly higher than that in the other groups
combined (P = 0.004).
Table 2 shows that four of the children who pre¬
sented with serious neurologic signs already had AIDS
or ARC before they met the definition of serious
neurologic involvement. The fifth already had serious
HIV-related symptoms. Three of these five children
presented with a progressive encephalopathy: one with
an intraventricular hemorrhage and one with persist¬
ent developmental delay. None of them had drug
withdrawal symptoms.
Case 1 had no perinatal problems. He presented at
4 months with persistent oral candidiasis, lymphade¬
nopathy and hepatomegaly (ARC) and mild motor
delay. While hospitalized for cytomegalovirus inter¬
stitial pneumonitis at 5 months he had seizures and a
further loss of developmental milestones. The cranial
computer tomography scan showed bilateral low den¬
sity areas with multiple round opacities in the basal
ganglia region. There was no enhancement when using
contrast medium. The child died of respiratory failure
caused by cytomegalovirus pneumonia at 6 months.
TABLE 1. Serious neurologic signs in 39 HIV-infected












Asymptomatic 9 0 0 149.4 3-47
HIV-related 14 0 0 285.0 1-39
symptoms
AIDS/ARC 16 5 31 207.8 1-38
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1 M 3.22 40 Encephalopathy
Lymphoma (postmortem)
ARC 6*
2 F 1.84 37 Encephalopathy AIDS 19'
3 F 2.65 41 Encephalopathy AIDS 19
4 M 1.20 28 Intraventricular hemor¬
rhage
Symptoms 12
5 F 2.34 36 Developmental delay ARC 8"
ifected
6 F 2.15 36 Acute encephalopathy 22
' M 1.68 31 Cerebral palsy 31
HIV clinical status at onset of criterial neurologic episode.
Died.
itmortem examination revealed interstitial pneu-
nia, fatty infiltration of the liver and disseminated
omegalovirus infection. Frontal sections of the
in showed a neoplastic deposit localized at each
al ganglia; the histopathologic diagnosis was cen-
nervous system lymphoma.
!ase 2 was small for gestational age but was other-
e normal. ARC was diagnosed at 8 months follow-
persistent generalized lymphadenopathy, oral
idida infection and hepatosplenomegaly. At 10
iths AIDS was diagnosed as was also failure to
ve, two episodes of sepsis (Staphylococcus aureus
. Staphylococcus epidermidis) and lymphocytic in-
ititial pneumonitis. By 16 months progressive en-
halopathy was evident, with acquired microce-
ly, and gross loss of developmental milestones. A
lial computer tomography scan at 19 months
wed severe cortical atrophy, attenuation of white
iter and bilateral symmetrical calcifications of the
al ganglia. The child died at 20 months with Pneu-
:ystis carinii pneumonia. Postmortem examination
he brain confirmed the cranial computer tomog-
hy scan findings. Microscopic examination showed
or of the white matter, reactive astrocytosis, dif-
! inflammatory cell infiltrates, perivascular calci-
tions in the region of basal ganglia and the pres-
3 of typical multinucleated cells, considered to be
ted to HIV infection.
ase 3 had no perinatal problems and at 4 months
sloped pneumonia of unknown origin that resolved
r antibiotic therapy. At 5 months she presented
l P. carinii pneumonia and at 10 months she had
ertonia, pathologic reflexes and mild develop-
ital delay. This developed to progressive encepha-
ithy with tetraparesis and severe developmental
y at 14 months.
ase 4, a premature infant (28 weeks gestation, 1.2
developed Group B streptococcal sepsis at birth
a bilateral intraventricular hemorrhage. At 4
iths he had a Group B streptococcal pneumonia
at 6 months oral candidiasis, lymphadenopathy
hepatosplenomegaly (ARC). AIDS was diagnosed
at 10 months after a second episode of Group B
streptococcal pneumonia. Head circumference and
gross motor development were normal, though fine
motor and language development at 12 months was
considered impaired. He spent his first 4 months in
the hospital before adoption. This infant's neurologic
findings were not considered to be HIV-related.
Case 5 had no perinatal problems but at 6 weeks
presented with Klebsiella sepsis (untyped), Haemophi¬
lus influenzae pneumonia, lymphadenopathy, oral can¬
didiasis, hepatosplenomegaly, protein energy malnu¬
trition and hepatitis B infection. At 3 months AIDS
was diagnosed after a second bacterial pneumonia
(Streptococcus Group B), and she died at 7 months.
The child had been hospitalized since birth; fine mo¬
tor, language and personal/social development had
never progressed but gross motor development was
normal.
There were a further two infected children in whom
minor neurologic signs or developmental problems
were reported. One with AIDS was noted to have
abnormal reflexes during prolonged hospitalization
while being treated with immunoglobulin and az-
treonam, but these signs were no longer present after
discharge. The other child with HIV-related symp¬
toms had signs of general developmental delay for a 2
month period while institutionalized.
Among the 39 infected children 7 had been treated
with zidovudine and immunoglobulin, and a further 7
had received immunoglobulin alone. Therapy was
given to children with AIDS or occasionally to older
children who had developed significant HIV-related
symptoms for several months together with persistent
immunologic dysfunction. Of those with serious neu¬
rologic involvement, all but one were treated after
these symptoms started. Of those without serious neu¬
rologic involvement when last seen, only 9 (26%) were
treated at all, and in 7 the therapy was begun in the
second year of life, after the period when the onset of
neurodevelopmental symptoms tends to occur.
Uninfected children. Case 6 had drug withdrawal
symptoms at birth and at 3 months developed an acute
I. 9, No. 6, June, 1990 THE PEDIATRIC INFECTIOUS DISEASE JOURNAL 405
mtoencephalopathy of unknown origin.12 This re-
ted in severe brain damage with epilepsy, cerebral
tonic palsy and mental retardation,
lase 7 was a premature infant with drug withdrawal
iptoms and neonatal meningitis. This resulted in
Irocephalus requiring a ventriculoperitoneal shunt,
is infant had cerebral palsy with VI and VII cranial
ve involvement, spastic diplegia and ataxia. Devel-
nental progress was slow but satisfactory when last
n.
l further five uninfected children were reported to
e had signs of developmental problems which re-
zed. All five had drug withdrawal symptoms at
;h. One child was noted to have pathologic reflexes
he 7- and 10-month examinations and gross motor
ry at 7 months. In the other 4 children psychomotor
1/or language delay had been reported in a 2- to 4-
ath period. In one child these difficulties could be
•ibuted to prolonged hospitalization for pneumonia
1 to her mother's suicide. A second child taking
oids for nephrotic syndrome and brought up by an
erate grandmother was reported to have a global
i ofmilestones at 22 months. For the other children
re was no explanation for their developmental de-
'he occurrence of neurologic or developmental
blems among uninfected children was associated
l the presence of drug withdrawal. Among 41 un-
cted children with drug withdrawal, 6 had serious
ninor neurologic signs or developmental problems
ing a total of 853 months at risk compared with 1
L23 other children followed for a total of 2563
iths (P = 0.0013).
mong the 41 uninfected children with drug with-
val, the 6 with serious or minor neurologic signs
e, on average, 0.55 kg lighter at birth (95% confi-
ce interval, 0.19 to 0.91), and were born on average
weeks earlier (95% confidence interval 1.8 to 5.3).
vever, the two groups did not differ in weight for
ational age.
CUSSION
i this study 5 of 39 HIV infected children had
ous neurologic signs. This included one premature
nt with intraventricular hemorrhage, unlikely to
HIV-related, and another whose developmental
y is likely to have been a result of prolonged
jitalization. Depending on whether these latter
cases are regarded as HIV-related, the prevalence
erious neurologic signs was 8 to 13% in infected
dren, or 19 to 31% among children with AIDS or
2. All 5 children developed HIV-related disease, in
t cases severe, before any neurologic involvement
apparent. Although there have been reports of
'-infected children whose initial presentation was
rologic,13,14 the finding that neurologic manifesta¬
tions appear after the diagnosis of AIDS/ARC has
been reached is consistent with the majority of docu¬
mented cases.15
The low proportion of children treated in this study
and the timing of treatment relative to the onset of
neurologic signs and symptoms make it very unlikely
that treatment could have substantially altered the
rate of development of neurologic illness.
The 164 children who lost antibody were presumed
to be uninfected, although antibody loss has been
reported in healthy but infected children.6 Two of the
children had serious neurologic signs, although not of
a type previously associated with HIV, and both had
experienced drug withdrawal symptoms in the peri¬
natal period. Drugwithdrawal was also associatedwith
a higher risk of minor neurodevelopmental problems.
This association may be a result of the direct effects
of drug addiction or to continuing drug abuse which
is likely to result in a less stimulating, more deprived
environment for these children. The case histories at
the time of onset tended to support the latter view.
Among infants with drug withdrawal in the peri¬
natal period, neurologic signs were more likely to
develop among those born earlier and smaller. This
may reflect an increased vulnerability to the effects of
prematurity in this group, or again prematurity could
itself be a further marker of extreme social depriva¬
tion. Allowance must be made for preterm delivery in
developmental assessment. There are conflicting
views about the etiology of developmental problems
in infants born to drug-dependent mothers16-18 and it
may not be possible to distinguish between the effects
of drug use in pregnancy and social and obstetric
factors.19 Ultmann et al.20 also stress that neurodevel¬
opmental assessments of HIV-infected children must
take into account both low birth weight and prema¬
turity associated with maternal drug use, and the
medical and social problems associated with drug use
and HIV infection.
We report a lower incidence of neurologic involve¬
ment than in previous studies from the United States.
In a study of 68 children from New York (median age,
16 months) with symptomatic HIV infection (50
AIDS, 18 ARC), 61 (90%) had central nervous system
dysfunction.1 These findings are similar to those re¬
ported in an earlier paper in a similar cohort in which
77% of the children with AIDS or ARC showed neu¬
rologic involvement.2What makes this discrepancy all
the more striking is that in the European Study 3 of
5 children with severe neurologic problems died 2 to 7
months after the onset of AIDS/ARC and might not
have been included in studies where follow-up began
not at birth but at referral with symptoms. In the New
York study it is possible that referral may have de¬
pended partly on the stage of HIV disease progression
or even on the presence of neurologic signs.
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In a report of 38 symptomatic HIV-infected children
i France,3 8 cnildren were described as having severe
eurologic problems including mental retardation,
lotor delay and buccofacial dyspraxia, and a further
had moderate neurologic involvement. The preva-
mce of 21% severe neurologic abnormalities in chil-
ren with AIDS or ARC is consistent with the present
ndings. A subsequent follow-up of a larger number
f children in this French study confirmed the close
ilation between the degree of neurologic involvement
ad the level of immunodeficiency.21
In a prospective study Belmann et al.22 compared
aildren born to HIV-positive women in New York,
ith others born to HIV-negative drug-abusing con-
ols. Four of 9 of those remaining seropositive at 1
iar had neurologic or neurodevelopmental problems
i the first 24 months (maximum follow-up) compared
ith 2 of 18 in the HIV-negative group. Although both
•oups have a higher prevalence than in the European
udy, the sample sizes are too small to make a valid
imparison. Nevertheless studies undertaken in the
nited States consistently report a higher prevalence
'
neurologic involvement in pediatric HIV patients
lan in European studies. It is not yet clear whether
lis is a result of methodologic differences in patient
cruitment, to different viral strains, to other cofac-
>rs or to the level of social and health care available.
Further follow-up of children in the European Col-
borative Study will show whether the pattern of
mrologic involvement changes with increasing age
id will provide the opportunity to assess the more
ibtle neurologic impairments in the infected and
linfected children.
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Diagnosis ofPneumocystis carinii pneumonia from
non-invasive sampling of respiratory secretions
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Abstract
An infant infected with HIV presented with
fever, tachypnoea, hypoxia, and radiological
evidence of bilateral pneumonitis. Fluor¬
escent antibody technique identified Pneu¬
mocystis carinii within 24 hours from
secretions obtained by nasopharyngeal aspira¬
tion. This rapid, non-invasive method should
be the first line investigation of suspected P
carinii pneumonia in immunocompromised
patients.
Pneumocystis carinii is an important pathogen in
the immunocompromised child, and must be
considered in the differential diagnosis of any
such child presenting with respiratory symp¬
toms. Characteristic radiological appearances
are of diffuse reticulogranular infiltrates, par¬
ticularly in the perihilar region, progressing to
consolidation, but a normal chest radiograph is
compatible with the diagnosis.1 Cytomegalo¬
virus or mycobacteria infection may produce
similar findings.
Definitive diagnosis has previously relied on
the demonstration of silver staining cysts in
material obtained from open lung biopsy or
bronchioalveolar lavage, requiring an invasive
procedure in an acutely ill child.2 3 Sputum
induction in infants and small children is not a
practicable technique,4 and serology is
unhelpful.5 We report a case in whom the
diagnosis was made from nasopharyngeal se¬
cretions using a fluorescent antibody technique.
Case report
A white infant girl whose HIV seropositive
mother developed P carinii pneumonia at 35
weeks' gestation was delivered at term weighing
3050 g. There were no neonatal problems, and
her initial progress was complicated only by
persistent candidal infection of the oral cavity
and napkin area.
At 4-5 months she presented with a two week
history of mild upper respiratory symptoms,
two days of fever, an unproductive cough, and
increasing tachypnoea, sufficiently severe to
impair feeding. Examination showed a pale,
mildly cyanosed and lethargic, but responsive
infant. She had a tachycardia of 160/minute and
respiratory rate of 80/minute, with bilateral
intercostal and subcostal indrawing and scat¬
tered crepitations on auscultation. Lympha-
denopathy and hepatosplenomegaly were noted
and there was candidal dermatitis of the napkin
area.
A chest radiograph showed extensive bilateral
pneumonitis (figure). She was hypoxic (oxygen
saturation 60%), with a carbon dioxide tension
(PC02) of 5*37 kPa and hydrogen ion concen¬
tration of 39-7 mmol/1. On admission the
neutrophil count was 6200x 106/1, T4 lympho¬
cyte count 1079x106/1, and T4/T8 ratio T4.
Serum IgG concentration was normal (4 g/1),
and IgA and IgM raised (0-9 g/1 and 2T g/1).
HIV p24 antigen was positive (140 pg/ml).
Secretions obtained by nasopharyngeal aspira¬
tion were sent for microbiological investigation.
Pending results the infant received oxygen
supplementation and high dose cotrimoxazole
and acyclovir intravenously. The identification
of P carinii was confirmed the next day (see
below). The infant's condition initially stabil¬
ised, but deteriorated 24 hours later. Despite
giving hydrocortisone and intravenous im¬
munoglobulin, she failed to maintain oxygen
saturation of >80% even with fractional inspira¬
tory oxygen of 100%, and developed carbon
dioxide retention (PC02 9-75 kPa) and respira¬
tory acidosis (hydrogen ion concentration 73'7
mmol/1). Definite knowledge of the diagnosis,
and its implications for the child's long term
prognosis meant that the parents could be
counselled appropriately. Their wish for her
not to receive mechanical ventilation was
respected, and she died on the fourth day of her
admission. Postmortem examination confirmed
the widespread alveolar exudate within the
lungs in which round organisms were detectedst radiograph showing bilateral interstitial pneumonitis.
diagnosis ofPneumocystis carinii pneumonia from non-invasive sampling ofrespiratory secretions 1365
by silver staining. No other organisms were
detected.
Method
After addition of an equal volume of sputoly-
sin (Behring Diagnositics) and glass beads the
sample was vortexed for one minute and the
incubated at 37°C for three minutes. A total of
10 ml of phosphate buffered saline (PBS) pH
7-2 was added and the mixture centrifuged at
2500 g for 20 minutes. The pellet was resus-
pended in 1 ml PBS and cytospin preparations
made on two polyl-lysine coated slides. A
cytospin preparation of positive rat lavage ma¬
terial was used as a positive control. After fixa¬
tion for 30 minutes in equal volumes (50%)
methanol and acetone, trypsin (0*25%) diges¬
tion for 10 minutes at 37°C followed. A standard
wash procedure of three five minutes with PBS
was carried out.
Mouse monoclonal antibody to P carinii
(Northumbria Biologicals Limited) was added
to the test and positive control slides and PBS
only, and incubated for 40 minutes. After
repeat washing antimouse IgG (F'ab) conju¬
gated to fluorescein isothiocyanate was added
and a further incubation of 40 minutes fol¬
lowed. After a last wash procedure substituting
PBS pH 8 4 for the final change, the slides were
mounted and viewed under ultraviolet light.
The sample was considered positive when
three typical cysts showing all over fluorescence
were seen, further confirmed by methenane
silver treatment of the control slide.
Discussion
In HIV infection, the diagnosis of P carinii
pneumonia has important implications, not only
for the treatment of the acute illness, but also
for longer term prognosis. In New York 13 out
of 15 children less than 6 months old with P
carinii pneumonia died during the acute epi¬
sode, and all were dead by one year (J Chow, K
Shah, K Li, et al; abstract presented at V
International Conference on AIDS, Montreal,
June 1989. Because of the risks involved in, and
the technical expertise required for, paediatric
bronchoscopy treatment is usually empirical. If
the child dies, postmortem examination may
give the answers, but if the child responds to
high dose cotrimoxazole, the differential
diagnosis between a bacterial pneumonia and P
carinii pneumonia remains unresolved. This
then creates difficulties in classification and
staging of the child's disease, and in making
therapeutic decisions, such as whether to com¬
mence zidovudine or prophylaxis for P carinii
pneumonia.
Identification of P carinii pneumonia from
upper respiratory tract secretions may only be
possible in cases of overwhelming infection, and
failure to detect it by this method does not
exclude the diagnosis. It is in the most severe
cases, however, that the patient is least able to
tolerate more invasive procedures. Because our
technique is rapid, other methods can still be
used thereafter without undue delay. We
believe therefore that it should be used as the
first line investigation of suspected P carinii
pneumonia.
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Abstract
We used an oral topical antibiotic preparation
to try and prevent oropharyngeal carriage of
Pseudomonas aeruginosa in patients with
cystic fibrosis. Ten of 15 patients treated with
a two week course of intravenous ceftazidime
together with a 90 day course of an antibiotic
containing gel continued to carry P aerugi¬
nosa in the oropharynx.
The technique of selective decontamination of
the digestive system uses oral antibiotic com¬
binations to prevent the overgrowth of certain
groups of organism (typically Gram negative
aerobes), and allows the more usual flora to
maintain colonisation resistance.1 It has applica¬
tion particularly in the immunocompromised
patient undergoing cytotoxic chemotherapy and
in long term ventilated patients,2 where Gram
in (1990) 61: 66-67
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immary. A four year old boy with symptoms of HIV in-
:tion and serum IgG of 53.2 g/1 had been treated for
months with regular infusions of intravenous immu-
iglobulin (IV IgG). During one such infusion he devel-
ied temporary neurological symptoms and signs sugges-
e of the hyperviscosity syndrome. Serum relative visco-
y was raised at 5.0 (normal range 0.42-2.78). Sub¬
altern IV IgG infusions given at a slower rate have been
thout adverse reactions. In a study of eight HIV infect-
children including the index case, and 20 children not
fected with HIV, serum relative viscosity was signifi-
ntly raised in the HIV infected children (p < 0.01; stu¬
nts t-test). Viscosity correlated with total serum IgG,
lich was raised in all HIV infected children, and with
"urn IgM. In HIV infected children with very high levels
serum IgG a slow rate of IV IgG infusion should there-
re be chosen due to the possibility of hyperviscosity.
:y words: HIV infected children - Hyperviscosity -
IgG
Iroduction
travenous immunoglobulin (IV IgG) is now used in the
atment of Human Immunodeficiency Virus (HIV) in-
:ted children with recurrent bacterial sepsis, suggestive
defective humoral immunity [3,5,9,10]. Although
:h children have a pattern of infections resembling
Dse experienced by patients suffering from primary
pogammaglobulinaemia, serum levels of IgG, IgA and
VI are typically raised [1], and can be 3 or 4 times the
per limit of the normal range. It has previously been re-
rted that a polyclonal hypergammaglobulinaemia may
associated with a raised serum viscosity in very rare
;es [reviewed in 7], and we report on a HIV infected
'print requests to: P. L. Yap, Edinburgh and SE Scotland Blood
tisfusion Service, Lauriston Place, Edinburgh EH3 9HB Scotland,
child in whom infusion of IV IgG lead to serious symp¬
toms suggestive of hyperviscosity.
Case report
The patient (Case 1, Table 1) became infected with HIV after blood
transfusions at the age of 4 months, before screening of blood for
HIV antibody was available. He remained well until 14 months
when he began to develop recurrent upper respiratory tract infec¬
tions, and at 21 months of age developed an immune thrombocyto¬
penic purpura (ITP) refractory to treatment with high dose IV IgG,
and to prednisolone. At the age of 3 years 6 months, his platelet
count had returned to normal but he continued to have recurrent
respiratory infections, failed to thrive, and had generalized lymph-
adenopathy and hepatosplenomegaly. The serum IgG, IgA and IgM
levels were respectively 34.8, 2 and 2.8 g/1 (normal ranges were
5-13, 0.47-2.63 and 0.36-1.92 g/1 respectively). HIV infection
was then diagnosed, based on HIV antibody detection and he was
commenced on regular infusions of IV IgG manufactured by the
Scottish National Blood Transfusion Service [5,6] at a dosage of
200 mg/kg every 3 weeks, infused at 2.4 ml/kg/h at a IgG concen¬
tration of 50 g/1. This IV IgG preparation consists almost entirely
of IgG with a normal distribution of IgG subclasses.
Treatment with IV IgG was not associated with any adverse re¬
actions until the age of 4 yrs 10 months, when, due to an infusion
pump malfunction, the patient received the infusion 30% faster
than usual. He suddenly became confused, distressed, and was un¬
able to see. He was dysarthric before becoming totally aphasic, and
a transient right facial palsy was noted. Pupils remained equal and
reactive to light, eye movements remained full and no abnormality
could be detected on ophthalmoscopy. Tone, power and reflexes re¬
mained equal and symmetrical. The IV IgG was immediately dis¬
continued and a normal saline infusion set up. After 30 minutes,
he fell asleep. Two and a half hours later there was no residual neu¬
rological symptoms or signs. In retrospect, his parents commented
that he had very brief episodes of confusion and drowsiness during
previous IV IgG infusions, on one occasion waking up after a sleep
appearing unable to speak. The effect had lasted a matter of
minutes.
On the day of his severe adverse reaction his serum IgG, IgA
and IgM levels were 53.2 g/1, 1.3 g/1 and 4.8 g/1 respectively. No
paraprotein bands were found on protein electropheresis. His serum
relative viscosity measured by capillary viscometer was 5.0 before
and after the infusion (normal range 0.42-2.78). A computerized
tomography scan subsequently showed no abnormality, and the pa¬
tient has had no recurrence of symptoms suggestive of hyperviscos-
9
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e 1. Serum viscosity and immunoglobulin levels of HIV infect-
hildren
. CDC Serum levels g/1 Serum
ber stage IgG IgA IgM viscosity
P2C 53.2 1.3 4.8 5.0
P2F 29.6 3.3 2.4 3.5
P2C 46.8 0.3 2.3 3.5
P2A 14.8 1.6 1.1 3.0
P2A 17.2 1.2 0.9 3.2
P2A 18.8 0.7 1.2 3.6
P2A 24.0 0.7 2.2 2.0
P2D3 14.4 2.2 1.3 2.0
:ontinuing his 3 weekly infusions at a slower rate of 1.3 ml/kg
l. Subsequent viscosity measurements have varied between 3.0
5.0 (data not shown) and there was no difference in viscosity
s before and after IV IgG therapy. Immune complexes were
measured before and after IV IgG therapy and no change was
rved.
Following this incident, we studied a further 7 children (Cases
, Table 1) treated with IV IgG [8], who are described elsewhere
}f whom none had suffered side-effects associated with IV IgG
dons. We also investigated 20 other children born to HIV sero-
:ive mothers who were being followed in the Edinburgh perina-
ansmission study [6]. These children were presumed uninfect¬
ing over 18 months old, HIV antibody negative, and free
i symptoms suggestive of HIV infection. Serum immunoglobu-
evels were measured by laser nephelometry [6]. The mean
D) viscosity in the HIV infected group was significantly raised
a value of 3.2 ± 0.96 compared with the non-HIV infected
p (2.3 ± 0.39; < 0.01, student's /-test).
The relationship between serum IgG, IgA and IgM levels and
lerum relative viscosity was investigated in the above samples
additional samples collected from the HIV infected children
the serum relative viscosity was found to correlate both with
levels (r = 0.74, p < 0.001) and with IgM levels (r = 0.66,
0.001). There was no significant correlation between serum vis-
y and IgA levels (Table 1). In other HIV infected children,
Ti viscosity was measured on stored samples taken before and
ediately following IV IgG infusions. No rise in viscosity could
emonstrated in any sample. Protein electropheresis revealed no
>clonal or monoclonal bands in any of the specimens tested.
tussion
avenous immunoglobulin has been used widely for
treatment of primary hypogammaglobulinaemia and
. Adverse reactions are rare and in most clinical situa-
s serum immunoglobulin levels are low or normal in
recipients. In HIV infection, serum IgG levels prior to
IgG infusion are usually high and problems with
erviscosity have only once been previously described
n HIV infected adult [7],
rhe hyperviscosity syndrome has been described in
Its with paraproteinaemias [4] and in patients with
)immune and rheumatic diseases, when it is attribut-
o aggregates of intermediate size or to polyclonal IgG
/mers [11], Although we have shown that the serum
osity is raised along with serum immunoglobulin
Is in these children, there have been no previous re¬
ts of hyperviscosity symptoms occuring after IV IgG
sion. Clinical manifestations are rare in patients with
67
viscosities less than 4 [12], However, the 'symptomatic
threshold' may be very variable, although remaining con¬
stant for any given patient. In this patient, the threshold
was exceeded during one of the IV IgG infusions, and
only the index patient developed symptoms during a
rapid infusion of IV IgG.
Central nervous system (CNS) involvement by HIV as
well as other infections (bacterial, viral or parasitic) have
been documented [2], We could not definitely exclude
CNS infection in our patient as we did not have the op¬
portunity to examine his cerebrospinal fluid. Nonethe¬
less, it is possible that in a HIV infected patient with very
high IgG levels, hyperviscosity might contribute to symp¬
toms previously attributed to CNS infections and that
methods of treatment which lower viscosity may be bene¬
ficial.
On the basis of our findings, we therefore recommend
that in HIV infected children with very high serum immu¬
noglobulin levels, the clinician is alerted to the problem
of hyperviscosity. Caution should be exercised in these
circumstances, and a slow rate of infusion of IV IgG
chosen.
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Children born to women with HIV-1 infection:
natural history and risk of transmission
European Collaborative Study*
600 children born to HIV-infected mothers by June
15, 1990, in ten European centres were followed to
study the natural history of HIV infection and the
vertical transmission rate. They were seen at birth,
every 3 months up to 18 months of age, and every 6
months thereafter. At last follow-up, 64 children
were judged to be HIV infected and 343 had lost
antibody and were presumed uninfected. The initial
clinical feature in infected children was usually a
combination of persistent lymphadenopathy,
splenomegaly, and hepatomegaly, though 30% of
children presented with AIDS, or with oral
candidosis followed rapidly by AIDS. An estimated
83% of infected children show laboratory or clinical
features of HIV infection by 6 months of age. By 12
months, 26% have AIDS and 17% die of HIV-related
disease. Subsequently, the disease progresses more
slowly and most children remain stable or even
improve during the second year. The vertical
transmission rate, based on results in 372 children
born at least 18 months before the analysis, was
12-9% (95% CI 9-5-16-3%). Virus has been
repeatedly isolated in an additional small proportion
of children (2-5%, 95% CI 0-7-6-3%) who lost
maternal antibody and have remained clinically and
immunologically normal. Without a definitive
virological diagnosis, the monitoring of immuno¬
globulins, CD4/CD8 ratio, and clinical signs could
identify HIV infection in 48% of infected children
by 6 months, with a specificity of more than 99%.
Lancet 1991; 337: 253-60,
Introduction
Knowledge of the natural history of vertically acquired
human immunodeficiency virus-1 (HIV-1) is based mainly
on studies of children presenting with symptoms to
specialist centres.1-6 Prospective studies ofvertically infected
children should provide a more accurate understanding,7'
though increasing use of treatment could bias results.
Information about earlier or less severe features of the
disease and its progression is needed for the design ofclinical
trails, and to assist in management and early diagnosis of
infected children. The European Collaborative Study
(ECS) is a prospective study of children bom to HIV-
infected mothers.10-12 We here report results relating to the
natural history of HIV infection and the vertical
transmission rate.
Children and methods
By June 15, 1990, 600 children bom to HIV-1 seropositive
mothers had been recruited and followed from birth in ten
European centres (Padua, Berlin, Edinburgh, Madrid, Valencia,
Amsterdam, Stockholm, Genoa, Brussels, Barcelona). Children
were included only if their mothers were known to be infected at or
before delivery; all such children were included.10-12
•Prepared by: Dr A. E. Ades, PhD, Or M. L. Newell, MB, Prof C. S.
Peckham, MD (coordinating centre). Department of Paediatric
Epidemiology. Institute of Child Health. 30 Guilford Street.
London WC1N 1 EH. UK.
Collaborators: Dr C. Giaquinto. Prof F. Zacchello. Dr A. De Rossi, Prof
L Chieco-Bianchi (Universtta degli Studi di Padova, Italy); Or I.
Grosch-Worner, Dr S. Koch (Freie Universitat, Universitatsklinikum
Rudolf Virchow, West Berlin); Dr J. Y. Q. Mok, Dr R. Hague (City
Hospital, Edinburgh, UK); Dr F. Omenaca Teres, Dr M. C. Garcia
Rodriguez, Dr R. Martinez-Zapico, Dr M. I. de Jose. Dr G. Fontan
Casariego (Hospital Infantil La Paz, Madrid. Spain); Dr C. A. Canosa. Dr
M. C. Otero. Dr D. Perez Tamarit, Dr D. Granda. Dr M. Gobernado. Dr A
Gonzalez Molina (Departamento de Pediatria "La Fe Valencia. Spain);
Dr H. J. Scherpbier, (Academisch Medisch Centrum, Amsterdam, the
Netherlands): Dr A. B. Bohlin, Dr M. Forsgren (Department of
Paediatrics. Huddinge Hospital and Central Microbiological Laboratory,
Stockholm, Sweden); Dr A. Ferrazin. Dr A. De Maria, Dr C. Gotta. Prof A.
Terragna (I Clinica Mallattie Infettive University. Istituto G. Gaslini,
Genova, Italy); Dr J. Levy (Hospital St. Pierre, Brussels, Belgium); Prof
J. Llorens-Terol. Dr A. Mur, Dr H. Yazbeck, Dr F. Prats (Hospital del Mar.
Barcelona. Spain).
Correspondence to Prof C. S. Peckham.
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Clinical, serological, and immunological examinations
At birth, gestational age, birthweight, and head circumference
were recorded, in addition to information about maternal health,
risk behaviours, and mode of delivery. Clinical and laboratory
examinations were done. According to the protocol, clinical and
developmental examinations were done and an interval history was
taken even- 3 months up to age 18 months, and every 6 months
thereafter. Any examinations between scheduled clinic visits were
also recorded. At each visit a blood sample was taken for the
determination of HIV-specific antibody by enzyme-linked
immunosorbent assay (ELISA) and western blot (WB); p24
antigen; total IgG, IgA, and IgM; and CD4 (T4) and CD8 (T8)
lymphocyte subsets. Every 6 months, virus isolation was attempted
in six centres. Repeat tests were done on separate samples when
virus was isolated from antibody-negative children.
British and North American reference data were used to derive
standard deviation (SD) scores for birthweight and head
circumference at birth (coriuoiliiig for gestational age and sex) and
for weight and head circumference (controlling for age and sex).
Approximate upper limits for IgG, IgA, and IgM were derived
from the reference ranges used in the collaborating centres. An
approximate lower reference standard forT4/T8 rado (see footnote,
table II) was derived from data on children who subsequently lost
antibody, and in whom no virological evidence of infection was
found.
The criteria for HIV infection were: acquired immunodeficiency
syndrome (AIDS),13 death considered to have resulted from HIV
infection, persistence ofantibody beyond 18 months, positive virus
culture, or antigen detection in two samples. Lymphoid interstitial
pneumonitis (LIP), as judged by severe respiratory symptoms
confirmed by radiograph, was regarded as an AIDS indicator
disease, but radiographic findings alone were not. The estimated
vertical transmission rate was based on the 372 children of known
infection status bom at least 18 months before June 15, 1990.
Statistics
Multiple regression was used to estimate simultaneously the
independent effects of HIV infection status, collaborating centre,
and mothers' recreational drug taking on birthweight, head
circumference, length of gestation, and SD scores. The categories
used for infection status were: infected, presumed uninfected, and
indeterminate; and formothers' intravenous drug taking: baby with
drug withdrawal, drug use in the final 6 months of pregnancy,
previous drug user, and never used drugs. Statistical significance
was assessed by x2 tests.
We estimated the incidence rates of signs and symptoms in
infected pre-AIDS and uninfected children by dividing the number
with at least one occurrence by the total time at risk. The definitions
given in table II for each sign and symptom were used. Time at risk
was age at first occurrence, age at the last visit, or age atAIDS onset,
whichever was earliest. Time at risk of getting hyper-IgG,
hyper-IgA, or hyper-IgM (hyper-IgG, A, M) was stopped at the
onset of immunoglobulin therapy. The incidence rate ratio was the
incidence rate in infected pre-AIDS children divided by the
incidence rate in the uninfected children, and reflects the ability of
the sign/symptom to discriminate between the two groups. The null
hypothesis that the rate was not higher in infected children was
tested with the one-tailed 'mid-P' probability test. The same
methods were used in table III, except that risk time stopped at 12
months. The incidence rates in infected and uninfected children led
to the following definition for HIV-related initial signs and
symptoms (HIV-ISS): oral candidosis, or any two concurrently of
lymphadenopathy, hepatomegaly, and splenomegaly, persisting for
more than 2months. Children whose initial presentation wasAIDS
were recorded as having HIV-ISS at that date.
Survival curves were calculated by non-parametric methods
designed for interval-censored data14 because changes in clinical or
immunological status were not observed directly; they were seen
only at the age when they were first detected and the age at the
previous assessment. This method estimates for each age interval
a the probability fM a that the marker M first occurs at age a.
The probabilLy that no episode has occurred by age a, SM , is
1
< a fM,i'
The survival curves in fig I include all known antibody-posit
infected children. All those bom less than 18 months previously f
virological evidence of infection irrespective ofwhether AIDS f
developed. There is therefore no selection bias in favour of
children.
The sensitivity ofHIV-ISS, hyper-IgG,A,M, and low T4/Tf
6 and 12 months as predictors of infection (table V) were taken fn
the fig 1 survival curves. To take account of the 2 mont
persistence built into the definition of HIV-ISS, the sensitivity
HIV-ISS was the probability of a first occurrence by 4 and
months, respectively—eg, SM 1Q. Likewise, the estimat
sensitivity of immunological and combined markers was t
probability of a first occurrence by 5 and 11 months, respective
Specificity is estimated from similar survival curves (not shown)
the time to each marker in children who lost antibody, but t
proportion remaining antibody positive. S at each age a. w
taken into account. For example, the specificity of low T4/T8 at
months was estimated by
E f S
a< 11 'Ma ABa
Results
The 600 children were predominantly white caucasi:
(92%). 66% of their mothers (mean age 25 years) we
married or cohabiting. Many of the children had been bo
into deprived circumstances: more than 20% had bet
adopted, fostered, or institutionalised; 28% had dn
withdrawal symptoms at birth; and a further 52% h;
mothers with a history of intravenous drug use (IVDU).
children had congenital syphilis, and 2 had symptomle
congenital CMV, though ascertainment of these infectioi
was not complete. Mean birthweightwas 2 -85 kg; 17% we
premature (born ^ 36 weeks). 24% of the cohort we:
delivered by caesarean section (16% elective, 8C
emergency). 5% were breastfed for periods from 1 to :
weeks (median 2-5). Most mothers were symptom free: on
2-8% had AIDS at delivery or within 3 months afci
delivery, and a further 2-2% had generalise
lymphadenopathy.
64 children were known to be infected: AIDS ha
developed in 18, of whom 9 had died (table I); there was
HIV-related death; 27 children were known to be infecte
based on persistence ofantibody beyond 18 months; and 1
were antibody positive, aged less than 18 months, bi
considered infected following virus isolation or antige
detection. Among the 353 who lost antibody, 10 had at lea:
one positive virus culture. The natural history of this grou
differed substantially from that of antibody-positiv
infected children and will be described separately. 9 death
were not regarded as HIV-related, of which 8 were i
children of indeterminate HIV infection status. 4 died fror
respiratory complications associated with prematurity, an
3 with sudden infant death syndrome (SIDS). 1 child die
with meningococcal meningitis at 9 months during a loo
outbreak. An antibody-negative child died at 32 month
from tracheobronchitis and streptococcal septicaemia.
Length of follow-up and compliance
Of the 600 children, 380 had been followed for at least
year, 216 for more than 2 years, and 100 for more than
years. 419 children had been bom at least 18 months befor
the date ofanalysis, but the infection status of47 (11 -2%) c
these was not known (table I) because they were antibod
positive and under 18 months of age when last tested. O
these 47 children, 5 had died from non-HIV-related cause
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Indeterminate 183 (8) 47 (5)
Follow-up < 1 mo 89 (5) 27 (3)
Follow-up > 1 mo 94 (3) 20 (2)
Lost antibody 353 (1) 324 (1)
HIV-infected 64 48
AIDS 18 (9) 16 (8)
HIV-rclatcd death, ab + ve
< 18 mo 1 (1) 1 (1)
Persistent antibody > 18 mo 27 27
Antibody positive < 18 mo
with virus or antigen 18 4
Total 600 419
No of deaths in parentheses: ab = antibody
ana a further 22 had not been seen since 1 month ofage, the
parents having moved away shortly after their birth. Any
bias was therefore likely to be restricted to the remaining 20
children (4-8% of those bom more than 18 months earlier).
In the first year of life, the median time between
examinations was 2-6 months (5th and 95th centiles, 0-6 and
4-4 months), 3 0 (11, 6-7) in the second year, and 4-8 (1-2,
11 -9) thereafter.
Treatment
Treatment was less likely to be started in children without
AIDS, especially in the first 12 months of life. Of the 49-1
total years of observation of infected children younger than
12 months old without AIDS, only 4 0% were spent under
zidovudine treatment, and only 41% (partly overlapping)
with immunoglobulin (IG) therapy. After the first year, this
had increased to 16% for zidovudine and 46% for IG
therapy. By contrast, after the onset of AIDS, 66% of the
observation time was during zidovudine treatment, and
79% during IG therapy.
Perinatal findings
None of the clinical findings in the perinatal period
discriminated between infected and uninfected children.
There was no excess of congenital abnormalities in the
infected children, and HIV dysmorphic syndrome was not
seen. In regression analyses, mothers' IVDU was
significantly related to gestation, birthweight, and head
circumference, and SD scores for birthweight and head
circumference (SD head circumference score X* = 8-4,
p = 0 04; all other indices X*>19, p< 0 0003). Children
with drug withdrawal symptoms were bom an average 6
days earlier, were 325 g lighter, had a 7-5 mm smaller head
circumference, and had lower SD scores (by 0-57 points on
birthweight and 0-48 on head circumference) than children
bom tomothers with no history of IVDU. Childrenwith no
drug withdrawal symptoms but whose mothers had used
recreational drugs in the final 6 months of pregnancy were
intermediate on all these indices, whereas children offormer
drug users did not differ significantly from those bom to
women who had no historyof IVDU. Therewere, however,
no statistically significant effects of infection status, and for
all indices the lower 90% confidence limit for the difference
between infected and uninfected children was less extreme
than the mean effects associated with drug withdrawal. In
further analyses of infected children who were followed for
18 months, controlling for centre and drug status, there was
a tendency for those who had acquired AIDS to be bom
TABLE II—SIGNS AND SYMPTOMS ASSOCIATED WITH
HIV INFECTION
Infected Presumed Rate
Sign/symptom pre-AIDS uninfected ratio P
Oral candidosis* 13 2 515 <0 001
Parotitis 7 2 280 <0 001
Pctcchiac 2 1 15 1 002
Eczema 12 33 29 0 002
Unexplained fever 9 11 6-5 <0 001
Diarrhocat 20 47 40 <0 001
Bronchitis/bronchiolitis 3 28 0-8 06
Gram-negative septicaemia/
septicaemia > 1 mo
duration 7 0 <0 001
Gram-negative-pncumonia 4 2 15-4 0-001
Other pneumonia 13 21 5-3 <0 001
Chronic otitis media 6 18 2-5 003
Chronic purulent rhinitis 10 44 1-8 006
Encephalopathy 1 0 0-1
Other abnormal neurology** 2 5 30 0-2
Failure-to-thrivc§ 2 3 49 0-08
Lymphadenopathy** 33 44 9-6 <0 001
Hepatomegaly* 37 54 9-5 <0 001
Splenomegaly* 27 16 17-4 <0 001
Hyper IgGil 40 8 908 <0001
Hyper IgAil 16 5 350 <0001
Hyper IgM'l 10 5 20-5 <0 001
Low T4/T8** 32 15 220 <0 001
No of children 64 343
No of years of observation 1025 753-1
No of examinations 441 2566
No of children with at least one episode for each sign and symptom.
*On 2 consecutive examinations at least 2 mo apart.
tPersisting >21 days.
^Abnormal reflexes or gait, seizures, paresis.
SFall of >10 in weight for age SD score to < - 2 5. or >0 5 to < -3 0.
• On at least 2 sites, bilaterally.
! > 125% of upper reference level for age; in 2 consecutive samples at least 1 mo
apart.
**ln 2 consecutive samples at least 1 mo apart: below reference level R—
R = 1 2-A/100 if 0 < A <20. and R =» 1 0 if A ^20 where A is age in months.
earlier, lighter, and smaller for dates than those who had not,
although these effects were not statistically significant.
Signs andsymptoms associated with HIV infection before
onset ofAIDS (table u)
The incidence rates show that oral candidosis and
parotitis were highly discriminating indices, occurring
many times more often in HIV-infected than in presumed
uninfected children. Septicaemia and pneumonia with
gram-negative bacteria were also strongly associated with
HIV infection, although only 4 of the 11 episodes
contributed to a subsequent disagnosis of AIDS.
Encephalopathy, other neurological abnormalities, and
failure-to-thrive were uncommon in the pre-AIDS period;
all were associated, but not significantly, with infection.
Although therewas ahighly significant statistical association
between many of the signs and HIV-infection status, only a
few were specific. For example, of the 67 children with
eipsodes of non-cryptosporidium diarrhoea as many as 47
(70%) were uninfected. Lymphadenopathy, hepatomegaly,
and splenomegaly were common findings in infected
children, but, as evidenced by the low rate ratios, were
relatively non-specific on their own, as were eczema, fever,
rhinitis, otitis, and pneumonia (except when associated with
gram-negative bacteria). By contrast, there was a high
incidence of abnormal immunological indices; they
discriminated well between uninfected and pre-AIDS
infected children, occurring between 20 and 90 times more
often in infected children. That bronchitis and bronchiolitis
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TABLE III—PRECURSORS OF AIDS IN FIRST 1 2 MONTHS
64 35 28 24
No at risk of AIDS
16 12
Fig 1—Non-parametric survival curves for 64 antibody-positive
infected children.
Time to HIV-related death (O). to AIDS (A), to low T4/T8 (□), to
HIV-ISS (•), to hyper-IgG, A. M. (A), and to the first of any of these
features (■).
were not associated with HIV infection suggests that the
other results were unlikely to be due to more frequent
examinations of children who were already becoming ill.
Progression of disease in infected
antibody-positive children
Signs and symptoms in infected and uninfected children
are shown in table 11.Ofthemore specific symptoms, such as
septicaemia, pneumonia, parotitis, or petechiae, none
preceded HIV-ISS; the exception was 1 child in whom
septicaemia preceded HIV-ISS by 4 months.
Of the 64 antibody-positive infected children, 30%
presented with AIDS within 6 months of age, or with oral
candidosis followed rapidly by AIDS. Fig 1 gives the
estimated survival curves for time to AIDS onset and for
time to HIV-related death. Separate curves for time to
HIV-ISS, to hyper-IgG, A, M, and to low T4/T8 are also
shown. By 12 months of age, an estimated 17% die of
HIV-related causes, 29% have AIDS, 52% low T4/T8
ratios, 73% HIV-ISS, and 81% hyper-IgGAt,M.
Altogether, 64% will have shown some feature of HIV
disease by 3 months, 83% by 6 months, and 90% by 12
months. Further progression to any of these end-points
slowed substantially during the following 2 years. No child
got AIDS after 20 months of age (see fig 1 for number at
risk).
27 infected children survived without AIDS to 18
months; in 9, no symptoms developed in the average
29 months of observation. In the remaining 18 (67%),
followed for an average 30 months, lymphadenopathy,
hepatomegaly, and/or splenomegaly developed at a median
age of 6 months. In 11 children (41%), these symptoms
persisted during follow-up, but in 7 (26%) the symptoms
resolved within 5-25 months, in most cases without
treatment. Continuing symptoms were prolonged periods
of at least two of lymphadenopathy, splenomegaly, and
AIDS/HIV No AIDS/HIV
death within death within Rate
— 12 mo 1 2 mo ratio P
Oral candidosis 11 2 35 7 <0 001
LHS* 7 18 1-8 0 1
Hyper-1gG 5 23 09 0 7
Hyper-1 gA 2 11 17 02
Hyper-IgM 4 4 5-8 0 009
Low T4/T8 7 14 2-2 0 1
No of children 17 35
No of years of
observation 7-2 35 0
No of examinations 130 465
•Any 2 concurrently, of lymphadenopathy, hepatomegaly, and splenomegah
persisting for 2 mo.
Other definitions as in table h
hepatomegaly, and in some children episodes of parotitis
petechiae, septicaemia, unexplained fever, and pneumonia
Resolution of symptoms was seldom complete, anc
persistent lymphadenopathy tended to remain. By contrast
immunological disorders rarely resolved. No chile
recovered normal T4/T8 levels once the ratio had faller
below reference levels (see table II). Hyper-IgG resolved ii
only 1 instance, though this feature could have beer
concealed in some of the 19 children who were receiving IC
therapy. Hyper-IgA and hyper-IgM were generally
transient.
Fig 1 shows that hyper-IgG,A,M is usually the firs
feature of disease, followed by HIV-ISS, low T4/T8 ratio
and finally AIDS. Most of the infected children have so fai
shown a progression consistent with this order. Hyper-
IgG,A,M, was the first or equal first sign in 74%. Tht
relative timing of the low T4/T8 ratio was more variable: ii
came after the onset of AIDS in 44% of those in whorr
AIDS developed, and predated HIV-ISS in 20% of those
in whom pre-AIDS HIV-ISS or low T4/T8 were
recorded.
TABLE IV—CLINICAL SPECTRUM OF AIDS OR HIV-RELATED
DEATH: INDICATOR DISEASE AND PROGRESSION
Initial AIDS indicators








PCP (5) FTT, encephalopathy (13) 31
PCP (3) BCG-itis (10) 24
PCP (3) 10
PCP (3) 21
CMV, encephalopathy (5) 6*
CMV (3) 3*
CMV (2) FTT, PCP, encephalopathy
(5) 9*
Septicaemia, LIP (10) FTT (15), PCP, encephalo¬
pathy (19) 19*
Pneumonia (10) 26
Pneumonia (3) FTT (7) 8*
Septicaemia (5) 17
LIP (3) 4*
LIP (5) Encephalopathy (24) 30
LIP (4) 4*
Cryptosporidium (17) 31
Cryptosporidium (18) FTT (9), pneumonia (34) 34
None Oral Candida (3), SUD (6) 6*
•Died.
PCP = Pneumocystis carinii pneumonia; CMV = disseminated cytomegalovin
infection: LIP = lymphoid interstitial pneumonitis: FTT = failure-to-thriv
SUD = sudden unexplained death.
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Precursors ofAIDS onset in the first 12 months
The 17 children who got AIDS or died of HIV-related
illness in the first 12 months are compared with the 35
antibody-positive infected children who survived to 12
months without AIDS (table III). Oral candidosis was
highly predictive of imminent AIDS, but combinations of
lymphadenopathy, hepatomegaly, and splenomegaly were
only marginally associated with progression to AIDS.
Immunological indices were less strongly predictive of
AIDS than they were ofHIV infection, with the exception
of hyper-IgM.
In a separate analysis, of the children who got AIDS, 10
out of 13 (77%) had at least one positive antigen test in the
pre-AIDS period (14 of a total 32 tests were positive),
compared with 20 out of 27 (74%) of antibody-positive
infected children who did not get AIDS and who were
followed for over 18 months (74 of a total 184 tests).
Clinical features ofAIDS
Table IV shows the indicator diseases and clinical course
in the 19 children who got AIDS or who died of
HIV-related causes. Within the first 6 months, 15 had
AIDS or died, and significantHIV-ISS and hyper-IgG had
already developed in the remaining 4. 1 child died
unexpectedly at 6 months: oral candidosis had developed
more than two months previously. (Because of the poor
outcome associated with oral candidosis in this study, this
death was assumed to be HIV-related, and has been
includedwith the 18AIDS children in the analyses). 2 ofthe
children with encephalopathy had microcephaly; diagnosis
roughly coincided with onset of AIDS. Failure-to-thrive
was seen in 4 out of 6 of those with encephalopathy
compared with 2 of 13 of those without this disorder
(Fisher's two tailed, p = 005). 1 of the 2 children with
encephalopathy but normal growth had a brain lymphoma
and may have been atypical. Of those with failure-to-thrive
but no encephalopathy, 1 was reportedly malnourished and
the other had Cryptosporidium diarrhoea. A further child,
0.0-1 1 1 1 1 1 1 1 \ 1
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Fig 2—Survival estimates of the proportion of the cohort
remaining antibody positive.
Data adjusted for HIV-related deaths
TABLE V—SENSITIVITY AND SPECIFICITY OF CLINICAL AND
IMMUNOLOGICAL INDICES AS MARKERS OF INFECTION
Sensitivity (%) Specificity (%)
Index 6 mo 12 mo 6 mo 1 2 mo
Hyper-IgG, A, M 77 77 97 97
Low T4/T8 31 49 99 98
Hyper-IgG, A, M or low T4/T8 79 82 96 95
HIV-ISS 47 63 97 94
HIV-ISS, hyper-IgG, A, M, or low
T4/T8 83 90 94 90
Two ofHIV-ISS, hyper-IgG, A, M,
or low T4/T8 48 69 100 100
without AIDS, had both failure-to-thrive and abnormal
neurological signs—features which were rare in pre-AIDS
children (table ii).
9 of the 18 children with AIDS have died, 5 within a
month ofdiagnosis. Of the 9 remaining alive, 5 (all ofwhom
had AIDS indicator diseases for which there is moderately
effective treatment) had lymphadenopathy or hepatomegaly
when last seen. 2 children with AIDS became seronegative
at or shortly after the onset ofAIDS; both have died.
Loss ofantibody
In children who lost antibody, there were differences of
up to 5 months between centres in the mean age of the first
negative antibody test. The differences were much larger
than could be accounted for by variation in the scheduling of
tests, and were probably due to the different antibody test
systems used. However, most samples were tested by both
ELISA and western blot, and no child was persistently
positive by one system while remaining negative by the
other.
Fig 2 gives the survival curve estimate of the proportion
who remain antibody positive at each age, and is based on
the 520 cohort members with an antibody determination
after their birthdate. Antibody loss is assumed to have
occurred after the last positive test but before the first
negative test, if there was one. Children who died with
AIDS/HIV are assumed to be antibody positive at the time
ofanalysis, and the 2 children withAIDS who subsequently
lost antibody are assumed to have remained seropositive.
With these adjustments, the curve reaches an asymptote at
13-4% (95% confidence interval [CI]: 9-7-171%), and this
is an estimateofthe vertical transmission rate (see below). Of
thosewhowill loseantibody, an estimated 10-2% lose itafter
15 months, and 2-5% after 18 months.
343 children have been followed for a total of 390 years
after their first negative antibody result, including 80
followed beyond their 3rd birthday; none has yet developed
AIDS or persistent immune deficiency, or has again
developed persistent antibody or antigen.
Recognition of infection in antibody-positive children,
without definitive laboratory diagnosis
The sensitivity and specificity of signs and symptoms as
predictors of infection in antibody-positive children are
shown in table V. Hyper-IgG,A,M, was the most sensitive
indicator, identifying at least 77% of infected children by 6
months, with an estimated false positive rate of 3% in
uninfected childrenwho are still seropositive. Combinations
of hyper-IgG,A>M, low T4/T8, or HIV-ISS increased
sensitivity at 6 months but lowered specificity. A
combination of any two of the three variables would
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recognise 48% of infected iniants by 6 months. None of the
325 children who lost antibody and who were followed for
over 12 months met this criterion in the first 12 months. The
specificity is therefore estimated to be 100% and with this
sample size is unlikely to be less than 991% (lower 90%
confidence limit).
Vertical transmission rate
Of 419 children bom 18 months or more before June 15,
1990, 372 were of known infection status and of these 48
were infected (table I). This represents a transmission rate of
12-9% (95% CI 9-5-16-3%), which agrees closely with the
estimate of the surviving fraction of 13-4% in fig 2. There
were no statistically significant differences in transmission
rates between centres, nor were there changes over time. Of
the 353 children who lost antibody, virus isolation had been
attempted in 163; in 10 (61%), positive results were
obtained at least once.With the exception of 1 child in whom
a static encephalopathy uncharacteristic ofHIV developed
following a Reye-like syndrome,1215 these 10 children did
not seem to differ clinically or immunologically from the
other 343 children who lost antibody. 1 child had hyper-
IgG, another a low T4/T8 ratio, and a third
lymphadenopathy and hepatomegaly. However, these signs
all resolved within a few months, and taken together they
represent an incidence of the same order as would be
expected in children who lost antibody. In 4 children the
initial positive culture was confirmed on subsequent
samples by repeat vims culture and/or polymerase chain
reaction (PCR). But in the remaining 6, a total of eighteen
attempted cultures were negative, and laboratory error or
contamination cannot be completely ruled out. The data do
not, therefore, support an estimate greater than 4/163
(2-5%, 95% CI 0-7-6-3%).
Discussion
As a description of the natural history ofHIV-1 infection
up to diagnosis ofAIDS in the first 3 years of life, we believe
that the ECS is substantially unbiased by treatment. While
confirming the wide spectrum of disease found by other
investigators,1"»1<>-" the ECS provides additional
information on the timing of initial symptoms, and the
frequencies of clinical and immunological features.
Birthweight, gestation, head circumference at birth, or
birthweight adjusted for gestation did not discriminate
between infected and uninfected children; this also
confirms earlier results.7-11 The lower birthweight of
children bom to women with AIDS or with symptomless
HIV infection than of those bom to seronegative women
reported in two African-based studies22-24 ismore likely to be
due to differences in the mothers' socioeconomic or health
circumstances than to interuterine infection, since these
findings have not been seen in New York25 or Scotland.26
Our findings show that without a definitive diagnosis,
immunological and clinical signs can be regarded as
predictors of HIV infection in children under 18 months
old. Although several signs and symptoms are associated
with HIV infection, the ECS shows that many are not
specific enough to be useful markers either of infection or of
the development of AIDS. Otitis media, rhinitis, non-
cryptosporidium diarrhoea and unexplained fever were all
poor indicators of infection compared with hypcr-
IgGA,M, which identified 77% of infected children at 6
months with 97% specificity. In a population ofwhom 15%
a.c infected, this implies a positive predictive value of on:
80%, and may not therefore be an indication for thcrapi<
with side-effects. A combination of any two of hypei
IgG,A,M, lowT4/T8 ratio, or HIV-ISS was highly specif
and could be used as a criterion for treatment or inclusion i
a therapeutic trial. However, these findings should not t
applied to children whose mothers are not known to fc
positive, because immunological signs could have very loi
predictive value in the general population. Moreover, oc
findings would not be applicable in countries wher
hyper-IgG, lymphadenopathy, and hepatosplenomegah
due to chronic infections are common.27 The relativ
frequency ofAIDS indicator diseases in the ECS is simila
to earlier reports.72028 The possible association betwee:
failure-to-thrive and encephalopathy would point to
central nervous system mechanism for failure-to-thrive tha
is different from the opportunistic diarrhoea! infections tha
probably underlie failure-to-thrive in African studies.
Our findings have implications for clinical managemen
and for the design of clinical trials. Firstly, treatment wii
have to be started very early—within the first 2 or !
months—to prevent the early onset ofAIDS in about 30°/(
of infected children.7 Except in laboratories with higl
expertise, such an early diagnosiswould be hard to achieve a
present. Also, during the second and third years of life, th<
progression of HIV disease seems to be slow, with mori
children improving than deteriorating. Long-tern
treatment of symptom-free children or those with mile
symptoms may be necessary to show any benefit; this no:
only creates difficulties in the design of trials for treatment!
with side-effects, but also raises doubts about earlier, oper
therapeutic studies that attributed to treatmeni
improvements that might have occurred spontaneously.2'-"
Our 13% estimated transmission rate is lower than rates
published in all but one study,31 which was a subset of the
ECS. It is possible that a higher frequency of risk factors
such as breastfeeding or mothers' clinical condition could
account for these differences. However, estimates in many
earlier studies may have been biased upwards. For example,
in one study, virus cultured from cord blood was taken as
proof of infection.22 In a study citing 39% transmission,
47% of the cohort had been lost to follow-up;24 and those
remaining may have been more likely to have been ill. A
29% rate was cited in a New York Study.32 However, that
analysis included antibody-negative children only if they
had been followed for 15 months, whereas infeaed children
were included with shorter follow-up. In studies in which
some children are recruited retrospectively, the requirement
that themother should be seropositivemay be insufficient to
prevent a bias towards selective recruitment ofsick children.
A further requirement is that collaborating centres report all
children bom to seropositive mothers. This type ofbias may
have occurred in the Italian Multicentre Study23 (33%
transmission),which is register based; in the French Study,7
which has 51 collaborating centres (27% transmission); and
also in earlier reports from the ECS.1011 The requirement
for inclusion in the transmission rate that children should
have an antibody test after 18 months" rather than have a
birth date 18 months earlier also biases estimates upwards
because parents ofchildren who lose antibody earlier are less
likely to bring the children back for continuing follow-up.
Even if all the children who were lost to follow-up were
infeaed, the transmission rate would still only be 23%.
Deaths in children of indeterminate infertion status, of
which there were 7 in the ECS, also make the calculations of
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transmission rates difficult. The mortality rates we found
are higher than the 1/600 SIDS33 and the 5/1000 neonatal
mortality rates34 in the UK, though the social deprivation of
our cohort must be taken into account. Even if all these
deaths are included as HIV related, the estimated
transmission rate would only be increased by 1-2%. The
24% transmission rate cited in an earlier report from the
ECS" included the children who lost antibody but in whom
virus was detected. However, virus isolation in healthy
antibody-negative children reported by the ECS35 and
elsewhere3 is difficult to quantify since laboratory error
cannot be ruled out in every instance. Our results do not
suggest that this finding occurs in more than 2-5% of those
who remain antibody negative and free of immune
deficiency. Further reports of viral DNA detected by PCR
in antibody-negative children,36 unconfirmed by viral
isolation, are even more difficult to interpret37 and require
further evaluation.38
We have not yet seen any child first loseantibody and then
become persistendy antibody positive or show any
immunological or clinical signs of infection. This failure to
duplicate earlier reports of seroreversion in 2-year-old
children,39 despite follow-up of some 80 children beyond
age 3, not only is reassuring, but also implies that infection of
children through household contact must be rare since it has
not occurred once in 390 person-years observation of
antibody-negative children.
The mode of vertical transmission remains unknown.
The early onset of clinical and immunological features in
80-90% of infected children points to intrauterine
transmission rather than transmission at delivery. However,
rapid onset ofHIV-related illness has also been reported in
children infected by transfusion at birth,40 with clinical
illness in 1 child as early as 4 months.20
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Mortality in hereditary antithrombin-lll
deficiency—1830 to 1989
F. R. Rosendaal H. Heijboer E. Bri£t H. R. BCller
D. P. M. Brandjes K. de Bruin D. W. Hommes
J. P. Vandenbroucke
To determine whether antithrombin-lll (AT-III)
deficiency leads to an excess mortality, we studied
171 individuals from ten families with a proven
hereditary deficiency. 73 were classified as certainly
deficient either by direct measurement of AT-III
concentration or by mendelian inheritance patterns.
98 individuals had a high probability (0 5) of
deficiency. The 64 deaths recorded did not exceed
those expected for the general population adjusted
for age, sex, and calendar period. We suggest that a
policy of prophylactic anticoagulation for patients
with AT-III deficiency cannot be recommended.
Lancet 1991; 337: 260-62.
Introduction
Hereditary antithrombin-III (AT-III) deficiency is an
uncommon autosomal disorder that is associated with a
tendency to venous thromboembolism in heterozygous
individuals.1-2 The severity of venous thrombosis ranges
from superficial thrombophlebitis to pulmonary embolism
but the risk ofsevere thromboembolism in AT-111 deficient
individuals is largely unknown.
The decision to anticoagulate symptom-free AT-III
deficient individuals prophylacncally is therefore difficult
and a randomised trial of anticoagulant treatment against
placebo is unfeasible since the disorder is rare and a long
follow-up would be required to give a definitive answer.
Furthermore, the risks of long-term anticoagulant
treatment are substantial.3
To study the natural history of AT-III deficiency, we
comparedmortality inAT-III deficient families with that of
the general population. If the mortality were lower in the
general population, one could estimate the potentially
beneficial effect ofanticoagulant treatment.
Subjects and methods
Study population
All Dutch families, with amember known to beAT-III deficient
and who was under the care of the Departments ofHaematology of
the University Hospitals of either Leiden or Amsterdam, were
eligible for study. Diagnosis was based on AT-III antigen
concentrations less than 75% of normal, in the absence of heparin
treatment, chronic liver disease, or nephrotic syndrome. Only
families with 2 or more deficient individuals were studied, to avoid
inclusion ofpatients with an acquired deficiency. Furthermore, we
included only families with at least one symptomatic deficient
individual.
In all families, non-deficient individuals were excluded and for
untested family members information from relatives was used to
assign a probability of deficiency. Since AT-III deficiency is an
autosomal disorder, some untested individuals can be taken as
heterozygous for AT-III deficiency—these family members have
passed on the affected gene from common ancestors to deficient
individuals. Mendelian probabilities can be assigned to all
individuals in a pedigree. We restricted our study population to
those who were deficient with certainty or had a probability of
deficiency of 0-5. We rejected the possibility of recent mutations,
which may theoretically have taken place in smaller pedigrees,
because of the low frequency ofAT-III deficiency. This method
requires complete pedigrees. Since 1809 it has been mandatory by
law in the Netherlands to report all births and deaths to the
municipal registries. All information in this study has been verified
by reference to thesemunicipal and national registries.
Analysis
The mortality of the study population (observed) was compared
with the general population adjusted for age, sex, and calendar
period (expected). The ratio of observed to expected number of
deaths (O/E) is the standardised mortality ratio (SMR). "ITie
expected mortality is derived by multiplying the total number of
years lived by the study population in each calendar period, and for
each age and sex category, by the mortality rates (age and sex
specific) of the general population for each calendar period.
Confidence limits for the SMR are based on a Poisson distribution
for the observed number of deaths.4
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SHORT COMMUNICATION
Increased expression of the CD45RO (memory) antigen
on T cells in HIV-infected children
Karin S. Froebel, Kathleen V. Doherty, James A. Whitelaw,
Rosemary A. Hague*, Jacqueline Y. Mok* and A. Graham Bird
Expression of the CD45RO putative memory cell antigen on CD4 (helper) and CD8
(cytotoxic/suppressor) lymphocytes of children born to HIV-infected women was
investigated using the UCHL1 antibody. Significantly raised numbers of CD45RO +
CD8 lymphocytes were found in all nine of the infected children compared with
uninfected and control children. Expression of CD45RO on CD4 lymphocytes was
variable; absolute numbers were not increased, although the percentage was increased
in four out of nine infected children. All the infected children except two (who
had comparatively low numbers of CD45RO+ CD8 cells) were clinically well, which
suggests that an increase in CD45RO + CD8 cells may be indicative of a functionally
active immune response against HIV.
AIDS 1991, 5:97-99
Keywords: Paediatric HIV infection, leucocyte common antigen,
cell-mediated immunity, phenotypic markers.
ntroduction
[IV destroys the immune system by infecting and grad-
ally eliminating, both numerically and functionally, the
elper T-cell subpopulation of lymphocytes. One of the
rst functional immune responses to decline is the mem-
ry T-cell response, manifest by a loss of skin test respon-
iveness to recall antigens, and a fall in the in vitro pro-
ferative response to these same antigens. The CD45RO
ntigen, recognized by UCHL1 antibody, is a 180 kD vari-
nt of the leucocyte common antigen, resulting from al-
;rnative splicing of the mRNA, and is expressed on a pro-
ortion of T cells, monocytes and polymorphonuclear
ells [ 1 ]. In the peripheral T-cell population the CD45RO
iriant is thought to be a marker for antigenically primed
r memory cells [2], Ontologically, CD45RO expression
n T cells is minimal at birth, and rises during the first
:w years of life, presumably as a child is exposed to new
itigenic challenges, reaching a level of between 40 and
3% by 15 years of age [3].
ecause of the disturbance of the memory T-cell pop-
lation in HIV infection, we decided to investigate the
expression of CD45RO on T lymphocytes in infants and
children born to HIV-positive women. There are now 103
such children in Edinburgh, of whom eight are confirmed
as HIV-infected and are still alive. We analysed both the
CD4 and CDS T-cell subpopulations, and our results have
shown that, rather than there being an absence of these
putative memory cells, the development of CD45RO +
cells is accelerated in children known to be infected with
HIV, reaching levels far in excess of those found in un
infected children or in infected adults.
Subjects and methods
Subjects
The subjects were children bom to HIV-infected women
who were being regularly followed up at the Infectious
Diseases Unit at the City Hospital, Edinburgh, Scotland,
UK. In addition, one sample was taken from a 75-month-
old child who had been infected through a blood trans¬
fusion. Cord blood samples were obtained from the
om the HIV Immunology Unit, University Department of Medicine, and the 'Infectious Diseases Unit, City Hospital, Edinburgh,
zotland, UK.
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mpson Maternity Hospital both from babies born to
[V-infected women and from normal deliveries. Asymp-
matic children were confirmed as being HIV-infected
lly if their serum HIV antibody test remained positive
I months after delivery. One child of 15 months who
id symptomatic disease and who was HIV-antibody- and
-us-culture-positive was included in the 'infected' group.
1 other children younger than 18 months were con
iered to be 'indeterminate' with regard to HIV infec-
>n. Control samples were taken (1) from children bom
HIV-positive women who were over 18 months and
ronegative or who had seroreverted (defined as 'pre-
med uninfected'), and (2) to age-match the older pa¬
nts, from selected routine samples sent to the Depart-
snt of Paediatric Haematology, Edinburgh Royal Hos-
ial for Sick Children. An analysis of variance was car-
id out on the data obtained from the normal control
ildren and the presumed uninfected children which
owed that there was no significant difference between
ese groups in the percentage of CD45RO + , CD3 +
nphocytes (f = 0.372 with 27 d.f., data not shown). We
erefore assumed that CD45RO expression on CD4 and
18 subsets would also be similar, and pooled the data
>m these two groups for subsequent analysis.
ithods
vphocyte subpopulations
riole EDTA blood (100 pi) was incubated with 5 pi each
fluorescein isothiocyanate (FITC)- conjugated UCHL1
tibody (Dako, High Wycombe, UK) and phycoerythrin
E)- conjugated CD3, CD4 or CD8 antibody (Becton-
ckinson, Oxford, UK), and the samples were analysed
a Becton-Dickinson FACScan. Analysis was performed
a lymphocyte gate defined both by forward and side
itter characteristics and also on phenotypic evaluation
ecton-Dickinson 'leucogate').
cause of the age variation in children in both the num-
r of circulating lymphocytes and in the percentage of
)45RO-bearing cells, the data were analysed in four age
nds: cord blood, 0- 17 months, 18-36 months and
-80 months. Results for patients and controls in each
2 band were compared using a Mann-Whitney U test.
Results
The results are shown in Table 1 and Fig. 1. In 20 cord-
blood samples and 22 samples from children under 17
months of age there were no significant differences in
CD45RO expression on CD3 cells in the 'at risk' chil¬
dren compared with normal control children (data not
shown).
0 II) 2 0 JO 4 0 5 0 6 0 7 0 8 0
Age (Months)
Fig. I.Expression of CD45RO on CD8+ T cells in normal controls
(A), presumed uninfected children of HIV-infected mothers (O),
and HIV-infected children (•).
In children over 18 months old the percentage of
CD45RO+ CD4 cells was higher in infected children
compared with the group of uninfected 'at risk' and nor¬
mal children. However, when the results are expressed as
absolute numbers of CD4 cells to take into account the
lower number of CD4 cells in the infected children, the
number of CD45RO +, CD4 + cells was not significantly
different in the two groups (Table 1).
In the CD8 subset, both the percentage and the abso¬
lute number of CD45RO + cells were significantly raised
in HIV-infected children compared with the uninfected
'at risk' and control children (Table 1, Fig. 1). In all of
seven infected children over 3 years the percentage of
CD45RO + CD8 + cells exceeded the upper limit of the
normal range [3].
ile 1. Expression of CD45RO on CD4 and CD8 cells in children between 18 and 80 months of age.
CD45RO expression
CD4 CD8
; (months) HIV status No. % n/pl % n/pl
36 Infected 2t 35 330 35* 490*
Uninfected/control 9 15 410 18 180
80 Infected 7 56" 280 71" 1370"
Uninfected/control 6 31 345 16 125
ents significantly higher than controls (Mann-Whitney U test): 'P < 0.05; "P < 0.01. fIncludes one 15 months-old patient (see text).
CD45RO expression in HIV-infected children Froebel et al.
)iscussion
)ur results show abnormally enhanced expression of the
1D45RO antigen on peripheral blood T cells of HlV-in-
ected children. The increased expression occurs primar-
y in the CD8 (suppressor/cytotoxic) subset of T cells,
rith all of the infected children having results above the
lormal range, and in two out of nine cases over 95%.
ncreased percentages of CD4 (helper) T cells were ob-
erved in four out of nine infected children. Taking into
ccount the differences in absolute numbers of CD4 and
:D8 cells in the HIV-infected and HIV-uninfected and
ontrol children, the differences in the CD45RO + CD8 +
ubpopulation becomes even more marked, whereas the
iifferences in the CD45RO+ CD4+ subpopulation are
educed to the extent that only one patient has a higher
-'vel than that observed in uninfected children.
layward et al. [3] first showed that expression of
1D45RO on both CD4+ and CD8+ lymphocytes in-
reases over the first years of life from 2 and <0.5%, re-
pectively, at birth to 45 and 35%, respectively, at 6 years
if age, rising to a maximum of 55 and 48%, respectively,
ly 20 years. This finding together with functional strid¬
es have led to the conclusion that CD45RO is a marker
or memory T cells in both the proliferative (helper) and
ytotoxic subsets [2,4,5]. Whether or not these cells are
anctionally active in the HIV-infected children and, if so,
/hether they are HIV specific, has still to be determined.
J1 but two of the children in this study have remained
symptomatic, and these two (the children aged 15 and
4 months in Fig. 1) have relatively fewer CD45RO + CD8
ells than those who are asymptomatic, suggesting that
:D45RO+ CD8 cells may be functionally important in
uppressing viral replication. The extent of CD45RO ex-
iression observed in the HIV-infected children has not to
iur knowledge been described previously in peripheral
ilood T cells, and the immune processes which drive the
majority of CD8 cells into 'memory' cells are unknown.
'an Nossel et al [6] have recently reported that ex-
iression of another putative marker of memory cells,
ae CD29 antigen, falls in HIV-positive homosexual men.
)ur own preliminary observations on HIV-infected adults
how no significant differences in CD45RO+ CD4 or
:D8 cells between groups of patients with normal or re-
luced absolute CD4 counts (unpublished observations),
"he reason for the apparent discrepancy between their
esults and those reported here is unclear. One possi-
ile explanation is that the CD8 cell-mediated immune
esponse to HIV differs in children infected perinatally
nd in adults. Further phenotypic studies are in progress
/hich should clarify this point.
Expression of CD45RO on CD4 cells was variable, and
there was no clear relationship between CD45RO expres¬
sion on CD4 cells and HIV infection. However, it is of
interest to note that, in the HIV- infected patients in a
situation of a falling CD4 count, the CD45RO + cells ap¬
peared to be preferentially retained in the circulation.
The function of the CD45 leucocyte common antigen
molecule is still poorly understood, but it may serve as
a regulatory molecule of cell activation [7], and it may
be that the different isoforms have different regulatory
functions. This study has shown a clear phenotypic dif¬
ference in the CD8 lymphocyte subpopulation between
HIV-infected and uninfected children. The demonstration
of accelerated expression ofCD45RO + CD8 + cells may
be a useful early indicator of HIV infection in at-risk chil¬
dren. Evidence of this, however, has been hindered by
the very low level of vertical HIV infection in the Edin¬
burgh children cohort and awaits the results of an exten¬
sive longitudinal study which is now under way. Whether
the enhanced expression of CD45RO on CD8 lympho¬
cytes represents a functionally active subpopulation of
immune cells or whether it represents an HIV-induced
aberration of the normal differentiation pathway also re¬
mains to be established.
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HLA ANTIGEN FREQUENCIES IN CHILDREN
BORN TO HIV-INFECTED MOTHERS
► D. C. KILPATRICK, R. A. HAGUE*, P. L. YAP AND J. Y. Q. MOK*




Tissue-typing for HLA-A, B, and DR antigens was carried out on 53 babies, 47 of them
unrelated, born to mothers known to be HIV-infected from intravenous drug usage or sexual
contact with drug users. These babies were followed up to assess whether HLA phenotype
was associated with vertical transmission of HIV infection or disease progression. Of the 47
unrelated babies, eight became infected with HIV. The frequency of HLA-DR3 was three
times higher in the HIV-positive infants compared to the HIV-negative infants (43 per cent vs
15 per cent) in our study population. Conversely, HLA-A3 was three times less common in the
HIV-positive infants (12-5 per cent vs 42 per cent). A comparison of HLA antigens between
our study group babies and babies born to healthy mothers unselected for HIV status
revealed higher proportions of HLA-B18, B7, and DR2 in the study group. Moreover, the
combination, A3, B7, DR2 was four times commoner in our study population relative to
controls (RR = 3-9; p < 0 003), but was found only in babies who were not HIV infected. The
combination A1, B8, DR3, in contrast, was found less often than expected in our study group
(R/? = 0-39) and was disproportionately represented amongst the infected babies. We have
observed an unexpectedly low (6 percent) mother-to-infant transmission rate ofHIV among
prospectively studied intravenous drug users. We speculate that the unusually high ratio of
the common antigen combinations (often halotypes), A3, B7, DR2 to Al, B8, DR3 in this
population may be contributory.
key words HIV Paediatric AIDS HLA disease associations Vertical transmission of
HIV
INTRODUCTION
Human immune deficiency virus (HIV) disease is rather variable in course, which
may in part be a reflection of individual differences in genetic susceptibility. Several
studies have associated HLA specificities with aspects of HIV infection. Examples
include HLA-B35 and progress from lymphadenopathy syndrome (CDC stage 3) to
AIDS (CDC stage 4) in subjects infected predominantly from intravenous drug use
(Smeraldi et al., 1986; Smeraldi et al., 1988); HLA-DR5 with HIV-associated
Kaposi's sarcoma (Pollack et al., 1983; Prince et al., 1984), and thrombocytopenia
(Raffoux et al., 1987) in homosexuals; and HLA-DR3 with disease progression in
haemophiliacs (Steel et al., 1988; Kaslow etal., 1990; Fabio etal., 1990), but not in a
predominantly homosexual population where the opposite trend was apparent
(Kuntz and Bruster, 1989). In addition to individual specificities, the combination or
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haplotype HLA-(A1, B8, DR3) has been associated with relatively rapid loss of
circulating CD4-positive lymphocytes (Steel et al., 1988; Kaslow et al., 19y0;
Cameron et al., 1991), and possibly with an increased susceptibility to infection
(Steel et al., 1988).
One group at risk for HIV infection which has not previously been studied in
relation to tissue type is the children of HIV-infected mothers. Although trans¬
placental infection is well documented, not all babies are born infected. In principle,
HLA phenotype might influence disease susceptibility in utero, or, amongst those
affected, influence disease progression in infancy. We therefore carried out a
preliminary study to look for HLA associations in such children.
PATIENTS AND METHODS
The subjects were 53 neonates or infants born to mothers known to be HIV-1
positive. The study group was basically part of a wider perinatal transmission study
described elsewhere (Mok et al., 1989), although we also obtained samples for tissue
typing from five (three unrelated) other Scottish infants known to be HIV positive.
Most of the mothers were drug users infected directly from needle sharing, but five
were apparently infected sexually by HIV-positive male drug users. Most of the
mothers lived in Edinburgh, were Scottish, and shared a social milieu characterized
by multiple deprivation. Whenever possible, tissue typing was performed immedi¬
ately after birth from cord blood; otherwise samples were obtained during follow-up
visits.
Infants who remained HIV-antibody positive 15 months after birth and who had
symptoms consistent with, or suggestive of, paediatric HIV infection (European
Collaborative Study, 1988) were diagnosed as HIV positive. Infants who had
become seronegative by 15 months of age, were healthy, and had normal immune
function, were presumed uninfected.
Tissue typing for HLA-A, B, and DR antigens was carried out as previously
described (Jazwinska and Kilpatrick, 1987). Control data from unselected babies
born to healthy mothers were taken from a previous study (Jazwinska and
Kilpatrick, 1987).
RESULTS
The HLA antigen frequencies obtained from 47 unrelated babies born to HIV-
infected mothers are listed in Tables 1 and 2. The frequencies for the total group
under study differed little from those of the control group born to healthy mothers
(unselected for HIV status). However, there were marked increases in frequencies
of HLA-B18 CRT? = 7-9; x2= 7-9; p = 0-005), B7 (RR = 1-9; /?>005), and DR2
(RR = 2 0; x2 = 3-74; p= 0-05). The associations with HLA-B18 and DR2 were not
prinr hypotheses, however, and so are not statistically significant after correction for
the number of antigens tested.
Comparing HLA antigen frequencies between babies positive and negative for
HIV, the most striking difference was in HLA-DR3, which was three-fold higher in
the infected infants. Frequencies of HLA-A1 and HLA-A2 were also elevated in
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Table 1. HLA Class 1 antigen frequencies in unrelated neonates born to women infected with
HIV-1
Specification % HIV-positive
neonates (n = 8)
%HIV-negative
neonates (« = 38)
% Total
neonates (n = 46)f
Al 50 23-7 28 (39)
A2 75 36-8 41 (52)
A3 12-5 42 37 (32)
All 0 18 15 (11)
A23 0 0 0 (4-5)
A24 12 5 15-8 13 (17)
A25 0 15-8 13 (4-5)
A26 25 0 4-3 (3)
A28 12-5 2-6 4-3 (4-5)
A29 0 5-3 4-3 (5-3)
A30/31 12-5 5-3 6-5 (5-3)
A32 12-5 7-9 8-7 (3-8)
B5 0 5-3 4-3 (4-2)
B7 37-5 47 46 (31)
B8 25 18 20 (31)
B13 12-5 2-6 4-3 (5)
B14 0 10 5 8-7 (9)
B15 0 7-9 6-5 (10 6)
B16 0 5-3 4-3 (6-8)
B17 25 10-5 13 (8)
B18 12-5 10-5 11 (1-5)
B21 25 0 4-3 (4-5)
Bw22 0 7-9 6-5 (5-3)
B27 0 5-3 4-3 (6-8)
B35 12 5 15-8 15 (14)
B37 0 0 0 (3)
B40 0 10-5 8-7 (114)
B44 25 15-8 17 (27)
tFigures in parentheses are the corresponding proportions for control neonates bom to healthy mothers
unselected for HIV status (Jazwinska and Kilpatrick, 1987).
the infected group, while HLA-A3 was proportionately more abundant in the
HIV-negative group.
The rather high frequencies of both B7 and DR2 prompted us to examine the
second commonest HLA antigen combination in the general population, A3, B7,
DR2, as well as the much commoner A1, B8, DR3 combination which has formerly
been implicated in disease susceptibility by others (Table 3). The combination A3,
B7, DR2 (which often occurs as a haplotype) was four-times commoner in our study
population relative to the controls (RR = 3-9; x2 = 9-1 \p< 0-003), but was found only
in babies who were not HIV infected. The combination Al, B8, DR3, in contrast,
was found less often than expected in our study group (RR = 0-39; p = 0-06) and was
disproportionately represented amongst the infected babies.
Five families were also studied. (One member of each was included in the un¬
related series). There were three sets of dizygotic twins, a pair of brothers, and a set
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Table 2. HLA Class 2 antigen frequencies in unrelated neonates born to women infected with
HIV-1
Specificity % HIV-positive
neonates (n = 7)
% HIV-negative
neonates (n = 39)
% Total
neonates (« = 46)f
DR1 0 10 8-7 (12)
DR2 43 44 43 (28)
DR3 43 15 19 6 (39)
DR4 29 28 28 (25)
DR5 14 18 17 (13)
DRw6 29 18 19 6 (34)
DR7 29 33 32-6 (26-5)
DRw8 0 2-6 2 (3-8)
DRw9 0 51 4-3 (0)
tFigures in parentheses are the corresponding proportions for control neonates bom to healthy mothers
unselected for HIV status (Jazwinska and Kilpatrick, 1987).
Table 3. HLA antigen combinations in unrelated neonates born to
HIV-infected women
Combination % HIV- % HIV- % Total % Controls
positive negative neonates cTmII
neonates neonates (« = 45)
(«= 7) (n= 38)
Al, B8, DR3 26-8 7-9 111 24-2
A3, B7, DR2 0 28-9 24-4 7-6
of three sisters. Ofall the twins, only one child was HIV infected and she shared one
haplotype with her uninfected sister; the two uninfected twin pairs shared one and
two haplotypes, respectively. The brothers, neither of whom were infected, shared
one haplotype. Two of the three sisters, all of whom were HIV infected, were HLA
identical (A2, A28; B7, B21; DR2, DRw6): one died aged 25 months ofHIV wasting
syndrome, the other has interstitial pneumonitis but remains well at 5 years of age.
The third sister (A24, A28; B7, B16; DR uncertain) shared one haplotype with the
other two, and died at 67 months, cachectic after persistent bacterial pneumonia.
DISCUSSION
Early data on mother-to-infant transmission of HIV infection indicated a rate as
high as 64 per cent (Scott et al., 1985). However, later reports from Europe
(European Collaborative Study, 1988), France (Blanche et al., 1989), Zaire (Ryder
et al., 1989), and Haiti (Halsey et al., 1990) agree on a transmission rate ofaround 30
per cent, although the most recent European data suggests a vertical transmission
rate of 13 per cent (European Collaborative Study, 1991). In the families under
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study here, 10/53 (=19 per cent) or 8/47 (=17 per cent) of unrelated children
acquired HIV from their mothers, but our sample was biased towards infected
children. Data based on children over 18 months old in the Edinburgh cohort under
prospective study indicate a mother to infant transmission of only three out of 47 or
6 per cent (Mok et al., unpublished data). This rate is substantially lower than we
expected and may be related to genetic characteristics ofour study population.
The HLA antigen frequencies in the babies reported here, representing a relatively
deprived social group, differed somewhat from our controls, which were babies of
healthy parents unselected for HIV status but who were by comparison affluent and
with no known history of intravenous drug use. Most notably, the relative incidence
of the two commonest HLA antigen combinations (which usually occur as haplo-
types) were reversed. Our data are consistent with an earlier report that A1, B8, DR3
may be weakly associated with susceptibility to infection (Steel et al., 1988), and
support the speculation that A3, B7, DR2might confer some measure ofprotection.
On the basis of this small survey, it is clear that tissue typing would be of little
value as a predictive test in babies born to mothers known to be HIV positive. There
were no absolute differences in any antigenic specificity when comparing HIV-
positive and HIV-negative neonates, and our family studies revealed no obvious
relationship between haplotype inheritance and disease susceptibility or pro¬
gression. However, HLA antigens may be associated directly or indirectly with
susceptibility to transplacental infection and this might manifest itself as varying
transmission rates in different populations. In particular, a high A3, B7, DR2/A1,
B8, DR3 ratio may contribute to a low transmission rate, and this possibility may
merit further investigation as a specific hypothesis.
Our results must be considered preliminary, but this is the first investigation into
genetic susceptibility to HIV infection in infants of seropositive mothers. This study
therefore could form a useful starting point for larger and more detailed surveys.
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Patients infected with the human immunodeficiency virus (HIV) may have an
antibody deficiency and a deficiency of cellular immunity. Intravenous
immunoglobulin (IVI-G) preparations may benefit HIV-infected children and adults
with recurrent bacterial infections at doses of 200 to 400 mg/kg every 2 to 4 weeks.
In addition, IVIG{1 to 2 g/kg) is effective at raising platelet counts to hemostatic
levels in HIV-infected patients with idiopathic thrombocytopenic purpura and life-
threatening bleeding, indirect evidence also suggests that IVIG may be effective in
preventing Pneumocystis carinii pneumonia. Finally, recent studies suggest that
specific anti-HIV antibody preparations may have a therapeutic role, either as
immunoglobulin concentrates or as immunoadhesins and immunotoxins. However,
further investigations are needed to exclude antibody enhancement of HIV infection
by the Fc receptor or the complement receptor. Cancer 68:1440-1450, 1991.
PATIENTS with acquired immune deficiency syndrome(AIDS) and other symptoms associated with human
immunodeficiency virus (HIV) infection have a severe
deficit ofcelluiar immunity associated with the progressive
depletion ofCD4-positive hclper-induccr lymphocytes. As
a result, they are infected with various opportunistic or¬
ganisms. and attempts at immunotherapy primarily
focused on treating the cellular immunodeficiency.
However, patients infected with HIV also have other im¬
munologic deficits, including various abnormalities of B-
lymphocytc function (Table 1). Some of these abnor¬
malities may be a result of the lack ofadequate CD4 helper
cell function associated with the decline in the CD4 helper
cell numbers that occurs with progression ofHIV disease.
Despite the hypergammaglobulinemia observed, more
frequent infections of the respiratory tract occur in
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children1-2 and adults3 with HIV infection, and such
fections may be caused by encapsulated gram-positive
ganisms. Because this pattern of infection is suggestive
antibody deficiency, intravenous immunoglobulin (IVI
therapy has been assessed, and early studies in cl
dren""* suggest that such therapy might be beneficial
reducing the number of recurrent infections. Several otl
studies support a role for IVIG in HIV-infected patie
(Table 2), and this review will describe such studies
HIV-infected children and adults, in HIV-infected patie
with idiopathic thrombocytopenic purpura (1TP), a
possibly in Pneumocystis carinii pneumonia (PCP). It \
also highlight some new developments that have occuri
since this subject was reviewed last.7
Intravenous Immunoglobulin for Children With Hum
Immunodeficiency Virus Infections
Vertically transmitted infection with HIV in infa
may result in a deficiency of antibody and cellular i
munitv. The usual clinical presentation in infants w
recurrent bacterial infections is similar to that of X-tinl
agammaglobulinemia. Despite the polyclonal increase
scrum immunoglobulin (Ig) concentrations, the poor ]
mary and secondary specific responses to antigen cl
lenge render such infants susceptible to bacterial infec'.i
Clinical benefit may therefore result from the admii
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Five had recurrent purulent pulmonary infections, and
the sixth had recurrent prostatitis and mastoiditis. They
were given infusions of 200 mg/kg IVIG (manufactured
by the Scottish National Blood Transfusion Service) every
3 weeks as outpatients in an open study.23 At each hospital
attendance, both before and during IVIG treatment,
symptoms of infection and antibiotic consumption were
documented. At the end of the treatment period, the hos¬
pital records were scrutinized, and the antibiotic con¬
sumption and number of inpatient days because of in¬
fection were noted. For comparison, the same information
was obtained from the hospital records for the 6-month
period immediately preceding the start of IVIG therapy.
Information concerning the dose ofantibiotics prescribed
was not analyzed, no distinction was made between in¬
travenous and oral routes of antibiotic administration,
and full compliance with prescribed oral antibiotic therapy
was assumed.
A statistical analysis of the differences between the pre¬
sentment and treatment periods in the percentage of time
spent as an inpatient and the percentage of time receiving
antibiotics was performed using the Wilcoxon rank-sum
method on paired data. We found a statistically significant
reduction in inpatient hospitalization (P < 0.05) and an¬
tibiotic consumption (P < 0.05) in the period after IVIG
therapy compared with the preceding 6-month period
when each patient was used as their own control (Fig. 3).
Patients varied in the improvement associated with IVIG
treatment. Although regular IVIG infusions did not pre¬
vent the occurrence of infections completely during the
period of follow-up. there were fewer infections obsen/ed
by a reduction in antibiotic requirements in all except
Patient 4. whose requirement did not change. There was
also a reduction in the hospitalization required for infec¬
tion in all except Patients 4 and 6 (not shown), who did
not spend any time as inpatients during control or treat¬
ment periods.
Case 1 Case 2 Case 3 Case 4
fie;. y. Individual data lor Patients I through 4 comparing percentage
of'time taking antibiotics before (stippled) and alter (striped top left to
lower right) IVIG therapy, and percentage of time in hospital Ixrforc
(striped top right to lower left) and after (solid) IVIG therapy.
The regimen of IVIG therapy administered was ti
same as that initially given as replacement therapy f
primary hypogammaglobulinemia. Using 300 mg/
IVIG every 2 weeks, a similar improvement was seen
one patient studied by others.'4 There is no conscns
concerning the optimal dose of IVIG or the frequency
administration in this situation as is the case in the ma
agement of primary hypogammaglobulinemia.
We were particularly interested in calculating the cc
of IVIG therapy because it is high (currently £15 (sterling
g in the United Kingdom). We made the assumption th
each patient would require inpatient hospitalization f
the same percentage of time after the commencement
IVIG as before its institution. The cost of materials w
calculated on the basis of £ 15/g for the IVIG and £5 f
the disposables used at each infusion, multiplied by t
number of infusions administered. Staff time and oth
factors required for each 2-hour infusion cost £87.24 ai
inpatient care cost £200 per day.25
The cost of IVIG therapy (100 infusions) was £21,1
for the 1.41 kg of IVIG given, £500 for disposables, ai
£8700 for the staffand other costs, a total cost of£30,3:
Treatment was associated with a reduction in hospit;
ization (Fig. 3), the difference between expected and c
served hospitalization being 115.3 days for the six cas<
This resulted in an avoided expense of£23,060. Howevi
in this study, we chose to treat two patients with recurre
infections who had not required hospitalization in t
pretreatment period (Patients 4 and 6) and. therefore. I
whom potential saving on hospitalization cost was no
existent. Subtracting the cost of their treatment (27 i
fusions of 360 g of IVIG, £7SS4) and considering the oil-
four cases only, the treatment costs were £22.466 coi
pared with an avoided expense for reduced hospitalizatii
of £23.060. suggesting that in carefully selected cases
quiring hospitalization for infections, IVIG therapy m
be cost-effective.
In summary, using an IVIG dose of 200 mg/kg eve
3 weeks, we showed in the four cases requiring hospit
ization for recurrent infections that IVIG treatment w
cost-effective. However, our preliminary data suggest
that IVIG therapy may not be cost-effective in patiei
who do not require hospitalization for recurrent infcctio
and further studies, preferably of piaccbo-controlU
crossover design, are required to determine the place
this therapy in the management of the HIV-infected {
tieni with recurrent bacterial infections.
Intravenous Immunoglobulin in (he Prevention and
Treatment of Pneumocystis Infection
The most significant opportunistic infection in patiei
with AIDS. P. carinii is a major cause ol morbidity a
mortality, even in patients receiving treatment for H
infection with zidovudine. Currently, the available trc




Weight gain kg/month Hospital days/month
1
1 2 3 < 5 6 7 8
Patient
E3 Pre IVIG Post IVIG
Fig. I. Individual data showing reduction in (A) the number of episodes of infection. (B) weight gain, and (C) the number of days spent in th<
hospital in eight HIV-infected children treated with IVIG. Patient 5 had no infections before or after IVIG and Patients I and 7 had no infection:
after IVIG therapy. Patient 7 had no hospitalization before or after IVIG therapy and Patient 5 had no hospitalization after IVIG therapy.
but in none of the six patients with elevated concentrations
at entry to the study did the levels normalize with treat¬
ment. On the basis of their results, the authors recom¬
mended that IVIG should become standard therapy in
symptomatic pediatric HIV infections. However, in this
pilot study. IVIG therapy was only of6 months' duration
in four of the seven children studied, and there was no
adequate control period of comparison before the initi¬
ation of regular IViG therapy.
Our group therefore undertook a prospective open
study in which eight children with symptoms of HIV in¬
fection were treated for 12 to 26 months (median. 14
months) with three weekly infusions of IVIG (200 mg/
kg).10 Because of the heterogeneity of clinical symptoms
in the HIV-infected children, particularly in the frequency
of infection and weight gain, each child acted as their own
control. A significant improvement was seen in all chil¬
dren during the IVIG treatment period in the number of
inlectious episodes, weight gain, and days spent in the
hospital compared with the control period preceding IVIG
therapy (Figs. IA to IC). The IVIG treatment resulted in
a 49,ro saving in management costs compared with those,
arising previously as a result of inpatient admissions.
Serum Ig levels, increased at the start of treatment, were
not altered, and T4 counts continued to decline slowly
(Fig. 2). as reported previously.''
One finding of particular interest was the observation
that HIV core antigen, detected in four children before
therapy, disappeared after IVIG therapy was commenced.
This ellect was sustained in three children.'" We therefore
postulated that IViG therapy might reduce viral replica¬
tion by preventing the lymphocyte activation and proiif
eration induced by bacterial infection and hence migh
delay the progression of HIV-relaied disease.
A critical issue in the therapy ofHIV-infected childrer
with IVIG is the point in the illness at which IVIG treat
ment should be initiated. We consider that after two oi
more serious infections, particularly with encapsulatec
gram-positive organisms, long-term treatment with I VIC
is indicated. In the case of asymptomatic HIV-infectec
children and symptomatic HIV-infected children who dc
not have bacterial infections, c.^.. those with failure it






















. Mean CO4 (helper) lymphocyte counts in ctfcht HlV-infecte
Ivtore and alter IVIG therapy.
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ABt.t I. Immunologic Abnormalities in Human Immunodeficiency
Virus Infection
|uantitative abnormalities of T-lymphocytcs
Decreased numbers of helper-induccr (CD4) cells
Elevated, normal, or decreased number of supprcssor-cvtotoxic
(CDS) cells
unctional abnormalities of T4ymphocvtcs in vivo
Host susceptibility of infection
Host susceptibility of neoplasms
Decreased dclaycd-lype hypersensitivity responses
unctional abnormalities ofT-lymphocytcs in vitro
Elevated spontaneous proliferation
Decreased proliferative responses to mitogens and antigens
Decreased virus-specific cytotoxic Svmphocvtc !ufiction
Decreased ability to provide help to B-lymphocytcs
unctional abnormalities of B-lymphocytes in vivo
Elevated serum immunoglobulin levels
Circulating immune complexes
Inability to mount an appropriate serologic response after
immunization
anctional abnormalities of B-lymphocytes in vitro
Elevated spontaneous proliferation
Elevated numbers of spontaneous plaque-forming cells in the
peripheral blood
Enhanced responsiveness to B-ccll growth factors
Refractoriness to the normal in vitro signals for B-ccll activation
bnormal suppressor phenomena in AIDS
Suppressor factors in sera
Antilvmphocyte antibodies
T-ccll-derived suppressor substances
AIDS: acquired immune deficiency syndrome.
Reproduced with permission from Lane HC. Fauci AS. Immunologic
tnormalities in the acquired immunodeficiency syndrome. Annit Rev
rtrnunol 1985: 5:477-500.
ation of IVIG due to its content of antibodies with a
ide range of specificities, including those against gram-
ositive encapsulated bacteria. Several studies have at-
:mpted to evaluate whether infants and children with
IDS or AIDS-relatedcomplex (ARC) benefit from IVIG
lerapy."10
In one retrospectively reviewed series of 3 1 children
ith AIDS treated at the Children's Hospital ofNew Jersey
itween 19S1 and I9S3. 19 were treated with 200 mg/kg
flG every 4 weeks for at least 5 months, and 1 2 received
3 IVIG therapy. The two groups were comparable with
regard to symptoms and clinical course, and over a period
of follow-up ofat least 2 years for each patient, only three
of the IVIG-trcated children died (16%) compared with
ten of the control group (83%). a significant difference in
mortality between the two groups occurring in association
with IVIG therapy."
In another study in New York. 14 of 41 children with
AIDS and recurrent bacterial infections were treated with
a course of IVIG consisting of infusions of 50 and 100
mg/kg during week I. 150 and 200 mg/kg during week
2, 200 mg/kg twice during week 3. and 300 mg/kg during
weeks 4. 6. and 8.5 The remaining 27 patients did not
receive IVIG therapy, although the basis for selecting
which cases to treat with IVIG was not clear. Over a period
of follow-up of 20.4 ± 9.2 months, only three febrile ep¬
isodes lasting longer than 1 week occurred in the 14 cases
treated with IVIG, with one episode of sepsis. In the 27
untreated cases, there were 26 such febrile episodes during
the same follow-up period, vftth 18 episodes of sepsis.
Given the historically controlled or uncontrolled nature
of these studies, it is difficult to be certain of the efficacy
of IVIG therapy in reducing either the morbidity from
bacterial infections or the mortality in children who have
AIDS.5
A more detailed analysis of the clinical benefit of IVIG
therapy in HIV-infected children was undertaken by oth¬
ers.9 In a prospective study of seven HIV-infected children
for 6 to 24 months after the start of IVIG therapy, the
treatment schedule consisted of IVIG at a dose of 0.4 g/
kg on 5 consecutive days and then 0.4 g/kg every 2 weeks
for 3 months, followed by 0.4 g/kg every 4 weeks. There
was a sharp reduction of febrile and infectious episodes,
a normalization of physical and psychomotor develop¬
ment. and an absence ofmortality. However, no beneficial
effect of IVIG on cellular immunity in terms of in vitro
lymphocyte responses to mitogens and skin test reactivity
to recall antigens was observed, and a gradual decrease
in total and CD4-positive helper lymphocytes occurred
during the course of the study. The mean value of cir¬
culating immune complexes was lower during treatment.
Taolg 2. Some Applications of' Intravenous Immunoglobulin Preparations in Human Immunodeficiency Virus-lnt'ectcd Patients
Patient group Dose Comment
Iiildren with recurrent bacterial 200—1()0 mg/kg every 2—i weeks Value oflVIG therapy in asymptomatic HIV-infected
tnlections children unknown
dulls with or without recurrent 200—HX) mg/kg every 2—* weeks Trials in progress—value of this therapy unknown
bacterial infections
T associated with HIV 1-2 g/kg over 1-5 days Thcrapv wuh zidovudine may be an alternative: useful
infection for life-threatening bleeding
sc to delav progression to Not known Specific anti-HIV antibody preparations required:
AIDS initial trials in progress
ITP: idiopathic thrombocytopenic purpura; HIV: human immuno- intravenous immunoglobulin.
:ficicncy virus: AIDS: acquired immune deficiency syndrome; IVIG:
> IVIG IN AIDS
starting IVIG. It is possible that intercurrent infection
i organisms other than HIV may be a co-factor in the
jression of HIV infection.7
inally. there remains the question of whether all in-
s born to HIV-seropositive mothers should be con-
red for IVIG therapy. The main difficulty lies in the
lonstration in infants ofHIV infection: all infants born
eropositive mothers have circulating anti-HIV anti-
y of maternal origin that disappear after a variable
od. Furthermore, the current low vertical transmission
s (15% to 20%) make it unlikely that IVIG will be
atcd generally in the management of HIV-infected
Jrcn before the development ofsymptoms. Resolution
lis issue will depend on better laboratory methods for
diagnosis of HIV infection in the first 6 months of
such as the use of the polymerase chain reaction."
i summary, two early retrospective studies and two
nt prospective studies, all with relatively small num-
ofsymptomatic HIV-infected children, indicated that
:ment with IVIG at doses of 200 to 400 mg/kg every
4 weeks is associated with clinical benefit. However,
inal proof of the efficacy of IVIG will await the results
he large, double-blind, placebo-controlled trial in
ptomatic HIV-infected children now in progress in
Jnited States. To date, no studies of IVIG have taken
e in asymptomatic HIV-infected children, and such
ies will have to await the general availability ofmeth-
ofdiagnosing HIV infection early in life.
ravenous Immunoglobulin for Adults With Human
Immunodeficiency Virus Infection
dults with AIDS have profoundly impaired cellular
unity and suffer various opportunistic infections,
c patients infected with HIV, especially intravenous
abusers, whether or not they have progressed to
S. have more frequent bacterial infections of the re-
torv tract, suggesting specific antibody deficiencies."11"
organisms usually implicated are encapsulated gram-
ive bacteria, and the overall clinical picture bears a
ig resemblance to primary antibody deficiency svn-
ics. Thus, it is possible that replacement therapy with
} may be beneficial in such patients. However, studies
jaiing the efficacy of IVIG therapy in HIV-infected
patients are difficult to do because only a minority
recurrent bacterial infections, they are heterogeneous
regard to symptoms and laboratory indices, and it
ficult to control for the effects of other factors such
jarcttc smoking and continued drug abuse. Although
tudy showed a decrease in mortality in HIV-infected
s treated with IVIG." there were no significant rc-
ons in the number of bacterial or viral infections.
: are currently no published reports of any trials of
treatment in HIV-infected adult patients with re-
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current bacterial infections and only one anecdotal report
about a single HIV-infected adult with recurrent pyogenic
infections who appeared to benefit significantly from IVIG
therapy.14
We can make a strong case for reducing intercurrent
infections in HIV-infected adult patients because it is
possible that infection with organisms other than HIV
may be a co-factor in the progression of HIV-rcIatcd dis¬
ease. Respiratory infections are common in HIV-infected
patients.15 but accurate estimates of the proportion of
HIV-infected patients with recurrent bacterial infections
currently are not available.
Infections should occur more frequently when specific
antibody secretion is impaired, and cases with such im¬
pairment should benefit from IVIG therapy. Lower levels
of antipneumococcal antibody are found in homosexual
patients with AIDS than in seronegative heterosexual
control subjects: a poorer antibody response occurs after
vaccination with pneumococcal vaccine.16 In addition
HIV-seropositive homosexual patients with ARC have
lower postimmunization titers than heterosexual control
subjects.17 and a defective response to immunization was
found in seropositive hemophiliac patients." Ifthe ability
to produce an antipneumococcal antibody response were
regarded as a marker for the ability to produce antibodies
directed against other gram-positive organisms, then one
logical approach would be to commence IVIG in cases
where the serologic response to successive pneumococcal
vaccinations declined.
In an attempt to assess whether such therapy is as ben¬
eficial in adults as it is in children, we recently undertook
a pilot study in a group ofsix HIV-infected adult patients
with recurrent bacterial infections, the results of which
were reported briefly elsewhere." We chose to select only
patients with recurrent bacterial infection and to study
each patient as their own control. A comparison of con¬
secutive periods with and without IVIG therapy was used:
each patient should have remained unchanged clinically
or become worse <as a result of the progressive nature of
HIV infection) rather than better during the period of
IVIG therapy. No change in other prescribed drug therapy
(such as zidovudine) was made during the study, and there
were no changes in the patterns of continuing drug abuse
in current abusers (data not shown).
To evaluate the efficacy of IVIG therapy, we used two
relatively simple indices—days in the hospital and days
of antibiotic use. These were useful in the evaluation of
this therapy in patients with primary hypogammaglob¬
ulinemia*""" and HIV infection."' Each patient studied
had recurrent infections that did not respond satisfactorily
to antibiotic treatment before IVIG therapy. The cases
studied were six adults whose HIV infections were ac¬
quired by blood transfusion (Patient 1). intravenous drug
abuse (Patients 2 to 5). and homosexuality (Patient 6).
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Table 3. Elfcct of Intravenous Immunoglobulin in Human Immunodeficiency Virus-Associated Idiopathic Thrombocytopenic Purpura
No. of Range of peak
patients Patients platelet counts
Author (year) treated IVIG dose responding" IIO'/D
Panzer ct at. (1985)"° 5 1 g/kg (2) 5 78-250
2 g/kg (3)
Imbach cl at. (mi)" 4 1.6 g/kg (2) 4 > 150
Tertian cl at. (1987)*'
2 g/kg (2)
1 1 1 g/kg (8) 9t 5S-I93
Okscnhandlcr ct at. (I987)*2
2 g/kg(3)
17 1.2-2.0 g/kg 12
Busscl and Haimi (1988)"' aa 1 t»/l'O— o» "tJ tot * 86—104
Pollack cl at. (1988)" 3 - g/kg 3 60-215
Beard and Savidge (I988)*5 5 2 g/kg 5 97-300
Landonio cl at. (1990)" 17 2 g/kg 5 Not stated
Total 84 62 (75%)
IVIG: intravenous immunoglobulin. t Six rcspondcrs received I g/kgofiVlG.
" Initial increment in platelet count to > 50 X lO'/l.
two recent reports showed that a dose of I g/kg over 2
days was equally effective in raising the platelet count in
both acute and chronic ITP patients (Table We
had similar results in the treatment of both HIV-infected
cases and classic ITP with six of our first 12 patients
achieving a useful rise in platelet count by day 3 (platelet
count. > 30 X 109/k A.A.M.T., P.E.W., andP.L.Y., un¬
published data). In addition, when maintenance therapy
is required, this can be reduced from the standard 1 g/kg
to 0.5 g/kg without apparent detriment in terms of initial
response or duration of response/5 In children, theeost
of a course of IVIG therapy is relatively inexpensive and
may be recouped by the reduced need for hospitalization.
The mechanism of action of IVIG is not understood
completely/6 Modulation ofFc receptor expression and
Fc receptor blockade were found, and there is increasing
evidence that reticuloendothelial blockade is the main
mechanism of action, at least in the immediate response.
Inhibition of antibody synthesis may occur by a direct
effect on B cells or modulation of T-suppressor activity.
Antiidiotype antibodies in the IVIG preparation could
suppress aberrant innate idiotype-antiidiotvpe control
mechanisms that allow the production of antiplatelet an¬
tibodies. Alternatively, the IVIG may act by clearing a
putative viral agent (although evidence for this is lacking).
Others"' recently found increased production of the cy¬
tokines. tumor necrosis factor (TNF) and intcrleukin-l,
in HIV-infected monocytoid cells. These substances have
a potentially suppressive elfect on hemopoiesis, and an
additional hypothesis for an effect of IVIG on platelet
production can be postulated. Suppression of TNF pro¬
duction by rabbit macrophages was found using a human
IgG preparation/" This mechanism has not been inves¬
tigated in HIV-associatcd ITP to date.
Anti-Rh (anti-D) Ig therapy was valuable in patients
with classic ITP and. more recently, in HIV-associatcd
cases/"00 The effect appears to depend on an interaction
between the Rh antibody and its antigen because anti-D
is only effective in D-positive patients unless given as in
v/tro-sensitized cells. The therapy may divert the reticu¬
loendothelial system from platelet destruction to seques¬
tration of IgG-coated erythrocytes. The efficacy appears
similar to that of high-dose IVIG, but when used at the
doses reported, it can be less expensive. Transient posi-
tivity of the direct Coombs test and rise in bilirubin are
seen, but significant hemolysis is not normally a problem.
The limited availability ofanti-D suitable for intravenous
administration currently inhibits more widespread use of
this treatment, but this may no longer apply when mono¬
clonal anti-D preparations become available.
Finally, the requirement for specific therapy for ITP
may diminish with the more widespread use of zidovu¬
dine.51 There is increasing evidence showing the efficacy
of zidovudine in raising the platelet count in approxi¬
mately 50% of those treated, at least in part by stimulating
increased marrow production.52 This lends support to :he
hypothesis that HIV may have a direct role in the patho¬
genesis of the ITP.
In summary, 1VIG appears to have a useful role in the
treatment of HIV-rcIatcd ITP. having at least a transient
effect in most of those treated and lacking the immuno¬
suppression that is a potential disadvantage of' many al¬
ternative therapies. The main disadvantage of its cost may
be reduced by using a reduced dose schedule that appears
to be equally effective. The possibility of unlimited sup¬
plies of monoclonal anti-D offers exciting prospects lor
an economic alternative therapy. Zidovudine may negate
the requirement for other treatments in a large proportion
of HIV-infected thrombocytopenic patients.
Therapy Based on Specific Anti-Human
Immunodeficiency Virus Antibody Preparations
Only IVIG preparations derived from healthy blood
donors have been considered thus far. These preparations
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not contain any anti-HIV antibodies, unlike specific
-HIV Ig preparations. When used for the prevention
-IIV infection, specific anti-HIV preparations might
in several ways (by neutralizing free virus in the blood,
renting binding to the target cell, or preventing early
y into the cell). Such preparations also may play a
in preventing the progression ofHIV-rcIatcd disease
increasing the interval from primary HIV infection
le development ofAIDS. They may be useful in com-
ition with other therapies, e.g., with continuous un¬
ities. antiviral agents, such as zidovudine, and with
j.
major difficulty with developing an anti-HIV Ig
>aration is in defining the mechanism by which HIV
ts its cytopathic effect and the fine specificity of the
-HIV antibodies required. Several events occur during
cycle of HIV infection and replication, which could
to cell death.53 In some of these steps, specific anti-
'
antibody preparations may have a therapeutic role.7
/ever, a major difficulty in their development lies in
ling which antibodies, ifany, confer protection in vivo.
re are various reports of the existence of neutralizing
lodies in the serum ofHIV-infected patients and also
itibody-dependent cellular cytotoxicity (ADCC), in-
ing antibodies against HIV. It appears that ADCC
nodies may be related to neutralizing antibodies.34 An
ciation between virus neutralizing activity and the
cal progression of HIV disease was found.53-56 sug-
ng that neutralizing antibodies can be protective fac-
during the evolution ofHIV-related disease. However,
rent isolates of HIV strains showed a variability in
:xtent ofsensitivity to neutralization by sera obtained
i different HIV-infected individuals,55 and this vari-
tv has been attributed to the existence of various HIV
ypes.57 The mechanism for antibody neutralization
investigated further by the use of monoclonal anti¬
cs.7 and relatively specific neutralization epitopes were
jnized.58 One study indicated that there arc at least
rlasses ofbiologically active antibodies to HIV.59 One
of antibodies is isolate restricted and directed pri-
ly to a hypervariablc loop structure ofgpl20 that is
nvolved in CD4 binding. The second class of ncu-
:ing antibodies is directed at a more conserved struc-
which may include those involved in CD4 binding,
addition to preventing binding of HIV to lympho-
or monocytes. anti-HIV antibodies may prevent
ige caused by toxic components ofHIV. For instance,
native and recombinant gpl20 proteins from HIV-
re found to produce neuronal injurs- in the mam-
in central nervous system, and this neurotoxicity was
ght to involve a rise in intracellular Ca'*. Immu-
ecipiiaiion ofgpl20. using anti-gp 120. could prevent
"isc.6" and this observation may be relevant for the
anopathology of HIV outside the central nervous
m. Another possible application of specific anti-HIV
antibody preparations may be in preventing primary in¬
fection after needle-stick injuries: zidovudine prophylaxis
will not necessarily prevent HIV-I infection."' The use of
antibody preparations for this application would be similar
to the use of specific Ig preparations for the postexposure
prophylaxis of hepatitis B. rabies, measles, and varicella-
zoster. However, it should be noticed that there is a very
high affinity of gpl20-CD4 interaction with an affinity
constant of approximately 4 X I0~V3 An antibody effec¬
tively inhibiting this should have an affinity tenfold to
100-fold higher (10~10 or 10""). and thus it may be dif¬
ficult to produce. Large doses of antibody might have to
be administered for postexposure prophylaxis, and virus
also might be transmitted by cell-to-ceil contact: antibod¬
ies might not gain access to relevant epitopes.
The production of specific anti-HIV Ig preparations
may be difficult, but two studies were done, using anti-
HIV antibodies in the form of plasma. There have been
three attempts made to produce specific anti-HIV Ig
preparations. In one study,63 the infusion of plasma rich
in anti-p24 antibodies, collected from healthy HIV-in¬
fected persons, resulted in the clearance of HIV antige-
nemia. These plasma infusions were followed by fewer
symptoms of HIV disease, a reduction in the frequency
of opportunistic infections, and a decline in the rate at
which HIV could be cultured from plasma or lympho¬
cytes. Another similar study64 used plasma rich in neu¬
tralizing antibodies. However, the results from this study-
are difficult to interpret, and the results of further studies
using plasma containing high levels ofanti-HIV antibodies
are not known currently.
Three groups attempted to prepare specific anti-HIV
lg preparations. One group from New York used such a
preparation, manufactured from plasma rich in neutral¬
izing antibodies against HIV. in protection experiments
involving chimpanzees.65 Unfortunately, all four chim¬
panzees in the experiment became infected with the same
strain of HIV used in the neutralization assays in vitro.
The period of incubation to virus isolation in specific anti-
HIV Ig recipients did not differ significantly from the cor¬
responding period observed in a control chimpanzee that
received normal anti-HIV-frec Ig. In a detailed analysis
of this disappointing result."" the authors suggested several
reasons for the experimental failure, including the pos¬
sibility that loo high a challenge dose of HIV was used,
although Fc receptor-mediated, antibody-dependent en¬
hancement. or complement-mediated, antibody-depen¬
dent enhancement also may have occurred. Results from
repeat experiments using a lower dose of HIV arc antic¬
ipated.
Another anti-HIV Ig preparation, manufactured in Ja¬
pan. was shown to prevent the spread of HIV in vitro."'
However, no in vivo experiments using this globulin prep¬
aration arc available yet. Finally, another group from the
United States also developed an anti-HIV Ig preparation.
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and initial clinical trials showed that the half-life of the
anti-p24 antibody administered was 16 days. In Ig recip¬
ients who were HIV p24 antigen positive, the half-life was
shorter.Large-scale clinical trials of such specific anti-
HIV immune globulin preparations may be difficult to
perform because of the limited availability of suitable
plasma for fractionation. Although HIV-antibody-positive
blood donors could be used as a source of neutralizing
antibody, the screening of such donors, the collection of
their plasma, and its fractionation to yieia a noninfective
IV1G preparation would present formidable challenges.
Furthermore, removal of plasma containing neutralizing
antibodies from HIV-antibody-positivc donors might
cause them harm. Mouse and human monoclonal neu¬
tralizing antibody cell lines have been developed,7 but the
former may only be suitable for single courses of therapy,
and production of the latter is limited by the supply of
immune B-cells.
Finally, Ig molecules may be involved in two alternative
approaches to the therapy of HIV infection. First, there
is increasing interest in the use of soluble CD4 molecules
as a means of diverting free HIV virions from infecting
susceptible host cells. However, soluble CD4 has a short
half-life, necessitating frequent injections, and a chimeric
molecule was developed where theFab region of the IgG
molecule is replaced by CD4.69 Such chimeric molecules,
or CD4 immunoadhesins, were shown in primate exper¬
iments to possess the gpI20 binding and HIV blocking
properties of recombinant soluble CD4 and the long
plasma half-life of IgG. Fc receptor binding, the ability
to mediate ADCC, and to cross the placenta.70 A penta-
meric CD4-fgM chimeric molecule, which is at least 1000-
fold more active in syncytium inhibition assays, with re¬
tention of Fc binding and the ability to activate comple¬
ment, also was described.71
Second, the use of antibody-toxin <immunotoxin)
conjugates in HIV infection was investigated in vitro.'1
Such n cnnjiignre using monoclonal anti-gp!20 with ricin
A chain was shown to cause a dramatic reduction in the
number of infectious virions produced by immunotoxin-
trcaccd cells. It will be interesting to see how such an im-
munotoxin compares with the use of a recombinant CD4-
Pscudomonas exotoxin hybrid protein which has recently
been reported to kill HIV-infected cells selectively.'7
Conclusions
In general. IVIG preparations are safe in HIV-infected
patients, and there is only one published report ofa serious
adverse reaction, involving an HIV-infected child where
rapid administration of 1V1G caused neurologic symp¬
toms suggestive of the hyperviscosity syndrome.74 How¬
ever. there has been considerable interest in the possibility
that antibody administration may enhance HIV in¬
fection'7 bv increasing the entry of HIV into the cell
through the Fc receptor7''-77 or the complement receptor.7*
More recently, serum enhancement ofHIV infection was
correlated with theclinical stage ofdisease in HIV-infected
individuals, suggesting that enhancing antibodies may
contribute to the progression of HIV disease.79 Although
more in vivo data on the importance of anti-HIV anti¬
bodies enhancing HIV infection are required before the
significance of these observations is understood fully, the
possibility that specific anti-HIV antibody preparations
are harmful must be excluded before the widespread in¬
troduction of specific anti-HIV Ig preparations. None¬
theless. IVIG preparations have an important role to play
in the management of HIV-infected patients and should
be used more widely in the prevention of recurrent bac¬
terial infections, and in the treatment of 1TP.80~*5
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Prognostic Value of HIV Antigen and Core
Antibody Measurement in HIV-infected
Children: A Longitudinal Study
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Introduction
Human immunodeficiency virus (HIV) core pro¬
tein, or p24 antigen (HIV Ag), can be detected in the
plasma of HIV-infected individuals.1 Studies in
adults have shown that in primary infection, detec¬
tion of HIV Ag may precede detection of HIV anti¬
body.2 Subsequent disappearance of HIV Ag may be
due to a low level of virus replication or to the
formation of immune complexes after the initial an¬
tibody response. Reappearance of detectable HIV
Ag, together with a decline in HIV anticore antibody
(p24 Ab) levels, is associated with progression of
clinical HIV disease.3 A larger proportion of asymp¬
tomatic children than adults have persistent antigen¬
emia.4 While this might reflect a different balance
between active and latent HIV infection in children,1
persistent antigenemia has been reported to be asso¬
ciated with disease progression and a poor progno¬
sis.5 No reports are available on the course of HIV
Ag and p24 Ab levels in children over periods longer
than 2 years, for correlation with the progression and
clinical symptomatology of HIV infection. Our aim
in this study of 11 HIV-infected children was to
measure HIV Ag and p24 Ab levels quantitatively,
and relate the measurements to the onset of symp¬
toms, clinical progression, and therapeutic interven¬
tion.
Patients and Methods
Eleven children born to HIV seropositive mothers
with clinical and laboratory evidence of HIV infec¬
tion were identified at age 0-47 months (median 21
months). Three had been followed since birth, two
were identified while still asymptomatic, and 6 pre¬
sented with symptomatic disease. The median dura¬
tion of follow up was 21 months (range 4-57). In
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irviving, the median follow up was 36
'range 12-57).
\.g was measured by quantified enzyme im-
;ay (Abbott, UK), and expressed as pg/ml,
i standard supplied by the manufacturer with
cut-off of 3 pg/ml. P24 Ab was also mea-
ing the Abbott HIV-1 anticore enzyme im-
;ay. A quantitative value, expressed as p24
>(, was derived by dividing the optical den-
e of the sample tested by the cut-off value,
tracting this from 1.0 (1-OD sample/OD
serum). Thus, the higher the value the
he competition (and amount of p24 AB) in
»le. Zero values indicate lack of antibody.
:hildren (cases 1-3, 5, 7-11) received intra-
mmunoglobulin (IVIgG) infusions of 200
/ery 3 weeks.6 Plasma was obtained by plas-
sis from donor 11, selected during a previ-
y by Jackson et al.7 for high serum titers of
and neutralizing antibody and treated as
ly described.7 Plasma was titered for anti-
i p41/gp 120 and neutralizing antibody, but
not for antibody to the hypervariable loop. It was
then infused in patients 1 and 5 at a dose of 2 ml/kg
every 6 weeks initially, increasing to every 3 weeks
after three infusions in case 5. Five children (cases
1,2,5,7,8) received oral zidovudine a( doses ranging
from 400-600 mg/m2/day.
Results
Of the 11 children, 10 had symptoms and signs of
HIV infection during the study period. One child
(case 6) had lymphadenopathy, hypergammaglobu¬
linemia (IgG of 20 g/L) and a reversed T4/T8 ratio
(0.8), but remained clinically well. Clinical details
of all 11 children are summarized in Table 1, and
laboratory data in Table 2. Of the five children
(cases 1-5) who were negative for core antibody,
and had HIV Ag levels above 50 pg/ml, four have
died at ages 67 months (case 1), 43 months (case 2),
25 months (case 3), and 4 months (case 4), and one
(case 5) has progressed to AIDS at age 51 months
(group 1). Five children (cases 7-11) had low or
Table 1. Clinical Data on the HIV-infected Children (Numbers = Age in Months)
Length of 1st Progression Current IV IgG AZT
Last Seen Follow Up Symptoms to P2B-Da Stage3 Started Started Symptoms
67 (D) 21 9 45 Dead 47 49 Recurrent pneumonia
Esophageal Candida
Failure to thrive (wasting)
43 (D) 21 22 26 Dead 26 28 Recurrent pneumonia
Encephalopathy
PCP
25 (D) 14 22 24 Dead 23 Oral Candida
Encephalopathy
Wasting syndrome
4(D) 4 1 4 Dead Oral and cutaneous Candida
PCP
72 33 12 51 P2C/E 36 58 ITP
LIP
Ewing's sarcoma
33 12 — — P1B — — Asymptomatic
57 57 3 P2A 9 28 Recurrent pneumonia (at <1 yr)
Molluscum contagiosum
69 51 9 P2F 24 42 Recurrent pneumonia
Molluscum contagiosum
Cardiomyopathy
48 48 9 P2F 14 — Recurrent respiratory infection
ITP
63 27 33 P2A 39 — Recurrent respiratory sepsis
Diarrhea
63 36 18 24 P2C 24 Recurrent pneumonia
lassified by CDC.13 Abbreviations: (D) = Age at death; ITP = immune thrombocytopenic purpura; PCP = Pneumocystis
Limonia; LIP = lymphocytic interstitial pneumonitis.
i"*> Vgy-.VC A<: 'AsX' V
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(IIV Ag values, and of these none has died
essed to AIDS during the period of follow
57 months (group 2). Two children (cases 5
nained positive for p24 Ab, but were also
genemic (group 3). Both were clinically
hat time; case 6 has remained stable, but in
bsequent loss of p24 Ab preceded clinical
ion. Group 1 children also showed a signif-
reater rate of fall in CD4+ cells than
) 2 children (p < 0.01, Wilcoxon rank
. CD4+ lymphocytes remained stable in
e available on 6 children in the first 2 years
d 3 were followed from birth. Case 4 was
or p24 Ab from birth, with rapidly increas-
\g levels to 145 pg/ml at her death at the
months. Cases 6, 7, and 8 had positive
p24 Ab initially, but levels declined, coin-
h emergence of low levels of HIV Ag. In
iren, who remained clinically stable, HIV
le negative and p24 Ab was subsequently
as illustrated by case 9 in Figure 1.
lildren received IV IgG for 2-48 months
4 months). Of these, 6 (cases 1,2,3,7,8,9)
tive for HIV Ag when therapy was com-
3ase 3 received IV IgG for only 2 months
death, but during this time HIV Ag levels
from 62 to 0 pg/ml. Data on case 5 are
e. Of the remaining 5 children, there was a
reduction in HIV Ag in 4 (cases 2,7,8,9),
sly reported,6 but numbers are too small to
stical significance. No effect of IV IgG on
vels was observed.
and 5 received plasma rich in anti p24
on two and six occasions, respectively,
received IV IgG infusions for 18 months,
(case 1) had received zidovudine in the
past, but this had been discontinued because of tox¬
icity 3 months previously. She was extremely ill
with unresolving pneumonia, and died 8 weeks later.
Case 5 remained clinically stable during treatment.
The plasma infusions were effective in clearing HIV
Ag completely, and raising p24 Ab levels 2 hours
after completion of the infusion (Fig. 2). However,
as p24 Ab levels declined, HIV Ag reappeared be¬
tween 7 and 14 days later, returning to the pretreat-
ment level by 6 weeks. On the 3-weekly infusion
regimen, HIV Ag reemerged despite positive p24 Ab
testing.
Five children received zidovudine. No clear rela¬
tionship was observed between commencement of
therapy and change in HIV Ag or p24 Ab levels
(Fig. 3). HIV Ag reemerged during therapy in cases
1,5, and 8 after 1-14 months, probably representing
zidovudine resistance.
Our results indicate that HIV Ag assay is valuable
as an early diagnostic test in children born to HIV
seropositive mothers. Nine of eleven infected chil¬
dren were positive for HIV Ag, 6 of whom were at
the time either asymptomatic or had symptoms not
specific for HIV infection. Our study also empha¬
sizes the importance of regular prospective follow up
of all children born to HIV-infected mothers, be¬
cause peak HIV Ag levels may occur in the asymp¬
tomatic phase and would be missed if the child were
not identified prior to becoming ill.
One previous study has correlated persistent HIV
antigenemia and loss of p24 Ab with a poor progno¬
sis.5 Our results suggest that high levels of HIV Ag
in the absence of p24 Ab rather than the duration of
antigenemia are significant in predicting those HIV-
Discussion
Table 2. Laboratory Data on the HIV-infected Children
1st Sample 1st Ag+ Peak Ag Last Ag 1st Ab Last Ab Last T4 Count Rate of T4 Decline
(Months) (Months) (pg/ml) (pg/ml) (Months) (Index) (X 109/ml) (Average/Year)
47 47 >150 >150 47 0 0.01 95%
24 24 97 2 24 0 0.01 88%
11 15 >150 0 11 0 0.02 99%
0 2 145 145 0 0 1.08 90%
42 42 >150 >150 49 0 0.10 60%
21 21 >150 48 — 0.42 1.11 0%
3 9 11 0 6 0.59 0.60 15%
18 24 28 15 24 0 0.68 25%
3 6 21 0 6 0.50 0.67 18%
36 0 0 — 0.77 0.60 25%
24 0 0 0.94 0.60 10%
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children whose disease will progress rap-
ir observation of a difference in the rate of
}f CD4+ lymphocytes between groups 1 and
m described in adults,8 but there has been no
; report in children.
line in p24 Ab has been reported to precede
tigenemia as a correlate of prognosis in
In children born to HIV seropositive
such a finding is difficult to interpret be-
'
the inevitable decline of passive maternal
r levels in the first year of life. There have
previous reports relating p24 Ab levels at
th progression of disease in children, al-
he maternal p24 Ab level during pregnancy
appear to correlate with the risk of transmis-
)ur preliminary longitudinal study of three
suggests that absence of maternal p24 Ab at
iy be associated with rapid progression of
ociated disease in children who are infected,
ler studies on larger groups of children are
if the children studied (group 3) were simul-
y p24 Ab+ and HIV antigenemic. In a pre-
Dort,4 this feature was found in half of the
studied, but no attempt was made to corre-
finding with prognosis. In adults it occurs
infrequently.8 This may be because high levels of
antibody are produced as a response to HIV Ag by
the immune system of the child. It is possible that
active viral replication is more common in children;
the rate of spontaneous mutation of HIV is such that
the p24 Ab produced by the host lacks specificity,
and thus avidity. It is interesting, however, that in
the two children who were concurrently positive for
antibody and antigen this state was not associated
with rapid clinical deterioration.
We have previously reported a trend toward re¬
duced HIV Ag levels following commencement of
IV IgG therapy,6 and we have found that this effect
persists for 3-48 months. However, in the current
study reduction in HIV Ag levels was not suffi¬
ciently marked to reach statistical significance in the
small number of children studied. One possible
mechanism for HIV Ag suppression is that bacterial
and viral infections can cause lymphocyte activa¬
tion, and trigger HIV gene expression. The reduc¬
tion in the number of episodes of infection achieved
by IV IgG may therefore reduce HIV activation.
The use of plasma rich in p24 Ab has not been
reported in children, although clinical benefit has
been described in adults.7 We therefore chose a dose
of plasma equivalent to that which has been used in
▼ V
Age (months)
HIV Ag ° p24 Ab index
▼ 1st symptoms V IV IgG commenced
Figure I. HIV Ag and p24 Ab levels in case 9, from 3 to 45 months.
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ts,7 and continued until death in case 1, and as
as supplies lasted in case 5. Little is known
it the role of host immunity in HIV infection, but
IV antibody has a protective role then passive
specific immunization may be beneficial once
oral immunity becomes defective. If HIV Ag
itself is a direct cause of symptoms or progression in
HIV infection, a reduction of HIV Ag levels may
also be beneficial.7 We demonstrated that infusion of
plasma rich in p24 Ab was temporarily effective in
removing circulating HIV Ag. However, HIV Ag
reappeared in 2 weeks. Further studies are required
B






Figure 2. HIV Ag (A) and p24 Ab (B) levels in case 5 during therapy with plasma rich in p24 Ab, starting at time 0.
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Figure 3. HIV Ag levels before and after zidovudine therapy, commenced at time 0
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mine the dosage, volume, and frequency of
tration necessary for sustained antigen sup-
t, before clinical effects can be evaluated.
>atients all commenced treatment with oral
ine when HIV Ag levels were low or nega-
e were, therefore, unable to confirm previ-
:ported observations that the levels of HIV
following therapy with zidovudine.5-11-12
r, despite a raised mean corpuscular volume
of the red blood cell, suggesting adequate
:ompiiance and absorption of the drug, HIV
ime positive in two children and persisted
n therapy, and reappeared transiently in a
wo. This suggests either that viral suppres-
y be incomplete or that there is development
ance to zidovudine. We were unable to dem-
any consistent increase in p24 Ab antibody
g therapy with zidovudine." Therapeutic
tion did not alter the differences in prognosis
I between groups 1 and 2.
anclude that HIV antigenemia may precede
ns in HIV-infected children, and thus aid
ignosis. High levels of HIV Ag and loss of
are poor prognostic signs, irrespective of
dinical status, or therapeutic intervention.
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Summary
In order to determine whether the rates of respiratory viral infection and the severity
of respiratory symptoms in HIV-infected children were higher than those in non-
infected children, nose and throat swabs for viral isolation were taken at 3-month
intervals during the first 2 years of life from 50 children born to HIV-infected women.
Similar samples were obtained during the first year of life from 19 control children
born to HIV seronegative mothers. Of the 50 children, five proved to be HIV-infected
while 45 were presumed to be uninfected. HIV-infected children had significantly
more respiratory symptoms and a higher proportion of samples from which viruses
were isolated than the non-HIV-infected children. Also, more infected episodes
required admission to hospital in the HIV-infected group. There was no such
difference between the non-HIV-infected and the control children. Three HIV-
infected children received intravenous immunoglobulin therapy. Among these the
proportion of positive samples for viral isolation was greater before than after
treatment began. These results suggest that HIV-infected children are more
susceptible to recurrent viral infection and that passive immunotherapy may be of
benefit to such children.
Introduction
The susceptibility of HIV-infected children to respiratory infections caused
by bacteria and other opportunistic organisms is well-recorded,1"3 but the
natural history of respiratory infections due to viruses in such children has
received little attention. We therefore undertook a prospective study of HIV-
infected children in order to determine whether the rates of respiratory viral
isolation and the severity of respiratory symptoms in HIV-infected were
higher than in non-HIV-infected children using as controls children from the
same socio-economic group.
Patients and methods
All the children were among those participating in the Edinburgh HIV
Perinatal Transmission Study.4,5 Fifty children born to HIV seropositive
mothers below the age of 2 years were studied prospectively. Five (group A)
§ Address correspondence to: Dr R. A. Hague, Department of Paediatrics, Royal Victoria Infirmary,
Newcastle upon Tyne NEi 4LP, U.K.
0163-4453/92/010031 +06 $03.00/0 © 1992 The British Society for the Study of Infection
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proved to be infected with HIV.fi One died at 4 months, the remaining four
being aged 33-71 months. Three of these children were treated with
intravenous immunoglobulin (iv IgG), 200 mg/kg every 3 weeks as previously
described.7 Another group of 45 children (group B) were considered not to be
infected with HIV since they were clinically well and repeatedly HIV antibody
and antigen negative. As an additional control group, 19 children whose
fathers were HIV seropositive but whose mothers wereHIV seronegative were
also investigated for a period of 1 year (group C), thereafter declining further
participation.
All children in the study were seen at 3 monthly intervals and symptoms
suggestive of respiratory infection since the previous visit were recorded.
Children were examined for signs of respiratory infection. Nose and throat
swabs were taken and placed together in viral transport medium. One set of
swabs was taken at each visit but results of specimens taken during admission
to hospital were not included in this study. R.esults were analysed by means of
the x2 test f°r statistical significance.
Virological methods
Nose and throat swabs taken from each child were combined in a single vial of
viral transport medium containing antibiotics to suppress bacterial growth as
well as fetal calf serum to stabilise the virus. The samples were transported to
the laboratory within 2 h. If any delay was anticipated, swabs in transport
medium were stored at 4 °C before transport. In the laboratory, cells collected
on the swabs were resuspended in a small volume of transport medium before
they were inoculated into cultures of primary baboon kidney, human epithelial
cells (HEp2) and human fibroblasts (MRC5). The inoculated cells were
incubated at 36 °C and examined twice weekly for evidence of a cytopathic
effect. Further confirmatory tests were made on cells affected. Influenza,
parainfluenza, respiratory syncytial (RS), measles, and herpes simplex viruses
were confirmed by means of monoclonal or polyclonal antibodies in a
fluorescent antibody test.8 Adenovirus, Coxsackie and Echo viruses were
identified by neutralisation tests.9 Rhinovirus was identified by acid stability
testing. Cytomegalovirus (CMV) was identified by its characteristic cytopathic
effect on MRC5 cells.
Results
A total of 301 samples was collected over a period of 24 months. Results are
summarised in Table I. Although a few opportunities for sampling were
missed, these did not differ between groups. Group A had significantly more
respiratory infections and more samples positive for viral isolation than group
B. Over the first year, however, groups B and C did not differ significantly
(Table II).
The viruses isolated are listed in Table III. There was no significant
difference among the three groups in the proportion of positive virus isolations
associated with symptoms. Symptoms usually accompanied infections with
influenza A, parainfluenza, RS and adenovirus infections, whereas isolation of
CMV or Coxsackie virus was more often asymptomatic. Six of the 10 proven
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Table I Episodes of respiratory infection and virus isolation in HIV-infected
and non-infected children in the first 2 years of life
Group A B P*
Number of patients 5 45
Number of samples 30 220
Age range (mean, median) 3-24 (14-5, 15) 3-24 (14-0, 15) N.S.
Number of missed sampling 4/34 (1 r8) 22/242 (9-1) N.S.
opportunities (%)
Number of symptomatic episodes of 14 4i < 0-01
respiratory infection
Number of positive virus isolations 10 32 < 0-05
* According to the f test-
N.S., Not significant.
Table II Episodes of respiratory infection and virus isolation in the two




Age range (mean, median)
Number of missed sampling opportunities
(%)
Number of symptomatic episodes








Table III Virus isolations from HIV-infected and non-infected children in the
first 2 years of life. Comparison of symptomatic and asymptomatic children
Symptomatic Asymptomatic
Virus A B A B Total
Adenovirus 2 2 0 1 5
Influenza 0 3 0 0 3
Parainfluenza 2 2 0 1 5
Respiratory syncytial 0 3 0 1 4
Rhinovirus 1 4 0 3 8
Cytomegalovirus 3 1 2 5 11
Herpes simplex I 0 1 0 1 2
Coxsackie B 0 0 0 2 2
Measles 0 1 0 0 1
Echovirus 0 0 0 1 1
Total 8 17 2 15 42
2 JIN 24
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viral hifections in group A necessitated admission to hospital, compared with
9/32 in group B, a difference which was significant (P < 0-05). All three
children with influenza A infection were admitted to hospital. Others were
infected with RSV (three in group B), parainfluenza (two in group A, were in
group B), adenovirus (two in group A, one in group B) and measles (one in
group B). None of the children required assisted ventilation or specific
antiviral therapy. Although upper respiratory tract symptoms sometimes
accompanied isolation of CMV, CMV pneumonitis was not evident.
The three children from group A who suffered from recurrent infections
were given infusions of intravenous immunoglobulin (iv IgG) as prophylaxis
against recurrent bacterial infections. In these children, the proportion of
positive virus isolation specimens before treatment began was 7/11, compared
with 3/13 subsequently, a decrease which also was significant (P < 0-05).
None of the children was treated with zidovudine during this time.
In one child in group B, influenza A infection was associated with a
profound drop in the CD4+ lymphocyte count from 2-04 x io9/ml-
0-27 x io9/ml and in the T4/T8 cell ratio form 1 •9-0-5. These returned to their
previous values on recovery from the illness. We therefore analysed the effects
of respiratory symptoms and viral isolation on mean T4 cell counts for groups
A and B. No significant difference in mean values was observed between
samples taken when the children were asymptomatic and when they had
symptoms or a virus was isolated for either group, although the mean was
lower in all infected children (0-99 x io9/l in group A and 2-69 x io9/l in group
B). Similarly, no change was seen in CD8 + lymphocyte concentrations.
Discussion
The susceptibility of HIV-infected children to bacterial respiratory infection
is well-known,1 and coincides with a deficiency of antibody. Since HIV-
infected children also have a cellular immunodeficiency, they might be
expected to be more susceptible to acute viral infections but only two case
reports supporting this suggestion have so far been published.10,11
Despite the smaller number of children proving to be HIV-infected among
those we studied (5/50) than we had anticipated,12,13 we found a significantly
increased rate of respiratory viral isolation in the first 2 years of life compared
with appropriate controls. This may be due either to HIV infection causing
greater susceptibility after exposure to viruses other than HIV, or to a greater
virus load and more prolonged excretion during any given episode, so making
viral isolation on sampling at intervals more likely. We have not seen the
chronic excretion of agents such as parainfluenza virus, which has been
reported by others.11 Moreover, it was perhaps fortuitous that our HIV-
infected children escaped RSV when infections were widely prevalent in the
community, since prolonged viral carriage and a mortality rate as high as 20 %
in severely immunocompromised HIV-infected children has been reported.10
In our study, we used two different control groups of children who had the
same social background as the HIV-infected children. We have thereby
demonstrated that children born to HIV seropositive mothers who are not
HIV-infected do not differ in their rates of respiratory infection from those not
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exposed to the risk of HIV infection. In all three groups, poor housing,
overcrowding, and parental smoking habits may have contributed to a higher
than average morbidity in this respect.
The finding of fewer positive viral isolates in HIV-infected children
following IV IgG therapy should be interpreted with caution since data are
available on only three children. One possible explanation could be that
children outgrow susceptibility to viral infection after the first year of life but
this is not borne out by the rates in group B children which were constant
between the 2 years. Immunoglobulin therapy has been shown to prevent
Echovirus infection,14 reduce the shedding of RSV,15 and may have beneficial
effects in CMV infection,16 suggesting that the reduction of viral isolates may
have been a beneficial side-effect of iv IgG therapy.
We conclude that respiratory viral infections arise more often in HIV-
infected children. Given the ubiquitous nature of these agents and the lack of
available specific therapy for treatment or prophylaxis, further studies are
required in larger groups of HIV-infected children to assess the incidence of
recurrent viral infections and their influence on the progression ofHIV disease
together with the role of immunotherapy such as the early use of iv IgG.
(R. A. Hague was supported for this work by the Medical Research Council. We would
like to thank the AIDS Virus Education and Research Trust for financial support as
well as J. Whitelaw, of the Edinburgh and South East Scotland Blood Transfusion
Service HIV immunology laboratory for providing the data on lymphocyte subsets.)
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function in the process lead' lg to the initiation ofparturition
in human beings, possibly by shifting the balance of the
production of eicosanoids in favour of those derived from
n-3 rather than n-6 fatty acids.5'8 Biochemical and
physiological studies are needed to clarify how and at what
concentrations dietary n-3 fatty acids could affect formation
of eicosanoids in human pregnancy and to compare the
biological properties in the uteroplacental system of those
derived from n-3 and n-6 fatty acids. Our findings suggest
an easy and cheap intervention to prevent preterm delivery.
However, prolongation ofgestation by fish oilmay not result
in reduced frequencies of the complications associated with
preterm delivery;1 whether it will or not depends on the
extent to which preterm delivery is a necessary link in the
causal chain leading to the complications. Furthermore,
fish-oil supplementation could lead to more post-term
deliveries, which are also associated with complications.2-3A
carefully monitored, controlled trial of fish oil to women at
high risk of preterm delivery seems justified, and a
multicentre trial is in progress.18-20
We thank Prof Jorn Olsen and Prof Thorkild I. A. Serensen for valuable
discussions;Mr JacobHjort for his help in making the data ready for analysis;
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Risk factors for mother-to-child transmission of HIV-1
European Collaborative Study
Children born to women known to be infected
with human immunodeficiency virus type 1 (HIV-1)
before delivery were followed prospectively from
birth in nineteen European centres. This analysis,
encompassing the period end-December, 1984, to
beginning-August, 1991, focuses on risk factors
for mother-to-child transmission of HIV-1
infection.
Rate of vertical transmission, based on 721
children born to 701 mothers more than 18 months
before the time of analysis, was 14 4% (95% CI
12 0-17-1%). Transmission was associated with
maternal p24-antigenaemia and a CD4 count of less
than 700/p.l. In a multivariate analysis, odds ratios of
transmission were: 2-25 (95% CI 0-97-5-23) in
breastfed children vs never-breastfed children; 3 80
(1-62-8-91) in children born before 34 weeks'
gestation; and 0-56 (0-30-1 -04) in children
delivered by caesarean section. Transmission was
higher with vaginal deliveries in which episiotomy,
scalp electrodes, forceps, or vacuum extractors were
used, but only in centres where these procedures
were not routine.
On the basis of these results, HIV-infected women
contemplating pregnancy should be counselled
according to their immunological findings and, if
they have p24-antigenaemia or a low CD4 count,
warned of an increased risk of viral transmission.
Caesarean deliveries may have a protective effect,
although it is premature to recommend routine
operative delivery. The mechanism for the higher
infection rate in children born before 34 weeks'
gestation is unclear, but could reflect inadequate
passive or active immunity at that age, combined
with substantial transmission during labour or
delivery. The balance of evidence suggests that
mothers with established infection can transmit HIV
infection through breastmilk, although the relative
importance of this route remains to be defined.
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Introduction
Reported rates of transmission of human
immunodeficiency virus type 1 (HIV-1) infection from
mother to child range from 7 to 39%.*"® It is unclear to what
extent this variation is due to methodological differences or
to different distributions of risk factors in the populations
studied. There is some evidence that stage ofmaternal HIV
infection, as indicated by clinical and immunological status,
is associated with increased transmission.2-4'9-10 Some
researchers1112 have suggested that most HIV infection is
acquired around the time of delivery. Mode of delivery has
not been shown to play a part in HIV transmission,113 but
there is no information about the role ofobstetric procedures
or events in the intrapartum period. Although breastfeeding
during primary infection poses a risk,11 the additional risk of
breastfeeding in established maternal infection is poorly
quantified.13-15
In this report we analyse data collected by participants in
the European Collaborative Study from end-December,
1984, to beginning-August, 1991.5 Our aim was to
investigate the role of factors that may be associated with
vertical transmission of HIV-1 infection—for example,
clinical and immunological status of the mother during




In ten participating centres infants bom to women known to be
HIV-1 seropositive at or before delivery were enrolled at birth and
followed-up regularly according to a standard protocol.5-16 At the
time of birth, we obtained information about maternal clinical
status, mode of delivery, length of gestation, and birthweight for
these children, and we sought further information about maternal
immunological variables and obstetric procedures from the
obstetricians in these centres. In 1991, obstetricians in an additional
nine centres provided similar information which they had already
collected systematically on all HIV-1 seropositive mothers who
were known to be infected before delivery, and on the subsequent
infection status of the children.
All infants bom 18 months ormore before the date ofanalysis are
included. HIV-1 infection in the child was defined as: AIDS;17
HIV-related death; persistence of antibody beyond 18 months; or
detection of virus or p24-antigenaemia in at least two samples. 4
children who became seronegative but who were repeatedly vims
positive were excluded from the analysis.5 The remaining
seronegative children are judged to be uninfected.
All laboratory assessments were carried out locally; lymphocyte
subsets were determined by immunofluorescence with
cytofluorometric readout.18 The presence of p24-antigenaemia
was determined by commercially available enzyme-linked
immunosorbent assays (Abbott, Du Pont, Pasteur, Organon) or, in
one centre, by an in-house system.19 The result closest to delivery
was used in the analysis provided the maternal sample was taken
during pregnancy or less than 1 month after delivery. 86% of the
p24 antigen tests were done during the third trimester or at the time
ofdelivery, as were 76% ofthe lymphocyte subset estimations. CD4
counts were divided into three groups of approximately equal
numbers by means of cut-off values of 400 and 700 per pi. The
CD4/CD8 ratio was divided similarly, the values being 0-6 and 0-9.
This approach was found to be more appropriate than conventional
categories such as CD4 counts of less than 200/pi since only 9
women in this largely symptom-free cohort fell into this category.
Women were included as HIV-symptomatic (Centers for
Disease Control [CDC] stage III or IVA) if any HIV-related
symptom or sign was recorded by the clinician on two or more
occasions up to 3months post partum. AIDS was defined according
to the CDC classification,20 and a mother was regarded as having
AIDS if the diagnosis was made no later than 1 year post partum, to
allow for increased infectiousness before onset of AIDS.21






infection status Uo(%) 95% CI
All children 831 721 104 (14) 12-17
Maternal characteristics
Intravenous drug use
Ever 654 571 75 (13)t 10-16
Never 174 148 28 (19) 13-26
Parity
Primiparous 489 437 62 (14) 11-18
Multiparous 323 269 42 (16) 12-20
Race*
White 769 666 93 (14) 11-17
Black 39 32 6 (19) 8-35




None 685 602 84 (14) 11-17
Signs, no AIDS 100 83 14 (17) 10-26
AIDS 13 13 4(31) 11-59
p24-antigenaemia
Negative 336 288 30 (10)}| 7-14
Positive 45 42 12 (29) 16-44
CD4 count/pit
<400 83 72 14 (19)§ 11-30
400-699 90 80 18 (22) 14-33
5*700 85 78 5 (6) 2-14
CD4/CD8 ratiot
<0-60 106 88 21 (24)§ 16-34
0-60-0-89 78 73 9 (12) 6-21
5*0-90 67 63 1 (11) 5-21
Delivery and breast feeding
Mode of delivery*
Vaginal 614 547 85 (16) 13-19
Elective caesarean 155 127 16 (13) 8-19
Emergency caesarean 60 45 3 (7) 2-17
Gestational age
^ 34 weeks 774 678 93 (14)}\ 11-17
^ 33 weeks 43 33 11 (33) 19-51
Child ever breast fed
No 790 683 93 (14)§ 11-17
Yes 38 36 11 (31) 17-47
Numbers do not always add up to total because of missing data.
*Significance assessed by test for heterogeneity; tSignificance assessed by test for
trend; tp < 0-1; §p < 0 05; 1lp<0 01.
Zidovudine was not prescribed during pregnancy in the
participating centres, but 4 women, all symptomatic, were already
receiving the drug when their pregnancy was diagnosed.
Gestational age was recorded to the nearest completed week and
assessed by ultrasound when available or otherwise by date of last
menstrual period or clinical judgment.
Statistical analysis
Variation between centres was assessed by unconditional logistic
regression, after allowance for the risk factors listed in table II.
Conditional (upon centre) logistic regression was used to estimate
independent effects ofselected risk factors on transmission (tables n
and IV). Exact mid-p CIs were calculated for proportions.
Results
Rates of transmission
Between end-December, 1984, and beginning-August,
1991, 1005 children had been enrolled from the nineteen
centres, of whom 831 were born at least 18 months before
the date ofanalysis. HIV-infection status was determined in
721 (87%) children of 701 mothers. Of the remaining 110
(13%) children whose infection stams was not known, 13
had died of causes not thought to be related to HIV
infection, 45 were lost to follow-up within 1 month ofbirth,
and 52 were either lost to follow-up after that age or had not
been seen at the appropriate scheduled times. 104 children
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TABLE II—MULTIVARIATE ANALYSIS OF RISK FACTORS
FOR TRANSMISSION
Odds ratio
Crude* Adjustedt Adjustedt 95% CI pt
Mode of delivery
Vaginal 100
Elective caesarean 0-78 0-74 0-65 0-32-1 31 0-23
Emergency caesarean 0-39 0-34 0-37 0 11-1 25 0 11
Gestational age
> 34 weeks 100
< 33 weeks 315 307 3-80 1-62-8-91 0 002
Child ever breast fed
No 1 00
Yes 2-79 2-22 2-25 0-97-5-23 0-06
Intravenous drug use
Ever 100
Never 1 54 1-45 1-28 0-73-2-26 0-39
Analysis based on 664 children (101 infected).
•Derived from tabie I. t'or centre; tier centre, mode of delivery, gestational age.
breastfed, clinical progression, IVDU, parity, and race.
were infected, ofwhom 34 had been diagnosed with AIDS
and 1 had died with persistent oral candidosis, a sign
previously found to be predictive of imminent onset of
AIDS. Rate of vertical transmission was 14-4% (95% CI
12 0-171%). There was no trend over time (x2 trend = 0-80,
p = 0-37), nor was there significant variation between the
centres (x2 = 22-30, adjusted for risk factors, 18 df, p = 0-22).
In particular, there was no difference in transmission rate
between the ten original centres and the nine additional ones
(X2 = 0-47, ldf,p = 0-49).
Table I shows the number of children with known
infection status and rate of transmission by selected risk
factors. Although ascertainment of infection status wasmore
complete for children of mothers with high CD4/CD8
ratios, for children delivered vaginally, and for those bom
after 33 weeks' gestation, these differences are unlikely to
have biased the results substantially.
554 (79%) women had acquired HIV infection through
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Transmission rate by gestational age.
Figure has been smoothed by plotting 3-point averages—eg, value at
36 weeks is observed transmission rate for 35-37 weeks. Numbers born by
gestational age are shown in 2-week intervals.
history of IVDU, 62 (42%) had an IVDU partner and 25
(17%) came from, or had a partner who came from, a
high-risk area. Rate of transmission was lower in women
with a history of IVDU, largely due to a low rate (8%) in
former drug users. Vertical transmission was not
significantly associated with parity, race (table I), or
maternal age at delivery.
The risk of infection was greatest (31%) for infants bom
to the 13 womenwithAIDS, but less advanced HIV-related
manifestations were not predictive or transmission. Rate of
transmission rose sharply for a CD4 count below 700/pi or
for a CD4/CDS ratio below 0-6, and was strongly associated
with p24-antigenaemia. 4 women were classified as CDC
stage I (acute primary infection) at the time of delivery; all 4
were p24 antigen negative and 2 of the children were
infected.
Most (76%) children were delivered vaginally, and the
crude rate of transmission in this group was similar to that of
children delivered by elective caesarean section. The lower
rate of transmission in children delivered by emergency
caesarean section than by an elective operation may be a
chance finding (x2 = 0-66, 1 df, p = 0-42).
The relation between transmission rate and gestational
age was non-linear, with ahigher risk of infection in children
bom before 34 weeks but little further reduction in risk
beyond this age (see figure). The 33 children bom before 34
weeks' gestation had a 33% infection rate vs 14% for
children bom thereafter (table I). Ofthe 11 infants delivered
by caesarean section before 34 weeks, 3 (27%) were infected,
which was not significantly different from the rate in infants
delivered vaginally (8/22, 36%).
When uninfected children were taken as a standard, and
with adjustment for maternal IVDU, birthweight of the
infected children was appropriate for gestational age, both in
the cohort as a whole and in the group of children bom
before 34 weeks' gestation.
In all centres, HIV-positive women were discouraged
from breastfeeding. 36 (5%) mothers nevertheless chose to
breastfeed, although duration of breastfeeding tended to be
short (median 4 weeks). Rate of vertical transmission was
significantly higher in breastfed (31%, table I) than in
never-breastfed infants (14%), but there was no association
with duration of breastfeeding. 6 of 17 (35%) children
breastfed for less than 4 weeks were infected vs 5 of 19 (26%)
breastfed for longer.
Risk factors for vertical transmission:multivariate analysis
Multivariate analysis was done to assess the effect of
selected risk factors while controlling for other factors
(table n). Adjustment for centre effectively produced a
stratified analysis and additional adjustment for other risk
factors allowed for associations between risk factors within
centre. The association between mode of delivery and
transmission was strengthened, largely as a consequence ofa
higher proportion of symptomatic women in the elective
caesarean section group. Odds of infection in children
delivered by elective caesarean section was 0-65 times that of
children delivered vaginally, or 0-56 (95% CI 0-30-1 04,
p = 0-07) times ifelective and emergency caesarean sections
are combined (table II). IVDU was a risk factor for
prematurity; after allowance for this fact, children bom
before 34 weeks' gestation had a nearly four-fold higher
odds of infection than those bom after 33 weeks.
Breastfeeding was more more common in some centres;
controlling for centre weakened the association because the
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TABLE ill—MATERNAL CLINICAL AND IMMUNOLOGICAL










Vaginal 172 520 249 28 (11) 533 62 (12n
Elective caesarean 45 520 57 11 (19) 120 29 (24)
Emergency caesarean 13 500 22 1 (5) 43 5 (12)
Gestational age
> 34 weeks 209 680 308 34 (11)§ 658 87 (13)t
< 33 weeks 15 580 18 6 (33) 30 8(27)
Child ever breast fed
No 225 520 319 38 (12) 660 94 (14)
Yes 5 530 9 2 (22) 36 2 (6)
Intravenous drug use
Ever 174 520 258 31 (12) 551 75 (14)
Never 56 500 70 9 (13) 145 21 (14)
Clinicalprogression^
None 172 550« 265 26 (ion
Signs, no AIDS 53 410 55 12 (22)





*Significance assessed by tests for heterogeneity.
tSignificance assessed by tests for trend.
tp<0T;!jp<0 05; «!p<0 01.
centres was higher than among non-breastfeeders in
general. Infants of black mothers (6) and of non-IVDU
mothers (17) and those delivered vaginally (31) were
over-represented among breastfeeders, but adjustment for
these and other risk factors made little difference to the
estimated effect of breastfeeding. The negative association
between IVDU and transmission was further reduced after
adjustment for centre, mode of delivery, gestational age,
clinical progression, parity, and race.
Maternal clinical and immunological markers
The model shown in table n did not include maternal
p24-antigenaemia or CD4 count because this information
was routinely collected as part of the protocol only in some
centres after a centre-specific date. Table III shows the
association between selected risk factors and maternal
clinical and immunological variables. Too few breastfeeding
mothers had p24 antigen tests or CD4 counts recorded to
exclude the possibility that they were more infectious than
other mothers. IVDU women did not differ from women
without a history of IVDU. Clinical signs attributed to
HIV-1 infection and p24-antigenaemia were more frequent
TABLE IV—RISK OF TRANSMISSION ASSOCIATED WITH










No 50 6 (12) 100
Yes 157 - 29 (18) 1-66 5-59 002
Scalp electrodes
No 382 59 (15) 1 00
Yes 91 13 (14) 0-91 2-35 005
Instrumental
No 521 79 (15) 100
Yes 26 6 (23) 1-68 2-70 007
*p values are "exact" one-sided.
tlnformation on use of episiotomy collected only in later stages of the study.
in women who bad an elective caesarean section and in the
mothers of children bom before 34 weeks' gestation. The
significantly lower CD4 counts and higher rate of p24
antigenaemia in the symptomatic women suggest that
maternal signs were related to HIV infection.
Procedures/interventions during vaginal delivery
Rate of transmission in children bom by vaginal delivery
was similar irrespective of the use of episiotomy, scalp
electrodes, or instruments (table IV). However, there was
wide variation between centres in the use of these
procedures and within-centre comparisons suggested that
such interventions were associated with an increased risk of
transmission in centres where they were not routinely
adopted. Further allowance for the risk factors in table II did
not alter this finding.
Discussion
The lack of significant variation in transmission rates
between centres suggests that there are no major
unrecognised local risk factors. It has been suggested that
IVDU could adversely affect the immune system, thereby
increasing the risk of vertical transmission ofHIV infection.
However, in this study IVDU was not associated with
adverse immunological findings or with higher rates of
transmission. Similarly, neither parity nor age ofmother at
the time of the delivery was associated with transmission.
Previous reports ofan association between maternal CD4
count and risk of vertical transmission have been
contradictory,2A22 and p24-antigenaemia has been linked to
an increased rate of transmission in a small cohort of
mother/child pairs.22 Our study establishes that a low CD4
count and p24-antigenaemia are predicitive of vertical
transmission, whereas non-specific clinical manifestations
ofHIV infection are not. CD4 counts and p24-antigenaemia
can be used as surrogate markers for viral load, although
infectiousness is best estimated by quantification ofvirus in
cells and plasma.23 Our findings should provide an impetus
for studies of antiretroviral therapy or anti-HIV
immunoglobulin21 during pregnancy, although the effect of
these drugs on the unborn child will need to be considered
carefully.
HIV seropositive women contemplating pregnancy or
considering termination of pregnancy should be counselled
on the basis of both laboratory and clinical investigations.
Women who have p24-antigenaemia or a low CD4 count
should be advised that they are about twice as likely to
transmit the virus to their offspring. Risk of vertical
transmission seems to increase for CD4 counts below
700/gl, higher than the standard concentrations currently
used for initiating antiretroviral or prophylactic treatment in
adults.25 Most antigen andCD4 testing was done in the third
trimester of pregnancy. Although a low CD4 count early in
or before pregnancy is likely to be followed by a low count
later in pregnancy,26 the predictive value of early
antigenaemia remains to be established.
The high frequency of HIV infection in children bom
before 34 weeks' gestation could be explained in several
ways. First, HIV infection in utero could affect fetal
development and lead to premature delivery. By analogy
with other congenital infections,27 it would then be expected
that infected children would be small-for-dates as well as
premature, but this was not observed. Second, women who
are more likely to be infectious, as indicated by antigenaemia
or AIDS, may be more likely to deliver before 34 weeks.
Third, concurrent infections, especially those of the genital
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tract, may increase both the risk ofpremature delivery28 and
the risk of transmission of HIV infection. The latter could
arise through chorioamnionitis29 or by attracting HIV-
infected lymphocytes to the birth canal. We have no data on
the presence or absence ofgenital tract infections and cannot
test this hypothesis. These suggestions would accord with a
continued decrease in the rate of transmission with
gestational age. Finally, infants bom before 34 weeksmay be
more susceptible to intrapartum HIV-1 infection because
of diminished immunocompetence and, possibly, low
concentrations of passively acquired antibodies. Goedert et
al4 reported a high rate of transmission in children bom
before 38 weeks' gestation, which they specifically
attributed to low concentrations of maternal gp-120
antibodies, but the protective effect of gp-120 antibodies in
the transmission ofHIV was not supported by results from
the New York collaborative study.30 For prematurity to be
risk factor for acquisition of infection, a substantial
proportion of infants should acquire infection during labour
or delivery. Our data showed a levelling off in rate of
transmission after 34 weeks' gestation, which would accord
with rapid transfer ofmaternal antibodies late in pregnancy
and increased susceptibility of very premature infants.
Scalp electrodes, episiotomy, and instrumental vaginal
deliveries were associated with subsequent infection in
infants only in centres where these procedures were not
routine, which suggests that such factors per se do not pose a
genuine risk. A more plausible explanation is that in these
centres interventions are used selectively in more complex
deliveries. Although transmission can occur early in
pregnancy,31 the association with scalp electrodes &c lends
further support to the view that a substantial proportion of
infection is acquired around the time of delivery.11 The
report by Goedert et al12 that the first-bom twin had a
significantly higher risk of being infected than the second-
bom twin specifically implicated transmission in the birth
canal. Transmission around the time ofdelivery could occur
through mixing of maternal and fetal blood,32 or via
ingestion ofHIV-containing body fluids.
Although the relative importance of transmission at
delivery is becoming apparent, prospective studies11213 have
shown similar rates of transmission in children delivered
vaginally and by caesarean section. In our study, there was
some evidence ofa protective effect ofoperative delivery but
the result was not statistically significant. If one assumes a
15% risk of transmission by vaginal delivery, the results
from our model predict that the risk by caesarean section
would be 9% (95% CI 5-16%). Thus the data accord both
with section reducing the risk of transmission approximately
three-fold (from 15% to 5%) and with the procedure
offering no protective effect. However, some obstetricians
weremore likely to carry our an elective caesarean section on
women who were antigenaemic or HIV-symptomatic, and
there may be other biases of which we are unaware.
Available evidence is therefore not sufficiently clear to
recommend routine caesarean section, and randomised
controlled trials are warranted to evaluate the effect ofmode
of delivery on the risk of transmission.
Van de Perre et al14 found a high risk of transmission (at
least 4 of 11) of HIV infection through breastfeeding in
primary infection after delivery. Since viraemia is common
shortly after infection,33J4 and since these children would
not possess passively acquired maternal HIV-antibodies,
the relevance of this finding for mothers with established
infection is unclear. World Health Organisation guidelines35
discuss the need to balance the benefits of breastfeeding by
HIV-infected women against the additional risk of
transmission through breastmilk. Prospective studies have
failed to recruit both breastfed and exclusively bottlefed
infants in sufficient numbers: Blanche et al1 and Ryder et al15
reported higher rates of transmission in breastfed children,
whereas Hutto et al13 reported a marginally smaller risk
among breastfeeders. We found a two-fold increase in the
risk of infection among breastfed children, although the
number of children in this group was small. The balance of
evidence suggests that mothers with established infection
can transmit HIV infection through breastmilk, although
the relative importance of this route remains to be
quantified.
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Detection of mycobacterial DNA in sarcoidosis and
tuberculosis with polymerase chain reaction
Syed A. Saboor Norman McI. Johnson Johnjoe McFadden
The cause of sarcoidosis is unknown. However,
the histological similarity between the disorder and
tuberculosis suggests that mycobacteria might
contribute to the pathogenesis of sarcoidosis. We
have used the polymerase chain reaction (PCR) to
detect mycobacterial DNA in clinical samples from
patients with sarcoidosis.
104 patients were included in the study (62
referred for possible tuberculosis and 20 for possible
sarcoidosis, and 22 control patients who had
undergone bronchoscopy for other reasons).
Bronchoalveolar lavage samples, bronchial
washings, and tissue specimens (1 from each
patient) underwent assay by PCR as well as
bacteriological, histological, and cytological
examination. We used two PCR reactions: in the first
the complex-specific insertion sequence IS986/
IS6110 was used to specifically detect DNA from
Mycobacterium tuberculosis complex bacteria; in
the second, conserved sequences of the
mycobacterial groEL gene were used to detect DNA
from mycobacteria other than M tuberculosis. Thi
PCR was more sensitive than culture for diagnosis o
tuberculosis. However, the false-positive PCR rati
forM tuberculosiswas 9%. M tuberculosis DNA wa:
found in half the sarcoidosis patients, and non
tuberculosis mycobacterial DNA in a further 20%.
The findings that a significant proportion of thi
sarcoidosis patients in this study have mycobacterii
in their lungs and that most of these mycobacterii
belong to M tuberculosis complex suggest ar
aetiological role for mycobacteria in sarcoidosis.
Lancet 1992; 339: 1012-1E
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